false FY 0001930313 false FY 0001930313

 SBC:CommonStock0.0001ParValuePerShareMember

 SBC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember

 2024-06-28

 2025-02-28

 us-gaap: NonrelatedPartyMember

 us-gaap: NonrelatedPartyMember

 us-gaap: NonrelatedPartyMember

 us-gaap: NonrelatedPartyMember

 SBC:SBCMedicalGroupCoLtdMember

 2023-04-30

 SBC:SBCMedicalGroupIncMember

 2023-09-30

 SBC:SBCMedicalGroupIncMember

 SBC:SBCMedicalGroupIncMember

 SBC:SBCMedicalGroupCoLtdMember

 SBC:SBCMedicalGroupCoLtdMember

 SBC:LAngeCosmetiqueCoLtdMember

 SBC:LAngeCosmetiqueCoLtdMember

 SBC:ShobikaiCoLtdMember

 SBC:ShobikaiCoLtdMember

 SBC:LiestaCoLtdMember

 SBC:LiestaCoLtdMember

 SBC:SBCSealaneCoLtdMember

 SBC:SBCSealaneCoLtdMember

 SBC:SBCMarketingCoLtdMember

 SBC:SBCMarketingCoLtdMember

 SBC:MedicalPaymentCoLtd. Member

 SBC:MedicalPaymentCoLtd. Member

 SBC:SBCMedicalConsultingCoLtd. Member

 SBC:SBCMedicalConsultingCoLtd. Member

 SBC:ShoubikaiMedicalVietnamCoLtdMember

 SBC:ShoubikaiMedicalVietnamCoLtdMember

 SBC:SBCHealthcareIncMember

 SBC:SBCHealthcareIncMember

 SBC:SBCIrvineLLCMember

 SBC:SBCIrvineLLCMember

 SBC:AestheticHealthcareHoldingsPteLtdMember

 SBC:AestheticHealthcareHoldingsPteLtdMember

 SBC:WenAndWengFamilyClinicPteLtdMember

 SBC:WenAndWengFamilyClinicPteLtdMember

 SBC:WenAndWengMedicalGroupPteLtdMember

 SBC:WenAndWengMedicalGroupPteLtdMember

 SBC:RochorClinicPteLtdMember

 SBC:RochorClinicPteLtdMember

 SBC:DermasolutionsPteLtdMember

 SBC:DermasolutionsPteLtdMember

 SBC:DermasolutionsServicesPteLtdMember

 SBC:DermasolutionsServicesPteLtdMember

 SBC:CurrentJPYUSDollarOneExchangeRateMember

 SBC:CurrentJPYUSDollarOneExchangeRateMember

 SBC:AverageJPYUSDollarOneExchangeRateMember

 SBC:AverageJPYUSDollarOneExchangeRateMember

 SBC:CustomerAMember

 SBC:CustomerBMember

 SBC:CustomerCMember

 SBC:CustomerAMember

 SBC:CustomerBMember

 SBC:CustomerCMember

 SBC:CustomerDMember

 SBC:CustomerAMember

 SBC:CustomerBMember

 SBC:CustomerCMember

 SBC:CustomerDMember

 SBC:CustomerAMember

 SBC:CustomerBMember

 SBC:CustomerCMember

 SBC:CustomerDMember

 us-gaap: SupplierConcentrationRiskMember
 SBC:NoVendorMember

 us-gaap: SupplierConcentrationRiskMember
 SBC:VendorAMember

 us-gaap: SupplierConcentrationRiskMember
 SBC:VendorBMember

 SBC:VendorAMember

 SBC:VendorBMember

 SBC:VendorAMember

 SBC:VendorBMember

 SBC:VendorCMember

 us-gaap: BuildingAndBuildingImprovementsMember
 srt: MinimumMember

 us-gaap: BuildingAndBuildingImprovementsMember
 srt: MaximumMember

 SBC:MachineryEquipmentAndAutomobilesMember
 srt: MinimumMember

 SBC:MachineryEquipmentAndAutomobilesMember
 srt: MaximumMember

 SBC:AircraftMember
 srt: MinimumMember

 SBC:AircraftMember
 srt: MaximumMember

 SBC:SoftwareMember

 us-gaap: PatentsMember

 us-gaap: TrademarksMember

 us-gaap: CustomerRelationshipsMember
 srt: MinimumMember

 us-gaap: CustomerRelationshipsMember
 srt: MaximumMember

 SBC:OtherMember

 us-gaap: FairValueInputsLevel1Member

 us-gaap: FairValueInputsLevel2Member

 us-gaap: FairValueInputsLevel3Member

 us-gaap: FairValueInputsLevel1Member

 us-gaap: FairValueInputsLevel2Member

 us-gaap: FairValueInputsLevel3Member

 SBC:AestheticHealthcareHoldingsPteLtdMember

 2024-11-20

 SBC:AestheticHealthcareHoldingsMember

 2024-11-20

 2023-04-03

 2023-04-03

 2024-11-20

 2024-12-23

 SBC:HariverIncMember

 2024-12-23

 2024-12-23

 SBC:ConvertiblePromissoryNoteMember

 2023-05-31

 us-gaap: CommonClassAMember

 2023-05-31

 SBC:ConvertiblePromissoryNoteMember

 2024-02-29

 SBC:ConvertiblePromissoryNoteMember

 us-gaap: LandMember

 us-gaap: LandMember

 us-gaap: BuildingMember

 us-gaap: BuildingMember

 us-gaap: MachineryAndEquipmentMember

 us-gaap: MachineryAndEquipmentMember

 us-gaap: AirTransportationEquipmentMember

 us-gaap: AirTransportationEquipmentMember

 us-gaap: SoftwareDevelopmentMember

 us-gaap: SoftwareDevelopmentMember

 us-gaap: ConstructionInProgressMember

 us-gaap: ConstructionInProgressMember

 2023-08-01
 2023-08-31

 SBC:AssembledWorkforceMember

 SBC:AssembledWorkforceMember

 us-gaap: PatentsMember

 us-gaap: TrademarksMember

 us-gaap: CustomerRelationshipsMember

 us-gaap: CustomerRelationshipsMember

 us-gaap: OtherIntangibleAssetsMember

 us-gaap: OtherIntangibleAssetsMember

 SBC:FixedRateLoansMember

 SBC:FixedRateLoansMember

 SBC:VariableRateLoansMember

 SBC:VariableRateLoansMember

 SBC:UnsecuredLoansMember
 SBC:FixedRateLoansMember

 SBC:UnsecuredLoansMember
 SBC:FixedRateLoansMember

 SBC:UnsecuredLoansMember

 SBC:UnsecuredLoansMember

 SBC:TokyoCreditGuaranteeAssociationMember
 srt: ChiefExecutiveOfficerMember

 SBC:TokyoCreditGuaranteeAssociationMember
 srt: ChiefExecutiveOfficerMember

 SBC:KanagawaCreditGuaranteeAssociationMember
 srt: ChiefExecutiveOfficerMember

 SBC:KanagawaCreditGuaranteeAssociationMember
 srt: ChiefExecutiveOfficerMember

 SBC:KanagawaCreditGuaranteeAssociationMember

 SBC:KanagawaCreditGuaranteeAssociationMember

 us-gaap: ForeignCountryMember
 country: JP

 us-gaap: ForeignCountryMember
 country: JP

 us-gaap: ForeignCountryMember
 country: VN

 us-gaap: ForeignCountryMember
 country: SG

 us-gaap: CommonClassAMember

 SBC:WolverineFlagshipFundTradingLimitedMember

 SBC:AmethystArbitrageInternationalMasterFundMember

 SBC:RadcliffeSpacMasterFundLPMember

 SBC:VeritionMultiStrategyMasterFundLtdMember

 SBC:WarrantAgreementMember

 2022-11-18
 2022-11-18

 SBC:WarrantAgreementMember

 2022-11-18

 SBC:WarrantAgreementMember

 SBC:WarrantAgreementMember

 2024-09-27

 us-gaap: WarrantMember

 us-gaap: WarrantMember

 2022-01-01

 us-gaap: WarrantMember

 us-gaap: WarrantMember

 us-gaap: PrivatePlacementMember

 us-gaap: PrivatePlacementMember

 SBC:FranchisingMember

 SBC:FranchisingMember

 SBC:ProcurementServicesMember

 SBC:ProcurementServicesMember

 SBC:ManagementServicesMember

 SBC:ManagementServicesMember

 SBC:RentalServicesMember

 SBC:RentalServicesMember

 SBC:OtherMember

 SBC:OtherMember

 SBC:CustomersMember

 SBC:CustomersMember

 SBC:HariverIncMember

 SBC:HariverIncMember

 SBC:SBCMedicalPromotionFoundationMember

 SBC:SBCMedicalPromotionFoundationMember

 SBC:GeneralIncorporatedAssociationSBCMember

 SBC:GeneralIncorporatedAssociationSBCMember

 SBC:SBCTokyoMedicalUniversityMember

 SBC:SBCTokyoMedicalUniversityMember

 SBC:MizuhoYamashitaMember

 SBC:MizuhoYamashitaMember

 SBC:AmuletIncMember

 SBC:AmuletIncMember

 SBC:AIMedIncMember

 SBC:AIMedIncMember

 SBC:SBCIrvineMCMember

 SBC:SBCIrvineMCMember

 SBC:MedicalCorporationAssociationFurinkaiMember

 SBC:MedicalCorporationAssociationFurinkaiMember

 SBC:MedicalCorporationAssociationJunikaiMember

 SBC:MedicalCorporationAssociationJunikaiMember

 SBC:GeneralIncorporatedAssociationTaiseikaiMember

 SBC:GeneralIncorporatedAssociationTaiseikaiMember

 SBC:SBCShonanOsteopathicClinicCoLtdMember

 SBC:SBCShonanOsteopathicClinicCoLtdMember

 SBC:MedicalCorporationAssociationFurinkaiMember

 SBC:MedicalCorporationAssociationFurinkaiMember

 SBC:MedicalCorporationAssociationJunikaiMember

 SBC:MedicalCorporationAssociationJunikaiMember

 SBC:SBCTokyoMedicalUniversityMember

 SBC:SBCTokyoMedicalUniversityMember

 SBC:AIMedIncMember

 SBC:AIMedIncMember

 SBC:SBCMedicalPromotionFoundationMember

 SBC:SBCMedicalPromotionFoundationMember

 SBC:SBCShonanOsteopathicClinicCoLtdMember

 SBC:SBCShonanOsteopathicClinicCoLtdMember

 SBC:SBCIrvineMCMember

 SBC:SBCIrvineMCMember

 SBC:MedicalCorporationAssociationJunikaiiMember

 SBC:MedicalCorporationAssociationJunikaiiMember

 SBC:FormerDirectorMember

 us-gaap: SubsequentEventMember
 SBC:MehanaCapitalLLCMember

 2025-02-01
 2025-02-28

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

 FORM

 (Mark
One)

 ANNUAL
 REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended December 31, 2024

 OR

 TRANSITION
 REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

 Commission
File Number 001-41462

 SBC
Medical Group Holdings Incorporated

 (Exact
name of registrant as specified in its charter)

 Delaware

 88-1192288

 (State
 or other jurisdiction of

 incorporation
 or organization)

 (I.R.S.
 Employer

 Identification
 No.)

 Spectrum Center Dr. STE 300

 Irvine,
 CA

 92618

 (Address
 of principal executive offices)

 (Zip
 Code)

 Registrant's
telephone number, including area code: 949 - 593-0250

 Securities
registered pursuant to Section 12(b) of the Act:

 Title
 of each class

 Trading
 Symbol(s)

 Name
 of each exchange on which registered

 Common
 Stock, $0.0001 par value per share

 SBC

 The
 Nasdaq Stock Market LLC

 Redeemable
 Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share

 SBCWW

 The
 Nasdaq Stock Market LLC

 Securities
registered pursuant to Section 12(g) of the Act: None

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes
 No

by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes
 No

by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes No

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer,"
"smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large
 accelerated filer

 Accelerated
 filer

 Non-accelerated
 filer

 Smaller
 reporting company

 Emerging
 growth company

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 The
aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 28, 2024, the last
business day of the Registrant's most recently completed second fiscal quarter, was $ 21,257,087,
calculated by using the closing price of the Registrant's Common Stock on such date on the Nasdaq Stock Market LLC of $13.07.

 The
number of shares of registrant's Common Stock outstanding as of February 28, 2025 was 103,611,251, after deducting 270,000 shares of treasury stock.

 DOCUMENTS
INCORPORATED BY REFERENCE

 The
registrant intends to file a proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December
31, 2024. Portions of such proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.

 CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS

 This
Annual Report contains forward-looking statements regarding, among other things, the plans, strategies and prospects, both business
and financial, of the Company. These statements are based on the beliefs and assumptions of the management of the Company. Although
the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are
reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking
statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts,
including statements concerning possible or assumed future actions, business strategies, events or results of operations, are
forward-looking statements. These statements may be preceded by, followed by or include the words "anticipate,"
"believe," "continue," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "possible," "potential,"
"predict," "project," "should," "would" or similar expressions, but the absence of
these words does not mean that a statement is not forward-looking. Forward-looking statements contained in this Annual Report
include, but are not limited to, statements about:

 future
 financial performance of the Company;

 in the market and level of demand for our products and services;

 the
 expansion plans and opportunities of the Company;

 the
 ability of the Company to access additional capital;

 the
 ability of the Company maintain the listing of the Company's common stock on Nasdaq;

 public
 securities' potential liquidity and trading;

 the
 impact from the outcome of any known and unknown litigation;

 the
 ability of the Company to forecast and maintain an adequate rate of revenue growth and appropriately
 plan its expenses;

 expectations
 regarding future expenditures of the Company;

 the
 future mix of revenue and effect on gross margins of the Company;

 the
 attraction and retention of qualified directors, officers, employees and key personnel of
 the Company;

 the
 ability of the Company to compete effectively in a competitive industry;

 the
 ability to protect and enhance the Company's corporate reputation and brand;

 expectations
 concerning the relationships and actions of the Company and its affiliates with third parties;

 the
 impact from future regulatory, judicial, and legislative changes in the Company's industry;

 the
 ability to locate and acquire complementary products or product candidates and integrate
 those into the Company's business;

 future
 arrangements with, or investments in, other entities or associations;

 intense
 competition and competitive pressures from other companies in the industries in which the
 Company operates;

 the
 possibility that we may be adversely affected by other economic, business, and/or competitive
 factors;

 in applicable laws or regulations; and

 other
 factors detailed under "Part I, Item 1A. Risk Factors."

 These
forward-looking statements are based on information available as of the date of this Annual Report, and current expectations, forecasts
and assumptions, and involve a number of risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as
representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect
events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as
may be required under applicable securities laws.

 In
addition, statements that the Company "believes" and similar statements reflect such the Company's beliefs and opinions
on the relevant subject. These statements are based upon information available to the Company as of the date of this Annual Report, and
while such party believes such information forms a reasonable basis for such statements, such information may be limited or incomplete,
and these statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially
available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

 As
a result of a number of known and unknown risks and uncertainties, the actual results or performance of the Company may be materially
different from those expressed or implied by these forward-looking statements. Some factors that could cause the Company's actual
results to differ include:

 the
 outcome of any legal or regulatory proceedings that have been, or may be, instituted in the
 future against the Company;

 the
 ability of the Company to grow and manage growth profitably, maintain relationships with
 customers, compete within its industry and retain its key employees;

 risks
 related to macroeconomic or geopolitical developments;

 future
 exchange and interest rates;

 the
 risk that the Company fails to maintain an effective system of disclosure controls and internal
 controls over financial reporting, the Company's ability to produce timely and accurate
 financial statements or comply with applicable regulations could be impaired; and

 other
 risks and uncertainties indicated in this Annual Report, including those under "Part
 I, Item 1A. Risk Factors" herein, and other filings that have been made or will be
 made with the SEC by the Company.

 Summary of Material
Risks

 We
 are a holding company and depend upon our operating subsidiaries for our cash flows.

 We
 may need additional capital, and we cannot be sure that additional financing will be available.

 We
 may not grow our franchise system or we may lose business by failing to compete effectively
 or by failing to manage the reputation of our brand.

 The
 financial performance of our franchisees can negatively impact our business.

 The
 interests of our franchisees may conflict with ours or yours in the future and we could face
 liability from our franchisees or related to our relationship with our franchisees.

 We
 could face liability from or as a result of our franchisees.

 We
 have limited control with respect to the operations of our medical corporation customers, which could have
 a negative impact on our business.

 The
 challenging economic environment may affect our franchisees, with adverse consequences to
 us.

 If
 we are unable to obtain, maintain or protect intellectual property rights, in Japan, in Vietnam,
 in Singapore, in the U.S. and throughout the world, we may not be able to compete effectively
 in our market or globally.

 We
 have substantial franchisee concentration.

 Our
 reputation and the trading price of our common stock may be negatively affected by adverse
 publicity or detrimental conduct against us.

 We
 are a relatively young company with a short operating history, and we may not be able to
 sustain our rapid growth, effectively manage our growth or implement our business strategies.

 Our
 franchisee clinics may not be successful in competing in the cosmetic clinic industry.

 The
 Company may face competition from senior management who cease working for it, and the Non-Competition
 Agreements may be unenforceable and expire two years following the Closing.

 Any
 significant change in the franchisee clinic customer reward program could have a negative
 impact on our business.

 Any
 significant cybersecurity incident or disruption to our operating systems could subject us
 to significant reputational, financial, legal and operational consequences.

 We
 may be compelled to undertake product recalls or take other actions, which could adversely
 affect our brand image and results of operations.

 We
 may become subject to product liability claims or warranty claims, which could harm our financial
 condition and liquidity if we are not able to successfully defend or insure against such
 claim.

 We
 have little experience in providing management services to franchisee clinics located outside
 of Japan and we are subject to a variety of costs and risks due to our continued international
 expansion.

 Our
 operations may be interrupted by utility shortages or stoppages, fire, natural disaster or
 other calamities at or near our facilities.

 Our
 business and prospects depend significantly on our ability to build our Shonan Beauty Clinic
 brand.

 Our
 employees, agents, business partners or subcontractors may engage in misconduct or other
 improper activities, which could cause us to lose contracts, expose us to damages, harm our
 reputation and diminish investor confidence in our company.

 Any
 decline in the business of our business partners or the deterioration of our relationship
 with them could have a material adverse effect on our operating results.

 issues or public perceptions of safety issues concerning cosmetic services could have a material
 adverse impact on our business.

 If
 our franchisee clinics or our clinics in Vietnam and Singapore fail to comply with environmental
 and work safety laws and regulations, the Company and the franchisee clinics could become
 subject to fines or penalties or incur costs that could harm our business.

 If
 our business partners, independent contractors, suppliers, or franchisee clinics fail to
 use ethical business practices and comply with applicable laws and regulations, our brand
 image could be harmed due to negative publicity beyond our own control.

 to safeguard personal information could subject us to penalties, damage our reputation and
 brand, and harm our business and results of operations.

 by the MCs to comply with the Medical Care Act in Japan could subject us to penalties, damage
 our reputation and brand, and harm our business and results of operations.

 The
 execution of our business plans requires a significant amount of capital. In addition, our
 future capital needs may require us to sell additional equity or debt securities that may
 dilute the equity interests of our stockholders or introduce covenants that may restrict
 our operations or our ability to pay dividends.

 We
 are subject to risks associated with strategic alliances or acquisitions. If we cannot manage
 the growth of our business or execute our strategies effectively, our business and prospects
 may be materially and adversely affected.

 Our
 business could be adversely affected by trade tariffs or other trade barriers.

 We
 and our subsidiaries have limited insurance coverage, which could subject us to significant
 costs and business disruption.

 We
 are involved in litigation from time to time and, as a result, we could incur substantial
 judgments, fines, legal fees or other costs.

 Any
 financial or economic crisis or perceived threat of such a crisis may materially and adversely
 affect our business, financial condition and results of operations.

 We
 face risks related to natural disasters, which could significantly disrupt our operations.

 If
 the landlords of our and our subsidiaries' leased properties fail to properly maintain
 and renovate such premises, buildings or facilities in a timely manner or at all, the operation
 of our offices could be materially and adversely affected.

 The
 MCs may fail to pay us in accordance with the terms of their franchise and management services
 agreements, at times necessitating action by us to attempt to compel payment.

 We
 believe our success depends on continuing to invest in the growth of our worldwide operations
 by expanding franchisee clinics to new geographic markets. If the franchisee clinic opportunities
 in these new markets are less than anticipated, or if the customer growth or sales in these
 markets do not meet our expectations, our results of operations and financial condition may
 be adversely affected.

 If
 we fail to maintain an effective system of internal controls over financial reporting, including
 remediating known material weaknesses in our internal controls as of December 31, 2024, we
 may not be able to report our financial results timely and accurately or prevent fraud, which
 could adversely affect investor confidence in our company, and in turn, our results of operations
 and our stock price.

 Nasdaq
 may delist our securities from trading on its exchange, which could limit investors'
 ability to make transactions in our securities and subject the Company to additional trading
 restrictions.

 The
 Company is a "controlled company" within the meaning of the applicable rules
 of Nasdaq and, as a result, we qualify for exemptions from certain corporate governance requirements.
 If the Company relies on these exemptions, its stockholders will not have the same protections
 afforded to stockholders of companies that are subject to such requirements.

 These
and other factors that could cause actual results to differ from those implied by the forward-looking statements in this Annual Report
are more fully described under "Part I, Item 1A. Risk Factors" and elsewhere in this Annual Report. The risks described under
the heading "Part I, Item 1A. Risk Factors" are not exhaustive. Other sections of this Annual Report describe additional
factors that could adversely affect the business, financial condition or results of operations of the Company. New risk factors emerge
from time to time and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors
on the business of the Company, or the extent to which any factor or combination of factors may cause actual results to differ materially
from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. This is particularly
true for a company like the Company that has a limited operating history to reference. All forward-looking statements attributable to
the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements.

 Table
of Contents

 Page

 Item
 1.

 Business.

 Item
 1A.

 Risk
 Factors

 Item
 1B.

 Unresolved
 Staff Comments.

 Item
 1C.

 Cybersecurity.

 Item
 2.

 Properties.

 Item
 3.

 Legal
 Proceedings.

 Item
 4.

 Mine
 Safety Disclosures.

 Item
 5.

 Market
 for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 Item
 6.

 [Reserved].

 Item
 7.

 Management's
 Discussion and Analysis of Financial Condition and Results of Operations

 10 4

 Item
 7A.

 Quantitative
 and Qualitative Disclosures About Market Risk.

 Item
 8.

 Statements and Supplementary Data.

 Item
 9.

 Changes
 in and Disagreements With Accountants on Accounting and Financial Disclosure.

 Item
 9A.

 Controls
 and Procedures.

 Item
 9B.

 Other
 Information.

 Item
 9C.

 Disclosure
 Regarding Foreign Jurisdictions that Prevent Inspections.

 Item
 10.

 Directors,
 Executive Officers and Corporate Governance.

 Item
 11.

 Compensation.

 Item
 12.

 Security
 Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 Item
 13.

 Certain
 Relationships and Related Transactions, and Director Independence.

 Item
 14.

 Principal
 Accountant Fees and Services.

 Item
 15.

 Exhibits
 and Financial Statement Schedules

 Item
 16.

 Form
 10-K Summary

 PART
I

 Item
1.
 Business.

 Unless
the context indicates otherwise, any references herein to the "Company", "we", "us" and
"our" refer to (i) SBC Medical Group, Inc. (formerly known as SBC Medical Group Holdings Incorporated), a Delaware
corporation ("Legacy SBC"), and its
consolidated subsidiaries and variable interest entity ("VIE"), prior to the consummation of Business Combination
and to (ii) SBC Medical Group Holdings Incorporated, the Combined Entity and its consolidated subsidiaries and VIE following the
Business Combination, and reference herein to "Pono" refers to predecessor company prior to the
consummation of the Business Combination.

 Company

 History

 We
were originally incorporated in Delaware on February 12, 2021 under the name "Pono Capital Two, Inc.," referred to herein
as "Pono," as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange,
asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

 On August 9, 2022, Pono consummated its IPO of
11,500,000 units (the "Units" and, with respect to the Class A common stock included in the Units being offered, the "Public
Shares" and with respect to the warrants included in the Units, the "Public Warrants") (the "Pono IPO").

 Simultaneously
with the consummation of the closing of the Pono IPO, Pono consummated the private placement of an aggregate of 634,375 units (the "Placement
Units") at a price of $10.00 per Placement Unit in a private placement to the Sponsor (the "Private
Placement").

 On
September 26, 2022, the Class A common stock and Public Warrant included in the Units began separate trading on The Nasdaq Global Market
under the symbols "PTWO" and "PTWOW," respectively.

 On
January 21, 2023, Pono entered into an Agreement and Plan of Merger (as subsequently amended from time to time, the "Merger
Agreement") with Pono Two Merger Sub, Inc., a Delaware corporation ("Merger Sub") and then a wholly-owned
subsidiary of Pono, SBC Medical Group, Inc., then named SBC Medical Group Holdings Incorporated, a Delaware corporation
("Legacy SBC"), Mehana Capital LLC, a Delaware limited liability company ("Sponsor" or "Purchaser
Representative") in its capacity as the representative of the stockholders of Pono, and Yoshiyuki Aikawa in his personal
capacity and his capacity as the representative of the stockholders of Legacy SBC ("Seller Representative").

 On September 17, 2024, the closing (the "Closing") of the merger (the "Merger") and other transactions contemplated thereby (collectively, the "Business
Combination") took place and the Merger was
consummated with Merger Sub merging with and into Legacy SBC with Legacy SBC surviving the Merger as a wholly-owned subsidiary of Pono,
and Pono then changed its name to SBC Medical Group Holdings Incorporated and on September 17, 2024, Legacy SBC changed its named to
SBC Medical Group, Inc.

September 17, 2024, Pono's units ceased trading, and effective September 18, 2024, SBC's common stock began trading on the
Nasdaq Global Market under the symbol "SBC" and the public warrants began trading on the Nasdaq Capital Market under the
symbol "SBCWW."

 As
a result of the Closing of the Merger and the Business Combination, the business of SBC Medical Group, Inc. ("Legacy SBC"),
became the business of the Company.

 The
Company is a management company headquartered in Irvine California and Tokyo, Japan, that owns, operates, and provides management services
to cosmetic treatment centers mainly in Japan, with footprint also in Vietnam, Singapore and the United States. The history of Legacy SBC began with the establishment of L'Ange Cosmetique
Co., Ltd. in 2003 and SBCMG (formerly Aikawa Medical) in 2017 for the purpose of providing management services to medical corporations
and the medical clinics of the medical corporations. The history of the medical corporations and the medical clinics began in 2000 with
the opening of Shonan Beauty Clinic in Fujisawa City, Japan, where Dr. Aikawa opened in private practice. Subsequently, Dr. Aikawa opened
clinics in Yokohama in 2001 and Shinjuku in 2003, incorporated as Medical Corporation Shobikai in 2004, acquired a medical corporation
named Medical Corporation Kowakai in 2009 and Medical Corporation Nasukai in 2009.

 The
Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising
and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking
reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction
and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products
to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark
and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's
customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.

 In
2017, we began providing our management services to our franchisee treatment center. The Company and its subsidiaries now provide
management services to a total of 241 franchisee treatment centers located in Japan. The Company also (i) owns and operates 1
treatment center under its "SBC" brand name in Ho Chi Minh City, Vietnam, as well as (ii) provides management service to
1 treatment center under its "SBC" brand name in Irvine, California in the United States (the "CA Clinic"),
which is owned and operated by the related party. Our treatment center in Vietnam, and the franchisee treatment centers that we
provide management services to, provide an array of surgical and non-surgical medical services that vary based upon location,
including cosmetic surgery, dermatology, and dentistry. These medical services include but are not limited to breast augmentation,
liposuction, rejuvenation treatments (including treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs
of aging), laser skin toning and spot removal, eyes double fold surgery, rhinoplasty, treatment of osmidrosis and hyperhidrosis,
hair transplants, gynecological formation treatments, laser hair removal, face line surgeries, cosmetical dental procedures, tattoo
removal, lasik eye surgery, lateral canthoplasty, brow lift procedures, androgenetic alopecia treatment, and cheek sagging
prevention methods. In November 2024, we acquired 100% equity interest of Aesthetic Healthcare Holdings ("AHH") and its
subsidiaries, companies incorporated in Singapore and principally engaged in medical aesthetics business, with a cash consideration
of SGD$7.8 million (equivalent to approximately US$5.8 million). Through the acquisition of AHH, the Company currently operates
several clinics in Singapore.

 Since
our inception, we have been committed to delivering high quality management services to our franchisee clinics. We believe our team of
highly qualified and experienced professionals have underpinned our strong reputation as we continue to provide multifaceted management
services to our franchisee clinics.

 Business Segments

 The Company operates as a single
operating segment. The Company's Chief Executive Officer, who serves as the Chief Operating Decision Maker ("CODM"),
is responsible for evaluating performance and allocating resources. Our revenues are primarily derived from providing comprehensive management
services to franchisee cosmetic treatment centers, including advertising, staffing, procurement, IT solutions, and the licensing of medical
technologies and trademarks. For additional details, see Note 20, "Segment Reporting," in the accompanying notes to our consolidated
financial statements.

 Corporate
Structure

 The
Company's subsidiary, SBC Medical Group, Inc., primarily operates through 16 wholly owned subsidiaries, one majority owned subsidiaries
and one variable interest entity. The wholly owned subsidiaries consist of SBC Medical Group Co., Ltd., a Japan corporation ("SBC
Medical Sub"), L'Ange Cosmetique Co., Ltd., a Japan corporation ("Lange Sub"), Shobikai Co., Ltd., a Japan corporation
("Shobikai Sub"), Liesta Co., Ltd., a Japan corporation ("Liesta"), SBC Sealane Co., Ltd., a Japan corporation
("SBC Sealane"), SBC Marketing Co., Ltd., Japan corporation ("SBC Marketing"), SBC Medical Consulting Co., Ltd.,
a Japan corporation ("SBC Medical Consulting"), Shoubikai Medical Vietnam Co. Ltd., a Vietnam corporation ("SBC Vietnam"),
SBC Healthcare, Inc., a Delaware corporation ("SBC Healthcare"), SBC Irvine, LLC, a Delaware limited liability company ("SBC
Irvine"), Aesthetic Healthcare Holdings Pte., Ltd., a Singapore corporation ("AHH"), Wen & Wang Family Clinic Pte.,
Ltd., a Singapore corporation ("WWFC"), Wen & Wang Medical Group Pte., Ltd., a Singapore corporation ("WWMG"),
Rochor Clinic Pte., Ltd., a Singapore corporation ("RCC"), Dermasolutions Pte., Ltd., a Singapore corporation ("DS"),
and Dermasolutions Services Pte., Ltd., a Singapore corporation ("DSS"). The majority owned subsidiary is Medical Payment
Co., Ltd., a Japan corporation ("Med Payment"). The variable interest entity is Aikawa Medical Management, Inc.

 Disposal
of Kijimadairakanko Inc. ("Kijima") and Skynet Academy Co., Ltd. ("Skynet")

 On
December 17, 2024, the Company entered into definitive agreements to sell and transfer all of the shares in its subsidiaries, Kijima
and Skynet, to entities owned by Yoshiyuki Aikawa, CEO of the Company, for cash. The Company pursued the transactions to concentrate
business and management resources on its main medical business. The disposal of Kijima and Skynet did not constitute a strategic
shift that would have a major effect on the Company's operations and financial results. The transactions closed on December
23, 2024, subject to customary closing conditions. The Company received total cash consideration of one Japanese Yen ($0) for Kijima and $446,460
 for Skynet. In accounting for the disposals, operating results of Kijima and Skynet are included in the Company's
consolidated financial statements up to the disposal date. The difference between (i) the fair value of the net assets disposed and
(ii) the consideration received was recognized as an adjustment to Additional Paid-in Capital ("APIC"). No retrospective
adjustments have been made to prior-period consolidated financial statements. Following the completion of these transactions, Kijima
and Skynet ceased to be subsidiaries of the Company after December 23, 2024. Their financial results are therefore excluded from
the Company's consolidated financial statements for periods subsequent to the disposal date.

 Acquisition
of AHH

 On
November 20, 2024, the Company completed the payment of SGD 7.8 million in cash for the acquisition of 100% of the voting equity interest
AHH and its subsidiaries, following the execution of a Share Purchase Agreement with Dr. Ewen Chee Yew Wen, Dr. Lee Tee Kit, Dr. Phua
Vanessa Mae, Dr. Charlotte Kim Thomas, and Dr. Gary Si Khin Yuen. AHH is based in Singapore and operates aesthetic medical clinics, family
clinics, and quick facial aesthetics outlets. The founder, Dr. Ewen Chee, is known as one of the pioneers in the field of aesthetic medicine
in Singapore and is a co-chair of the first Asia Pacific Thread Lift Conference (APEM) and a board-certified physician by the American
Academy of Aesthetic Medicine. He is a frequent speaker at international conferences and workshops, and his expertise and knowledge have
been featured in numerous scientific publications. AHH's major brands and number of clinics are The Chelsea Clinics, Gangnam Laser
Clinic, SkinGo! and Family clinics. Due to AHH's fiscal year ending on September 30, the financial results of AHH and its subsidiaries have been
included in the Company's consolidated financial statements with a three-month lag. For the current period, only the balance
sheet information as of the acquisition date has been included in the consolidated financial statements.

 For
the fiscal years ended December 31, 2024 and 202 3,
the Company generated revenues of
$205,415,542 and $193,542,423, respectively, reported net income of $46,689,892 and $38,560,606, respectively, and cash flow
provided by operating activities of $20,582,933 and $50,670,322, respectively. As of December 31, 2024, the Company had
retained earnings of $189,463,007.

 SBC
Medical Group Co., Ltd., a Japan corporation ("SBC Medical Sub"), L'Ange Cosmetique Co., Ltd., a Japan corporation
("Lange Sub"), Shobikai Co., Ltd., a Japan corporation ("Shobikai Sub") are each designated as a "medical
service corporation" in Japan. In Japan, a medical service corporation is a legal entity that provides management service to "MCs".
The management services are conducted through FC contracts and service contracts between certain subsidiaries of the Company (SBC Medical
Sub, Lange Sub, and Shobikai Sub) and the MCs that own all 241 of the treatment centers in Japan.

 There are currently six MCs that the Company's subsidiaries have entered into franchisor-franchisee contracts
and service contracts with, consisting of Medical Corporation Shobikai, Medical Corporation Kowakai, Medical Corporation Nasukai, Medical
Corporation Aikeikai, Medical Corporation Jukeikai, and Medical Corporation Ritz Cosmetic Surgery (collectively, the "MCs").

 In
addition to the six MCs, we have entered into service contracts with Medical Corporation Association Furinkai (the service contract regarding
operation on November 22, 2023 and the service contract regarding management consulting on November 25, 2023 respectively) and Medical
Corporation Association Junikai (the service contract regarding operation and the service contract regarding management consulting both
on November 16, 2023). The scope of work ("SOW") of the service contracts with these two MCs is limited to marketing, introduction
of new treatment technologies and future business development while the SOW of the FC contracts with the six MCs are broad and define
general rules in order to allow MCs to use the SBC brand name. Accordingly, the service contracts with these two MCs are different from
the FC contracts with the six MCs and the clinics of these two MCs do not use the "Shonan Beauty Clinic" brand. Please see
"— Material Contracts between the Company and MCs — Service Contracts" for more information regarding the service
contracts with Medical Corporation Association Furinkai and Medical Corporation Association Junikai.

 All
of the MCs are deemed to be related parties of the Company since relatives of the CEO of the Company are the members (or shain)
of general meetings of members of the MCs. The CEO of the Company was previously a member of the six franchisee MCs until he ceased being
a member in July 2023. The Company, through SBC Medical, owns equity "deposit" interests (or mochibun) of the six
franchisee MCs. Although the Company, through SBC Medical, has an equity "deposit" interest to the rights to receive a distribution
of residual assets in proportion to the amount of contribution in certain circumstances as provided in the articles of incorporation
of each of the six MCs, the Company or SBC Medical does not have voting control over the corporate actions at general meetings of members
(or shain) of the MCs per the requirements of the Japanese Medical Care Act and the MCs' articles of incorporation.

 Mission

 Our
primary mission is to provide quality comprehensive management services to the MCs and expand our "Shonan Beauty Clinic"
brand. We plan to achieve the mission by maintaining and strengthening our market position and brand in the cosmetic medical treatment
management market in Japan, Vietnam, Singapore and the United States, and by continuing to grow our presence globally. Accordingly, we
have entered into franchise agreements and partner doctor independence support program agreements (the "Support Agreements")
with the MCs to define the scope of the management services that we provide to the MCs as well as the franchise operational provisions
that the MCs must comply with. The term of the Support Agreements is until August 31, 2026, provided that such Support Agreements will
continue to automatically renew for one (1) year successive periods unless either the Company or the respective MC provides notice of
termination at least six (6) months prior to the expiration date of the Support Agreement. We receive a portion of our overall compensation
for providing management services under the Support Agreements with the following MCs:

 Corporation Shobikai: from September 29, 2017

 Corporation Kowakai: from September 29, 2017

 Corporation Nasukai: from September 29, 2017

 Corporation Aikeikai: from September 29, 2017

 Corporation Jukeikai: from February 21, 2020

 Corporation Ritz Cosmetic Surgery: from May 31, 2021

 Material
Contracts between the Company and MCs

 The
Company has entered into a Partner Doctor Independence Support Program Agreement and an SBC Operating Agreement with each of the MCs.

 Partner
Doctor Independence Support Program Agreement

 The
Company has entered into a Partner Doctor Independence Support Program Agreement (the "PDISPA") with each of the MCs. The
term of the PDISPA is for a period of 5 years from September 1, 2021, to August 31, 2026. The PDISPA will be renewed under the same terms
for successive one-year periods upon conclusion of the initial term unless either party requests in writing to terminate the PDISPA 6
months prior to the expiration date of the PDISPA. Pursuant to the PDISPA, the Company agreed to provide the use of the name of the "Shonan
Beauty Clinic" and the "SBC Medical Group" (Medical Corporation Shobikai, Medical Corporation Kowakai, Medical Corporation
Nasukai, Medical Corporation Aikeikai, L'Ange Cosmetique Co., Ltd. and Shobikai Co., Ltd., which together are referred to as the
"SBC Medical") to the MCs for the purpose of operating clinics. The Company also granted to the MCs the right to use the
name "SBC Medical Group," the know-how of clinic operation, trademark, trade name, and the right to provide the treatment
designated by the Company, and the right to conduct business activities as a partner of the SBC Medical Group under a unified image.

 PDISPA
does not charge franchise fee or deposit fee, instead the MCs are to pay fees to the Company, which are to be calculated as follows:
total amount of sales at the clinic multiplied by 12% excluding consumption tax. If the total sales amount exceeds 100,000,000 yen per
MCs, the maximum amount fee will be 10,000,000 yen. For the purposes of the PDISPA the total amount of sales means the amount of sales
after discounting preferential tickets, and other campaigns and discounts.

 SBC's
Operating Agreement

 The
Company previously entered into an SBC Operating Agreement (the "SBCOA") with each of the MCs. The term of the SBCOA is from
April 1, 2023, to March 31, 2025. Either party may terminate the SBCOA by giving notice to the other party of the intended termination
at least 6 months prior to the scheduled termination date. Pursuant to the SBCOA the Company agreed to provide the MCs with the following
consulting services related to: (i) marketing related services for developing new clients (ii) aiming to ensure stable performance and
increase customer satisfaction through the creation of repeat customers (iii) the establishment and operation of a system seeking to
ensure medical safety (iv) securing attorneys and medical institutions to transport in the event of claims or medical accidents, (v)
measures to improve employee satisfaction, and design of organizational chart and personnel evaluation system (vi) the selection of medical
equipment and materials, (vii) the acquisition of properties for new medical facilities (trade area survey, area selection, lease agreement
signing, etc.) (viii) various types of general skills training for healthcare facility employees (ix) specialized and advanced skills
training in leadership, motivation, communication, etc., for chiefs, leaders, and other employees with subordinates (x) development of
new type of medical facilities (xi) development of new treatment methods (xii) hiring employees with national certifications, professional
skills, and interpersonal skills, such as doctors, nurses, and reception counselors (xiii) performance management, business analysis,
and management decision making utilizing financial statements such as income statements, cash flow statements, and balance sheets (xiv)
use of the likeness of the Company's officers or employees on websites, commercials, and other advertising media and (xv) efficient
operation methods that allow for more customer service during the same clinic hours.

 Under
the existing SBCOA, in exchange for the foregoing services, each MCs are to pay the Company 3,000,000 yen per month (excluding consumption
tax) for each medical facility where a MC provides medical services to its clients.

 In
light of the current challenging competitive environment, we are pursuing a long-term growth strategy aimed at expanding and stabilizing
our business foundation by creating an environment that can better facilitate the establishment of new clinics by MCs. In line with this
objective, we have decided to amend and renew the SBCOA with each MC, effective from April 1, 2025. Under the revised SBCOA, similar
with prior terms, either party may terminate the agreement by providing written notice to the other party no later than six months before
the scheduled expiration date.

 The
main revisions include:

 1.
 Revised
 Fee Structure

 First-Year
 Fee Reduction for Newly Opened Clinics: Fees will be reduced during the first year of operation
 for newly established clinics, significantly reducing initial cost burdens at a stage when
 clinics have yet to fully establish their customer base.

 Fees
 Based on Service Utilization from the Second Year Onward: Starting from the second year of
 operation, fees will be calculated based on the scale of services utilized and the operational
 size of each clinic.

 2.
 Changes
 to Provided Consulting Services Following the revision, consulting services provided by the
 Company to MCs will include:

 consulting for medical corporations and facilities

 Human
 resources and labor management services

 Recruitment-related
 services

 administrative services

 system management services

 Customer
 relations services

 Accounting,
 finance, and taxation services

 Legal
 services

 establishment and facilities management services

 Infrastructure
 introduction, improvement, and operational support services related to insurance-covered
 medical treatments

 For
the financial impact of these revisions, please refer to the "Item 7. Management's Discussion and Analysis of Financial Condition
and Results of Operations—Recent Developments—Upcoming Changes to Service Fee Structure."

 Service
Contracts

 We
entered into service contracts with Medical Corporation Association Furinkai (the service contract regarding operation on November 22,
2023 and the service contract regarding management consulting on November 25, 2023 respectively) and Medical Corporation Association
Junikai (the service contract regarding operation and the service contract regarding management consulting both on November 16, 2023).
The scope of work ("SOW") of the service contracts with these two MCs is limited to marketing, introduction of new treatment
technologies and future business development while the SOW of the FC contracts with the six MCs are broad and define general rules in
order to allow MCs to use the SBC brand name. Accordingly, the service contracts with these two MCs are different from the FC contracts
with the six MCs and the clinics of these two MCs do not use the "Shonan Beauty Clinic" brand.

Consignment Agreement for Management Consulting Services to Medical Corporation Association Furinkai

 The
material terms of our business consignment agreement for management consulting services to Medical Corporation Association Furinkai are
as follows:

 Signing
 Date:

 22, 2023

 Services by the Company to Medical Corporation Association Furinkai

 on the use of business systems used in medical facilities

 on the development of new treatments and manuals

 for repeat customer acquisition measures related to cosmetic dermatology

 on the efficient operation with more customer service during the same clinic hours related
 to cosmetic dermatology consulting

 for building management strategies related to cosmetic dermatology treatment

 Period

 1, 2024 until August 31, 2027

 if
 neither party expresses an intention not to renew the agreement before the expiration of
 the effective period, the agreement shall be renewed for another two (2) years under the
 same terms and conditions

 Termination
 Provisions & Penalties

 Either
 party may terminate this agreement by notifying the other party at least six months prior
 to the scheduled termination date.

 Fees
 Payable Under the Agreement

 JPY60,000,000
 per month (excluding consumption tax).

Consignment Agreement for Operational Support to Medical Corporation Association Furinkai

 The
material terms of our business consignment agreement for operational support services to Medical Corporation Association Furinkai are
as follows:

 Signing
 Date

 22, 2023

 Services by the Company to Medical Corporation Association Furinkai

 secure
 stable business performance and increase customer satisfaction through creation of repeat
 customers related to cosmetic dermatology

 selection
 of medical devices and medical materials for cosmetic dermatology

 establishment
 and operation of a system to ensure the safety of cosmetic dermatology treatment

 general
 skills training associated with cosmetic dermatology treatment for medical facility employees

 efficient
 operation methods that enable more customers to be served during the same clinic hours related
 to cosmetic dermatology

 planning
 management strategies related to cosmetic dermatology treatment

 development
 of new treatment methods, formulation of manuals, and support for implementation

 support
 and management of business system implementation

 design
 and implementation support, operation and maintenance of servers, networks and IT infrastructure

 Period

 1, 2023 until August 31, 2027

 if
 neither party expresses an intention not to renew the agreement before the expiration of
 the effective period, the agreement shall be renewed for another two (2) years under the
 same terms and conditions

 Termination
 Provisions & Penalties

 Either
 party may terminate this agreement by notifying the other party at least six months prior
 to the scheduled termination date.

 Fees
 Payable Under the Agreement

 JPY1,700,000
 per month for each medical facility (excluding consumption tax).

Consignment Agreement for Management Consulting Services to Medical Corporation Association Junikai

 The
material terms of our business consignment agreement for management consulting services to Medical Corporation Association Junikai are
as follows:

 Signing
 Date

 16, 2023

 Services by the Company to Medical Corporation Association Junikai

 on the use of business systems used in medical facilities

 on the development of new treatments and manuals

 for repeat customer acquisition measures related to cosmetic dermatology

 on the efficient operation with more customer service during the same clinic hours related
 to cosmetic dermatology consulting

 for building management strategies related to cosmetic dermatology treatment

 Period

 1, 2024 until August 31, 2026

 if
 neither party expresses an intention not to renew the agreement before the expiration of
 the effective period, the agreement shall be renewed for another two (2) years under the
 same terms and conditions

 Termination
 Provisions & Penalties

 Either
 party may terminate this agreement by notifying the other party at least six months prior
 to the scheduled termination date.

 Fees
 Payable Under the Agreement

 JPY10,000,000
 per month (excluding consumption tax).

Consignment Agreement for Operational Support to Medical Corporation Association Junikai

 The
material terms of our business consignment agreement for operational support services to Medical Corporation Association Junikai are
as follows:

 Signing
 Date

 16, 2023

 Services by the Company to Medical Corporation Association Junikai

 secure
 stable business performance and increase customer satisfaction through creation of repeat
 customers related to cosmetic dermatology

 selection
 of medical devices and medical materials for cosmetic dermatology

 establishment
 and operation of a system to ensure the safety of cosmetic dermatology treatment

 general
 skills training associated with cosmetic dermatology treatment for medical facility employees

 efficient
 operation methods that enable more customers to be served during the same clinic hours related
 to cosmetic dermatology

 planning
 management strategies related to cosmetic dermatology treatment

 development
 of new treatment methods, formulation of manuals, and support for implementation

 support
 and management of business system implementation

 design
 and implementation support, operation and maintenance of servers, networks and IT infrastructure

 support
 and advisory services for the use of marketing analysis tools, etc.

 Period

 1, 2023 until August 31, 2027

 if
 neither party expresses an intention not to renew the agreement before the expiration of
 the effective period, the agreement shall be renewed for another two (2) years under the
 same terms and conditions

 Termination
 Provisions & Penalties

 Either
 party may terminate this agreement by notifying the other party at least six months prior
 to the scheduled termination date.

 Fees
 Payable Under the Agreement

 JPY800,000
 per month for each medical facility (excluding consumption tax).

 The
use and regulatory status of certain products

 The
Company acts in the capacity of a purchasing agent by reselling medical supplies, cosmetic products, and medical equipment to the MCs
for use in their clinics.

 The
Company acts as a purchasing agent, for the following cosmetic products: MT Stem Eye Cream, MT Cleansing Gel, MT Contour Lotion, MT Essential
Serum, MT Contour B Cream, MT Premium Coffret 2024, MT Facial Foaming Wash, MT Protect UV Gel, MT Condense C Serum, MT Crystal Shot.
These products are used to enhance the attractiveness, change the appearance, or maintain the health of the skin or hair of a person
and more specifically are used as eye cream, cleanser, toner, serum, moisturizing cream, skincare set face wash, and sunscreen gel.

 The
following table describes the primary use and regulatory status of each of the products that we resell:

 Available
 for Sale In

 Category

 Line

 Primary
 Use

 Vietnam

 Japan

 MT
 Stem Eye Cream

 Eye
 cream

 P

 P

 P

 MT
 Cleansing Gel

 Cleanser

 P

 P

 P

 MT
 Contour Lotion

 Toner

 P

 P

 P

 MT
 Essential Serum

 Serum

 P

 P

 P

 MT
 Contour B Cream

 moisturizing
 cream

 P

 P

 P

 MT
 Premium Coffret 2024

 Skincare
 Set

 P

 P

 P

 MT
 Facial Foaming Wash

 face
 wash

 P

 P

 P

 MT
 Protect UV Gel

 sunscreen
 gel

 P

 P

 P

 MT
 Condense C Serum

 Serum

 P

 P

 P

 MT
 Crystal Shot

 Serum

 P

 P

 P

 The
Company acts as a purchasing agent, for the following medical equipment: Embryo Scope, PQX Pico Laser, Nordlys, Coolsculpting ELITE,
Stellar M22 IPL, General-purpose video scope for upper gastrointestinal tract GIF-1200N, Sperm motility analyzer with SMAS Biological
Microscope, Surgitron DualEMC, Gas Sterilizer CT-540C, Centrifugal Separator H-36. This equipment is used for the diagnosis, treatment,
or prevention of human or animal diseases, or to affect the structure or function of the human or animal body, and more specifically
is used for observation of fertilized eggs, skincare treatment, fat removal, observation, imaging, diagnosis, and treatment of the upper
gastrointestinal tract, analysis of sperm motility, skin incision and coagulation for surgical use, sterilization of medical supplies
vulnerable to high pressure, and separation of aspirated fat.

 The
following table describes the primary use and regulatory status of each of the products that we resell:

 Available
 for Sale In

 Category

 Line

 Primary
 Use

 States*

 Vietnam**

 Japan

 Incubator

 EmbryoScope

 Observation
 of fertilized eggs An incubator for growing fertilized eggs of patients. A camera takes pictures at regular intervals, and the division
 can be observed like a movie on the monitor.

 Time-lapse
 incubator

 No

 No

 P

 Laser
 Therapy Machine

 PQX
 Pico Laser

 Skin
 Care Treatment

 Picotoning,
 Picolaser Fractional

 No

 No

 P

 Laser
 Therapy Machine

 Nordlys

 Skin
 Care Treatment

 IPL
 Light Therapy (Photo Double/Photo Triple)

 No

 No

 P

 Slimming
 equipment

 coolsculpting
 ELITE

 fat
 reduction

 Fat
 cooling (slimming)

 No

 No

 P

 Laser
 Therapy Machine

 Stellar
 M22 IPL

 Skin
 Care Treatment

 IPL
 Light Therapy (Photo Double Photo Triple)

 No

 No

 P

 Endoscope

 General-purpose
 video scope for upper gastrointestinal tract GIF-1200N

 Observation,
 imaging, diagnosis, and treatment of the upper gastrointestinal tract

 No

 No

 P

 Analyzer

 Sperm
 motility analyzer with SMAS Biological Microscope

 Analysis
 of sperm motility The system automatically tracks moving sperm and displays and outputs a number of measurement results accurately
 and quickly, including the number of moving sperm, their movement trajectories, discrimination from immobile sperm, and various types
 of motility.

 No

 No

 P

 Electrosurgical
 instrument

 Surgitron
 DualEMC

 Skin
 incision and coagulation for surgical use

 MD-style
 minimal downtime

 No

 No

 P

 Sterilizer

 Gas
 sterilizer CT-540C

 Sterilization
 of medical supplies vulnerable to high pressure Sterilizer, low temperature up to 40 C

 No

 No

 P

 Centrifugal
 separator

 Centrifugal
 separator H-36

 Separation
 of aspirated fat

 condense
 rich face

 No

 No

 P

 The
Company does not distribute the products above in the US or in Vietnam for the following reasons.

 *

 A foreign entity must apply
 to Food and Drug Administration, "FDA," with regard to medical equipment in advance in order to import and distribute it
 in the U.S., and needs to pass examination by the FDA. In addition, the entity must register the equipment after passing examination.
 However, the Company has not applied yet and has no current intention to apply and accordingly does not distribute any of the above
 products in the U.S.

 **

 A foreign entity should apply
 to Ministry of Health, "MOH", with regard to medical equipment in advance in order to import and distribute it in Vietnam.
 In particular, the entity should obtain circulation number and declaration of eligibility to trade medical equipment. However, the
 Company has not applied yet and has no current intention to apply and accordingly does not distribute any of the above products in
 Vietnam.

 The
Company acts as a purchasing agent, for the following medical supplies: Coolsculpting Elite Reorder Pack, Allergan VISTA, Juv Voluma,
Condense Rich Syringe, Juv Volift, MiraDry BioChips, Juv Volbella, VISTA Ultra Plus XC, Juv Volux, Cellution Disposable Kit. The supplies
are used for the diagnosis, treatment or prevention of human or animal diseases and are not quasi-drugs, regenerative medicine products
or machinery and equipment such as dental materials and hygiene products and more specifically is used for treatment to reduce fat cells
and improve body contours, wrinkle-improving injection, medical consumables, hyperhidrosis treatment.

 The
following table describes the primary use and regulatory status of each of the products that we resell:

 Available
 for Sale In

 Category

 Line

 Primary
 Use

 States*

 Vietnam*

 Japan

 coolsculpting

 coolsculpting
 Elite reorder pack

 Body
 Contouring Equipment Consumables; Reduces fat cells and improves body contours;

 No

 No

 P

 Botox
 injection

 Allergan
 VISTA

 No

 No

 P

 Juv
 Voluma

 No

 No

 P

 fat

 condense
 rich syringe

 medical
 consumables

 No

 No

 P

 Juv
 Volift

 No

 No

 P

 MiraDry

 MiraDry
 BioChips

 hyperhidrosis
 treatment

 No

 No

 P

 Juv
 Volbella

 No

 No

 P

 VISTA
 Ultra Plus XC

 No

 No

 P

 Juv
 Volux

 No

 No

 P

 fat

 Cellution
 Disposable Kit

 medical
 consumables

 No

 No

 P

 The
Company does not distribute the products above in the US or in Vietnam for the following reasons.

 *

 A foreign entity must register
 its facility, such as a clinic, drug store, etc., with the Food and Drug Administration, "FDA," in order to distribute
 medical supplies in advance in the US. However, the Company has not registered yet and has no current intention to register and accordingly
 does not distribute any of the above products in the U.S.

 **

 A foreign entity should obtain
 the pharmaceutical approval in order to distribute medical supply in advance in Vietnam. However, the Company has not obtained approval
 yet and has no current intention to seek approval and accordingly does not distribute any of the above products in Vietnam.

 Types
of Services Provided

 Advertising
and Marketing Services.

 The
Company, through its subsidiary SBC Marketing, provides advertising and marketing services primarily to the MCs, including but not limited
to the promotion of the MCs' clinics' services and brand on social media networks. We use various marketing and advertising
methods to increase awareness of the "Shonan Beauty Clinic" brand.

 The
marketing services that we provide to the MCs include raising the profile of products and services, creating demand, promoting sales,
and building brand image. Our public relations staff has set up target audiences, created promotional materials, and understand patient
characteristics and needs, and continue to deliver effective messages to target audiences. Additionally, we utilize social media platforms
such as Instagram and YouTube to establish a direct connection with end-users and foster a community. We also believe it is important
to measure the effectiveness of marketing advertising and analyze the results. Our public relations staff evaluates the effectiveness
of our advertising and makes the necessary adjustments to maximize the MC's return on investment (ROI) and optimize it on a frequent
basis, including but not limited to focusing on the types of services that are popular in each specific geographical location of our
franchisee clinics.

 Staff
Recruitment, Training, and Management.

 The
Company, through its subsidiary SBC Medical Consulting and Shobikai Sub, provides staff recruitment and management services to the MCs.
The Company maintains a working relationship with SBC Tokyo Medical University, previously known as Ryotokuji University, a medical professional education institution located in Urayasu
City of Chiba Prefecture in Japan, which acts as a platform for our recruitment management services. The university provides instruction
and professional education to the students of the educational institution, including but not limited to physicians and nurses. We work
directly with the university in an effort to recruit students that have completed the applicable education course, to work at one of
our franchisee treatment centers. This allows our franchisee treatment centers to reduce recruitment costs by having access to a continuous
flow of employee candidates that are newly trained for positions that the franchisee treatment centers need to fill. It also increases
employee retention rates at our franchisee treatments centers since we have assisted in the recruitment of an employee that is trained
for a specific position at the franchisee treatment center. Our staff recruitment service provides our franchisee clinics with access
to a pool of skilled professionals who are well-prepared to make meaningful contributions to their respective healthcare environments.
This allows for cost-effective talent acquisition, talent mobility, and enhanced retention rates.

 We
also provide training program services for all of the employees of our franchisee clinics. This training program is designed to provide
employees with the knowledge and skills needed in our franchisee clinic operations, and is intended to improve employee competence and
overall company productivity. The content of the training program is wide-ranging. First, we provide team-building training to strengthen
cooperation and communication skills among employees. By fostering teamwork, we ensure that cooperation among staff members is smooth
and efficient store operations are achieved.

 We
also provide training on clinic hygiene standards to help the MCs' employees understand the importance of clinic hygiene. Adherence
to strict standards in clinic hygiene is essential, and we ensure that the MCs' employees are well-informed to protect the health
and safety of the franchisee clinics' patients.

 The
program also provides training on the basic operating rules and protocols. We train the MCs' employees to make appropriate decisions
in order to provide appropriate services to the patients of the franchisee clinics.

 In
a further effort to improve the work environment and promote respect for employees, we also provide sexual harassment training services.
We emphasize the importance of creating a safe working environment for all staff.

 Customer
Management.

 The
Company, through its subsidiary Medical Payment, provides payment management services to the MCs. These services include but are not
limited to the use of payment tools at the point of sale for the MC's collection of payment from customers of the franchisee clinics.

 Additionally,
we earn revenue through our points services, which involves managing the customer rewards program offered to customers of
the franchisee clinics. The customer rewards program gives customers points for their birthday, certain referrals, and purchasing products
or services at the franchisee clinic locations. The customers also receive additional loyalty benefits in connection with their accumulated
points once they reach a certain number of visits to our franchisee clinics or reach certain spending thresholds, as further described
below. The three tiers of the customer points ranking system are silver, gold, and diamond. The silver tier rank is the lowest tier rank
and does not require a specific number of visits or spending amount to obtain. Silver tier rank customers receive 5,000 points on their
birthday, 1% of the total spending amount back in points if the payment method for clinic services is cashless, 3% of the total spending
amount back in points if the payment method for clinic services is in cash or through a medical loan, and 0% of the total spending amount
back in points if the payment method for clinic services is entirely through medical insurance. The gold tier rank is achieved when the
customer visits the franchisee clinics more than 6 times or spends more than 500,000 yen in a two-year period. Gold tier rank customers
receive 10,000 points on their birthday, 2% of the total spending amount back in points if the payment method for clinic services is
cashless, 4% of the total spending amount back in points if the payment method for clinic services is in cash or through a medical loan,
and 0% of the total spending amount back in points if the payment method for clinic services is entirely through medical insurance. The
diamond tier rank is achieved when the customer visits the franchisee clinics more than 8 times or spends more than 1,000,000 yen in
a two-year period. Diamond tier rank customers receive 15,000 points on their birthday, 3% of the total spending amount back in points
if the payment method for clinic services is cashless, 6% of the total spending amount back in points if the payment method for clinic
services is in cash or through a medical loan, and 0% of the total spending amount back in points if the payment method for clinic services
is entirely through medical insurance. The customers may use the earned points for discounts on select services offered by our franchisee
clinics, and each point may be used for a discount amount equal to 1 yen. The customer's points expire if the customer does not make any additional qualified purchase at a participating clinic within a year. Accordingly, at the time that a customer's points expire, the Company earns 1 yen for each customer
point that expires.

 Employee
Services.

 The
Company, through its subsidiary Liesta, provides employee management services to the MCs, including assistance with the location and
securement of rental housing in Japan for employees of the MCs as well as facility rentals in Japan for the MCs.

 Construction
and Design.

 The
Company, through its subsidiary SBC Sealane, provides construction and design management services to the MCs, by coordinating engagement
with our preferred general contractors for the clinic construction and design, as well as overseeing the process.

Equipment and Supplies.

 The
Company acts in the capacity of a purchasing agent by supplying medical devices, medical equipment (including through leases of such
equipment), implants, injection materials, other medical consumables, as well as skin care and beauty products that we resell to the
MCs for use in their clinics.

 Licensure
of Intellectual Property and Technologies.

 The
Company licenses the use of patent-pending and non-patented intellectual property, including but not limited to medical technologies,
trademark, trade names, and brand use, to the MCs. Each of the clinics owned by the MCs licenses the use of our brand name, "Shonan
Beauty Clinic", as well as the right to use the name "SBC Medical Group".

 We
have also granted the MCs the right to use the know-how of the clinic operations, offer the procedures designated by us, conduct business
activities under our brand name, and utilize our specialized technologies for procedures. We license the use of our highly standardized
operational procedures, developed through years of industry experience and accumulated know-how, to the MCs. Our specialized technologies
for procedures enhance the safety and efficiency of these cosmetic surgery procedures and include, but are not limited to, puncture devices
for buried double eyelid procedures, simplified buried method surgical equipment, proprietary surgical sutures, silicone bags for breast
augmentation simulations, and microscopic hair volume evaluation method for the treatment of androgenetic alopecia. Additionally, we
license the use of patent-pending and non-patented safety management methods to the MCs for procedures such as full-incision double eyelid
surgery, lateral canthoplasty, brow lift procedures, cheek sagging prevention methods, hair removal safety management methods, tattoo
removal treatments, and hyperhidrosis procedures.

 The
Company licenses the use of simulation technology to the MCs aimed at enhancing the skills, standardization, and education of professional
staff that are providing medical services at the MCs' clinics, and licenses the use of such technologies to the MCs. By utilizing
our collection of medical cases and artificial intelligence, we employ technologies such as virtual reality, rendering, computing, 5G/6G,
and Web3.0 to create simulators for the services that the MCs' treatment centers provide. For example, SBC AI Eye is the industry's
first double AI simulation service. The highly accurate double AI simulation service has been achieved by learning from actual case data
of franchisee's clinic, which totals 600,000 double layer cases, using an AI model based on the most advanced AI technology, GAN
(adversarial generative network). This service enables a 10-step simulation of double layer width on "your own face", whereas
double layer surgery has generally been studied using photographs of other people's cases. These new technologies offer benefits
to our franchisee treatment centers, such as efficient education, knowledge sharing, improved procedural accuracy, proactive support,
and remote operations. Through simulation technology, medical professionals can simulate various scenarios and anticipate potential complications,
enabling them to develop proactive strategies and responses. We believe this improves the level of patient safety and care at our franchisee
clinics. The integration of advanced technologies, such as 5G/6G, allows for remote operations and consultations, enabling medical experts
at our franchisee clinics to provide guidance and perform procedures from a distance, expanding access to specialized care and expertise.

 Supplementary
information regarding other business activities and service overview diagram

 Subsidiaries
under our group operate businesses not only our core medical business services. Corporations whose sales account for less than 1% of
the group are omitted.

 Our revenues

 The
Company generates franchising revenue (royalty income) by licensing its intellectual properties, including but not limited to the Company's
brand name ("Shonan Beauty Clinic"), trade name, and trademarks, as a franchisor pursuant to franchise agreements with certain
MCs (the "MC") in Japan. Prior to April 2023, royalty income was based on a percentage of sales and recognized at the time
when the related sales occur; since April 2023, it is based on a fixed amount to each clinic of the MCs; since September 2023, it is
based on a fixed amount to each MC and a fixed amount to each clinic of the MCs and recognized over time as services are rendered.

 Starting
in April 2025, the Company plans to revise its fee model for newly opened clinics by reducing fees in the first year to better reflect
the lower service utilization during the initial period, before transitioning to a performance-based structure thereafter. This change
aims to create a more sustainable long-term revenue model while aligning fees with the actual operations of newly opened clinics.

 The
Company generates procurement services revenue by purchasing primarily advertising services and medical materials from qualified vendors
on behalf of MCs to maintain brand quality consistency. Procurement services revenue is recognized at the point in time upon the delivery
of products or over time as services are performed. Occasionally, the Company receives vendor discounts on certain large purchases. It
recognizes revenue based on actual payments and will return the over-collection resulting from such discounts to MCs.

 The
Company provides loyalty program management services, labor supporting services, function supporting services, and management consulting services to MC.

 Loyalty
program management services

 The
Company awards loyalty points on behalf of MCs to MCs' customers, who earn loyalty points from each qualified purchase made at
the loyalty program participating clinics of MCs, in exchange for a handling fee. The revenue is based on a percentage of the related
payment amount made by MCs' customers and is recognized when the loyalty points are awarded.

 At
the time loyalty points are awarded, a MC pays the Company cash in an amount equivalent to the awarded loyalty points, which is recorded
as advances from customers. When a MC's customers redeem the loyalty points, the Company returns the cash back to the MC in an
amount equivalent to the redeemed loyalty points. The awarded loyalty points expire if a MC's customer does not make any additional
qualified purchase at a participating clinic within a year. The Company accumulates and tracks the points on behalf of MCs until the
loyalty points expire, at which time the Company recognizes an amount equivalent to the expired loyalty points as revenue, which is normally
not significant.

 The
Company also awards certain points to MCs' customers on behalf of MC for free in order to increase the volume of MCs' sales,
from which the Company earns other types of revenues, such as royalty income. When a MC's customers redeem such points, the Company
reimburses MC in an amount equivalent to the used free points and records it as a reduction of the revenue recognized.

 The
Company is an agent in the management of loyalty programs, and as a result, revenues are recognized net of the cost of redemptions.

 Labor

 The
Company generates revenue by dispatching staff to MCs to provide a range of services, primarily including clinic operation, IT, and administrative
services, among which, clinic operation service has been fully terminated since October 2024. The Company recognizes the revenue over the time
when services are rendered.

 Function

 The
revenue is derived from providing functional supporting services to MCs, such as accounting and human resources services. The Company

consulting services

 The
Company generates revenue by providing consulting services to MCs in relation to business operations of cosmetic dermatology. The Company

 The
Company generates rental income from operating leases and sales-type leases, which is accounted for under ASC Topic 842. Operating lease
revenue is generally recognized on straight-line basis over the terms of the lease agreements and sales-type leases revenue is generally
recognized on the lease commitment date.

 Other

 The
Company generates other miscellaneous revenues such as accommodation services income, medicine dispensed sales revenue, brokerage services
revenue, construction services revenue, pilot training services revenue, interest income, etc. These revenues are recognized when the
Company satisfies performance obligations.

generated from these different revenue streams by the Company consist of the following:

 For

 2024

 2023

 $
 61,033,032

 $
 42,103,380

 54,814,399

 53,186,662

 53,113,155

 72,282,549

 16,141,714

 7,336,768

 Other

 20,313,242

 18,633,064

 Total

 $

 $

 Our
Strengths

 Brand.
 Our group's brand name "Shonan Beauty Clinic" has been developed for over 20 years in the medical industry on the
basis of safe and reliable medical services that are primarily cosmetic in nature. We maintain high standards for quality control and
customer service in both our directly owned and operated clinic, as well as our franchisee clinics in order to continue to build upon
this foundation. In addition, some of the doctors that provide services at our franchisee clinics also publish medical related articles
and participate in conferences in Japan and overseas. We believe that this cohesive approach and consistent quality of service promotes
global recognition of our brand name.

 Comprehensive
Medical Services. The Company's directly owned and franchisee clinics provide a variety of medical treatments to meet all of
the clinics' patients' needs. Both the Company and the MC franchisees focus on building long-term relationships with patients,
and customer satisfaction rate ranks highly among Japanese beauty medical service providers. According to an internal report from our
MCs' franchisee clinics, the franchisee clinics have an average repeat customer rate of over 71%, and a total of over 6.0 million
customers globally during 2024. Accordingly, we have been able to continue to provide a high level of management services to the MCs
while benefiting from the increasing number of clinics.

 Technology.
 The Company focuses on developing and licensing simulation technology aimed at enhancing the skills, standardization, and education
of professional doctors that are providing medical services at our franchisee clinics. By utilizing our collection of medical cases and
artificial intelligence, we employ technologies such as virtual reality, rendering, computing, 5G/6G, and Web3.0 to create simulators
for the services that our treatment centers provide. These simulators offer benefits to our treatment centers, such as efficient education,
knowledge sharing, improved procedural accuracy, proactive support, and remote operations. Through simulation technology, medical professionals
can simulate various scenarios and anticipate potential complications, enabling them to develop proactive strategies and responses. We
believe this improves the level of patient safety and care at our franchisee clinics. Our goal is to achieve standardized medical techniques
through the development of these technological advancements. The integration of advanced technologies, such as 5G/6G, allows for remote
operations and consultations, enabling medical experts to provide guidance and perform procedures from a distance, expanding access to
specialized care and expertise.

Services. The management services that we provide to our franchisee clinics, through our subsidiaries, include but are not limited
to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and
training), booking reservations for customers, assistance with franchisee employee housing rental, facility rentals, construction and
design, medical equipment procurement ( resale), the provision of cosmetic products to franchisees for resale at the franchise
locations ( resale), licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT
software solutions for remote medical consultations, and payment tools for franchisee customers. We believe that our advertising and
marketing services (including but not limited to promotion on social media networks) help create effective campaigns that promote our
franchisee clinic services and attract a wider audience of customers. We also believe that our maintenance and operation of the booking
and reservation process for customers ensures a seamless user experience when booking services at our franchisee clinic locations. These
services provide valuable guidance and expertise to our franchisee clinics, helping them optimize their operations, improve patient experience,
and enhance overall performance. We believe this to be a crucial component of fostering our franchisees' growth and success.

 Internal
Processes and Protocols. To promote high standards of quality and service, we have implemented internal processes and protocols.
These measures include ongoing training and education programs for our employees and the employees of our franchisee clinics, continuous
monitoring of treatment outcomes, and adherence to industry guidelines and regulations. By upholding these standards, we aim to maintain
and enhance our franchisees' reputation as a trusted provider of cosmetic medical services.

 Our
Growth Strategies

 Pursue
New Clinic Development. We have pursued a disciplined new clinic growth strategy, having expanded our concept and franchisee model
across varying clinic sizes and geographies. We plan to leverage our expertise in opening new clinics and our success in the Japan market
to fill in existing markets and expand into new geographies with the same careful planning as we have demonstrated in the past. We will
continue to utilize our existing strategy of exploring opportunities for directly owned and operated clinics (including but not limited
to merger and acquisition transactions) as well as additional franchisee clinics. See also our real estate strategy under "Site
Development and Expansion — Site Selection Process." We believe that our revenue will increase if we are able to increase
the number of franchisee clinics that we provide management services to, since we would be providing our services to additional locations.
We believe that we have the potential to increase global recognition of our brand. However, we cannot predict the time period over which
we can achieve any level of franchisee clinic growth or whether we will achieve this level of growth at all. Our ability to achieve new
franchisee clinic growth is impacted by a number of risks and uncertainties beyond our control, including those described in "Part
I, Item 1A. Risk Factors".

 Deliver
Consistent Comparable Franchisee Clinic Sales Growth. We believe we will be able to generate comparable franchisee clinic growth
by growing our customer base through increased brand awareness, consistent delivery of quality surgical and non-surgical medical services
by our clinic and our franchisee clinics, acquiring and developing cutting edge medical services to be licensed to our franchisee clinics,
and franchisee clinic renovations. We will continue to manage our franchisee clinics and pricing as part of our overall strategy to increase
the number of customers and the average amount spent by customers. We continue to explore initiatives to increase skin care product sales,
enhance the services offered by our clinic and our franchisee clinics, and improve our appointment booking process. Our franchisee client
rewards program, which has been rolled out across the entire franchisee clinic base in Japan, tracks customers' spending and awards
customers with points based upon such spending (1 point for each 1 yen spent). The rewards program also gives customers points for their
birthday and certain referrals. The customers also receive additional loyalty benefits in connection with their accumulated points once
they reach a certain number of visits to our franchisee clinics (tiers for a total of 6 visits and 8 visits in 2 years) or reach certain
spending thresholds (tiers for a total of 500,000 yen spent and 1,000,000 yen spent in 2 years). The customers may use the earned points
for discounts on select services offered by our franchisee clinics.

 Increase
Profitability. During our expansion, we have invested in our infrastructure and personnel, which we believe positions us to continue
to scale our business operations. As we continue to grow, we expect to drive higher profitability at the corporate level by leveraging
our existing support infrastructure, as we believe that as the number of the franchisee clinics that we provide management services to
grows, our general and administrative costs over several years will increase at a slower rate than our revenues.

 Heighten
Brand Awareness. We intend to continue to pursue targeted local and global marketing efforts and plan to increase our brand awareness
(including but not limited to advertising on social media platforms). We intend to continue to promote limited time discounts on services
provided by the franchisee clinics through our advertising services to build customer loyalty and brand awareness. The number of patients
that undergo cosmetic procedures at our franchisee clinics and patient growth trajectory have been a key indicator of our success and
brand awareness. In 2021, our franchisee clinic patient base reached 3.0 million individuals. This figure increased further in 2024,
reaching approximately 3.9 million users. This growth reflects the growing demand for cosmetic surgery procedures and the confidence
that patients have in our brand and services.

 Procedure
and Product Development. We intend to continue to collect and analyze extensive medical data, develop innovative procedures and products,
and obtain intellectual property rights to new products and procedure methodologies relating to skin care and the medical services provided
by our franchisee clinics. These assets are then provided to our franchisees. We intend to continue to offer guidance and technical training
to our franchisee clinics' employees with respect to these new products and procedure methodologies in order to stay at the forefront
of medical advancements.

 Site
Development and Expansion

 Site
Selection Process

 We
consider franchisee clinic site selection to be critical to our success. As part of our strategic site selection process, our team receives
potential site locations from networks of local real estate brokers, which are then reviewed by our development and senior management
teams. This review includes site visits, key deal terms, and analyses of the estimated profitability of clinics at the proposed properties
for our franchisee clinics.

 Our
current real estate strategy focuses on high-traffic markets with a diverse population and above-average household income. In site selection,
we also consider factors such as visibility, traffic patterns, accessibility, parking, and competition when considering approval of a
location for a franchisee clinic. We also utilize site analytics tools for demographic analysis and data collection for both existing
and new market areas, which we believe allows us to further understand the market area (including but not limited to the types of services
desired by the local residents) and set clear market development strategies. Our existing framework and experienced management team allow
us to efficiently manage the opening of new franchisee clinics on behalf of the MCs in desired locations and penetrate markets in both
suburban and urban areas.

 Expansion
Strategy and Market Share

 The
strong market share presence of our franchisee clinics in the Japanese cosmetic surgery industry reflects the success of our brand and
customer satisfaction. With our cutting-edge technology, the MC's skilled medical professionals, and the comprehensive range of
services offered at our franchisee clinics, we have established our brand as a trusted and preferred choice among patients seeking cosmetic
enhancements. We plan to pursue a two-pronged expansion strategy by opening new clinics in both new and existing markets (directly and
through our franchisee partners). We believe this expansion will be crucial to executing our growth strategy, as well as building awareness
of "Shonan Beauty Clinic" as a global brand and provider of surgical and non-surgical medical services and skin care products.
Expansion into new markets occurs in parallel with ongoing growth in existing markets, with the goal of maintaining a pipeline of top-tier
development opportunities.

 Upon
selecting a new market, we typically manage the opening of one or two clinics to prove concept viability in that market. We have a remote
management system whereby our operations team can monitor clinics in real-time from our headquarters to maintain operational quality
in new markets.

 When
selecting sites, we look to replicate the site attributes, trade area quality, and co-tenant mix of our most successful clinics. We frequently
reevaluate our market area development plan (targeted areas and pacing for development) and our site selection strategy within those
targeted areas.

Design

 Franchisee
clinic design is handled by our in-house development team on behalf of the MCs in conjunction with outsourced vendor relationships. Our
franchisee clinics' sizes currently average approximately 357 square feet. Our average customer capacity per franchisee clinic
varies greatly depending upon the services being provided at the time. Our franchisee clinic layout evokes a relaxing experience characterized
by an efficient use of staff and patient space as well as modern furniture.

 Construction
of a new franchisee clinic takes approximately 6 months. We oversee and coordinate engagement with our preferred general contractors
on behalf of the MCs for the franchisee clinic construction process. On average, our franchisee clinics opened during fiscal year 2024
required a cash build-out cost of approximately $333,000 per clinic, net of landlord tenant improvement allowances; however, this amount
could be materially higher or lower depending on the utilization of union labor, market, clinic size, and condition of the premises upon
landlord delivery. The franchisee MCs are responsible for paying for the build-out cost of the respective franchisee location.

 Human
Capital Management

 As
of the date of this Annual Report, we had approximately 863 employees globally, a majority of which are located in Japan, Singapore,
Vietnam, and the United States. As of the date of this Annual Report, there were no unions represented within our employee base. We anticipate
that we will continue to expand our workforce as our company grows.

 We
believe that empowered employees make a difference in our ability to execute our strategy. As such, we strive to provide an inclusive,
rewarding and engaging environment for employees to develop professionally and contribute to our success.

 Competition

Service Competition.

 With
respect to our management services, we do not face significant competition from third parties because all of our management service revenue
is derived from our relationship with the MCs, which are related parties.

and Brand Competition

 Our
franchisee clinics face significant competition from a variety of locally owned beauty clinics and Japanese chain beauty clinics offering
both cosmetic medical services, as well as cosmetic products. Major competitors of our franchisee clinics including those in Japan but
also in the global cosmetic surgery market such as Aesthetic Medispa, Alma Lasers, B. Braun SE, Cynosure Aesthetics, Evolus, Inc., Galderma
S.A., Genesis Biosystems, Inc., Inmode Ltd., IRIDEX Corporation, Lumenis Be Ltd., Revance Therapeutics, Inc., Sientra, Inc., Sinclair
Pharma Limited, Stryker Corporation, and Surgery Partners. To further strengthen our competitive position in the international market,
we acquired a Singapore-based cosmetic surgery group in November 2024. Our clinics in Vietnam and our related party's clinic in
the US are still in the early stages of development in our efforts to penetrate global competition. However, we believe that our franchisee
clinics, clinics in Singapore, a clinic in Vietnam and a clinic in the US compete primarily based on service quality, patient experience,
ambience, location, convenience, value perception, and price. The competition continues to intensify as competitors to our clinic in
Vietnam and Singapore and our franchisee clinics increase the breadth and depth of their cosmetic medical service and cosmetic product
offerings, and open new clinics. A decrease in the revenue of the MCs' franchisee clinics as a result of such increased competition
would directly result in a reduction of the Company's revenue since we receive substantial revenue from the MCs as part of our
compensation for management services.

 We
investigate the brand image and concept of competitors to our clinic and our franchisee clinics from the viewpoint of brand and awareness.
It is important to understand the franchisee clinic's impact on its patients because each competitor offers unique characteristics
and value. Also, famous chain clinics and locally popular clinics can be a competitive factor.

 In
terms of pricing strategies, we compare pricing strategies from competitors to our clinic and our franchisee clinics, such as price ranges,
extent of services provided, and discount campaigns. Because prices have a significant impact on consumer choice, we understand price
competition with competitors and consider our own pricing strategy when we set the guidelines for the pricing of services for our franchisee
clinics and our clinics in Vietnam and Singapore. However, it is important to strike a balance, because customers value quality and service
as well as price.

 In
terms of quality and service, we evaluate the quality of service provided by and the working experience of our franchisee clinics'
competitors' employees. Because patients want high quality service and highly experienced staff members (such as doctors and nurses),
the aim is to understand the quality provided by competitors and to find the point of differentiation of the company. We use review sites
and word-of-mouth information to gather patient opinions and understand the potential for improvement of our franchised brand.

 In
terms of the number of clinics and development, we evaluate our regional competitiveness by comparing the number of clinics and the regions
in which the franchisee clinics' competitors operate. We track franchisee clinics' competitors' plans to open new clinics
and their expansion strategies to understand the status of competition in the market. This provides us with useful information to consider
when determining franchisee clinic growth opportunities.

 In
terms of customer satisfaction and feedback, we analyze patient satisfaction surveys and feedback from the patients of our clinics in
Vietnam and Singapore and the franchisee clinics as part of our management services to the MCs. The goal is to understand the patient's
assessment and find ways to improve our franchised brand. We compare the patient experience at the franchisee clinics with that of our
competitors and consider differentiation strategies and service improvement measures in order to preserve our franchised brand integrity.
Considering the above points of view, we analyze competitors to understand our strengths and competitive challenges, and conduct strategic
decision making. By comparing the competitors to our franchisee clinics and our clinics in Vietnam and Singapore, we are determining
the direction to improve the competitiveness of our franchise in the market.

Trends

 In
the cosmetic medical service and product industry, patient preferences and needs are very important. Service trends and patient interests
can change. For example, there is a growing demand for non-invasive cosmetic services. The key to success is for our clinics in Vietnam
and Singapore and the franchisee clinics to offer cosmetic services and products tailored to patient's needs and preferences. The
success of the MCs' franchisee clinics would directly impact our success since we receive substantial revenue from the MCs as part
of our compensation for management services.

 The
cosmetic medical industry is highly dependent on general economic conditions. During economic boom times, patient discretionary income
tends to increase and demand for cosmetic medical services and products tends to increase. In particular, due to inflation, costs and
wages are on an upward trend. In the event of rapid inflation, there is a risk of deterioration in business performance, such as inability
to pass on higher purchase costs and other costs to price. To date, inflationary pressures have not materially impacted our operations.
On the other hand, during economic downturns, demand may fall due to economic uncertainty and the impact of spending cuts, especially
since many of the cosmetic medical services our franchisee clinics and our clinic are elective.

 Depending
on economic conditions and individual circumstances, patient discretionary spending priorities may change, and some patients may place
a higher priority on obtaining cosmetic services and products and actively allocate their budget accordingly. Other patients may be more
likely to refrain from buying elective cosmetic services and products to save money. These trends have a significant impact on the demand
for our franchisee clinics' cosmetic services and products. A decrease in the revenue of the MCs' franchisee clinics as a
result of such increased economic conditions would directly result in a reduction of the Company's revenue since we receive substantial
revenue from the MCs as part of our compensation for management services.

 Demographic
trends, such as changes in population age structure, family structure, and lifestyle, are also important factors. For example, younger
and middle age generations may be more willing to undergo elective cosmetic procedures and purchase cosmetic products. Older generations,
on the other hand, may be more likely to be apprehensive about undergoing elective cosmetic procedures.

 Competitive
presence is an important factor in the cosmetic clinic industry. The presence of competitors in the same category or an increase in new
entrants can increase patient choices and diversify demand. Differentiation and uniqueness from competitors are required, especially
in high income geographical locations.

 These
factors also directly or indirectly affect consumer confidence. Patients choose beauty clinics they trust based on economic and competitive
conditions. Newly opened clinics, especially in new geographical locations, also tend to have an initial revenue peak, known as the honeymoon
period, followed by a decline.

 While
these factors influence the success of the beauty clinic industry, it is important to understand trends and customer needs across the
industry, and to develop flexible strategies and appropriate measures for preserving our brand integrity. Focusing on improving clinic
quality, service, and patient experience are required to maintain our franchised brand.

 Suppliers

 As
of December 31, 2024, we had a large and diverse network of suppliers, providing us with a diverse selection of medical equipment, supplies and medical
consumables. We facilitate the sale of medical equipment, supplies and medical consumables to the MCs as part of our management services.
Our suppliers fall into five key categories: medical devices, medical equipment, implants, injection materials and other medical consumables.

 We
have a system for selecting reliable and quality suppliers, with a selection and review process based on qualification of the business
and/or products, pricing, reputation, service quality, delivery schedule and product offerings. We maintain multiple suppliers for key
categories of purchases to ensure continuity and quality of supply. Payment terms with the majority of our suppliers are on open account.
Certain suppliers grant us credit periods ranging from 20 to 60 days, although we generally pay on delivery.

 We
have not previously encountered any major problems in sourcing despite not having long-term contracts with our suppliers, nor did we
encounter any business disruption due to supply shortages or delays. In any event, we believe any shortage or delay in the supply of
implants, injection materials and medical consumables will not have any material impact on us as we are able to switch to other suppliers
with comparable quality and prices. If these third parties experience shutdowns or continued business disruptions,
our ability to conduct our business and facilitate the sale of medical equipment, supplies and medical consumables to the MCs in the
manner and on the timelines presently planned could be materially and negatively impacted, including but not limited to delays in our
supply chain which could delay or otherwise impact our business. A decrease in the revenue of the MCs' franchisee clinics as a
result of supply chain delays and a decrease in the volume of purchases of medical equipment, supplies and medical consumables by the
MCs would directly result in a reduction of the Company's revenue.

 Our
customers

 The
majority of the customers of our directly owned and operated clinics, as well as our franchisee clinics, are individuals aged between
20 and 40.

 The
Company generates more than 90% of its revenue from provision of management services to the MCs pursuant to the franchisor-franchisee
agreements and/or service agreements.

 For

 Revenues from
 related parties

 2024

 2023

 $
 53,862,520

 $
 56,554,316

 46,756,189

 45,115,149

 46,355,437

 45,893,461

 17,997,072

 21,521,302

 5,666,907

 4,518,846

 7,435,446

 2,603,405

 Japan

 39,620

 488,023

 Hariver
 Inc.

 19,810

 21,740

 SBC Inc., previously known as SBC China Inc.

 2,512

 Public
 Utility Foundation SBC Foundation for Medical Promotion

 Incorporated Association SBC

 SBC Tokyo Medical University, previously known as Ryotokuji University

 45,286

 231,191

 SBC
 Shonan Osteopathic Clinic Inc.

 56,740

 69,227

 98,445

 67,516

 Mizuho
 Yamashita

 —

 19,214

 Amulet
 Inc.

 —

 3,587

 AI
 Med Inc.

 556,397

 SBC

 1,204,107

 1,298,539

 11,708,183

 2,923,608

 3,923,228

 851,105

 Incorporated Association Taiseikai

 —

 Total

 $
 195,173,889

 $
 182,738,049

 Misappropriations
of Funds

 In
January 2024, before the issuance of the Company's consolidated financial statements as of December 31, 2023 and for the year
then ended, in connection with a routine tax examination of SBC Medical Group Co., Ltd.'s income tax returns, the Japanese tax
authority discovered misappropriations of SBC Medical Group Co., Ltd. funds by a former manager of general affairs and legal
department of L'Ange Cosmetique Co., Ltd., which is a subsidiary of SBC Medical Group Co., Ltd. (the "former
manager"), who received kickbacks from multiple vendors of SBC Japan (collectively with the former manager, the
"participants") possibly beginning as early as 2012 until the misappropriations were discovered. The Japanese tax
authority, who has the authority to access bank deposit information of companies and individuals under investigation, uncovered this
misconduct during their examination of such deposits. The former manager was suspended immediately upon the discovery and was
terminated effective February 23, 2024. SBC Medical Group Co., Ltd. has commenced a criminal complaint in Tokyo against the
participants.

 Shortly
after this discovery, SBC Medical Group Co., Ltd. engaged independent legal counsel and forensic consultants to investigate the misappropriations.
The investigation, which was completed in March 2024, revealed that the participants had misappropriated approximately JPY632 million
($5.6 million), including consumption tax, from SBC Medical Group Co., Ltd., of which the former director received approximately JPY335
million ($3.0 million), between April 2016 and the discovery of the misappropriations in January 2024. The amount misappropriated prior
to April 2016 could not be accurately determined because certain data for the period prior to April 2016 was unavailable, SBC Medical
Group Co., Ltd. does not expect such amount to be material based on current estimates.

 SBC
Medical Group Co., Ltd. found no evidence that any other employee of SBC Medical Group Co., Ltd. was aware of, or colluded in, the
misappropriations of SBC Medical Group Co., Ltd. funds or that there was any unlawful activity apart from that associated with the
participants' misappropriations of SBC Medical Group Co., Ltd. funds. The misappropriated amounts, excluding the consumption
tax, representing advertising services purchased on behalf of a related-party MC, were originally included in the revenues reported
on a net basis. After discovery of the misappropriations, the amounts were reported as a misappropriation loss. For the year
ended December 31, 2023, the Company recorded a misappropriation loss of $ 409,030.

 Remediation
Plan

 Immediately
upon learning of the misappropriation of funds, SBC Medical Group Co., Ltd. engaged independent legal counsel and forensic consultants
to investigate the misappropriations. As stated above in this Annual Report, based on its internal investigation, SBC Medical Group Co.,
Ltd. found no evidence that any other employee of SBC Medical Group Co., Ltd. was aware of, or colluded in, the misappropriations of
Company funds or that there was any unlawful activity apart from that associated with the participants' misappropriations of Company
funds.

 Based
on the results of the investigation, management identified the following material weaknesses:

 1.
 Control
 Environment. SBC Medical Group Co., Ltd. did not maintain an effective control environment
 that fully emphasized the establishment of adherence to effective internal controls over
 financial reporting throughout SBC Medical Group Co., Ltd.'s management. SBC Medical
 Group Co., Ltd. did not give sufficient consideration to the risk of senior management override
 of internal controls. SBC Medical Group Co., Ltd. had not ensured that certain personnel
 were adequately trained to properly execute critical internal controls.

 2.
 Control
 Activities. SBC Medical Group Co., Ltd. did not effectively implement or maintain control
 activities, such as ensuring a sufficient functioning of the mechanism of reconciliation
 of invoices to contracts and multi-level approvals of contracts, invoices and payments. SBC
 Medical Group Co., Ltd. did not maintain sufficient segregation of duties with respect to
 certain activities and did not maintain adequate monitoring
 and oversight for those activities.

 3.
 Risk
 Assessment. SBC Medical Group Co., Ltd. did not have an effective risk assessment process
 and the related documentation.

 4.
 and Communication. SBC Medical Group Co., Ltd. did not adequately communicate to all
 employees of the organization information regarding the importance of internal controls over
 financial reporting and employees' duties and responsibilities, including segregation
 of duties.

 5.
 Monitoring
 Activities. SBC Medical Group Co., Ltd. did not maintain effective monitoring controls
 related to the evaluation and testing of its internal controls over financial reporting.

has implemented, or is in the process of implementing, the following changes to the Company's internal
control systems and procedures:

 We will clarify the organization structure and employee
 positions promoting (i) segregation of duties, (ii) monitoring and oversight, (iii) reconciliation
 of invoices to contracts and (iv) multi-level approvals of contracts, invoices and payments.

 We will communicate to all employees of the organization
 information regarding the importance of internal controls and employees' duties and
 responsibilities, including segregation of duties.

 We have initiated a project led by Head of Internal Control
 and Internal Audit Office, and aided by outside consultants, to fully document its processes
 to serve as the basis for activities during 2024 to assess its fraud risks and evaluate and
 test its internal controls over financial reporting.

 We are progressing with a project, led by our Head of Internal
 Control and Internal Audit Office, to design, implement, and document internal controls to
 address risks related to financial reporting. This year, our activities are focused on "laying
 the foundation to complete our response to key financial reporting risks by the end of 2025,"
 and we are making progress as planned.

 The
former manager was suspended immediately upon the discovery and was terminated effective February 23, 2024. Subsequently, SBC Medical Group Co., Ltd. filed a complaint, which was
accepted by the police on February 25, 2025. Meanwhile, SBC Medical Group Co., Ltd.
has initiated a search for a new manager of general affairs and legal department and hired an attorney(JP)-qualified manager in February
2025. In order to improve the overall level of competence in the accounting department, the Company is hiring personnel with accounting
experience at listed companies and personnel with CPA(JP).

focused on building internal controls in 2024. From 2025 onwards, we will test and monitor the operational effectiveness of
these controls and, if necessary, take additional corrective actions to address any deficiencies.

The Company believes the remediation measures described above will strengthen its internal control over financial reporting and
remediate the material weaknesses identified.

 Government
Regulation and Environmental Matters

 In

 The
Company and the MCs are subject to extensive and varied federal, state, and local government regulations globally, including regulations
relating, among others, to public and occupational health and safety, product labeling, healthcare, the environment, sanitation, and
fire prevention. We operate our clinic, and the MCs operate the franchisee clinics, in accordance with standards and procedures designed
to comply with applicable codes and regulations. However, an inability to obtain or retain health department or other licenses by us
or the MCs would adversely affect our operations. Although the Company and the MCs have not experienced, and do not anticipate, any significant
difficulties, delays or failures in obtaining required licenses, permits or approvals, any such problem could delay or prevent the opening
of, or adversely impact the viability of, a particular clinic or group of clinics. Additionally, difficulties, delays or failure to retain
or renew licenses, permits or approvals, or increased compliance costs due to changed regulations, by us or the MCs, could adversely
affect operations at our clinic and the MCs' franchisee clinics. A decrease in the revenue of the MCs' franchisee clinics
as a result of such difficulties, delays, or failure would directly result in a reduction of the Company's revenue since we receive
substantial revenue from the MCs as part of our compensation for management services.

 The
Company and the MCs are subject to federal, state and local environmental laws and regulations globally concerning waste disposal, pollution,
protection of the environment, and the presence, discharge, storage, handling, release and disposal of, or exposure to, hazardous or
toxic substances ("environmental laws"). These environmental laws can provide for significant fines and penalties for non-compliance
and liabilities for remediation, sometimes without regard to whether the owner or operator of the property knew of, or was responsible
for, the release or presence of the hazardous or toxic substances. Third parties may also make claims against owners or operators of
properties for personal injuries and property damage associated with releases of, or actual or alleged exposure to, such substances.
We are not aware of any environmental laws that will materially affect our earnings or competitive position, or result in material capital
expenditures relating to our clinic or our franchisee clinics. However, we cannot predict what environmental laws will be enacted in
the future, how existing or future environmental laws will be administered, interpreted or enforced, or the amount of future expenditures
that we may need to make to comply with, or to satisfy claims relating to, environmental laws. It is possible that the Company and the
MCs will become subject to environmental liabilities, and any such liabilities could materially affect our business, financial condition
or results of operations.

 We
are also subject to laws and regulations globally relating to information security, privacy, cashless payments, gift cards and consumer
credit, protection and fraud, and any failure or perceived failure to comply with these laws could harm our reputation or lead to litigation,
which could adversely affect our business, financial condition or results of operations.

 Furthermore,
we are subject to import laws and tariffs globally which could impact our ability to source and secure medical products, other supplies
and equipment necessary to supply our clinic and franchisee clinics.

 In
addition, as part of managing the development and construction of franchisee clinics for the MCs, we must ensure that the applicable
zoning, land use and environmental regulations in the applicable jurisdiction are being complied with.

 The
process of obtaining regulatory approvals and the compliance with appropriate federal, state, local and foreign statutes and regulations
require the expenditure of substantial time and financial resources. Because of the breadth of these laws and the narrowness of available
statutory and regulatory exemptions, it is possible that some of our business activities now and in the future could be subject to challenge
under one or more of these laws. If our operations are found to be in violation of any of the federal and state laws described above
or any other governmental regulations that apply to us, we may be subject to significant penalties, including criminal and significant
civil monetary penalties, damages, fines, imprisonment, exclusion of products from reimbursement under government healthcare programs,
integrity oversight and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate
our business and our results of operations. To the extent that any of our cosmetic products are sold in a foreign country, we may be
subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety
surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of
value to healthcare professionals.

 As
our business continues to expand in the U.S. and other jurisdictions, and as laws and regulations continue to be passed and their interpretations
continue to evolve in numerous jurisdictions, additional laws and regulations may become relevant to us.

 Japan
Laws and Regulations

 Personal
Information Protection

 In
Japan, the Act on the Protection of Personal Information (the "APPI") and its related guidelines impose various requirements
on businesses, including us, that use databases containing personal information. Under the APPI, the Company and the MCs are required
to lawfully use personal information we have obtained within the purpose of use we have specified and taken appropriate measures to maintain
the security of such personal information. The Company and the MCs are also restricted from providing the personal information of a person
(the "principal") to third parties without the consent of the principal. The APPI also includes regulations relating to the
handling of sensitive personal data and anonymous personal data and the transfer of personal information to foreign countries. A Personal
Information Handling Business Operator (as defined below) shall not transfer a person's personal data to third parties, including
its affiliated entities without the prior consent of the principal unless an exception applies (Article 27, Paragraph 1 of the APPI).

 A
"Personal Information Handling Business Operator" is defined as a person (including a judicial person and excluding any administrative
organizations) providing a personal information database for use in business (Article 16, Paragraph 2). The Company's business
collects personal information from customers, thereby subjecting the Company to the provisions applicable to the Personal Information
Handling Business Operator. Under the APPI, the prior consent of the principal to a transfer of such person's personal data (including
Sensitive Information (as defined below)) is not required if the transfer:

 (a)
 is
 specifically required or authorized by any laws or regulation;

 (b)
 is
 necessary for protecting the life, health, or property of an individual and consent of the
 principal is difficult to obtain;

 (c)
 is
 necessary for improving public health and sanitation, or promoting the sound upbringing of
 children, and the consent of the principal is difficult to obtain; or

 (d)
 is
 made in a case where there is a need to cooperate in regard to a central government organization
 or a local government, or a person entrusted by them performing affairs prescribed by laws
 and regulations, and when there is a possibility that obtaining the principal's consent
 would interfere with the performance of the said affairs.

 Furthermore,
the Personal Information Handling Business Operator shall, unless an exception listed above applies, not acquire Sensitive Information
(such as personal information relating to physical or mental disabilities, medical records, and medical and pharmacological treatment)
without obtaining prior consent from the principal (Article 2, Paragraph 3 and Article 20, Paragraph 2 of the APPI).

 The
MCs gather personal information from customers through questionnaires and other methodologies in connection with the provision of medical
services. Some of the information that the MCs collect could fall under the category of sensitive personal data under the APPI. In addition,
the MCs gather personal information including diagnosis records, which is understood to typically fall under the Sensitive Information.
Therefore, the MCs are required to obtain consent from the customers prior to the transfer of their information.

 When
storing personal information, it is necessary to manage it safely so that it will not be leaked or the database breached. For the safe
management, the APPI requires the Personal Information Handling Business Operator to establish an information security system. It includes
establishment of the fundamental rule of personal information management, appointment of personnel responsible for personal information
management, provisions of regular training courses on privacy and security breach, and physical security control.

 A
failure by the MCs to comply with the APPI may harm our franchised brand and directly result in a reduction of the Company's revenue,
since we receive substantial revenue from the MCs as part of our compensation for management services.

Governing our Franchises

 Japan
has antitrust laws that protect consumers and regulate how companies operate their businesses. Among the various Japanese antitrust laws,
the seminal antitrust law is the Act on Prohibition of Private Monopolization and Maintenance of Fair Trade (Act No. 54 of 1947, as amended)
(which we refer to as the "Antimonopoly Act"). The Antimonopoly Act prohibits certain activities that inappropriately induce
or mislead persons into entering into a business relationship with us through our granting of seemingly preferable trade terms and conditions
that could create false impressions in relation to other franchisors we compete with.

 The
Japan Fair Trade Commission (which we refer to as the "JFTC") enforces the Antimonopoly Act and other Japanese antitrust
laws. The JFTC issued the "Guidelines Concerning the Franchise System Under the Antimonopoly Act" on April 24, 2002 (last
amended on June 23, 2011) (which we refer to as the "Guidelines"), under which the JFTC suggests that, prior to entering
into a franchise relationship, a franchisor should adequately disclose and explain material trade terms to a potential franchisee in
order to prevent any misunderstanding of the material trade terms, and to prevent such potential franchisee from being misled or improperly
induced into entering into such franchise relationship. Material trade terms include terms relating to the following:

 the
 supply of products after the party becomes a franchisee (such as a system for recommending
 suppliers);

 guidance,
 procedures, frequency, and cost to the franchisee relating to the business activities of
 the franchise;

 nature
 and amount of payments to be collected when the party joins the franchise, whether the payments
 are refundable or may be returned, and the conditions for refunding or returning the payments;

 royalties
 that the franchisee pays to the franchisor for use of trademarks and trade names and for
 guidance relating to management procedures, including the amount of, procedure for calculating,
 and the time and method of payment, of royalties;

 loans
 the franchisor extends to the franchisee, including the interest rate and the mechanism and
 conditions of settlement;

 compensation
 for any losses the business incurs, including the details of such compensation and whether
 there is management support from the franchisor in the event of a decline in business;

 terms
 of the franchise agreement and the conditions and procedures for renewing or terminating
 the franchise agreement, including early termination prior to the expiration of its term;
 and

 restrictions
 with respect to the franchisor or other franchisees of the franchise setting up an identical
 or similar business near the proposed business of the potential party to join the franchise,
 including whether there are any plans to set up additional businesses and the details of
 such plans.

 In
addition, when a franchisor markets its franchise, in the event such franchisor provides a prospective franchisee with an estimate of
the revenue or profit that could possibly be generated upon becoming a franchisee, such estimated revenue or profit must be based on
a reasonable method of calculation and established facts, such as the results of an existing franchise operating in a similar environment.
The franchisor is required to present to the prospective franchisee such methods and facts.

 If
the JFTC finds any activities that violate the Antimonopoly Act, including any "deceptive customer inducement", then the
JFTC may order the offending franchisor to cease and desist from engaging in such unlawful activities, delete any applicable unlawful
clauses from the franchise contract, or carry out any other measures necessary to eliminate such unlawful activities.

 In
the event the JFTC suspects any violation of the Antimonopoly Act or alleges that we have misled or wrongly induced any of our franchisees
based upon any particular trade terms, we could be exposed to risks, including governmental action against us.

Governing Medical Care and Services

 The
MCs provide services strictly in accordance with the medical-related laws and regulations of the Medical Care Act (Law No. 205) adopted
on July 30, 1948, as amended. The Medical Care Act defines rights and obligations regarding medical treatment, advertisement, authority,
license, treatment of information, safety and security for patients, doctors and other individuals and organizations engaged in medical
activities. The purpose of the Medical Care Act is to protect the health of the nation by safeguarding the interests of medical care
recipients and ensuring a system that efficiently delivers high quality and well-suited medical care, by means of providing for the necessary
particulars to support well-suited choices about medical care by the recipients thereof, to ensure the safety of medical care, concerning
the establishment and management of hospitals, clinics, and birthing centers, and to develop such facilities and promote the sharing
of functions and cooperation between medical institutions. The MCs also comply with other laws such as the Medical Practitioners'
Act, Dental Practitioners Act, Radiology Technician Act, Clinical Trials Act, Industrial Safety and Health Act when providing relevant
services. A failure by the MCs to comply with the Medical Care Act may harm our franchised brand and directly result in a reduction of
the Company's revenue, since we receive substantial revenue from the MCs as part of our compensation for management services.

Governing our Recruiting License

 In
November 2022, we obtained a recruiting agency license (which we refer to as a "Recruiting License") from the Ministry of
Health, Labor and Welfare of Japan under the under the Act for Securing the Proper Operation of Worker Dispatching Undertakings and Improved
Working Conditions for Dispatched Workers (which we refer to as the "Dispatch Act"). We are required to obtain the Recruiting
License because we assist with the placement of staff and employee training at the MCs' franchisee clinics.

Governing our Use of Certain Substances

 The
MCs are required to comply with the Poisonous and Deleterious Substances Control Act (Act No. 303 of December 28, 1950, as amended) of
Japan. The purpose of this Act is to provide for the necessary control of poisonous and deleterious substances from the standpoint of
health and hygiene and regulates the use of deleterious substances. The aforementioned regulations apply to the MCs' franchisee
clinics' handling of such substances in Japan. A failure by the MCs to comply with the Poisonous and Deleterious Substances Control
Act may harm our franchised brand and directly result in a reduction of the Company's revenue, since we receive substantial revenue
from the MCs as part of our compensation for management services.

on Intellectual Property

 In
Japan, patents are protected by the Patent Act and the Utility Model Act of Japan (Act No. 123 of 1959 as amended). Designs are protected
by the Design Act of Japan (Act No. 125 of 1959 as amended), and trademarks by the Trademark Act (Act No. 127 of 1959 as amended). Copyrights
are protected by the Copyrights Act (Act No. 48 of 1970 as amended). Trade secrets are protected by the Unfair Competition Prevention
Act (Act No. 47 of 1993 as amended). The aforementioned regulations apply to our intellectual property rights in Japan, and accordingly
we are subject to complying with such regulations.

 Japanese
Employment and Labor Laws

 There
are various labor-related laws in Japan, including the Labor Standards Act (Act No. 49 of April 7, 1947, as amended), the Industrial
Safety and Health Act (Act No. 57 of June 8, 1972, as amended), and the Labor Contracts Act (Act No. 128 of December 5, 2007). The Labor
Standards Act regulates, among others, minimum standards for working conditions such as working hours, leave period, and leave days.
The Industrial Safety and Health Act requires, among others, the implementation of measures to secure employee safety and protect the
health of workers in the workplace. The Labor Contracts Act regulates, among others, the change of terms of employment contracts and
working rules, and dismissal and disciplinary action. A portion of our personnel in Japan are paid at rates related to the applicable
minimum wage, and further increases in the minimum wage or other changes in these laws could increase our labor costs. Our ability to
respond to minimum wage increases by increasing service and product prices will depend on the responses of our competitors and patients.
Our distributors and suppliers also may be affected by higher minimum wage and benefit standards, which could result in higher costs
of goods and services supplied to us. We may also be subject to lawsuits from our employees, Labor Standards Inspection Office, or others
alleging violations of federal and state laws regarding workplace and employment matters, discrimination and similar matters.

on Lease Agreements

 Our
lease agreements are generally subject to the Civil Code (Act No. 89 of April 27, 1896, as amended) and Act on Land and Building Leases
(Act No. 90 of October 4, 1991, as amended). We believe that the terms and conditions of our lease agreements are consistent with these
laws and are valid and enforceable as provided for in these agreements.

regarding Maintenance of Websites and E-commerce

 The
Act on Special Provisions to the Civil Code Concerning Electronic Consumer Contracts and Electronic Acceptance Notice (Act No. 95 of
June 29, 2001, as amended) and the Act on Specified Commercial Transactions (Act No. 57 of June 4, 1976, as amended) regulate sales of
goods through e-commerce within Japan. For example, under these acts, we as a seller must explicitly show prices of products, timing
and method of payment, timing of delivery, conditions for return of goods, our name and contact information, and name of representative
person, among others. We comply with these regulations.

regarding Product Quality and Customer Protection

 We
are subject to laws and regulations, as well as pending legislative and regulatory proposals, regarding product quality and customer
protection, which could affect us in jurisdictions in which we sell our products.

 In
Japan, the Product Liability Act (Act No.85 of July 1, 1994, as amended) and Consumer Contract Act (Act No. 61 of May 12, 2000, as amended)
mainly regulate the product quality and customer protection. The Product Liability Act sets forth the liabilities of a manufacturer,
processor, or importer for damages caused by defects in a product. A seller who was not involved in the manufacturing, processing, or
import of a product could still be liable under this act if its name, trade name, or trademark, etc. was indicated on the product as
the manufacturer, processor, or importer, such indications on the product might mislead others into believing that the seller was the
manufacturer, processor, or importer, or such indications on the product might be recognized by others as those of the substantial manufacturer,
processor, or importer. Liability under this act can be imposed even if the manufacturer, processor, or importer (and the said seller)
was not negligent. The Consumer Contract Act invalidates certain provisions in contracts with consumers, such as exemption of compensation
for damages to consumers and restrictions of termination by consumers due to the seller's breach of contract. We comply with these
regulations.

 Vietnam
Laws and Regulations

regarding the Environment

 We
are required to comply with the Environmental Protection Law No. 72/2020/QH14 adopted by the National Assembly on November 17, 2020 (as
amended from time to time), which regulates environmental protection activities, including the rights, duties, and responsibilities of
authorities, organizations, residential communities, households, and individuals involved in environmental protection activities. Specifically,
it establishes certain regulations regarding the protection of the environment in medical activities and the control of the effects of
environmental pollution on human health.

regarding Labor and Health

 We
are required to comply with several labor-related standards prescribed by the local laws and regulations. The principal statute is the
Labor Code No. 45/2019/QH14 adopted by the National Assembly on November 20, 2019 (as amended from time to time), which provides for
labor standards, the rights, duties, and responsibilities of employees, employers, employees' representative organizations at establishment,
and employers' representative organizations in labor-management relations, other relations directly related to labor-management
relations, as well as state control over labor.

 Law
on Occupational Safety and Hygiene

 The
Law on Occupational Safety and Hygiene No. 84/2015/QH13 adopted by the National Assembly on June 25, 2015 (as amended from time to time)
regulates measures to ensure occupational safety and hygiene, policies and compensation for victims of occupational accidents and diseases,
responsibilities and rights of organizations and individuals regarding occupational safety and hygiene activities, and state control
over occupational safety and hygiene.

 The
Law on Social Insurance No. 58/2014/QH13 adopted by the National Assembly on November 20, 2014 (as amended from time to time) regulates
mandatory social insurance benefits and policies, the rights and responsibilities of employees and employers, other institutions, organizations,
and individuals involved in social insurance, representative organizations of employees, representative organizations of employers, social
insurance authorities, social insurance funds, social insurance implementation procedures, and state administration of social insurance.
We will comply with the new Law on Social Insurance No. 41/2024/QH15, which will take effect from July 1, 2025.

 The
Law on Health Insurance No. 25/2008/QH12 adopted by the National Assembly on November 14, 2008 (as amended from time to time) regulates
mandatory health insurance system and policies regarding health insurance, health insurance funds, and the rights and responsibilities
of parties involved in health insurance, including enrollees, premium rates, health insurance premium sharing and payment methods, health
insurance cards, health insurance beneficiaries, medical care for insured persons, and the payment of medical expenses. We will also
comply with the Law on Amendment to the Law on Health Insurance No. 51/2024/QH15, which will take effect from July 1, 2025.

regarding Business Activities

 We
are required to comply with several regulations regarding investments and company-related activities such as (a) the Investment Law No.
61/2020/QH14 adopted by the National Assembly on June 17, 2020 (as amended from time to time) providing regulations on business investment
activities in Vietnam and business investment activities from Vietnam to foreign countries and (b) the Law on Enterprises No. 59/2020/QH14
adopted by the National Assembly on June 17, 2020 (as amended from time to time) regulating the formation, management, reorganization,
dissolution and related activities of companies consisting of limited liability companies, joint stock companies, partnership companies
and private companies, and groups of companies.

 Since
our beauty clinic service is considered as a commercial activity in general, we are also required to comply with the Commercial Law No.
36/2005/QH11 adopted by the National Assembly on June 14, 2005 (as amended from time to time). This law applies to commercial activities
(including the sale and purchase of goods, provision of services, investment, commercial promotion and other commercial activities) in
the territory of Vietnam.

 In
Vietnam, (a) massage services (comprising of the use of physical therapies for massage or manual therapies to improve human health) and
(b) plastic surgery services (comprising of using medical techniques to perform surgery for the purpose of alternation of shape or appearance
of body parts) are deemed to be "sensitive" services and therefore must comply with Decree No. 96/2016/ND-CP adopted by the
Government on July 1, 2016 regarding security and order conditions for a number of conditional business sectors.

regarding Medical Treatment

 We
are also subject to the Law on Medical Examination and Treatment No. 15/2023/QH15 adopted by the National Assembly on January 9, 2023
(as amended from time to time), which defines the rights and obligations of patients, physicians, and clinics in relation to matters
such as technical expertise in health diagnosis and treatment, health diagnosis and treatment provided by traditional medicine and by
a combination of traditional and modern medicine, humanitarian or non-profit health diagnosis and treatment, transfer of technical expertise,
the application of new technologies and methods and clinical trials, errors of technical expertise in medicine, operating assumptions,
as well as the mobilization and dispatch of resources to be used for medical examination and treatment in the event of natural disasters,
catastrophes, Group A infectious diseases, and emergency situations.

regarding Liability

 In
principle, our relationship with customers is a civil transaction and therefore governed by the Civil Code No. 91/2015/QH13 adopted by
the National Assembly on November 24, 2015 (as amended from time to time). This fundamental code specifies the legal status and legal
standards for the conduct of natural and juridical persons, as well as the rights and obligations of natural and juridical persons in
their civil relations.

 In
addition, we are subject to the Law on Product and Goods Quality No. 05/2007/QH12 adopted by the National Assembly on November 21, 2007
(as amended from time to time), which is a specialized legislation regulating the product liability of manufacturers and traders (i.e.,
importers, exporters, sellers, service suppliers). Under this law, enterprises engaging in manufacturing and/or trading products are
required to provide customers with accurate information on products, recover and remedy defective products, and compensate for losses
due to defective products.

 We
are also subject to the Law on Protection of Consumers' Rights No. 19/2023/QH15 adopted by the National Assembly on June 20, 2023
(as amended from time to time), which provides for principles and policies for protecting consumers' rights, the rights and obligations
of consumers, traders' responsibility to consumers, consumer right protection activities by agencies and organizations, settlement
of disputes between consumers and traders, as well as state management of protection of consumers' rights.

regarding Firefighting and Fire Prevention

 The
Law on Firefighting and Fire Prevention No. 27/2001/QH10 adopted by the National Assembly on June 29, 2001 (as amended from time to time)
regulates fire prevention, firefighting, human rescue, property rescue, assurance of operating conditions, as well as the rights, obligations,
and responsibilities of relevant agencies, organizations, households, and individuals in fire and rescue operations. We will comply with
the new Law on Fire and Rescue No. 55/2024/QH15, which will take effect from July 1, 2025.

States Laws and Regulations

Governing Disabilities Act

 Federal
and state environmental regulations have not had a material effect on our operations to date, but more stringent and varied requirements
of local governmental bodies with respect to zoning, land use and environmental factors could delay or even prevent construction and
increase development costs for new franchisee clinics. SBC Irvine MC is required to comply with the accessibility standards mandated
by the U.S. Americans with Disabilities Act with respect to the CA Clinic in the United States, which generally prohibits discrimination
in accommodation or employment based on disability. SBC Irvine MC may in the future have to modify clinics, for example, by adding access
ramps or redesigning certain architectural fixtures, to provide service to or make reasonable accommodations for disabled persons. While
these expenses could be material, SBC Irvine MC's current expectation is that any such actions will not require them to expend
substantial funds. A failure by SBC Irvine MC to comply with the U.S. Americans with Disabilities Act may harm our franchised brand and
directly result in a reduction of the Company's revenue, since we receive revenue from SBC Irvine MC as part of our compensation
for operational services that we provide to SBC Irvine MC.

Governing Labor

 Further,
we are subject to the U.S. Fair Labor Standards Act, the U.S. Immigration Reform and Control Act of 1986, the Occupational Safety and
Health Act and various other federal and state laws governing similar matters including minimum wages, overtime, workplace safety and
other working conditions. A portion of our personnel in the United States are paid at rates related to the applicable minimum wage, and
further increases in the minimum wage or other changes in these laws could increase our labor costs. Our ability to respond to minimum
wage increases by increasing service and product prices will depend on the responses of our competitors and patients. Our distributors
and suppliers also may be affected by higher minimum wage and benefit standards, which could result in higher costs of goods and services
supplied to us. We may also be subject to lawsuits from our employees, the U.S. Equal Employment Opportunity Commission or others alleging
violations of federal and state laws regarding workplace and employment matters, discrimination and similar matters.

Governing Healthcare Providers and Information

 The
Company's and SBC Irvine MC's current and future arrangements with healthcare providers, third-party payors, customers, and
others may expose the Company and SBC Irvine MC to broadly applicable fraud and abuse and other healthcare laws and regulations, which
may constrain the business or financial arrangements and relationships through which we research, as well as, sell, market and distribute
any product for which we obtain marketing approval.

 Health
Insurance Portability and Accountability Act ("HIPAA") also imposes, among other things, certain standards and obligations
on covered entities including certain healthcare providers, health plans and healthcare clearinghouses, as well as their respective business
associates and subcontractors that create, receive, maintain, or transmit individually identifiable health information for or on behalf
of a covered entity relating to the privacy, security, transmission and breach reporting of individually identifiable health information.
HIPAA imposes strict privacy, security, and breach notification obligations and standards on "covered entities" related to
their use and disclosure of individually identifiable health information, defined by HIPAA as Protected Health Information ("PHI").
Covered entities are defined under HIPAA to include healthcare providers that undertake certain electronic transmissions of PHI, such
as submitting electronic claims for reimbursement for the treatment of patients. SBC Irvine MC is considered to be a covered entity.
HIPAA also applies to Business Associates. HIPAA is generally enforced by the Office for Civil Rights ( the "OCR") that can
bring enforcement actions against companies that violate HIPAA's privacy, security or breach notification rules and levy significant
civil fines and/or require changes to the manner in which PHI is used and disclosed. The U.S. Department of Justice has jurisdiction
under HIPAA to bring criminal enforcement actions against covered entities, Business Associates and possibly other entities for fraudulent
misuse of PHI and other criminal acts. Further, HIPAA provides state attorneys general authority to file civil actions for damages or
injunctions in federal courts to enforce HIPAA and seek attorney's fees and costs associated with pursuing federal civil actions.
If we are in possession of PHI as a business associate or as part of our health plan covered entity and we have an unauthorized use or
disclosure of the PHI, we will be required pursuant to the HIPAA breach notification rule, to notify our customer covered entity, impacted
individuals, and/or OCR.

 Several
states, including, but not limited to, California, Colorado, Connecticut, Utah and Virginia, have adopted generally applicable and comprehensive
privacy laws, although most have an exception for information regulated by HIPAA. These new and developing state laws provide a number
of new privacy rights for residents of these states and impose corresponding obligations on organizations doing business in these states.
For example, the California Consumer Privacy Act (the "CCPA") imposes obligations on covered businesses to provide specific
disclosures related to a business' collecting, using, and disclosing personal data and to respond to certain requests from California
residents related to their personal data (for example, requests to know of the business's personal data processing activities,
to delete the individual's personal data, and to opt out of certain personal data disclosures). The CCPA provides for civil penalties
and a private right of action for data breaches which may include an award of statutory damages. In addition, the California Privacy
Rights Act ("CPRA"), which took substantial effect January 1, 2023 with enforcement scheduled for July 1, 2023, expanded
the CCPA. The CPRA, among other things, gives California residents the ability to limit use of certain sensitive personal data, establish
restrictions on personal data retention, expand the types of data breaches that are subject to the CCPA's private right of action,
and establish a new California Privacy Protection Agency to implement and enforce the new law. A failure by us or SBC Irvine MC to comply
with HIPAA may harm our franchised brand and directly result in a reduction of the Company's revenue, since we receive revenue
from SBC Irvine MC as part of our compensation for operational services that we provide to SBC Irvine MC.

 For
a discussion of the various risks we face from regulation and compliance matters, see "Part I, Item 1A. Risk Factors".

Laws and Regulations

 Licensing,
Operations, and Compliance

 We
are subject to the Healthcare Services Act 2020 (" HCSA ") and the regulations promulgated under it, which governs
the licensing, regulation, and operation of private healthcare institutions, including aesthetic clinics. We are required to obtain a
license under this legislation to operate our clinics.

 The
Healthcare Services (General) Regulations 2021 also require licensed healthcare service providers to adhere to strict standards of patient
care and service (including for the protection of patient privacy), and we must meet the necessary standards of infrastructure, medical
equipment, and operational procedures, as well as the maintenance of a safe and hygienic clinical environment.

 Regulation
of Our Doctors

 In
Singapore, the Medical Registration Act 1997 regulates the registration and professional conduct of medical practitioners. This legislation
mandates that only doctors who are properly registered as a medical practitioner and holding a valid practicing certificate may perform
medical procedures in aesthetic clinics. Under this legislation, any person who wishes to practice medicine or perform medical procedures
that involve medical risks, such as injectable treatments (e.g., botulinum toxin and dermal fillers) and laser treatments, must be performed
by registered medical practitioners holding a valid practicing certificate.

 Health
Products and Medicines

 The
Health Products Act 2007 (" HPA ") governs the regulation of health products (including, inter alia, medical
devices and therapeutic products) used in clinical settings, including aesthetic clinics. Under this legislation, we are prohibited from
using health products that are not approved by the Health Sciences Authority of Singapore (" HSA "), and we are
obligated to only use products that have passed the HSA's evaluation and are registered for clinical use in Singapore. If a product
is found to be defective or harmful, this legislation requires us to comply with any product recalls or safety notices issued by the
HSA. We are also obligated to report any adverse events or complications related to the use of medical devices and health products in
our clinics.

 The
Medicines Act 1975 (" MA ") regulates the importation, manufacture, and sale of medicinal products, including
drugs, vaccines, and injectable products used in aesthetic treatments in Singapore. Under this legislation, aesthetic clinics are prohibited
from using any unapproved or substandard medicines and must ensure that all prescription products are licensed and approved by the HSA.
This legislation also covers the distribution of medicines and medicinal products, and aesthetic clinics must ensure that any injectable
or medicinal product used in their treatments is legally sourced, licensed, and approved by the HSA for use in Singapore.

 Advertisements

 We
are subject to strict advertising guidelines for healthcare services issued by the HSA pursuant to the HCSA. Advertising materials, including
brochures, websites, and social media content, must comply with ethical advertising standards set by the HSA, and cannot be false, misleading,
unsubstantiated, or contain exaggerated claims about medical treatments. We are prohibited from using testimonials or endorsements that
violate patient confidentiality, and are required to provide accurate, clear, and truthful information about the services we offer, the
potential risks of treatments, and the expected outcomes.

 The
HPA also regulates the advertising of health products, including medical devices and therapeutic products. Under this legislation, we
are required to ensure that all advertisements for products such as dermal fillers, botulinum toxin, and lasers are not misleading, do
not overstate the efficacy of treatments, and clearly communicate any risks associated with such procedures. The Health Products (Advertisement
of Specified Health Products) Regulations 2016 also strictly prohibit the direct advertising of prescription-only medicines to the general
public, to ensure that treatments are only administered following proper medical consultation.

 The
MA also imposes restrictions on the advertising of medicinal products, including prescription-based treatments like botulinum toxin,
which are commonly used in aesthetic clinics and require oversight by licensed medical professionals. This legislation prohibits false
or misleading advertisements and representations of medicinal products.

 Consumer
Protection

 We
are also required to comply with the Consumer Protection (Fair Trading) Act 2003, which regulates the trade practices of businesses,
protects consumers from unfair practices which includes, inter alia: (a) misleading or deceiving a consumer, (b) falsifying claims
to a consumer, and (c) taking advantage of a consumer who may not be in a position to protect their interests due to not understanding
the nature of the transaction, and provide consumers with the right to seek remedies if they have been wronged. If a beauty product is
found to be defective or unsafe after purchase, consumers are entitled under this legislation to request a refund, replacement, and/or
repair (if applicable). This legislation prohibits practices such as false advertising, misleading statements, or failing to disclose
important information about products or services.

Quality

 In
addition to the HPA and the MA, we are also subject to the Sale of Goods Act 1979, which governs the sale of goods in Singapore, including
beauty products sold at aesthetic clinics. This legislation provides a framework for the contractual obligations between buyers and sellers
and ensures that products are among other things, safe, of satisfactory quality, and fit for their intended purpose.

 Personal
Data Protection

 The
Personal Data Protection Act 2012 governs, among other things, the collection, use, and protection of personal data in Singapore. As
a healthcare provider, we are required to comply with this legislation to safeguard the privacy and confidentiality of our patients'
personal and medical information, including obtaining consent from patients before collecting their personal information, such as contact
details, medical histories, and treatment records, implementing strict measures to protect patient data from unauthorized access, loss,
or misuse, and facilitating our patients' right to access their personal data, request corrections, and withdraw consent for the
use of their information. This legislation also requires healthcare providers to make reasonable efforts to ensure the accuracy of the
personal data collected from the patients as the personal data will likely be used to make a decision that affects the patient. If there
are reasons to believe in data breaches that affect a patient's personal data, the healthcare provider has a duty to assess the
severity of said breach. Given the confidentiality of the patients' medical information, should a breach be severe enough to result
in significant harm to the patient, or is of a significant scale, there will be a duty to notify the Personal Data Protection Commission.

 Employment
and Workplace Safety

 We
are subject to the Employment Act 1968, the key legislation governing employment practices in Singapore. This legislation outlines the
minimum terms and conditions of employment, covering aspects such as wages (including when and how they should be paid), working hours
and overtime, rest days, and employee benefits. It ensures the protection of employees' rights and provides a framework for fair
and lawful employment practices.

 We
are also subject to the Employment of Foreign Manpower Act 1990, which governs the employment of foreign workers in Singapore. This legislation
regulates the employment pass system and ensures that businesses that hire foreign workers comply with specific requirements related
to work passes, employment conditions, and other related responsibilities. Under this legislation, all foreign employees must hold a
valid work pass to work in Singapore and the onus lies on the employer to ensure that the foreign employee is permitted to work in Singapore.

 The
Workplace Safety and Health Act 2006 applies to all businesses in Singapore, including aesthetic clinics. Under this legislation, we
are required to adhere to stringent health and safety protocols to protect both our patients and staff, including maintaining work environments
that are safe and without risks to health, ensuring proper waste disposal, implementing emergency procedures, and training all staff
members in basic health and safety measures, including infection control and proper use of medical equipment.

 Intellectual
Property and Trademarks

 As
of December 31, 2024, the Company and its subsidiaries together had filed a significant number of patent and trademark applications in
Japan, as well as a substantial numbers of trademark applications with the International Bureau of the World Intellectual Property Organization.
The Company also holds registered patents and trademarks in Japan. Additionally, the only trademarks registered in Singapore are those
registered by the Singapore subsidiary acquired in late November. The Company does not have any registered trademarks, domain names,
or patents in Vietnam or the United States.

 Our
registered trademarks include, but are not limited to, "SBC", "Shonan Beauty Clinic", "SBCLABO",
"Hair Renaissance", "SBC MEDISPA", and "ACNEED", and are further described in the table below.

 Material
Contract with Intellectual Property and Trademarks

 The
Company and the MCs have each entered into a contract with regard to intellectual property as set forth below. The entry dates of these
agreements range from September 2017 to May 2021. The term of the agreements is for a period of 9 years. However, if neither the party
makes a written request at least 3 months prior to the expiration of the term, the term of these agreements will continue for successive
2 year terms going forward unless terminated by either party.

 Pursuant
to these agreements, the Company grants the MCs a non-exclusive right to use Company's trademarks, as listed in the agreements
for the goods and services offered by the MCs in Japan and the U.S. (including U.S. territories) for the duration of the agreement. Pursuant
to the Agreements, the MCs cannot grant a sublicense to a third party without the Company's written consent.

 Pursuant
to these agreements, the MCs agreed to pay the Company royalties for the license granted, in the form of a monthly fee ranging from 14,000,000
yen (excluding tax) to 53,000,000 yen (excluding tax). However, the parties may change such monthly fee by mutual agreement through consultation.

 The
agreements may be terminated by the Company without notice or demand in certain circumstances as listed out in the agreement, including
but not limited to, if a MC has their business license revoked or suspended by regulatory authorities, becomes insolvent or when one
of the notes or checks that they have drawn or accepted is dishonored, when a petition for commencement of bankruptcy proceedings, civil
rehabilitation proceedings, corporate reorganization proceedings, or special liquidation proceedings has been filed, against or when
a MC itself has filed such a petition or when there has been a material breach by a MC of their agreement with the Company. Additionally,
either party can terminate the agreements if the other party breaches the agreement and such breach is not corrected within 14 days after
written notice. Additionally, the parties can terminate the agreement mid-term by mutual agreement through consultation. Upon termination
of an agreement, regardless of the reason for such termination, or if the term of the agreement expires, a MC must immediately cease
using the Company's intellectual property and must destroy all information in its possession regarding the Company's intellectual
property.

 As
a result of these agreements, the Company collects the following royalty fees from each MC.

 Trademark

 Total

 53,000,000
 yen

 14,000,000
 yen

 67,000,000
 yen

 43,000,000
 yen

 57,000,000
 yen

 100,000,000
 yen

 24,000,000
 yen

 60,000,000
 yen

 84,000,000
 yen

 13,000,000yen

 4,000,000
 yen

 17,000,000
 yen

 700,000
 yen

 200,000
 yen

 900,000
 yen

 2,000,000
 yen

 3,000,000
 yen

 5,000,000
 yen

 Total

 135,700,000
 yen

 138,200,000
 yen

 273,900,000
 yen

 List
of Trademarks

 Jurisdiction

 No./

 Office's

 Reference No.

 Registration
 No.

 Trademark

 Reference
 Translation: Trademark

 Japan

 JP2004-113837

 4872872

 Ritz
 Medical Clinic

 Japan

 JP2005-118409

 4960547

 Beauty Surgery Clinic

 Japan

 JP2007-068373

 5137474

 SBC

 Japan

 JP2007-087297

 5154425

 Thoroughly liposuction

 Japan

 JP2008-006713

 5188529

 Petit
 Plastic Surgery of the Mind

 Japan

 JP2011-018430

 5432190

 goddess
 of (lucky) directions

 Japan

 JP2011-027111

 5446903

 1DAY
 Lift

 Japan

 JP2012-004740

 5504628

 Thoroughly
 Vaser Shaving Method

 Japan

 JP2012-035980

 5532879

 Roppongi
 Ladies Clinic

 Japan

 JP2012-070102

 5554735

 Multi-placenta

 Japan

 JP2013-088725

 5665240

 g

 Multi
 Gel Og (Organic)

 Japan

 JP2015-076589

 5827834

 §

 §

 Japan

 JP2015-123949

 5862075

 Gas
 pedal + brake therapy

 Japan

 JP2016-065374

 5922799

 VARIO
 desigin

 VARIO
 desigin surgery

 Japan

 JP2016-065380

 5922800

 Therma
 up

 Japan

 JP2016-108172

 5967546

 Tokyo
 Ritz Cosmetic Clinic

 Japan

 JP2016-108174

 5967547

 Tokyo
 Ritz Cosmetic Plastic Surgery

 Japan

 JP2018-005037

 6135218

 Forever
 Double Surgery

 Japan

 JP2018-109281

 6246705

 SBC

 Japan

 JP2018-123585

 6258359

 SBC

 Japan

 JP2019-006775

 6219739

 Hair
 Renaissance

 Japan

 JP2019-095442

 6316271

 Regno

 Japan

 JP2019-116526

 6311044

 SBC/MEDISPA

 Japan

 JP2020-007680

 6440611

 Rebast

 Japan

 JP2020-007681

 6440612

 Weekend
 Double Surgery

 Japan

 JP2020-007682

 6440613

 Square
 bifold surgery with minimal swelling

 Japan

 JP2020-007686

 6442941

 Rich
 face

 Japan

 JP2020-007689

 6440614

 bifid surgery

 Japan

 JP2020-007697

 6442942

 PrimaLift

 Japan

 JP2020-007698

 6452042

 D

 3D
 Injection Breast Augmentation

 Japan

 JP2020-007699

 6442943

 Premium
 Injection Breast Augmentation

 Japan

 JP2020-007719

 6411821

 Japan

 JP2020-087298

 6489169

 Pashazo

 Japan

 JP2020-106484

 6427255

 Finas

 Japan

 JP2021-057101

 6531256

 Size Down

 Japan

 JP2021-057102

 6531257

 Finas Medical

 Japan

 JP2021-057107

 6531258

 YELL

 YELL

 Japan

 JP2021-057108

 6531259

 YELL

 Beauty YELL Series

 Japan

 JP2021-057109

 6531260

 Baby
 Skin Light

 Japan

 JP2021-057110

 6571732

 Stain
 Removal 10

 Japan

 JP2021-057111

 6531261

 One
 Day Lift Up

 Japan

 JP2021-057112

 6551007

 1UP

 Pure
 Graft 1UP

 Japan

 JP2021-104550

 6554074

 Mist
 hair removal

 Japan

 JP2022-022482

 6753631

 Beauty Dermatology

 Japan

 JP2022-022483

 6611984

 Medical-size
 diet

 Japan

 JP2022-022488

 6668667

 Teen

 Teen
 double

 Japan

 JP2022-067044

 6858201

 SBC

 SBC
 Itaewon Beauty Clinic

 Japan

 JP2022-067045

 6858202

 SBC

 SBC
 Itaewon Beauty Clinic

 Japan

 JP2022-076824

 6673722

 Mist
 shower hair removal

 Japan

 JP2022-135452

 6693235

 ACNEED

 Japan

 JP2022-143150

 6793985

 SBC

 Japan

 JP2022-143151

 6735600

 Beauty Surgery

 Japan

 JP2022-143152

 6735601

 Japan

 JP2022-143153

 6772456

 Japan

 JP2022-143155

 6826211

 SBC
 Medical Group

 Japan

 JP2022-143156

 6735602

 SBCLABO

 Japan

 JP2022-143157

 SBC

 Japan

 JP2022-143158

 6826212

 SBC
 Medical Group

 Japan

 JP2022-143161

 6711813

 SBC

 Japan

 JP2022-143162

 6711814

 goddess
 of (lucky) directions

 Japan

 JP2022-143165

 6701663

 HR

 HR
 Tablet

 Japan

 JP2022-143166

 6701664

 HR

 HR
 Aqua

 Japan

 JP2022-143167

 6701665

 HR

 HR
 Spray

 Japan

 JP2022-143168

 6711815

 Gala
 Dr. Light.

 Japan

 JP2022-143169

 6711816

 soot-dry

 Japan

 JP2022-143171

 6702889

 Lush
 and beautiful hair cocktail

 Japan

 JP2022-143173

 6711817

 Juliet

 Japan

 JP2022-143179

 6711818

 Smart
 Shape Lift

 Japan

 JP2022-143181

 6708518

 acnesonic

 Japan

 JP2022-143184

 6708519

 Lipolysis
 Linear

 Japan

 JP2022-143187

 6708520

 Q

 Contouring
 Q+

 Japan

 JP2022-143189

 6708521

 Q

 Body
 Refresh Q+

 Japan

 JP2022-143190

 6708522

 photo
 double

 Japan

 JP2022-143191

 6702890

 Platinum
 Cocktail

 Japan

 JP2022-143194

 6708523

 smart
 mesotherapy

 Japan

 JP2022-143196

 6708524

 Lipo
 flat

 Japan

 JP2022-143197

 6708525

 Jet
 Mesotherapy

 Japan

 JP2022-143199

 6722690

 SBC
 Medical Group Holdings, Inc.

 Japan

 JP2022-143200

 6722691

 SBC
 Medical Group Holdings

 Japan

 JP2022-143201

 6793624

 SBC
 ARTMAKE SCHOOL

 Japan

 JP2022-147132

 6861583

 non-shaven

 Japan

 JP2022-147133

 6861584

 FUE

 Smart
 FUE

 Japan

 JP2022-147134

 6861585

 secret
 shaven

 Japan

 JP2022-147135

 6861586

 double
 matrix

 Japan

 JP2022-147136

 6861587

 smart
 method

 Japan

 JP2022-147137

 6861588

 Quick
 Meso

 Japan

 JP2022-147138

 6861589

 jet
 meso

 Japan

 JP2022-147139

 6757836

 Actress
 Injection

 Japan

 JP2022-147140

 6829876

 Quick

 Japan

 JP2022-147141

 6702893

 HQ

 Nano
 Method HQ

 Japan

 JP2022-147142

 6711819

 SBC

 SBC
 MEDISPA White Supplement

 Japan

 JP2022-147143

 6702894

 ACNEED

 ACNEED

 Japan

 JP2022-147144

 6829877

 SBC

 SBC
 Teen Double

 Japan

 JP2022-147145

 6829878

 SBC

 SBC
 Teen Hair Removal

 Japan

 JP2022-147146

 6711820

 SBC

 SBC
 Hybrid Ceramic

 Japan

 JP2022-147147

 6711821

 SBC

 SBC
 Mouthpiece

 Japan

 JP2022-150047

 6751859

 Reverse
 face

 Japan

 JP2022-150048

 6751860

 Reverse
 double

 Japan

 JP2022-150052

 6751861

 1DAY

 1DAY
 Model Small Face

 Japan

 JP2022-150053

 6751862

 1DAY

 1DAY
 Full Itaewon

 Japan

 JP2022-150054

 6751863

 1DAY

 1DAY
 Model Body Shape

 Japan

 JP2022-150056

 6751864

 1DAY

 1DAY
 Rich Face

 Japan

 JP2022-150060

 6774385

 Fat
 Pad

 Fat
 Pad Lift

 Japan

 JP2022-150061

 6774386

 Weekend
 Lift

 Japan

 JP2022-150062

 2days

 Weekend
 2days Slim

 Japan

 JP2022-150063

 Barbie
 Body

 Japan

 JP2022-150064

 1DAY

 1DAY
 dark circles removal

 Japan

 JP2022-150065

 6774387

 Aging
 Lift

 Japan

 JP2023-038087

 6744631

 SBC
 AI

 SBC
 AI

 Japan

 JP2023-038088

 6782966

 Eye
 bag 3 fat

 Japan

 JP2023-038089

 6782967

 Poroporo
 Hair Removal

 Japan

 JP2023-038090

 6782968

 Livestock
 Injection

 Japan

 JP2023-038091

 hair
 growth

 Japan

 JP2023-038092

 6782969

 extra
 hair

 Japan

 JP2023-038093

 Jade
 Skin Dermapen

 Japan

 JP2023-038094

 One
 Coin Hair Removal

 Japan

 JP2023-040937

 6737348

 HAIRSPA

 Japan

 JP2023-073150

 6777865

 SBC
 DreamMeeting

 SBC
 DreamMeeting

 Japan

 JP2023-073151

 6777866

 DreamMeeting

 DreamMeeting

 Japan

 JP2023-076804

 6826221

 SBC
 4-way lift

 Japan

 JP2023-080584

 6826223

 Japan

 JP2023-080585

 6826224

 SBC
 Medical Group Holdings

 Japan

 JP2023-080586

 Beauty Surgery Clinic

 Japan

 JP2023-080587

 6826225

 SBC

 Japan

 JP2023-080588

 Beauty Surgery

 Japan

 JP2023-080589

 6826226

 SBCLABO

 Japan

 JP2023-080590

 6826227

 SBC

 Japan

 JP2023-080591

 Japan

 JP2023-080592

 Japan

 JP2023-080593

 6826228

 QCW

 Japan

 JP2023-080594

 6826229

 Quick
 cosmetic double

 Japan

 JP2023-080595

 6826230

 Beauty Club

 Japan

 JP2023-099091

 Liposuction
 Injection

 Japan

 JP2023-123325

 6858214

 SBC
 ART

 Japan

 JP2023-140581

 Ptosis
 Fat

 Japan

 JP2023-140582

 Spontaneous
 Adhesion

 Japan

 JP2023-140583

 Natural
 Adhesion Bifid Surgery

 Japan

 JP2023-143680

 6858240

 SBC
 TIMELESS C

 Japan

 JP2024-010669

 Ritz
 Cosmetic Surgery

 Japan

 JP2024-033024

 Fat
 Cells(logo)

 Japan

 JP2024-033025

 Fat
 Cells (logo)

 Japan

 JP2024-033026

 Fat
 Cells(logo)

 Japan

 JP2024-033027

 Fat
 Cells

 Japan

 JP2024-040264

 Fat
 Extraction Injection

 Japan

 JP2024-040265

 Fat
 extraction

 Japan

 JP2024-056347

 Hair
 root regeneration injection

 Japan

 JP2024-057812

 Japan

 JP2024-068007

 Weekend
 Breast Augmentation

 Japan

 JP2024-068008

 Mom
 Breast Augmentation

 Japan

 JP2024-069739

 Customized
 Lift

 Japan

 JP2024-069740

 Customized
 Hyal

 Japan

 JP2024-077906

 6847737

 Hallyu
 Skin(LOGO)

 Japan

 JP2024-077907

 6847738

 Hallyu
 Skin

 Japan

 JP2024-092611

 M

 Bad
 M Hormone

 Japan

 JP2024-092612

 Height
 Projection Simulation

 Japan

 JP2024-100228

 Natural
 Fat Injection

 1753629

 QCW

 1753670

 Quick
 cosmetic double

 1753673

 SBC

 1753672

 SBC
 Medical Group Holdings

 1753626

 SBC

 1753625

 SBCLABO

 1753627

 1753628

 Beauty Club

 1754407

 1754273

 1754272

 Beauty Surgery

 1754271

 Beauty Surgery Clinic

 1754406

 SBC

 2017/3591939103Q

 40201708950W

 N/A

 The
 Chelsea Clinic

 2017/292151539X

 40201618496V

 N/A

 Gangnam
 Laser Clinic

 TM/19/05/2849

 40201910975V

 N/A

 SkinGO!
 (Singapore)

 TM/2021/09/036

 40202123160R

 N/A

 Bio
 White

 Our
patent applications, as further described in the table below, include, but are not limited to, specialized technologies for procedures
such as puncture devices for buried double eyelid procedures, simplified buried method surgical equipment, proprietary surgical sutures,
silicone bags for breast augmentation simulations, and microscopic hair volume evaluation method for the treatment of androgenetic alopecia.
Additionally, we have developed patent-pending safety management methods for procedures such as full-incision double eyelid surgery,
lateral canthoplasty, brow lift procedures, cheek sagging prevention methods, and hair removal safety management methods. Furthermore,
we have established unique safety management methods for tattoo removal treatments and hyperhidrosis procedures. By leveraging these
patent-pending technologies, our franchisee clinics enhance the safety and efficiency of these cosmetic surgery procedures.

 List
of Patent Rights

 Name
 of Patent right

 Type

 Jurisdiction

 Date
 of

 No.

 Status

 Feature
 and Content

 Microscope-Based
 Hair Quantity Evaluation Method

 Japan

 JP2023-136711

 of a medical audit system using a microscope and machine learning to observe and analyze hospital procedures

 Hair
 Quantity Evaluation Method

 Japan

 JP2023-136712

 learning model trained on beauty clinic procedure videos to auto-evaluate correct performance

 Utilization
 of Pre-Consultation Educational Videos for AGA Examination

 Japan

 JP2023-136713

 auditing system uses machine learning to evaluate procedural correctness in beauty clinics

 Case
 Imaging System

 Japan

 JP2023-136714

 audit system using image-based machine learning for procedural conformance

 Progress History Management System

 Japan

 JP2023-136715

 for documenting treatment procedures in beauty clinics using continuous image or video capture, supporting understanding, diagnoses,
 training of machine learning models, and auditing of procedure compliance.

 AGA
 Oral Treatment Drug

 Japan

 JP2023-136716

 An
 invention harnessing machine learning for evaluating procedural accuracy based on video data

 AGA
 Topical Treatment Drug

 Japan

 JP2023-136717

 Learning-Based Medical Audit System for Evaluating Hospital Procedures

 AGA
 Topical Treatment Drug

 Japan

 JP2023-136718

 A
 method that uses deep learning to verify procedural compliance in aesthetic clinics

 User
 Burden Reduction Method in Hair Transplant Surgery

 Japan

 JP2023-136719

 Patented
 medical audit system for hair transplant surgery which includes cutting and collection of hair roots, video recording of the procedure,
 and use of a learning model for audit.

 User
 Burden Reduction Method in Hair Transplant Surgery

 Japan

 JP2023-136720

 that captures and analyzes videos of the donor hair shaving process at aesthetic clinics to ensure procedure compliance, and provides
 a wig to reduce psychological stress.

 User
 Burden Reduction Method in Hair Transplant Surgery

 Japan

 JP2023-136721

 An
 invention involving a procedure of hair follicle collection, concealed by remaining hair, integrated with an algorithm for auditing
 surgical compliance

 User
 Positioning Guide Method

 Japan

 JP2023-136722

 Surgical
 Audit System for Hair Transplantation Using Machine Learning

 Japan

 JP2023-136723

 AI
 technology applied to auditing cosmetic clinic procedures for monitoring the appropriateness of specific treatments

 Japan

 JP2023-136724

 The
 present invention is a medical audit system that collects image data, generates a machine learning model for correct hair loss treatment
 using Botox, and evaluates newly acquired treatment videos using this model to assess the correctness of the procedure.

 Japan

 JP2023-136725

 procedures are photographed, features extracted, and using machine learning, models are created to determine conformity of new procedure
 recordings, suggesting improvements when necessary.

 Japan

 JP2023-136726

 Learning Based Audit of Hair Growth Treatments Using DermaPen, Growth Factors and Minoxidil

 Japan

 JP2023-136727

 Learning utilization for medical procedure compliance and improvement

 Method for Hair Transplant Cells

 Japan

 JP2023-136728

 for assessing medical procedures through machine learning models generated from video imagery

 Photo
 Capture Method for Hair Medical Purposes

 Japan

 JP2023-136729

 The
 invention initially involves photographing the user from various angles in a bright room, using the captured images to generate a
 machine learning model, which evaluates if the treatment procedure is carried out as per the procedure in new images or videos.

 Hair
 Growth Composition

 Japan

 JP2023-136730

 of a medical auditing system using machine learning to validate procedures from images taken during treatments at beauty clinics

 Hair
 Growth Composition

 Japan

 JP2023-136731

 An
 invention for auditing procedural compliance in a medical system using a learning model inclusive of IV drip mixture ratios and their
 impacts on health

 Processing System, Information Processing Method, and Program

 Japan

 2/24/2023

 JP2023-027740

 Technology
 capable of verifying the effects of double-eyelid surgery

 Processing System, Information Processing Method, and Program

 Japan

 2/24/2023

 JP2023-027741

 Technology
 capable of verifying the effects of double-eyelid surgery

 Japan

 JP2023-136732

 involves creating a learning model using images of handpiece operation, incorporating relationships between energy hertz number and
 moving speed along with the overlapping process at the large head, auditing new treatments based on this model.

 Japan

 JP2023-136733

 learning model generated from hair removal procedure videos for auditing procedural correctness and preventing hair growth

 Japan

 JP2023-136734

 The
 invention involves capturing hospital procedure activities, identifying procedural issues from the images, using these images as
 training data for machine learning models, and analyzing new videos with the model to ensure proper procedure adherence.

 Japan

 JP2023-136735

 A
 system that learns surgical procedures from images to generate a model for auditing and preventing omissions in future surgeries

 Japan

 JP2023-136736

 A
 method involving image capturing of hospital procedures, creating a learning model from those images using machine learning algorithms,
 and auditing new footage based on this model, with feedback provision for quality improvement if required.

 Japan

 JP2023-136737

 monitoring procedural operations in hospitals via learning model from activity images, checking correct execution of operations with
 specific procedures.

 Japan

 JP2023-136738

 Procedure
 for creating a learning model from surgical operation images for surgery evaluation and feedback

 Japan

 JP2023-136739

 The
 invention is an audit system using machine learning algorithms to verify and guide surgical procedures, ensuring that newly acquired
 procedure videos are following defined procedures.

 Japan

 JP2023-136740

 for auditing hospital procedures through machine learning analysis of captured images

 Japan

 JP2023-136741

 learning model generated from recorded procedures to evaluate new treatments for pain and acne

 Management Method for Ion Introduction Treatment

 Japan

 JP2023-136742

 creating machine-learning models from hospital procedure videos for treatment accuracy and quality control

 Management Method for Ion Introduction Treatment

 Japan

 JP2023-136743

 A
 system for managing, guiding, verifying, and automating needleless therapy procedures, using learning models from existing treatment
 videos

 Japan

 JP2023-136744

 of a medical audit system that uses machine learning to ensure adherence to correct hospital procedures

 Japan

 JP2023-136745

 Machine-learning
 algorithms are used to create a therapeutic protocol for phototherapy procedures, auditing new videos of the procedure for correctness
 and safety, reducing workload and ensuring effective treatment.

 Japan

 JP2023-136746

 for a skin treatment method and process analysis using specific wavelength light and machine learning procedure adherence verification

 Japan

 JP2023-136747

 Using
 Machine Learning for Auditing Beauty Treatment Procedures

 Japan

 JP2023-136748

 learning model for quality auditing of ThermaCool procedure

 Japan

 JP2023-136749

 of process using machine learning model to analyze hospital procedure images for automatic procedural audit.

 Japan

 JP2023-136750

 on creating a learning model using machine learning methods for auditing procedures in beauty clinics, particularly the 'Thermacool
 Eye' procedure, based on sequential image data.

 Japan

 JP2023-136751

 A
 medical audit system for beauty clinics utilizing machine learning for procedure adherence and quality improvement

 Japan

 JP2023-136752

 learning based auditing and feedback on beauty clinic procedures by using treatment images and analysis

 Japan

 JP2023-136753

 Enlighton's
 laser treatment procedure learning model based on hospital images and machine learning for auditing treatment alignment

 Japan

 JP2023-136754

 using machine learning to recognise and audit treatment procedures in clinics

 Management Method for Tattoo Removal Treatment

 Japan

 JP2023-136755

 The
 invention is a medical audit system that employs machine learning to formulate a hospital action model based on videos of treatment
 procedures, and verifies the appropriateness of spot size selection and wavelength utilization.

 Management Method for Hyperhidrosis Treatment

 Japan

 JP2023-136756

 A
 medical audit system using machine learning to analyze MiraDry beauty treatments, alerting deviations from normal procedures and
 improving from irregularities.

 Japan

 JP2023-136757

 An
 invention of an automated auditing procedure using a machine learning model created from filmed medical procedures, specifically
 for snoring treatments using a YAG laser

 Japan

 JP2023-136758

 Documentation
 of Device Power Setup, Filming and Light Exposure Procedure with Sterispot Handpiece for Training Model Creation

 Japan

 JP2023-136759

 Produces Learning Model for Medical Procedures from Hospital Images and Audits New Videos for Protocol Adherence

 Japan

 JP2023-136760

 Audit System Utilizing Machine Learning for Procedure Adherence Analysis

 Japan

 JP2023-136761

 embodying a machine learning model analyzing hospital surgery procedures from video data for adherence verification and progress
 monitoring

 Japan

 JP2023-136762

 records and analyses videos of HIFU shower treatment procedures in hospitals using a deep learning model.

 Japan

 JP2023-136763

 proposes the use of machine learning to monitor medical procedures via camera recordings, generating a model from recorded images
 for safe evaluation, and auditing new video content according to the model

 Japan

 JP2023-136764

 for a method in beauty clinics using machine learning to ensure correct procedure during High-Intensity Focused Ultrasound treatment

 Management Method for Salicylic Acid Facial Peeling Treatment

 Japan

 JP2023-136765

 learning used to ensure accuracy and safety in chemical peeling procedures with salicylic acid macrogol

 Management Method for Salicylic Acid Body Peeling Treatment

 Japan

 JP2023-136766

 The
 invention is a medical audit system that uses machine learning techniques to create a model from surgery images, analyzes new surgical
 procedures for guideline adherence, and suggests corrective measures for inappropriate procedures, thus improving procedure quality
 and safety.

 Management Method for Skin Treatment Using Plant-Based Activated Charcoal and Lactic Acid

 Japan

 JP2023-136767

 relating to a learning model for recognition and adherence to correct black peel application procedure

 Management Method for Skin Treatment Using Plant-Based Activated Charcoal and Lactic Acid

 Japan

 JP2023-136768

 A
 system that records and analyzes medical activities in a hospital using machine learning to detect specific patterns and improve
 accuracy.

 Japan

 JP2023-136769

 of a medical audit system that generates a learning model from images of specific beauty clinic procedures and evaluates new treatments

 Japan

 JP2023-136770

 Automated
 Medical Audit System for Beauty Clinics

 Japan

 JP2023-136771

 Learning System Developed to Enhance Quality of Medical Procedures

 Japan

 JP2023-136772

 Video
 analysis method for performance evaluation in beauty clinics using machine learning

 Japan

 JP2023-136773

 The
 system generates a learning model from pre-operative images, trains it using deep learning for ProShock Shape procedures, analyzes
 real-time videos for correctness, reports any anomalies, and counters the long tail problem using diverse treatment image datasets.

 Japan

 JP2023-136774

 of a medical auditing system that uses machine learning to analyze procedural adherence in clinics

 Japan

 JP2023-136775

 Procedure
 for auditing treatments using machine learning models derived from filmed treatment procedures

 Japan

 JP2023-136776

 Learning System for Safety and Quality Assurance in Beauty Clinics

 Japan

 JP2023-136777

 A
 procedural audit system for cosmetic treatments using machine learning model based on video footage of procedures

 Japan

 JP2023-136778

 creates a learning model for medical procedures using image recognition, information extraction, and machine learning, and compares
 new procedures against this model for accuracy and appropriateness.

 Japan

 JP2023-136779

 covers a machine learning method to ensure procedural standards in beauty clinics

 Japan

 JP2023-136780

 uses machine learning model to analyze images or video frames from hospital actions to deduce correctness of procedures

 Japan

 JP2023-136781

 An
 innovative surgical procedure combining cooling, disinfection, needle insertion, hemostasis, and various other techniques, with automatic
 auditing and learning models for improving treatment efficiency.

 Japan

 JP2023-136782

 auditing system using AI to verify adherence to cosmetic treatment procedures

 Japan

 JP2023-136783

 audit system using machine learning for validating skin treatments

 Japan

 JP2023-136784

 AI
 used for learning and verifying adherence to medical procedures in hospitals using collected image data.

 Japan

 JP2023-136785

 A
 medical audit system employing image recognition and machine learning to ensure correct hospital procedures

 Japan

 JP2023-136786

 of a Learning Model for Treatment Procedure Recognition and Surveillance in Beauty Clinics

 Japan

 JP2023-136787

 The
 invention documents beauty clinic procedures, especially HIFU treatments, creates a learning model using the recorded data and deep
 learning, using it for predictive analysis of new video data for real-time treatment auditing.

 Japan

 JP2023-136788

 for a machine learning model generated from a three-step procedure, used to audit the adherence of treatment videos to the established
 procedure

 Japan

 JP2023-136789

 A
 processing device audits beauty clinic procedures by extracting and learning from past treatment videos, evaluating new videos, reporting
 inaccuracies, and continually updating its learning model for accurate future audits.

 Japan

 JP2023-136790

 creates a learning model for auditing adherence to procedural steps in skin disease treatments using machine learning

 Japan

 JP2023-136791

 Beauty
 clinic procedure involving liver-spot treatment via pulsed needle oscillation being audited through a machine learning model.

 Japan

 JP2023-136792

 for recording and analyzing treatment processes using machine learning

 Japan

 JP2023-136793

 for a medical procedure using botulinum toxin, featuring a machine learning tool which audits the treatment process using filmed
 visual data

 Japan

 JP2023-136794

 audit system uses deep learning to analyze and monitor cosmetic clinic procedures

 Japan

 JP2023-136795

 uses machine learning to evaluate the accuracy of acne treatment procedures in a beauty clinic.

 Japan

 JP2023-136796

 learning model developed for analyzing fat freezing procedure videos to detect complications

 Japan

 JP2023-136797

 A
 three-step procedure at a beauty clinic uses photographic evidence collected during a fat cooling treatment to create a machine learning
 model that assesses procedure compliance and symptom occurrence.

 Japan

 JP2023-136798

 Learning
 model developed from hyaluronic acid injection videos monitors for side effects and provides response instructions

 Japan

 JP2023-136799

 A
 medical audit system learns from images of various treatments in hospitals, and uses this learning model to evaluate and update treatment
 procedures for ailments such as liver spots, red face, and pores, using devices such as VISIA_Evolution.

 Japan

 JP2023-136800

 Invasive
 short pulse bipolar high-frequency device utilizes a single-use chip with 25 micro needle electrode pins for facial treatments, with
 machine learning enhancing auditing of the process.

 Japan

 JP2023-136801

 of Machine Learning in Auditing and Improving RF Microneedling Therapeutic Procedures

 Japan

 JP2023-136802

 An
 invention that incorporates a machine learning model for assessing adherence to body contouring procedures in Asian patients using
 RF and BioEMS devices, coupled with image capture methods such as CT scan or ultrasound, through videos from beauty clinic treatments.

 Japan

 JP2023-136803

 This
 invention is a method for deploying a medical audit system using a Radio Frequency (RF) micro needling device to monitor and review
 treatment procedures.

 Japan

 JP2023-136804

 for auditing medical procedures using a learning model generated from collected images

 Japan

 JP2023-136805

 utilizes machine learning to analyze and validate procedure of age spot treatments in beauty clinics

 for Accelerating Recovery of Motor Ability After Anesthesia

 Japan

 JP2023-136806

 A
 staged auditing system utilizing machine learning from past surgical videos to provide guidelines on procedural technique, anesthetic
 dosage, and post-procedure recovery measures

 Estimation
 Method for Recovery Time of Motor Ability

 Japan

 JP2023-136807

 learning model using in-hospital images and parameters to estimate anesthetic duration and ensure procedural adherence

 Estimation
 Method for Anesthesia Effect

 Japan

 JP2023-136808

 for a system capturing and analyzing video footage of treatments in beauty clinics for machine-learning-based auditing of anesthesia
 administration.

 Device
 for Puncturing Buried Double Eyelids

 Japan

 JP2023-136809

 Deep
 learning model for evaluating surgical procedures at beauty clinics

 Simplified
 Buried Suture Surgery Apparatus

 Japan

 JP2023-136810

 and System for Auditing Surgical Procedures through Machine Learning

 Surgical
 Thread

 Japan

 JP2023-136811

 audit system using machine learning to assess the appropriateness of medical procedures in cosmetic clinics from images

 Silicone
 Bag for Breast Augmentation Simulation

 Japan

 JP2023-136812

 of a silicone bag for simulating breast augmentation surgery that assists in visualizing post-surgery appearance and monitoring surgical
 progress using a learning model.

 Reservation Reception System

 Japan

 JP2023-136813

 for optimizing medical services by matching users with suited physicians using a personalized database

 Surgery
 Applicability Determination System

 Japan

 JP2023-136814

 A
 system utilizing a database of medical histories and a machine learning model based on hospital video data to ascertain surgical
 feasibility and process understanding

 Surgery
 Applicability Determination System

 Japan

 JP2023-136815

 Automated
 System for Managing Treatment Intervals Using a Learning Model

 Sharing Fixed System

 Japan

 JP2023-136816

 learning method to monitor and analyze hospital procedures through images and video data

 Japan

 JP2023-136817

 that tracks and verifies the number of cotton balls used in surgery via image analysis and deep learning algorithms

 Japan

 JP2023-136818

 of a Medical Audit System Using Machine Learning for Procedure Verification and Reoperation Decision-Making

 Japan

 JP2023-136819

 for auditing medical procedures through machine learning from hospital images

 Management Method for Full Incision Method Double Eyelid Surgery

 Japan

 JP2023-136820

 An
 invention of an auditing system that uses a machine learning model to analyze medical procedures through images, ensuring procedures
 are carried out correctly without human visual inspection.

 Management Method for Outer Corner Cutting Surgery

 Japan

 JP2023-136821

 learning model generated from past surgical images to automatically audit new surgical videos for correct procedure

 Management Method for Brow Lift Surgery

 Japan

 JP2023-136822

 for a Learning Model to Monitor and Assess Correctness of Beauty Clinic Procedures Using Filmed Footage and Machine Learning

 Japan

 JP2023-136823

 uses Machine Learning to Evaluate the Compliance of Procedure Performance

 Japan

 JP2023-136824

 A
 machine learning model based on medical procedure steps for analyzing and verifying procedural adherence in new videos

 Japan

 JP2023-136825

 A
 medical audit system using machine learning to map surgical images to pre-surgical procedures, identify procedures in new surgical
 images, and verify their sequence against therapeutic procedures

 Japan

 JP2023-136826

 Innovation
 in a Surgical Procedure: Monitoring Compliance through Machine Learning

 Japan

 JP2023-136827

 of a learning model using recorded actions from blepharoptosis surgery to analyze new surgical videos

 Japan

 JP2023-136828

 Learning Model for Quality Analysis of Epicanthoplasty Procedures

 Japan

 JP2023-136829

 A
 medical audit system for ophthalmological procedures that uses a machine learning model to analyze surgical videos for procedural
 adherence.

 Japan

 JP2023-136830

 that creates learning model based on surgical images to audit newly recorded surgical procedures and provide detailed surgical records
 for future medical care

 Japan

 JP2023-136831

 Technology
 that uses surgical videos for machine learning to standardize medical procedures.

 Japan

 JP2023-136832

 learning model using Convolutional Neural Network identifies actions in beauty clinic treatment videos to ensure predetermined procedures
 are being followed.

 Japan

 JP2023-136833

 A
 medical audit system that uses machine learning to analyze image data and ensure procedural compliance in surgical operations

 Japan

 JP2023-136834

 A
 system that uses machine learning to audit and improve surgical procedures in a beauty clinic

 Japan

 JP2023-136835

 The
 medical audit system employs two methods; the first one uses a micropore and a Denver splint, while the second method uses an Orfit
 and hot water combined with a series of taping procedures

 Japan

 JP2023-136836

 of an audit system for capturing and analyzing physician's procedural steps during nose tip surgery

 Japan

 JP2023-136837

 involves a surgical procedure with application of machine learning model trained by deep learning to verify newly acquired images
 against procedure steps

 Japan

 JP2023-136838

 The
 process involves designing thread placement in surgery, creating a learning model using images, utilizing image recognition technology
 for feature extraction, and employing the model to analyze the adherence to proper procedures.

 Japan

 JP2023-136839

 A
 method for monitoring medical procedures using machine learning analysis of image data

 Japan

 JP2023-136840

 A
 method of using a machine learning model to monitor the removal and suturing of nasal wing skin in a cosmetic procedure, notifying
 stakeholders if the process is being improperly performed.

 Japan

 JP2023-136841

 learning method for error detection and quality improvement in alar reduction surgeries

 Japan

 JP2023-136842

 involves a procedure including creating a design, administering anesthesia, inserting a thread into the puncture site, carrying out
 hemostasis, auditing number of needles used, erasing the design and protecting the puncture site, all informing the creation of a
 learning model from hospital images for procedural compliance audit.

 Japan

 JP2023-136843

 for a machine-learning algorithm to record, analyze and provide feedback on the correctness of nasal septum extension procedures

 Japan

 JP2023-136844

 involves creating learning model from hospital procedure images for auditing accuracy of procedures using machine learning

 Management Method for Equipment

 Japan

 JP2023-136845

 for Efficient Management and Utilization of PDS Sheets in Medical Procedures

 Japan

 JP2023-136846

 Development
 of a learning model from image analysis of cosmetic surgery procedure for chin repositioning using prosthetic cartilage

 Cheek
 Sag Prevention Method

 Japan

 JP2023-136847

 audit system uses machine learning to record procedures, generate learning models, and evaluate new procedures' appropriateness.

 Japan

 JP2023-136848

 of a Monitoring System utilizing Machine Learning to Audit Procedures based on Captured Images

 Japan

 JP2023-136849

 related to an auditing system for ensuring adherence to prescribed steps in liposuction surgery to improve healthcare quality

 Japan

 JP2023-136850

 This
 patent describes a minimally invasive surgery procedure for obesity and body contouring, using an 18G perforator and fat suction
 injections, with the operation filmed and continuously improved through the advancement of machine learning models.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for the
 white face bandage (balance cargo) method.

 Japan

 JP2023-136851

 A
 patent system involving White Faceband (Balance Cargo) method with manual compliance monitoring and recording systems, display guide
 system, and a robotics application system.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for the
 chin-neck bandage (Lumbic) method.

 Japan

 JP2023-136852

 A
 system for monitoring, guiding, recording compliance, and utilizing robotics for the Ranbick method for Chin Neck Bandages.

 compliance monitoring system, manual display guide system, manual compliance recording system, and robotics application system for
 the upper arm S compression method.

 Japan

 JP2023-136853

 This
 is regarding various systems for implementing upper arm S compression, such as manual compliance monitoring, display guidance, recording
 systems, and robotic application.

 Abdomen,
 waist, and hip S Manual compliance monitoring system, manual display guide system, manual compliance record system, and robotics
 application system for compression methods.

 Japan

 JP2023-136854

 for manual monitoring, guidance, and recording of abdomen, waist, and lower back compression with robotics application

 Waist
 and waist S Compression method of liposuction — Amulet — Manual compliance monitoring system, manual display guide system,
 manual compliance record system, and robotics application system related to the method.

 Japan

 JP2023-136855

 A
 system for waist and abdominal fat liposuction using the 'Amulet' compression method with compliance monitoring, guidance
 display, record keeping, and robotic applications.

 Waist
 and waist liposuction compression method — abdominal band — manual compliance monitoring system, manual display guide
 system, manual compliance record system, and robotics application system related to the method.

 Japan

 JP2023-136856

 A
 system for monitoring compliance with manual guidelines in the compression method for waist fat suction using an abdominal band,
 including a guide display, record system, and application of robotics.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for the
 gluteal knee S compression method.

 Japan

 JP2023-136857

 regarding systems for applying major gluteal knee S compression methods including monitoring, guiding, recording compliance, and
 robotic application.

 compliance monitoring system, manual display guide system, manual compliance recording system, and robotics application system for
 the lower leg S compression method.

 Japan

 JP2023-136858

 Systems
 for monitoring and recording compliance with a manual for lower leg S compression method, manual guidance display, and application
 system for robotics

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for the
 lower body S compression method.

 Japan

 JP2023-136859

 Systems
 related to lower body comfort involving pressure techniques, including systems for manual adherence, guidance, recording compliance,
 and robotics applications.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 for thigh fixation methods.

 Japan

 JP2023-136860

 A
 femur fixation method with manual adherence monitoring, guidance display, compliance recording, and robotic application system.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 related to the two arm fixation method.

 Japan

 JP2023-136861

 for Monitoring and Recording Compliance with Upper Arm Securing Manual using a Guide Display and Robotics

 Induction
 Method for Hair Removal Device

 Japan

 JP2023-120738

 for Surgery Audit System Using Machine Learning for Quality and Safety Assessment

 Induction
 Method for Hair Removal Device

 Japan

 JP2023-120739

 Using
 a machine learning model to evaluate the accuracy of laser hair removal treatment based on observed laser movements

 Japan

 JP2023-120740

 uses machine learning to audit hospital procedures and compliance, checking actions against generated models and ensuring record
 keeping.

 Japan

 JP2023-120741

 Use
 of Multiscale Health Assessment Procedure with Machine Learning for Risk Evaluation and Compliance Check in Treatment Procedures

 Japan

 JP2023-120742

 involves utilizing captured images of hospital procedures to develop a learning model for operations, specifically for evaluating
 correct use of a spacer and guide light in irradiation range.

 Japan

 JP2023-120743

 Improve
 Laser Surgery Techniques and Cleanliness in Beauty Clinics using Machine Learning

 Japan

 JP2023-120744

 embodies a process of evaluating and reducing levels of pain, redness, swelling and hypersensitivity post exposure, and generates
 a learning model using machine learning algorithms to monitor new operations.

 Japan

 JP2023-120745

 for auditing medical procedures using a learning model generated from filmed actions, focusing on irradiation speed and overlap degree.

 Japan

 JP2023-120746

 for auditing health procedures using a learning model generated from recorded data

 Japan

 JP2023-120747

 A
 patent detailing a machine learning model that generates and uses a database of images captured within a hospital to analyze and
 determine proper actions

 Japan

 JP2023-120748

 An
 auditing system for procedures in aesthetic clinics utilizing hair removal lasers, providing monitoring, learning models, analysis
 and feedback on procedure accuracy.

 Checklist
 Manual compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system
 for implantation double prosthesis method.

 Japan

 JP2023-120749

 for monitoring, guiding, recording checklist compliance and applying robotics for buried double-treatment methods

 Checklist
 Manual compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system
 for the chin prosthesis method.

 Japan

 JP2023-120750

 The
 document discusses systems related to the Agoprosthesis method, including monitoring, guiding, record tracking, and robotics application.

 Checklist
 Manual compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system
 related to the bacar fat and molluscum contagiosum method.

 Japan

 JP2023-120751

 related to a system for monitoring adherence to the Checklist Buckelfat-Meelerfat method, displaying guidelines, logging compliance,
 and application in robotics.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system related
 to the fat injection breast augmentation method.

 Japan

 JP2023-120752

 and robotics systems for compliance monitoring, display guide, recording, related to fat injection for breast augmentation.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system related
 to the pure graft 1UP method.

 Japan

 JP2023-120753

 The
 patent pertains to the PureGraft 1UP method incorporating a manual compliance monitoring system, display guide system, recording
 system, and a robotics application system.

 A
 manual compliance monitoring system, a manual display guide system, a manual compliance record system, and a robotics application
 system related to the condensed rich liposuction method.

 Japan

 JP2023-120754

 A
 system pertaining to condensed rich fat injection featuring a monitoring system for manual compliance, a descriptive manual guide
 system, a record system, and a robotics application system.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system related
 to the serration method.

 Japan

 JP2023-120755

 about cell fusion techniques systems including supervision, display and recording of manual guidelines, and a robotics application
 system.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system related
 to the method of fat augmentation injection (petit breast augmentation) with anesthesia for peace of mind.

 Japan

 JP2023-120756

 for Monitoring and Automating Fat Grafting Breast Enhancement Injection Procedures

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system related
 to the submammary method of breast augmentation by inserting artificial breast implants.

 Japan

 JP2023-120757

 for monitoring and recording the compliance of implantation procedures for artificial breast augmentation with sub-mammary techniques

 Breast
 augmentation by insertion of artificial breast implants: Manual compliance monitoring system, manual display guide system, manual
 compliance record system, and robotics application system for the submammary method.

 Japan

 JP2023-120758

 A
 system for breast augmentation with artificial implants using subpectoral method featuring manual adherence monitoring, display guide,
 recording compliance, and application of robotics.

 Breast
 augmentation with artificial breast implants: Manual compliance monitoring system, manual display guide system, manual compliance
 record system, and robotics application system related to the subpectoral fascia method.

 Japan

 JP2023-120759

 A
 system related to breast augmentation surgery using the Subpectoral method, comprising a manual adherence monitoring system, display
 guide system, compliance record system, and robotics application.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for the
 ENT method.

 Japan

 JP2023-120760

 The
 manual paper discusses the ENT method including systems for manual compliance monitoring, display guides, recording adherence and
 the use of robotics.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 related to MMBAG compression methods.

 Japan

 JP2023-120761

 Document
 on MMBAG compression method featuring monitoring, display guide, compliance recording, and robotics application systems

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for MMBAG
 breath band fixation method.

 Japan

 JP2023-120762

 on MMBAG wristband fixation method in compliance monitoring, manual display guide, compliance recording and robotics application
 systems

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for SNP
 breast duct preservation method.

 Japan

 JP2023-120763

 related to SNP ductal preservation method including manual adherence monitoring, display guide, record system and robotics application

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for SNP
 conventional method.

 Japan

 JP2023-120764

 SNP
 method involves systems for monitoring, displaying, recording manual adherence, and applying robotics.

 LA
 Manual compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system
 for the nipple base excision method.

 Japan

 JP2023-120765

 Document
 on LA mammary papillary base resection method, discussing compliance monitoring, guide and recording systems, and robotic application

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for LA
 nipple circumference excision method.

 Japan

 JP2023-120766

 A
 system related to the LA nipple periphery excision method, featuring a manual compliance monitoring, display guide, recording system,
 and applications in robotics.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for the
 method of sunken nipple removal.

 Japan

 JP2023-120767

 A
 system related to the innie nipple method, including monitoring, display guide, compliance recording, and robotics application systems.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for Montgomery
 gland removal method.

 Japan

 JP2023-120768

 A
 method for removing Montgomery glands using a manual adherence monitoring, display guide, recording system, and robotics application
 system.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for breast
 reduction round method.

 Japan

 JP2023-120769

 for a manual and robotic system for monitoring, guiding and recording compliance in breast reduction surgeries using the 'Round
 method'

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for the
 inverted T-shape breast reduction method.

 Japan

 JP2023-120770

 An
 oversight and guidance system for 'Reverse T' breast reduction surgery ensuring procedural adherence and record compliance

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for rich
 face, CRF, and nano rich methods.

 Japan

 JP2023-120771

 A
 system involving RichFace, CRF, and NanoRich methods with manual compliance monitoring, display guide, recording systems and a robotics
 application.

 compliance monitoring systems, manual display guide systems, manual compliance record systems, and robotics application systems related
 to filagelar methods.

 Japan

 JP2023-120772

 The
 excerpt discusses a system connected to the Filagera method that incorporates manual compliance monitoring, display guide systems,
 compliance recording, and robotics application.

 compliance monitoring systems, manual display guide systems, manual compliance record systems, and robotics application systems related
 to balancer handling methods.

 Japan

 JP2023-120773

 Systems
 pertaining to balancer handling including monitoring adherence to manual, manual display guidance, compliance recording, and robotics
 applications.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 for muftogun methods.

 Japan

 JP2023-120774

 The
 Maftogan method encompasses systems for manual compliance monitoring, display guide, compliance recording, and robotics application,
 providing an efficient framework for procedural tasks execution and oversight.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 for the thread lift floating method in which the piercing part is not a hairy part.

 Japan

 JP2023-120775

 A
 system including a thread lift floating method, a compliance monitoring system, a display guide system, a compliance recording system,
 and a robotics application system without hairy area insertion.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for methods
 in which the thread lift floating insertion site is a hairy part.

 Japan

 JP2023-120776

 A
 method involving thread lift floating with hair insertion, alongside monitoring, display, recording systems for manual compliance,
 and an application for robotics.

 (Limited)
 A manual compliance monitoring system, a manual display guide system, a manual compliance recording system, and a robotics application
 system relating to a small face rejuvenation lift method.

 Japan

 JP2023-120777

 A
 facial rejuvenation lift system featuring compliance monitoring, display guide, compliance recording and a robotic application to
 ensure correct and efficient procedures.

 A
 manual compliance monitoring system, a manual display guide system, a manual compliance recording system, and a robotics application
 system relating to an incisional forehead lift method.

 Japan

 JP2023-120778

 A
 system related to the Incision Forehead Lift method including a manual compliance monitoring system, display guide, recording system,
 and a robotics application.

 A
 manual compliance monitoring system, a manual display guide system, a manual compliance record system, and a robotics application
 system related to the submental muscle binding method.

 Japan

 JP2023-120779

 about systems related to restraining submandibular muscles, including adherence monitoring, manual guide display, compliance record
 keeping, and robotics application.

 A
 manual compliance monitoring system, a manual display guide system, a manual compliance record system, and a robotics application
 system related to a baser shaving method.

 Japan

 JP2023-120780

 for systems that supervise, guide, and record manual compliance with 'Beyzer Shaving Methods' and apply robotics.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for shaving
 method.

 Japan

 JP2023-120781

 for monitoring adherence to a shaving manual, providing display guides, recording compliance, and applying robotics.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system related
 to the complete extraction method.

 Japan

 JP2023-120782

 Detailed
 extraction method system featuring manual compliance monitoring, display guide, record system, and robotics application.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 related to the Sooso OS method.

 Japan

 JP2023-120783

 SksoOS
 method concerning a monitoring system for manual compliance, a display guide system, documentation system for manual compliance and
 an application system for robotics

 Compliance Monitoring System, Manual Display Guide System, Manual Compliance Recording System, and Robotics Application System for
 Tattoo Removal Method by Excision.

 Japan

 JP2023-120784

 The
 system for tattoo removal by ablation includes compliance monitoring, instruction guide display, manual compliance record, and robotics
 application.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for tattoo
 removal by skin grafting.

 Japan

 JP2023-120785

 A
 patent about a tattoo removal system utilizing skin grafts, which includes features for operation manual compliance monitoring, display
 guidance, record keeping, and robotics application.

 Tattoo
 removal by skin grafting Manual compliance monitoring system, manual display guide system, manual compliance record system, and robotics
 application system for skin grafting method.

 Japan

 JP2023-120786

 A
 tattoo removal method using skin grafting with system to track and ensure adherence to the manual procedures, including a guide display
 and robotics application.

 Tattoo
 removal by skin grafting Manual compliance monitoring system, manual display guide system, manual compliance record system, and robotics
 application system for full-layer skin grafting methods.

 Japan

 JP2023-120787

 for tattoo removal via skin transplantation with compliance monitoring, display guide, recording system, and robotics application

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system related
 to the "Cachi" and "Folded ear" methods.

 Japan

 JP2023-120788

 incorporating manual compliance monitoring, display guide, recording systems, and applied robotics for manipulating ears

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for the
 split-ear straight line method.

 Japan

 JP2023-120789

 A
 system for monitoring, displaying, recording adherence to manuals, and a robotics implementation using the straight-line method of
 split ear.

 The
 manual compliance monitoring system, the manual display guide system, the manual compliance record system, and the robotics application
 system related to the cleft ear W-type method.

 Japan

 JP2023-120790

 A
 system related to the 'W-type' method for monitoring manual compliance, display guidance, record adherence, and robotics
 application.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system related
 to the split-ear Z-type method.

 Japan

 JP2023-120791

 Systems
 for the 'Split-ear Z-type' method involving manual compliance monitoring, display guide, compliance recording, and robotics
 application

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for NVL
 method.

 Japan

 JP2023-120792

 The
 text discusses NVL method-based systems for monitoring, displaying, recording compliance with manuals and applications for robotics

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for lip
 enlargement method.

 Japan

 JP2023-120793

 Lip
 enlargement method incorporating systems of compliance monitoring, guide display, adherence recording, and robotics utilization

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for lip
 reduction method.

 Japan

 JP2023-120794

 A
 system for monitoring, guiding, recording compliance, and applying robotics to a lip reduction method

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for gummiesmile
 and mucous membrane resection methods.

 Japan

 JP2023-120795

 A
 system for monitoring and recording adherence to a manual, guidance display, and application of robotics in the method of mucosal
 excision for gummy smile treatment

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for gum
 resection method.

 Japan

 JP2023-120796

 A
 system for gummy smile gingival resection including manual compliance monitoring, display guide, recording, and robotics application.

 compliance monitoring system, manual display guide system, manual compliance recording system, and robotics application system for
 the gummintomy method.

 Japan

 JP2023-120797

 A
 system for monitoring compliance, displaying manual guides, recording compliance, and applying robotics in muscle resection for gummy
 smile correction.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 related to lip lift methods.

 Japan

 JP2023-120798

 A
 lip lift procedure that employs a system for monitoring, guiding, documenting compliance with manual, and robot application.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 for osteotomy and mandibular angioplasty (gill osteotomy and osteotomy) methods.

 Japan

 JP2023-120799

 A
 system concerning bone cutting and mandibular angle formation procedural methods, incorporating manual adherence monitoring, display
 guide, compliance recording systems and a component for robotics application.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for osteotomy
 and mastoid (jaw) plasty methods.

 Japan

 JP2023-120800

 A
 system for bone cutting and jaw reshaping procedures with compliance monitoring, display guide, adherence recording features, and
 the application of robotic technology.

 compliance monitoring system, manual display guide system, manual compliance record system, and robotics application system for osteotomy
 (upper and lower setback) method.

 Japan

 JP2023-120801

 A
 system encompassing osteotomy method, manual compliance monitoring, manual display guide, records keeping, and robotics applications.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 related to forehead shaping methods.

 Japan

 JP2023-120802

 Methodology
 for designing a frontal area featuring a monitoring and guiding system for manual adherence, record-keeping for compliance, and application
 of robotics

 A
 manual compliance monitoring system, a manual display guide system, a manual compliance recording system, and a robotics application
 system related to the pre-procedure photography procedure and the points to keep in mind when taking photographs.

 Japan

 JP2023-120803

 The
 patent relates to various systems for manual adherence monitoring, manual display, recording adherence to manuals, and a robotic
 application, specifically regarding surgical imaging procedures.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 related to pre-procedure photography procedures and methods to keep in mind when taking photographs.

 Japan

 JP2023-120804

 A
 technology system for monitoring adherence to pre-treatment photography manual procedures, including a displaying guide, compliance
 recording, and a robotics application system.

 compliance monitoring systems, manual display guide systems, manual compliance recording systems, and robotics application systems
 related to cleaning methods.

 Japan

 JP2023-120805

 Methods
 of cleansing involving manual compliance monitoring, display guide, compliance recording systems, and robotics application system

 compliance monitoring systems, manual display guide systems, manual compliance record systems, and robotics application systems for
 equipment assembly and sterilization process methods.

 Japan

 JP2023-120806

 relating to systems for the assembly and sterilization process of equipment with monitoring, guidance, recording compliance, and
 robotic application features.

 We
recognize the importance of protecting and enforcing our intellectual property rights. We believe that we have registered all the principal
trademarks and internet domain names in Japan that are necessary for us to carry out our business operations. We believe that we have
filed all patent applications in Japan that are necessary for us to carry out our business operations. We have no patents or patent applications
in Vietnam, Singapore or the United States. We will take the necessary legal action to protect our intellectual property rights if we
discover any infringement of those rights.

 We
license certain intellectual property relating to our business to our franchisee clinics. In addition, we rely on trade secrets, proprietary
know-how, and concepts that are critical to our business, which we also license to our franchisee clinics. Any termination or limitation
of, or loss of intellectual property rights would have a material adverse effect on us and could adversely affect our business, financial
condition or results of operations.

 We
are not currently aware of any material infringement of our intellectual property rights and we believe that we have taken reasonable
measures to prevent infringement of our own intellectual property rights. We do not currently have any pending or, to our knowledge,
threatened claims against us or any of our subsidiaries relating to the infringement of any intellectual property rights owned by third
parties.

 It
is possible that our current patent applications, or patents which we may later acquire or develop, may be successfully challenged or
invalidated in whole or in part. It is also possible that we may not obtain issued patents from our pending patent applications or for
other inventions we seek to protect. Due to uncertainties inherent in prosecuting patent applications, sometimes patent applications
are rejected and we subsequently abandon them. It is also possible that we may develop proprietary products or technologies in the future
that are not patentable or that the patents of others will limit or altogether preclude our ability to do business. In addition, any
patent issued to us in the future, or any of our pending patent applications, may provide us with little or no competitive advantage,
in which case we may abandon such patent, or patent applications, or license them to another entity. Please refer to "Part I, Item
1A. Risk Factors — Risks Related to our Intellectual Property" for more information.

 Insurance

 We
do not maintain product liability insurance for the medical devices, products, and equipment that we sell to the MCs are part of our
provision of purchases services, since we are not the manufacturer of those products. We have fire insurance, leaseholder liability insurance,
and facility liability insurance for our leased spaces (consisting primarily of office space) in case of damages which may be caused
by any incidents or disasters. Further, we maintain cyber insurance in order to combat the increasing risks of cyber-attacks and theft
of patient information, which may lead to litigation, damage to our brand, loss of existing customers and potential customers, regulatory
violations, suspension of operations, and ultimately deterioration of business performance and financial position. We do not maintain
business interruption insurance or key employee insurance for our executive officers. The MCs are responsible for maintaining fire insurance,
leaseholder liability insurance, and facility liability insurance for the franchisee clinic properties. Accordingly, we might be subject
to liabilities that exceed our insurance coverage. See "Part I, Item 1A. Risk Factors — Risk relating to our business and
our industry — Our business is subject to liabilities for which we may not be insured."

 Available

 We
file our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports electronically
with the U.S. Securities and Exchange Commission ("SEC") and such reports can be accessed on our Investor Relations website
at sbc-holdings.com. Alternatively, you may access these reports at the SEC's website at www.sec.gov. We make available,
free of charge, copies of these reports as soon as reasonably practicable after filing these reports with the SEC or otherwise furnishing
it to the SEC. The contents of our website is not incorporated by reference into this Annual Report on Form 10-K or in any other report
or document we file with the SEC, and any references to our website is intended to be an inactive textual references only.

 Item
1A.
 Risk
 Factors

 An
investment in our securities carries a significant degree of risk. You should carefully consider the following risks, as well as the
other information contained in this Annual Report, including our historical financial statements and related notes included elsewhere
in this Annual Report, before you decide to purchase our securities. Any one of these risks and uncertainties has the potential to cause
material adverse effects on our business, prospects, financial condition and operating results which could cause actual results to differ
materially from any forward-looking statements expressed by us and a significant decrease in the value of our common shares and warrants.
Refer to "Cautionary Note Regarding Forward-Looking Statements."

 We
may not be successful in preventing the material adverse effects that any of the following risks and uncertainties may cause. These potential
risks and uncertainties may not be a complete list of the risks and uncertainties facing us. There may be additional risks and uncertainties
that we are presently unaware of, or presently consider immaterial, that may become material in the future and have a material adverse
effect on us. You could lose all or a significant portion of your investment due to any of these risks and uncertainties.

 Risks
Relating to Our Business and Industry

 We
are a holding company and depend upon our operating subsidiaries for our cash flows.

 We
are a holding company. Almost all of our operations are conducted, and almost all of our assets are owned, by our operating subsidiaries.
Consequently, our cash flows and our ability to meet our obligations depend upon the cash flows of our operating subsidiaries and the
payment of funds by these operating subsidiaries to us in the form of dividends, distributions or otherwise. The ability of our operating
subsidiaries to make any payments to us depends on their earnings, the terms of their indebtedness, including the terms of any credit
facilities and legal restrictions. Any failure to receive dividends or distributions from our operating subsidiaries when needed could
have a material adverse effect on our business, results of operations or financial condition.

 We
may need additional capital, and we cannot be sure that additional financing will be available.

we currently anticipate that our available funds and cash flow from operations will be sufficient to meet our cash needs for the foreseeable
future, we may require additional financing. Our ability to obtain financing will depend, among other things, on our development efforts,
business plans, operating performance and condition of the capital markets at the time we seek financing. We cannot assure you that additional
financing will be available to it on favorable terms when required, or at all. If we raise additional funds through the issuance of equity,
equity-linked or debt securities, those securities may have rights, preferences, or privileges senior to the rights of our common stock,
and the existing stockholders may experience dilution.

 We
may not grow our franchise system or we may lose business by failing to compete effectively or by failing to manage the reputation of
our brand.

 Our
success and growth prospects depend on the strength and desirability of our brand. We believe that potential franchisees choose clinics
based primarily on the value and quality of the brand and services, the extent to which affiliation with that franchisor may increase
the franchisee's revenue, and the franchise management service fees charged. Demographic, economic or other changes in markets
may adversely affect the desirability of our brand and, correspondingly, the number of clinics franchised.

 The
terms of new franchise management service agreements may not be as favorable as our current franchise management service agreements.
For example, we may be required to reduce or change fee structures due to regulatory changes, make greater use of financial incentives
such as loans and guaranties to induce the MCs to open new clinics and/or reduce the level of property improvements required before operating
under our brand names. This could potentially impact our margins negatively. In addition, unfavorable borrowing conditions may discourage
potential franchisees from expanding or constructing new clinics, thereby limiting a source of growth of the franchise management service
fees received by us.

 Also,
each of our franchisee clinics competes with major clinic chains in national and international markets and with independent companies
in regional markets. Our ability to remain competitive and to attract and retain franchisee clinic customers depends on our success in
distinguishing our management service, including but not limited to resale of cosmetic products, and services from those offered by competitors
to our franchisee clinics. If we are unable to compete successfully in these areas, this could adversely affect our market share and
our results of operations.

 The
financial performance of our franchisees can negatively impact our business.

 As
all of the MC's clinics, except clinics of Medical Corporation Association Furinkai and Medical Corporation Association Junikai
and one clinic located in Vietnam, were franchised as of December 31, 2024, our financial results are dependent in significant part upon
the operational and financial success of our franchisees. To the extent we are unable to increase the number of franchise clinic locations
in certain locations, are prevented from increasing franchise clinic locations due to historical performance, government regulations,
licensing, registrations, or other factors, we will have a material negative impact on future revenues. Our revenue model and cash flows
rely heavily on franchise management service fees as well as the expiration of clinic customer reward points. A significant reduction
in the total number of new franchisee clinics opened would have a material adverse effect on future revenues. We have established operational
standards and guidelines for our franchisees; however, we have limited control over how our franchisees' businesses are run. While
we are responsible for the anticipated success of our entire system of clinics and for taking a longer-term view with respect to system
improvements, our franchisees have individual business strategies and objectives, which might conflict with our interests. Our franchisees
may not be able to secure adequate financing to open or continue operating their clinics. If they incur too much debt or if economic
or sales trends deteriorate such that they are unable to repay existing debt, our franchisees could experience financial distress or
even bankruptcy. If a significant number of franchisees become financially distressed, it could harm our operating results through reduced
management services revenues and the impact on our profitability could be greater than the percentage decrease in the management services
revenues. Closure of franchised clinics would reduce our management services revenues and other sources of income and could negatively
impact margins, since we may not be able to reduce fixed costs which we continue to incur.

 The
interests of our franchisees may conflict with ours or yours in the future and we could face liability from our franchisees or related
to our relationship with our franchisees.

 The
MCs, even though considered related parties, may from time to time disagree with us and our strategies regarding the business or our
interpretation of our respective rights and obligations under the franchise and management services agreements and the terms and conditions
of the franchisee/franchisor relationship. This may lead to disputes with our franchisees, and we expect such disputes to occur from
time to time in the future as we continue to offer franchises. Such disputes may result in legal action against us. To the extent we
have such disputes, the attention, time and financial resources of our management and our franchisees will be diverted from the clinics,
which could have a material adverse effect on our business, financial condition, results of operations and cash flows even if we have
a successful outcome in the dispute.

 In
addition, various state and federal laws govern our relationship with our franchisees and our potential addition of a franchise clinic
location. A franchisee and/or a government agency may bring legal action against us based on the franchisee/franchisor relationships
that could result in the award of damages to franchisees and/or the imposition of fines or other penalties against us.

 We
could face liability from or as a result of our franchisees.

 Various
laws will govern the relationship between us and our franchisees and the potential addition of a franchise clinic location. If we fail
to comply with these laws, we could be liable for damages to franchisees and fines or other penalties. A franchisee or government agency
may bring legal action against us based on the franchisee/franchisor relationship. Also, under the franchise and management services
business model, we may face claims and liabilities based on vicarious liability, joint-employer liability, or other theories or liabilities.
Such legal actions could result in expensive litigation with our franchisees or government agencies that could adversely affect both
our profit and our important relations with our franchisees. In addition, regulatory or legal developments could result in changes to
laws or the franchisor/franchisee relationship that could negatively impact the franchise business model and, accordingly, our profit.

 We
have limited control with respect to the operations of our medical corporation customers, which could have a negative impact on our business.

 The
MCs, even though considered related parties, are independent business operators and are not our employees. Generally speaking, the
Company does not exercise control over the day-to-day operations of their clinics (except to the extent governed by our management
services contracts). In addition, the CEO of the Company is not able to exert influence over the MC. This is because he neither has
any equity interest of the MC nor is a member (or shain) or a director of the MC. In particular, however, the immediate
family members of CEO are able to exert influence over the MC to the extent of the voting rights, since they are shain of the
MC. The immediate family members of our CEO are members of the following MCs for which we provide services:

 The
immediate family members of our CEO account for two-thirds of the general meeting of member (or shain), which is the decision-making
body in these MCs.

 We
provide training and support to franchisees, and set and monitor operational standards, but the quality of franchised clinics may be
diminished by any number of factors beyond our control. Consequently, franchisees may not successfully operate clinics in a manner consistent
with our standards and requirements or may not hire and train qualified personnel. If franchisees do not operate to our expectations,
our image and reputation, and the image and reputation of other franchisees, may suffer materially and system-wide sales could decline
significantly, which would reduce our management services fees and other revenues, and the impact on profitability could be greater than
the percentage decrease in management services fees.

 The
challenging economic environment may affect our franchisees, with adverse consequences to us.

 We
rely substantially on our franchisees and the manner in which they operate their locations to develop and promote our brand and business.
Due to the continuing challenging economic environment, it is possible that some franchisees could file for bankruptcy or become delinquent
in their payments to us, which could have a significant adverse impact on our business due to loss or delay in payments of management
services fees and other fees. Bankruptcies by our franchisees could prevent us from terminating their franchise and management services
agreements so that we can offer their territories to other franchisees, negatively impact our market share and operating results as we
may have fewer well-performing franchisee clinics, and adversely impact our ability to open new franchisee clinics.

 We
cannot be certain that the MCs and other franchisees we select in the future will have the business acumen or financial resources necessary
to open and operate successful franchises in their franchise areas, and applicable franchise laws may limit our ability to terminate
or modify these franchise arrangements and management services agreements. Moreover, franchisees may not successfully operate clinics
in a manner consistent with our standards and requirements or may not hire and train qualified personnel. The failure of MCs and other
franchisees to open and operate franchises successfully could have a material adverse effect on us, our reputation, our brand and our
ability to open new franchisee clinics and could materially adversely affect our business, financial condition, results of operations
and cash flows.

 Franchisees
may not have access to the financial or management resources that they need to open the clinics contemplated by their agreements with
us or be able to find suitable sites on which to develop them. Franchisees may not be able to negotiate an acceptable lease or purchase
terms for clinic sites, obtain the necessary permits and government approvals or meet construction schedules. Any of these problems could
slow our growth and reduce our franchise revenues. Additionally, our franchisees typically depend on financing from banks and other financial
institutions, which may not always be available to them, in order to construct and open new clinics. For these reasons, franchisees may
not be able to meet the new clinic opening dates required under the franchise agreements.

 If
we are unable to obtain, maintain or protect intellectual property rights, in Japan, in Vietnam, in Singapore, in the U.S. and throughout
the world, we may not be able to compete effectively in our market or globally.

 Our
success depends in significant part on our and our licensees' ability to establish, maintain and protect patents and other intellectual
property rights and operate without infringing the intellectual property rights of others.

 The
patent prosecution process is expensive and time-consuming, and we may not be able to prepare, file and prosecute all necessary or desirable
patent applications at a reasonable cost or in a timely manner. Various foreign governmental patent agencies require compliance with
a number of procedural, documentary, fee payment and other similar provisions during the patent application process and certain periodic
maintenance and annuity fees following patent issuance. It is also possible that we will fail to identify patentable aspects of inventions
made in the course of development and commercialization activities before it is too late to obtain patent protection on them. The lack
of such patent protection may have a materially adverse effect on our business and financial condition.

 Finally,
our patent portfolio encompasses entire pending patent applications and unpatented intellectual property in various jurisdictions,
and the pending patent applications encompassing each of the different technology areas may be assigned different relative and future
values, either based on commercial relevance, patent position strength, patent coverage, claim scope, or any other variables associated
with intellectual property. That is, some aspects of our patent portfolio may be more valuable than other aspects of our patent portfolio.
Inability to obtain patents encompassing critical technologies could more adversely impact our business than inability to obtain patents
encompassing other aspects of our business. Thus, adverse events experienced within specific patent portfolios could critically hamper
our ability to commercialize and conduct business in these key technology areas.

 Globally,
filing, prosecuting, enforcing and defending patents in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in certain countries can be less extensive than those in other jurisdictions. In addition, as noted above,
the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in Japan. Consequently, we
may not be able to prevent third parties from practicing our inventions in all countries. Since we have not obtained patent protection,
competitors may use our technologies and our intellectual property rights may not be effective or sufficient to prevent them from competing.

 We
have substantial franchisee concentration.

 The
number of our franchisees is severely limited since our franchisees primarily consist of the MCs. There are inherent risks whenever a
large percentage of revenues are concentrated with a limited number of franchisees that mainly operate the franchise locations in Japan,
rather than in broad, mainstream commercial operations. We are unable to predict the future level of demand for our services that will
be generated by these franchisees.

 Our
reputation and the trading price of our common stock may be negatively affected by adverse publicity or detrimental conduct against us.

 Adverse
publicity concerning our failure or perceived failure to comply with legal and regulatory requirements, alleged accounting or financial
reporting irregularities, regulatory scrutiny and further regulatory action or litigation could harm our reputation and cause the trading
price of our common stock to decline and fluctuate significantly. The negative publicity and the resulting decline of the trading price
of our common stock may lead to the filing of stockholder class action lawsuits against us and some of our senior executive officers,
and may potentially have further severe impact on the market price of our common stock and divert management's attention from the
day-to-day operations of our company. Our management team plans to conduct additional procedures and actions to mitigate risks of the
short seller allegations that the Company may be subject to. We had not been the subject
of short seller allegations, and this risk factor is discussing allegations that may potentially occur in the future with regard to the
Company. As it is in short sellers' interest for the price of the security to decline, many short sellers publish, or arrange for
the publication of, negative opinions and allegations regarding the relevant issuer and its business prospects in order to create negative
market momentum and generate profits for themselves after selling a security short. These short attacks on public entities have, in the
past, led to selling of shares in the market. Much of the scrutiny and negative publicity in such circumstances has centered on allegations
of a lack of effective internal control over financial reporting resulting in financial and accounting irregularities and mistakes, inadequate
corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud. As a result, many of these companies
are now conducting internal and external investigations into the allegations and, in the interim, are subject to stockholder lawsuits
and/or SEC enforcement actions. Such a situation could be costly and time-consuming, and could divert management's attention from
the day-to-day operations of our company. Even if such allegations are ultimately proven to be groundless, allegations against us could
severely impact the market price of our securities and our business operations. However, we may be constrained in the manner in which
we can proceed against the relevant short sellers by principles of freedom of speech, applicable state law or issues of commercial confidentiality.

 We
may continue to be the target of adverse publicity and detrimental conduct against us, including complaints, anonymous or otherwise,
to regulatory agencies regarding our operations, accounting, revenues and regulatory compliance. Additionally, allegations against us
may be posted on the internet by any person or entity which identifies itself or on an anonymous basis. We and our subsidiaries may be
subject to government or regulatory investigation or inquiries, or stockholder lawsuits, as a result of such third-party conduct and
may be required to incur significant time and substantial costs to defend ourselves, and there is no assurance that we and our subsidiaries
will be able to conclusively refute each of the allegations within a reasonable period of time or at all. Our reputation may also be
negatively affected as a result of the public dissemination of allegations or malicious statements about us, which in turn may materially
and adversely affect the trading price of our common stock.

 We
are a relatively young company with a short operating history, and we may not be able to sustain our rapid growth, effectively manage
our growth or implement our business strategies.

 We
and our subsidiaries have been providing our management services since 2003. Although we have experienced growth, our historical performance
may not be indicative of our future performance due to our limited operating history. We are currently evaluating a continued expansion
of franchisee locations to countries other than Japan, and have a short history of franchise locations outside of Japan. There is only
a limited historical basis for making judgments on the demand for our franchisee clinic services in new locations in the future.

 You
should consider our business and future prospects in light of the risks and challenges associated with our ability to:

 ensure
 that our franchisee clinics are providing safe, convenient and effective cosmetic services;

 maintain
 reliable, secure, high-performance and scalable infrastructure;

 identify
 suitable facilities to expand franchisee clinic capacity and customer base;

 navigate
 the evolving and complex regulatory environment across all the markets in which we and the
 MCs' franchisee clinics operate;

 anticipate
 and adapt to changing market conditions, including technological developments and changes
 in the competitive landscape, and adjust, manage and execute our marketing and sales activities
 to cater to local economic and demographic conditions, cultural differences and customer
 preferences across all our current and future markets;

 successfully
 market our brand;

 improve
 and maintain our operational efficiency; and

 attract,
 retain and motivate talented employees.

 If
we fail to address any or all of these risks and challenges, our business may be materially and adversely affected.

 As
our business grows, we or our subsidiaries may adjust our management services offerings. These adjustments may not bring about expected
results and may instead have a material and adverse impact on our financial condition and results of operations. Our revenue structure
may continue to evolve in response to market demand in locations where the franchisee clinics are located. Our growth is dependent on
the opening of such new franchisee clinic locations. We may not accurately identify market needs before we invest in the development
of a new clinic service. In addition, we might face difficulties or delays in the development process, which may result in losses in
our market share and competitive advantages.

 In
pursuit of our growth strategy, we or our subsidiaries may enter into new strategic relationships to further penetrate our targeted markets.
Should these relationships fail to materialize and develop into demand for our services, or should we fail to work effectively with these
companies, we may lose opportunities to generate clinic growth and our business, results of operations and financial condition could
be adversely affected.

 Our
franchisee clinics may not be successful in competing in the cosmetic clinic industry.

 We
operate in the cosmetic clinic industry by providing management services to our franchisee clinics. Companies engaged in businesses similar
to those of our franchisee clinics are entering the market one after another, and competition is fierce, with a wide range of cosmetic
products and service formats. Our policy is to continue to respond to customer needs and enhance its services. However, if these efforts
do not produce the anticipated results, or if the emergence of competitor clinics offering cosmetic services leads to customers leaving
our franchisee clinics, leading to a decrease in revenues generated by our franchisee clinics, then our business and performance may
be affected since we receive substantial revenue from the MCs as part of our compensation for management services.

 Many
of our franchisee clinics' current and potential competitors, particularly international competitors, have significantly greater
financial, technical, manufacturing, marketing and other resources than we do and may be able to devote greater resources to the design,
development, promotion, and support of their clinics.

 We
expect competition in our industry to intensify in the future in light of increased demand for cosmetic services. Factors affecting competition
include, among others, ability to innovate, service quality, reliability, safety, pricing, and customer service. Increased competition
may lead to lower revenues generated by our franchisee clinics, which may result in downward price pressure and adversely affect our
business, financial condition, operating results and prospects, since we receive substantial revenue from the MCs as part of our compensation
for management services.

 The
Company may face competition from senior management who cease working for it, and the Non-Competition Agreements (as defined below) may
be unenforceable and expire two years following the Closing.

 Following
execution of the Merger Agreement, certain current and former key personnel of Legacy SBC, including Dr. Aikawa, Ryoji Murata, Yuya Yoshida
and Akira Komatsu, entered into non-competition and non-solicitation agreements (the "Non-Competition Agreements"), pursuant
to which they agreed not to compete with the Company and its subsidiaries during the two-year period following the Closing and, during
such two-year restricted period, not to solicit employees or customers or clients of such entities.

 We
cannot be sure that one or more of these parties to the Non-Competition Agreements will not compete with the Company or solicit its employees
or clients in the future. Even if ultimately resolved in its favor, any litigation associated with the Non-Competition Agreements could
be time consuming, costly and distract management's focus from operating the Company's business. Moreover, states and foreign
jurisdictions may interpret restrictions on competition narrowly and in favor of employees. Therefore, certain restrictions on competition
or solicitation may be unenforceable. In addition, the Company may not pursue legal remedies if it determines that preserving cooperation
and a professional relationship with the former employee, or other concerns, outweigh the benefits of any possible legal recourse or
the likelihood of success does not justify the costs of pursuing a legal remedy. Furthermore, the term of the Non-Competition Agreements
expires two years following the Closing. Upon expiration of the term, Dr. Aikawa, Ryoji Murata, Yuya Yoshida and Akira Komatsu, each
of whom are current or former key personnel of Legacy SBC, and continue to be key personnel of the Company, may solicit employees or
customers or clients of the Company. Such persons, because they have worked for Legacy SBC and the Company, may be able to compete more
effectively with the Company, or be more successful in soliciting its employees and clients, than unaffiliated third parties.

 Any
significant change in the franchisee clinic customer reward program could have a negative impact on our business.

 We
depend on the franchisee clinic customer reward program. The customer's points expire if the customer does not make any additional qualified purchase at a participating
clinic within a year. Accordingly, at the time that a customer's points expire, the Company earns 1 yen (approximately $0.0067) for each
customer point that expires. Any material disruption to or changes to the franchisee clinic customer reward program could harm our brand
and adversely affect our operating results. Further, if the franchisee clinics' customers practices change and the number of reward
points that remain unused and expire decreases, then our business and operating results could be adversely affected.

 Any
significant cybersecurity incident or disruption to our operating systems could subject us to significant reputational, financial, legal
and operational consequences.

 We
depend on our and our franchisees' operating systems to operate. Any material disruption to or slowdown of our operating systems
could cause delays in our management services, which could harm our brand and adversely affect our operating results.

 Problems
with our telecommunications network providers could adversely affect our services. Our telecommunications network providers could decide
to cease providing services to us without adequate notice. Any change in service levels of our telecommunications network or any errors,
defects, disruptions or other performance problems with our operating systems or infrastructure could harm our brand and potentially
affect our franchisee clinics access to our management services. If changes in technology cause our operating systems or infrastructure
to become obsolete, or if our operating systems are inadequate to support our growth, we could lose customers, and our business and operating
results could be adversely affected.

 The
Company, its subsidiaries, and the MCs could be subject to breaches of security by hackers. Although we proactively employ multiple measures
to defend our systems against intrusions and attacks, our measures may not prevent unauthorized access or use of sensitive data.

 A
cybersecurity breach could harm our reputation, deter customers and potential customers from buying products or services from our franchisee
clinics, and result in regulatory penalties due to the sensitive nature of our franchisee clinics' customers' medical information.
In addition, any such breach could cause us to incur costs to correct the breaches or failures, expose us to uninsured liability, increase
our risk of regulatory scrutiny, subject us to lawsuits and result in the imposition of material penalties and fines.

 We
may be compelled to undertake product recalls or take other actions, which could adversely affect our brand image and results of operations.

 The
cosmetic products, medical equipment, and medical supplies that we sell may not perform in line with customers' expectations. Any
product defects, accidents or any other failure of the cosmetic products, medical equipment, or medical supplies that we sell to perform
as expected could harm our reputation and result in adverse publicity, revenue loss, delivery delays and product recalls, which could
harm our brand and reputation. Any product recall or lawsuit seeking significant monetary damages may have a material adverse effect
on our business and financial condition. In the future, our suppliers may, voluntarily or involuntarily, initiate a recall if any of
the cosmetic products, medical equipment, or medical supplies that we sell, prove to be defective or noncompliant with applicable laws
and regulations. Such recalls, whether voluntary or involuntary, could cause us to incur significant expenses and adversely affect our
brand image in our target markets.

 We
may become subject to product liability claims or warranty claims, which could harm our financial condition and liquidity if we are not
able to successfully defend or insure against such claims.

 We
may be exposed to significant product liability claims if the cosmetic products, medical equipment, and medical supplies that we sell
do not perform as expected. Any defects in the cosmetic products, medical equipment, and medical supplies that we sell that we sell or
the misuse of the cosmetic products, medical equipment, and medical supplies that we sell could also result in injury, death or property
damage. Our risks in this area are reduced due to the fact that we only act as a seller of the cosmetic products and not as the developer
or manufacturer. A successful product liability claim against us could require us to pay a substantial monetary award. Moreover, a product
liability claim could generate substantial negative publicity about the cosmetic products, medical equipment, and medical supplies that
we sell and our business and inhibit or prevent the sale of current and future cosmetic products, medical equipment, and medical supplies
by us. Since we are not the developer or manufacturer of the cosmetic products, medical equipment, and medical supplies that we sell,
we do not have insurance coverage to cover potential product liability claims. Even if a claim is without merit or subsequently disproven,
the claim could nevertheless diminish our brand and divert management's attention and resources, which could have a negative impact
on our business, financial condition and result of operations.

 We
have limited experience in providing management services to franchisee clinics located outside of Japan and we are subject to a variety
of costs and risks due to our continued international expansion.

 One
of our core strategies is international expansion. We generally have less experience in marketing and providing management services to
franchisee clinics in markets outside Japan. International expansion will require us to invest significant capital and other resources,
and our efforts may not be successful. International franchisee clinic operations are subject to risks such as:

 limited
 brand recognition;

 costs
 associated with establishing new supplier networks;

 difficulty
 in finding qualified franchise partners;

 inability
 to anticipate changes in local market conditions, economic landscapes, and consumers'
 preferences and customs;

 difficulties
 in staffing and managing foreign operations;

 lack
 of familiarity with and understanding of the local legal, regulatory and policy frameworks,
 as well as burdens of complying with a wide variety of local laws and regulations, including
 those governing personal and customer data protection and safety control;

 political
 and economic instability;

 trade
 restrictions;

 differing
 employment laws and practices, as well as potential labor disruptions;

 the
 imposition of government controls;

 lesser
 degrees of intellectual property protection;

 tariffs
 and customs duties and the classifications of the cosmetic products, medical equipment, and
 medical supplies that we sell by applicable governmental bodies; and

 a
 legal system subject to undue influence or corruption.

 The
failure to manage any of these risks could negatively affect our international business and consequently our overall business and operating
results. In addition, the concern over these risks may also prevent us from entering into or marketing our franchisee clinics in certain
markets.

 Our
operations may be interrupted by utility shortages or stoppages, fire, natural disaster or other calamities at or near our facilities.

 Our
franchisee clinics and our clinic depend on a continuous supply of utilities, such as electricity and water, to operate. Any disruption
to the supply of electricity or other utilities may disrupt the services that are provided at our franchisee clinics and our clinics
in Vietnam and Singapore. This could adversely affect our ability to provide cosmetic services to the customers of our franchisee clinics
and our clinics in Vietnam and Singapore, and consequently may have an adverse effect on our business and results of operations since
we receive substantial revenue from the MCs as part of our compensation for management services. In addition, fire, natural disasters,
pandemics or extreme weather, including droughts, floods, typhoons or other storms, or excessive cold or heat, could cause power outages,
fuel shortages, water shortages, damage to our franchisee clinics and our clinics in Vietnam and Singapore, or disruption of transportation
channels, any of which could impair or interfere with the operations of our franchisee clinics and our clinics in Vietnam and Singapore.
We cannot assure you that such events will not happen in the future or that we will be able to take adequate measures to mitigate the
likelihood or potential impact of such events, or to effectively respond to such events if they occur.

 Our
business and prospects depend significantly on our ability to build our Shonan Beauty Clinic brand.

 Our
business and prospects are heavily dependent on our ability to build, maintain and strengthen the Shonan Beauty Clinic brand. If we do
not continue to establish, maintain and strengthen our brand, we may lose the opportunity to build a larger mass of customers for our
franchisee clinics. Promoting and positioning our brand will likely depend significantly on our franchisee clinics' ability to
provide high-quality cosmetic treatments and engage with the customers as intended. In addition, we expect that our ability to develop,
maintain and strengthen the Shonan Beauty Clinic brand will also depend heavily on the success of our branding efforts. Such efforts
mainly include advertising for the franchisee clinics as part of the management services that we provide to the MCs. To promote our brand,
we may be required to change our branding practices, which could result in substantially increased expenses. If we do not develop and
maintain a strong brand, our business, prospects, financial condition and operating results will be materially and adversely impacted.

 Our
Shonan Beauty Clinic brand could be subject to adverse publicity if incidents related to the services provided at our franchisee clinics
or our clinics in Vietnam or Singapore have occurred, whether or not we are at fault. In particular, given the popularity of social media,
including Facebook, X (formerly Twitter), TikTok, Linkedin and Instagram in Japan, any negative publicity, regardless of its truthfulness,
could quickly proliferate and harm consumer perceptions of and confidence in our brand. Furthermore, we may be affected by adverse publicity
related to our franchisees or other partners, whether or not such publicity is related to their collaboration with us. Our ability to
successfully position our brand could also be adversely affected by perceptions of the quality of the services at our franchisee clinics
and our clinics in Vietnam and Singapore. In addition, from time to time, the services at our franchisee clinics and our clinics in Vietnam
and Singapore are evaluated and reviewed by third party customers. Any unfavorable reviews could adversely affect consumer perceptions
of our brand and the quality of services provided at our franchisee clinics and our clinics in Vietnam and Singapore.

 Our
employees, agents, business partners or subcontractors may engage in misconduct or other improper activities, which could cause us to
lose contracts, expose us to damages, harm our reputation and diminish investor confidence in our company.

 We
are exposed to the risk that an employee or subcontractor could commit fraud or other misconduct, including noncompliance with laws (including
anti-bribery laws) or insider trading, which could subject us to civil or criminal investigations in the U.S. and in other jurisdictions,
lead to civil and criminal penalties and related stockholder lawsuits, cause us to incur significant legal fees, and damage our reputation.
As discussed elsewhere in this Annual Report, in January 2024, in connection with a routine tax examination of SBC Medical Group Co.,
Ltd.'s income tax returns, the Japanese tax authority discovered misappropriations of SBC Medical Group Co., Ltd. funds by a former
director of general affairs and legal department of L'Ange Cosmetique Co., Ltd., which is a subsidiary of SBC Medical Group Co.,
Ltd. (the "former director"), not a relative of the CEO of SBC Medical Group Co., Ltd. or any identified related party, who
received kickbacks from multiple vendors of SBC Japan (collectively with the former director, the "participants"). The investigation,
which was completed in March 2024, revealed that the participants had misappropriated approximately JPY632 million ($5.6 million), including
consumption tax, from SBC Medical Group Co., Ltd., of which the former director received approximately JPY335 million ($3.0 million),
between April 2016 and the discovery of the misappropriations in January 2024. This discovery has required us to incur investigative
expenses, required us to restate certain past annual financial statements, subjected us to certain government investigations, and diverted
management attention away from other activities of the business. Were we to discover additional instances of employee fraud or misconduct,
we anticipate such discovery would have similar adverse effects on our business and operations.

 Employee
or subcontractor misconduct could involve the improper use of our customers' sensitive or classified information, which could result
in regulatory sanctions against us, liability to third parties, and serious harm to our reputation and could result in a loss of customers
and a reduction in revenue or profitability.

 We
maintain a system of internal controls to prevent such occurrences, but it is not always possible to deter employee or subcontractor
misconduct, and the precautions we take to prevent and detect this activity may not be effective in controlling unknown or unmanaged
risks or losses. Any instances of employee or subcontractor fraud or misconduct could cause us to lose customers, cause a reduction in
our revenue, expose us to damages, harm our reputation and diminish investor confidence in our company.

 Any
decline in the business of our business partners or the deterioration of our relationship with them could have a material adverse effect
on our operating results.

 We
collaborate with various business partners to promote our Shonan Beauty Clinic brand. There can be no guarantee that those business partners
will continue to collaborate with us in the future. If we are unable to maintain good relationships with our business partners, or the
business of our business partners declines, the reach of our products and services may be adversely affected and our ability to maintain
and expand our user base may decrease.

 Most
of the agreements with our business partners do not prohibit them from working with our competitors or from offering competing services.
If our partners change their standard terms and conditions in a manner that is detrimental to our business, or if our business partners
decide not to continue working with us, or choose to devote more resources to supporting our competitors or their own competing products,
we may not be able to find a substitute on commercially favorable terms, or at all, and our competitive advantages may diminish.

issues or public perceptions of safety issues concerning cosmetic services could have a material adverse impact on our business.

 We
believe that the cosmetic services provided at our franchisee clinics and our clinics in Vietnam, Singapore and United States are generally
safe, however, there is a possibility of risk when undergoing any cosmetic procedure. On rare occasions, a cosmetic procedure may not
go as planned, which may result in an adverse reaction, injury, accidents, casualty, or damages, and subject us to lawsuits.

 Also,
negative public perceptions regarding the safety of cosmetic procedures, even if such incident does not involve our franchisee clinics
or our clinics in Vietnam, Singapore or United States, could seriously harm our business. While we have implemented safety procedures
related to the provision of cosmetic services at our franchisee clinics and our clinic, a safety issue related to the cosmetic services
provided could disrupt our operations, which could have a negative impact on our business, financial condition and result of operations
or could lead to adverse publicity.

 If
our franchisee clinics or our clinics in Vietnam or Singapore fail to comply with environmental and work safety laws and regulations,
the Company and the franchisee clinics could become subject to fines or penalties or incur costs that could harm our business.

 The
Company, its subsidiaries, and the MCs are subject to numerous environmental and work safety laws and regulations. For more details,
see "Part I, Item 1. Business — Government Regulation and Environmental Matters" in this Annual Report. The Company,
its subsidiaries, and the MCs also could incur significant costs associated with civil or criminal fines and penalties for failure to
comply with such laws and regulations. Environmental and social laws and regulations have tended to become increasingly stringent. There
has been increased global focus on environmental and social issues and it is possible that countries may potentially adopt more stringent
standards or new regulations in these areas. To the extent regulatory changes occur in the future, they could result in, among other
things, increased costs to the Company, its subsidiaries, and the MCs. In addition, the Company, its subsidiaries, and the MCs may incur
substantial costs in order to comply with current or future environmental and work safety laws and regulations. These current or future
laws and regulations may impair our franchisee clinic growth efforts. The Company, its subsidiaries, and the MCs' failure to comply
with these laws and regulations also may result in substantial fines, penalties or other sanctions, which could directly result in a
material adverse effect with respect to the Company and/or its subsidiaries, since we receive substantial revenue from the MCs as part
of our compensation for management services.

 If
our business partners, independent contractors, suppliers, or franchisee clinics fail to use ethical business practices and comply with
applicable laws and regulations, our brand image could be harmed due to negative publicity beyond our own control.

 Our
reputation is sensitive to allegations of unethical business practices. We do not control the business practices of our business partners,
independent contractors, suppliers, or franchisee clinics (except to the extent of the guidelines that we provided to the franchisee
clinics). Accordingly, we cannot guarantee their compliance with ethical business practices, such as environmental responsibilities,
fair wage practices, and compliance with child labor laws, among others. A lack of demonstrated compliance could lead us to seek alternative
business partners, independent contractors, or suppliers, which could increase our costs and result in disruptions of our operations.
Violation of labor or other laws by our business partners, independent contractors, suppliers, or franchisee clinics or the divergence
of their labor or other practices from those generally accepted as ethical in the markets in which we do business could also attract
negative publicity, diminish our brand image and reduce demand for cosmetic services at our franchisee clinics and our clinics in Vietnam
and Singapore.

to safeguard personal information could subject us to penalties, damage our reputation and brand, and harm our business and results of
operations.

 The
regulatory framework for privacy and personal information security issues worldwide is rapidly evolving and is likely to remain uncertain
for the foreseeable future. The U.S. federal and various state, local and foreign government bodies and agencies have adopted or are
considering adopting laws and regulations limiting, or laws and regulations regarding, the collection, distribution, use, disclosure,
storage, security and other processing of personal information.

 Concerns
or claims about our practices with regard to the processing of personal information or other privacy-related matters, even if unfounded,
could damage our reputation and results of operations. In Japan, governmental authorities have enacted a series of laws and regulations
to enhance the protection of privacy and data. We may need to adjust our business to comply with data security requirements and other
laws and regulations from time to time. In Japan, the Act on the Protection of Personal Information (the "APPI") and its
related guidelines impose various requirements on businesses, including us, that use databases containing personal information. Under
the APPI, the Company, its subsidiaries, and the MCs are required to lawfully use personal information we have obtained within the purpose
of use we have specified and taken appropriate measures to maintain the security of such personal information. The Company, its subsidiaries,
and the MCs are also restricted from providing the personal information of a person (the "principal") to third parties without
the consent of the principal. The APPI also includes regulations relating to the handling of sensitive personal data and anonymous personal
data and the transfer of personal information to foreign countries. A Personal Information Handling Business Operator (as defined below)
shall not transfer a person's personal data to third parties, including its affiliated entities without the prior consent of the
principal unless an exception applies (Article 27, Paragraph 1 of the APPI). A failure by the MCs to comply with the APPI may harm our
franchised brand and directly result in a reduction of the Company's revenue, since we receive substantial revenue from the MCs
as part of our compensation for management services.

 As
laws and regulations in Japan on the protection of privacy and data are constantly evolving, complying with new laws and regulations
could cause us to incur substantial costs or require us to change our business practices in a manner materially adverse to our business.

 Despite
our efforts to comply with applicable laws, regulations and other obligations relating to privacy, data protection and information security,
it is possible that our practices, offerings or platform could fail to meet all of the requirements imposed on us by such laws, regulations
or obligations. Any failure on our part to comply with applicable laws or regulations or any other obligations relating to privacy, data
protection or information security, or any compromise of security that results in unauthorized access, collection, transfer, use or release
of personally identifiable information or other data, or the perception or allegation that any of the foregoing types of failure or compromise
has occurred, could damage our reputation, discourage new and existing customers of our franchisee clinics and our clinics in Vietnam
and Singapore from obtaining services or result in investigations, fines, suspension of our app, or other penalties by government authorities
and private claims or litigation, any of which could materially adversely affect our business, financial condition and results of operations.
In addition, the interpretation and application of the aforementioned laws and regulations are often uncertain and in flux. Our practice
may become inconsistent with these laws and regulations.

 Our
platform and internal systems depend on the ability of software and hardware developed and maintained internally and/or by third parties
to store, retrieve, process and manage immense amounts of data, including personal information or other privacy-related matters. The
software and hardware on which we rely may now or in the future contain, undetected programming errors, bugs, or vulnerabilities which
may result in errors or compromise our ability to protect the data of our users and in turn adversely affect our business, financial
condition and operation results. Any systems failure or compromise of security that results in the unauthorized access to or release
of the data, photo or messaging history of our users could significantly limit the adoption of our services, as well as harm our reputation
and brand, result in litigation against us, liquidation and other damages, regulatory investigations and penalties, and we could be subject
to material liability.

 If
customers of our franchisee clinics or our clinics in Vietnam or Singapore allege that we have improperly used, released or disclosed
their personal information, we could face legal claims and reputational damage. We may incur significant expenses to comply with privacy,
consumer protection and security standards and protocols imposed by law, regulation, industry standards or contractual obligations. A
major breach of our network security and systems could create serious negative consequences for our business and future prospects, including
possible fines, penalties, reduced customer demand for services at our clinics in Vietnam and Singapore and franchisee clinics, and harm
to our reputation and brand. See "Part I, Item 1. Business — Government Regulation and Environmental Matters — Japan
Laws and Regulations" in this Annual Report for further details.

by the MCs to comply with the Medical Care Act in Japan could subject us to penalties, damage our reputation and brand, and harm our
business and results of operations.

 The
Medical Care Act defines rights and obligations regarding medical treatment, advertisement, authority, license, treatment of information,
safety and security for patients, doctors and other individuals and organizations engaged in medical activities in Japan. A failure by
the MCs to comply with the Medical Care Act may harm our franchised brand and directly result in a reduction of the Company's revenue,
since we receive substantial revenue from the MCs as part of our compensation for management services.

 The
execution of our business plans requires a significant amount of capital. In addition, our future capital needs may require us to sell
additional equity or debt securities that may dilute the equity interests of our stockholders or introduce covenants that may restrict
our operations or our ability to pay dividends.

 We
will need significant capital to, among other things, conduct research and development and expand our franchisee clinic locations. We
may also need significant capital to maintain our existing property and equipment. Our expected sources of capital include both equity
and debt financing. However, financing might not be available to us in a timely manner or on acceptable terms, or at all.

 Our
ability to obtain the necessary financing to carry out our business plan is subject to a number of factors, including general market
conditions and investor acceptance of our business plans. These factors may make the timing, amount, terms and conditions of such financing
unattractive or unavailable to us. If we are unable to raise sufficient funds, we will have to significantly reduce our spending, delay
or cancel our planned activities, substantially change our current corporate structure, or even curtail or discontinue our operations.

 In
addition, our future capital needs and other business concerns could require us to sell additional equity or debt securities or obtain
a credit facility. The sale of additional equity or equity-linked securities could dilute the equity interests of our stockholders. Additional
indebtedness would increase our debt-service obligations and may be accompanied by covenants that would restrict our operations or our
ability to pay dividends to our stockholders.

 We
are subject to risks associated with strategic alliances or acquisitions. If we cannot manage the growth of our business or execute our
strategies effectively, our business and prospects may be materially and adversely affected.

 We
have entered into strategic alliances with various business partners, including but not limited to the MCs with respect to the franchisee
clinics, and may in the future enter into other agreements with related parties and third parties to further our business purpose from
time to time. These alliances could subject us to a number of risks, including risks associated with sharing proprietary information,
non-performance by the related parties and third parties and increased expenses in establishing new strategic alliances, any of which
may materially and adversely affect our business. We may have limited ability to monitor or control the actions of these third parties.
If any of these strategic third parties suffers negative publicity or harm to their reputation from events relating to their business,
we may also suffer negative publicity or harm to our reputation by virtue of our association with any such third party.

we currently do not have any specific acquisition plans, if appropriate opportunities arise, we may acquire additional assets, products,
technologies or businesses that are complementary to our existing business. In addition to any required stockholders' approval,
we may also have to obtain approvals and licenses from relevant government authorities for the acquisitions and to comply with any applicable
Japanese laws and regulations, which could result in delays and increased costs, and may derail our business strategy if we fail to do
so. Furthermore, past and future acquisitions and the subsequent integration of new assets and businesses into our own require significant
attention from our management and could result in a diversion of resources from our existing business, which in turn could have an adverse
effect on our business operations. Acquired assets or businesses may not generate the financial results we expect. Acquisitions could
result in the use of substantial amounts of cash, potentially dilutive issuances of equity securities, the occurrence of significant
goodwill impairment charges, amortization expenses for other intangible assets and exposure to potential unknown liabilities of the acquired
business. Moreover, the costs of identifying and consummating acquisitions may be significant.

 Our
business could be adversely affected by trade tariffs or other trade barriers.

 The
United States and other countries may in the future impose tariffs on the importation of consumer products related to our business, such
as the resale of cosmetic products, medical equipment, and medical supplies. We plan to sell our cosmetic products, medical equipment,
and medical supplies in the United States and other countries. Any new tariffs on cosmetic products, medical equipment, and medical supplies
or other relevant products imposed by the United States or other countries may significantly increase our costs. It is not yet clear
what impact these tariffs may have or what actions other governments, including the Japanese government, may take in retaliation. In
addition, these developments could have a material adverse effect on global economic conditions and the stability of global financial
markets. Any of these factors could have a material adverse effect on our business, financial condition and results of operations.

 We
and our subsidiaries have limited insurance coverage, which could subject us to significant costs and business disruption.

 Our
company, its subsidiaries, and the related parties MC such as maintain equipment liability insurance, data security insurance and medical
accident liability insurance for each clinic. Additionally, for medical devices, pharmaceuticals, etc., for which we serve as a sales
agent, the manufacturer assumes primary product liability. However, our company, its subsidiaries, and related parties, such as MCs,
bear responsibility for the medical devices and pharmaceuticals used in treatments on end customers. Given the potential for lawsuits
or complaints related to medical errors, workmanship, or treatment results, we do not participate in the medical insurance of our company,
subsidiaries, or related parties. Due to the difficulty in determining the customer's subjectivity and the insurance company's
premium payment standards concerning treatment results, we abstain from such insurance coverage.

 The
financial condition, operational results, and reputation of our company, subsidiaries, or MCs could be adversely affected if a claim
is established against us, resulting from injuries or damages sustained by our franchised clinics or customers in Vietnam and Singapore.
Such claims, even if unsuccessful, may lead to negative publicity, significant defense costs, and a diversion of management's time
and attention. Furthermore, the absence of business interruption insurance exposes us to potential significant costs and resource diversion
in case of disruptions. Additionally, operating jurisdictions like Japan, the United States, or others may impose requirements for maintaining
specific minimum liability or other insurance for franchised clinics, potentially increasing service costs.

 The
Company has never faced substantial compensation payouts or multiple compensations due to medical accidents in the past, with no material
impact on business performance and a clean financial record. We have not incurred any significant liability in the past that was not
covered by our existing insurance coverage. Each MC carries medical professional liability insurance for the physicians who belongs to
each MC and we have not faced any significant claim beyond such insurance coverage. We believe that we maintain adequate levels of insurance
relative to our business operations.

 We
are involved in litigation from time to time and, as a result, we could incur substantial judgments, fines, legal fees or other costs.

 We
may be the subject of complaints or litigation from franchisees, customers, suppliers, employees or other third parties for various actions.
The damages sought against us in some of these litigation proceedings could be substantial. We cannot assure you that we will always
have meritorious defenses to the plaintiffs' claims. While the ultimate effect of these legal actions cannot be predicted with
certainty, our reputation and the result of operations could be negatively impacted. The proceedings we may be involved in from time
to time, including the aforementioned bankruptcy proceedings, could incur substantial judgments, fines, legal fees or other costs and
have a material adverse effect on our business, financial condition, results of operations and cash flows.

 Any
financial or economic crisis or perceived threat of such a crisis may materially and adversely affect our business, financial condition
and results of operations.

 We
are subject to risks inherent in economic volatility and disruptions that may arise. COVID-19 had a severe and negative impact on the
global economy from 2020 through 2022, and the global macroeconomic environment still faces numerous challenges. In response to inflation,
central bank interest rate increases, slowing of economic growth and other factors, stock markets across the world have experienced significant
volatility and downward price pressure. The Russia-Ukraine conflict, the Hamas-Israel conflict and attacks on shipping in the Red Sea
have heightened geopolitical tensions across the world. The impact of the Russia-Ukraine conflict on Ukraine food exports has contributed
to increases in food prices and thus to inflation more generally. It is unclear whether these challenges will be contained and what global
effects they each may have. There is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies
that have been adopted by the central banks and financial authorities of some of the world's leading economies, including Japan's.
Economic conditions in Japan are sensitive to global economic conditions. Any prolonged slowdown in Japan's economic development
might lead to tighter credit markets, increased market volatility, sudden drops in business and customer confidence, and dramatic changes
in business and customer behaviors.

 We
face risks related to natural disasters and health epidemics, which could significantly disrupt our operations.

 Our
clinics in Vietnam and Singapore and the franchisee clinics, as well as our corporate offices, are vulnerable to natural disasters and
other calamities such as typhoons, tornadoes, floods, earthquakes and other adverse weather and climate conditions, as well as the outbreak
of health epidemics. Although we have servers that are hosted in an offsite location, our backup system does not capture data on a real-time
basis, and we may be unable to recover certain data in the event of a server failure. We cannot assure you that any backup systems will
be adequate to protect us from the effects of fire, floods, typhoons, earthquakes, power loss, telecommunications failures, break-ins,
war, riots, terrorist attacks or similar events. Any of the foregoing events may also give rise to interruptions, breakdowns, system
failures, technology platform failures or internet failures, which could cause the loss or corruption of data or malfunctions of software
or hardware as well as adversely affect our ability to provide services to customers at our clinics in Vietnam and Singapore and the
MCs' ability to provide services at the franchisee clinics. In addition, our business could also be adversely affected if our employees
are affected by health epidemics and our business and operations may be disrupted. In addition, our results of operations could be adversely
affected to the extent that any health epidemic harms the Japanese and global economy in general.

 If
the landlords of our and our subsidiaries' leased properties fail to properly maintain and renovate such premises, buildings or
facilities in a timely manner or at all, the operation of our offices could be materially and adversely affected.

 We
and our subsidiaries lease all the premises used in our operations from related parties and third parties. We and our subsidiaries require
the landlords' cooperation to effectively manage the condition of such premises, buildings and facilities. In the event that the
condition of the office premises, buildings and facilities deteriorates, or if any or all of our and our subsidiaries' landlords
fail to properly maintain and renovate such premises, buildings or facilities in a timely manner or at all, the operation of our offices
could be materially and adversely affected.

 The
MCs may fail to pay us in accordance with the terms of their franchise and management services agreements, at times necessitating action
by us to attempt to compel payment.

 If
the MCs fail to pay us in accordance with the terms of our franchise and management services agreements, we may be adversely affected
both from the inability to collect amounts due and the cost of enforcing the terms of our agreements, including litigation and arbitration
costs. The risk of these issues increases with the term length of our franchise and management services arrangements. Furthermore, some
of the MCs may seek bankruptcy protection or other similar relief and fail to pay amounts due to us, or pay those amounts more slowly,
either of which could adversely affect our results of operations, financial condition and cash flow. We believe that this risk is reduced
by the fact that the MCs are deemed to be related parties.

 We
believe our success depends on continuing to invest in the growth of our worldwide operations by expanding franchisee clinics to new
geographic markets. If the franchisee clinic opportunities in these new markets are less than anticipated, or if the customer growth
or sales in these markets do not meet our expectations, our results of operations and financial condition may be adversely affected.

 We
believe our success depends on expanding our business into new geographic markets and attracting customers in countries other than primarily
in Japan. We anticipate continuing to expand our operations worldwide and have made, and will continue to make, substantial investments
and incur substantial costs as we permit franchisee clinics to open in new geographic markets. This includes investments in offices,
information technology investments, sales, marketing and administrative personnel and facilities. Often we must make these investments
when it is still unclear whether a franchisee clinic in the new market will justify the costs of these investments. In addition, these
investments may be more expensive than we initially anticipate. If our investments are greater than we initially anticipate or if the
customer growth or sales in these markets do not meet our expectations or justify the cost of the initial investments, our results of
operations and financial condition may be adverse affected. The failure of new franchisee clinics would directly impact our success since
we receive substantial revenue from the franchisee clinics as part of our compensation for management services.

 If
we fail to maintain an effective system of internal controls over financial reporting, including remediating known material weaknesses
in our internal controls as of December 31, 2024, we may not be able to report our financial results timely and accurately or prevent
fraud, which could adversely affect investor confidence in our company, and in turn, our results of operations and our stock price.

internal controls are necessary for us to provide reliable financial reports, prevent fraud and operate successfully as a public company.
Section 404 of the Sarbanes-Oxley Act of 2002 requires that companies evaluate and report on their systems of internal control over financial
reporting.

the tax investigation in January 2024, the Japanese tax authority had informed SBC Medical Group Co., Ltd.'s tax consultant about
significant fund transfers from several advertising agencies, to whom SBC Medical Group Co., Ltd. had outsourced work, to the bank account
of the former director of the general affairs and legal department at L'Ange Cosmetique Co., Ltd. The Japanese tax authority suggested
that these transfers could represent kickbacks that the former director allegedly received personally, extracted from the fees SBC Medical
Group Co., Ltd. paid to these agencies. The Japanese tax authority, who has the authority to access bank deposit information of companies
and individuals under investigation, uncovered this misconduct during their examination of such deposits.

 We
have identified material weaknesses as of December 31, 2024, in our internal controls over financial reporting resulting from our failure
to maintain an effective control environment, risk assessment processes and monitoring activities. Due to these material weaknesses in
our internal control over financial reporting, we have also concluded our disclosure controls and procedures were not effective as of
December 31, 2024.

 Our
system of internal controls failed to detect this misappropriation of funds due to the following material weaknesses of SBC Medical Group
Co., Ltd.

 1.

 Control
 Environment. We did not maintain an effective control environment that fully emphasized the establishment
 of adherence to effective internal controls over financial reporting throughout SBC Medical Group Co., Ltd.'s management. We
 did not give sufficient consideration to the risk of senior management override of internal controls. SBC Medical Group Co., Ltd.
 had not ensured that certain personnel were adequately trained to properly execute critical internal controls.

 2.

 Control
 Activities. We did not effectively implement or maintain control activities, such as ensuring a sufficient
 functioning of the mechanism of reconciliation of invoices to contracts and multi-level approvals of contracts, invoices and payments.
 SBC Medical Group Co., Ltd. did not maintain sufficient segregation of duties with respect to certain activities and did not maintain adequate
 monitoring and oversight for those activities.

 3.

 Risk
 Assessment. We did not have an effective risk assessment process and the related documentation.

 4.

 and Communication. We did not adequately communicate to all employees of the organization information
 regarding the importance of internal controls over financial reporting and employees' duties and responsibilities, including
 segregation of duties.

 5.

 Monitoring
 Activities. We did not maintain effective monitoring controls related to the evaluation and testing of
 our internal controls over financial reporting.

has implemented, or is in the process of implementing, the following changes to the Company's internal control
systems and procedures:

 We
 will clarify the organization structure and employee positions promoting (i) segregation of duties, (ii) monitoring and oversight,
 (iii) reconciliation of invoices to contracts and (iv) multi-level approvals of contracts, invoices and payments.

 We
 will communicate to all employees of the organization information regarding the importance of internal controls and employees'
 duties and responsibilities, including segregation of duties.

 We
 have initiated a project led by Head of Internal Control and Internal Audit Office, and aided by outside consultants, to
 fully document our processes to serve as the basis for activities during 2024 to assess our fraud risks and evaluate and test our
 internal controls over financial reporting.

 We
 have updated our delegation of authority over our banking activities, and are establishing a treasury function that will improve
 the segregation of duties surrounding the general manager to better safeguard cash.

 In
light of the material weaknesses described above, we performed additional procedures to ensure that the consolidated financial
statements are prepared in accordance with generally accepted accounting principles. Accordingly, management has concluded that the
consolidated financial statements included in this Annual Report present fairly, in all material respects, the financial position,
results of our operations and cash flows in accordance with U.S. generally accepted
accounting principles (GAAP). Our management has taken immediate action to begin remediating these material weaknesses, as discussed
in more detail under "Part I, Item 1. Business — Misappropriations of Funds — Remediation Plan," and is
committed to remediating them as expeditiously as possible. However, certain remedial actions have not started or have only recently
been undertaken, and while we expect to continue to implement our remediation plan through 2024, we cannot be certain as to when
such remediation will be fully completed. Implementing and monitoring effective internal controls requires us to incur significant
incremental expenses and diverts management's attention and resources from other activities of the business.

 If
our remedial measures are insufficient to address the material weaknesses, or if we, or our independent registered public accounting
firm, identify additional internal control deficiencies that could rise to the level of a material weakness or uncover errors in financial
reporting, the disclosure of that fact, even if quickly remedied, could reduce the market's confidence in our financial statements
and harm our stock price. In addition, a failure to maintain effective internal controls could cause a delay in compliance with our reporting
obligations, SEC rules and regulations or Section 404 of the Sarbanes-Oxley Act of 2002, which could subject us to a variety of administrative
sanctions, including SEC enforcement action, ineligibility for short form resale registration, the suspension or delisting of our common
stock from the stock exchange on which it is listed and the inability of registered broker-dealers to make a market in our common stock,
which could adversely affect our business and the trading price of our common stock.

 Risks
Related to Employee Matters

 If
we cannot maintain our company culture as we grow, we could lose the innovation, teamwork, passion and focus on execution that we believe
contribute to our success and our business may be harmed.

 We
believe that a critical component to our success has been our company culture, which is based on transparency and personal autonomy.
We have invested substantial time and resources in building our team within this company culture. Any failure to preserve our culture
could negatively affect our ability to retain and recruit personnel and to effectively focus on and pursue our corporate objectives.
As we grow and continue to develop the infrastructure of a public company, we may find it difficult to maintain these important aspects
of our company culture. If we fail to maintain our company culture, our business may be adversely impacted.

 Our
success depends on the continuing efforts of our key employees, including our senior management members and other key personnel. If we
fail to hire, retain and motivate our key employees, we could lose the innovation, collaboration and focus that contribute to our business.

 We
believe that our success depends substantially on the continued efforts of our key employees, including our senior management members
and other qualified and key personnel. We rely on our executive officers, senior management and key employees to generate business and
execute our initiatives successfully. Yoshiyuki Aikawa, our Chief Executive Officer, has a wealth of knowledge and business experience
in the cosmetic clinic industry and the related management services, the core business of our group, as well as numerous personal and
business relationships in this industry, and plays an extremely important role in the management of the Company. In addition, the relationships
and reputation that members of our management and key employees have established and maintain with government personnel and other business
partners contribute to our ability to maintain good relations and to identify new business opportunities. The loss of any key personnel
or our failure to attract additional talent could reduce our employee retention, disrupt our research and development activities and
operations, and impair our revenue growth and competitiveness. If one or more of our executive officers or key employees were unable
or unwilling to continue their services with us, we might not be able to replace them easily, in a timely manner, or at all, and we might
lose the innovation, collaboration and focus that contribute to our business.

 The
failure to attract and retain additional qualified personnel could prevent us from executing our business strategy.

 To
execute our business strategy, we must attract and retain highly qualified personnel. In particular, marketing, services, and content
management domain experts are very important to our brand success and are difficult to replace. We have from time to time in the past
experienced, and we expect to continue to experience in the future, difficulty in hiring and difficulty in retaining highly skilled employees
with appropriate qualifications. In particular, we have experienced a competitive hiring environment in Japan, where we are headquartered
and will continue to experience a competitive hiring environment as we recruit for remote talent worldwide. Many of the companies with
which we compete for experienced personnel have greater resources than we do. In addition, in making employment decisions, job candidates
often consider the value of the stock options or other equity incentives they are to receive in connection with their employment. If
the price of our stock declines, or experiences significant volatility, our ability to attract or retain key employees will be adversely
affected. If we fail to attract new personnel or fail to retain and motivate our current personnel, our growth prospects could be severely
harmed.

 Risks
Related to Intellectual Property

 We
and our subsidiaries may need to defend ourselves against claims of intellectual property infringement, which may be time-consuming and
costly.

 Companies,
organizations or individuals, including our competitors, may hold or obtain patents, trademarks or other proprietary rights that would
prevent, limit or interfere with the ability of our franchisee clinics and our clinics in Vietnam and Singapore to utilize our medical
technologies, which could make it more difficult for our franchisee clinics and our clinics in Vietnam and Singapore to operate competitively.
Companies holding patents or other intellectual property rights may bring suits alleging infringement of such rights by us, our subsidiaries,
and our franchisees, or otherwise assert their rights against us, our subsidiaries, and our franchisees. Moreover, our and our subsidiaries'
applications and uses of trademarks relating to our brand could be found to infringe upon existing trademark ownership and rights. We
or our subsidiaries may also fail to apply for key trademarks in a timely manner. We, our subsidiaries, and our franchisees may continue
to face intellectual property infringement claims in the future.

 If
we, our subsidiaries, or our franchisees are determined to have infringed upon a third party's intellectual property rights, we,
our subsidiaries, or our franchisees may be required to do one or more of the following:

 cease
 offering products or services that incorporate or use the challenged intellectual property;

 pay
 substantial damages;

 seek
 a license from the holder of the infringed intellectual property right, which license may not be available on reasonable terms or
 at all; or

 establish
 and maintain alternative branding for our brand and services.

 In
the event of a successful claim of infringement against us, our subsidiaries, or our franchisees failure or inability to obtain a license
to the infringed technology or other intellectual property right, our business, prospects, operating results and financial condition
could be materially and adversely affected. In addition, any litigation or claims, even if frivolous, could result in substantial costs,
negative publicity and diversion of resources and management attention.

 Our
or our subsidiaries' intellectual property rights may not protect us effectively.

 As
of December 31, 2024, we and our subsidiaries together had filed a significant number of patent and trademark applications in Japan,
and have registered numerous patents and trademarks in Japan. Additionally, a subsequent number of trademark applications have been filed
with the International Bureau of the World Intellectual Property Organization. Through the subsidiary acquired in late November, the
Company also holds several trademarks in Singapore. However, the Company does not have any registered trademarks, domain names, or patents
in Vietnam or the United States.

 We
cannot assure you that our or our subsidiaries' pending patent applications will be granted. Even if our or our subsidiaries'
applications are successful, patents may be contested, circumvented or invalidated in the future.

 In
addition, the rights granted under any patents issued in the future may not provide us with proprietary protection or competitive advantages.
The claims under any patents that issue from our or our subsidiaries' patent applications may not be broad enough to prevent others
from developing technologies that are similar or that achieve results similar to ours or our subsidiaries' results. It is also
possible that the intellectual property rights of others could bar us or our subsidiaries from licensing and exploiting any patents that
are issued from our or our subsidiaries' pending applications. Numerous patents and pending patent applications owned by others
exist in the fields in which we and our subsidiaries have developed and are developing our technologies. These patents and patent applications
might have priority over our or our subsidiaries' patent applications and could subject our or our subsidiaries' patent applications
to invalidation. Finally, in addition to those who may claim priority, any of our or our subsidiaries' existing or pending patents
may also be challenged by others on the basis that they are otherwise invalid or unenforceable.

 Implementation
and enforcement of Japanese laws on intellectual property rights have historically been deficient and ineffective. Accordingly, protection
of intellectual property rights in Japan may not be as effective as in the United States or other developed countries. Furthermore, policing
unauthorized use of proprietary technologies is difficult and expensive. We and our subsidiaries rely on a combination of trademark and
trade secret laws and restrictions on disclosure to protect our and our subsidiaries' intellectual property rights. Despite our
efforts to protect our and our subsidiaries' proprietary rights, third parties may attempt to copy or otherwise obtain and use
our or our subsidiaries' intellectual property or seek court declarations that they do not infringe upon our or our subsidiaries'
intellectual property rights. Any unauthorized use of our or our subsidiaries' intellectual property by third parties may adversely
affect our current and future revenues and our reputation. Monitoring unauthorized use of our and our subsidiaries' intellectual
property is difficult and costly, and we cannot assure you that the steps we or our subsidiaries have taken or will take will prevent
misappropriation of our and our subsidiaries' intellectual property. From time to time, we or our subsidiaries may have to resort
to litigation to enforce our and our subsidiaries' intellectual property rights, which could result in substantial costs and diversion
of our resources.

 The
Company may not be able to protect its intellectual property rights throughout the world.

 Filing,
prosecuting, and defending trademark and trade secret rights of the Company and its subsidiaries throughout the world would be prohibitively
expensive. The Company has (i) filed patent applications in Japan, (ii) filed trademark applications in Japan and with the International
Bureau of the World Intellectual Property Organization, and (iii) obtained trademarks in Japan. Competitors may use the Company's
technologies in jurisdictions where it has not obtained intellectual property protection.

 If
we fail to protect, or incur significant costs in defending or enforcing our intellectual property and other proprietary rights, our
business, financial condition and results of operations could be materially harmed.

 Our
success depends, in large part, on our ability to protect our intellectual property and other proprietary rights. We rely primarily on
trademarks, trade secrets, and unfair competition laws, as well as license agreements and other contractual provisions, to protect our
intellectual property and other proprietary rights. However, existing Japanese legal standards relating to the validity, enforceability
and scope of protection of intellectual property rights offer only limited protection, may not provide us with any competitive advantages,
and our rights may be challenged by third parties. The laws of countries other than Japan may be even less protective of our intellectual
property rights. Accordingly, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating
our intellectual property or otherwise gaining access to our technology. Unauthorized third parties may try to copy or reverse engineer
the medical technologies utilized at our clinics in Vietnam and Singapore and the franchisee clinics or otherwise obtain and use our
intellectual property. Moreover, many of our employees and the MCs' employees have access to our trade secrets and other intellectual
property. If one or more of these employees leave our employment to work for one of our competitors, then they may disseminate this proprietary
information, which may as a result damage our competitive position. If we fail to protect our intellectual property and other proprietary
rights, then our business, results of operations or financial condition could be materially harmed. From time to time, we may have to
initiate lawsuits to protect our intellectual property and other proprietary rights. Pursuing these claims is time consuming and expensive
and could adversely impact our results of operations.

 In
addition, affirmatively defending our intellectual property rights and investigating whether any of our medical technologies violate
the rights of others may entail significant expense. Our intellectual property rights may be challenged by others or invalidated through
administrative processes or litigation. If we resort to legal proceedings to enforce our intellectual property rights or to determine
the validity and scope of the intellectual property or other proprietary rights of others, then the proceedings could result in significant
expense to us and divert the attention and efforts of our management and technical employees, even if we prevail.

 Risks
Related to Government Regulation

to comply with laws and regulations could harm our business.

 Our
business is subject to regulation by various federal, state, local and foreign governmental agencies, including agencies responsible
for monitoring and enforcing employment and labor laws, workplace safety, environmental laws, consumer protection laws, anti-bribery
laws, import/export controls, federal securities laws and tax laws and regulations. In certain jurisdictions, these regulatory requirements
may be more stringent than those in Japan.

the Company, its subsidiaries, and the MCs strive to comply with these laws and regulations, including the APPI, Antimonopoly Act, the
Medical Care Act, Dispatch Act, Poisonous and Deleterious Substances Control Act, the Labor Standards Act, Act on Land and Building Leases,
Act on Special Provisions to the Civil Code Concerning Electronic Consumer Contracts and Electronic Acceptance Notice, and other laws
and regulations related to our business, it is possible that regulations will be unexpectedly enacted, amended, or abolished in the future,
or that planned deregulation will not proceed as planned. In such cases, if any of the Company, its subsidiaries, or the MCs receive
some administrative sanction for violating such laws and regulations, etc., or if excessive legal restrictions are applied in the future,
our activities may be restricted, which may affect our business and earnings. Noncompliance with applicable regulations or requirements
could subject us to investigations, sanctions, mandatory recalls, enforcement actions, disgorgement of profits, fines, damages, civil
and criminal penalties or injunctions. A failure by the MCs to comply with government regulations may harm our franchised brand and directly
result in a reduction of the Company's revenue, since we receive substantial revenue from the MCs as part of our compensation for
management services.

 We
are subject to anti-corruption, anti-bribery, anti-money laundering, financial and economic sanctions and similar laws, and noncompliance
with such laws can subject us to administrative, civil and criminal fines and penalties, collateral consequences, remedial measures and
legal expenses, all of which could adversely affect our business, results of operations, financial condition and reputation.

 We
are subject to anti-corruption, anti-bribery, anti-money laundering, financial and economic sanctions and similar laws and regulations
in various jurisdictions in which the Company, its subsidiaries, and the MCs conduct its business or operate franchisee clinics, including
the Japanese anti-corruption laws and regulations, the U.S. Foreign Corrupt Practices Act, or the FCPA and other anti-corruption laws
and regulations. The FCPA prohibits us and our officers, directors, employees and business partners acting on our behalf, including agents,
from corruptly offering, promising, authorizing or providing anything of value to a "foreign official" for the purposes of
influencing official decisions or obtaining or retaining business or otherwise obtaining favorable treatment. The FCPA also requires
companies to make and keep books, records and accounts that accurately reflect transactions and dispositions of assets and to maintain
a system of adequate internal accounting controls. The Japanese anti-corruption laws and regulations prohibit bribery to government agencies,
state or government owned or controlled enterprises or entities, to government officials or officials that work for state or government
owned enterprises or entities, as well as bribery to non-government entities or individuals. There is uncertainty in connection with
the implementation of Japanese anti-corruption laws. A violation of these laws or regulations could adversely affect our business, results
of operations, financial condition and reputation.

 We
have direct or indirect interactions with officials and employees of government agencies and state-owned affiliated entities in the ordinary
course of business. We have also entered into joint ventures and/or other business partnerships with government agencies and state-owned
or affiliated entities. These interactions subject us to an increased level of compliance-related concerns. We are in the process of
implementing policies and procedures designed to ensure compliance by us and our directors, officers, employees, representatives, consultants,
agents and business partners with applicable anti-corruption, anti-bribery, anti-money laundering, financial and economic sanctions and
similar laws and regulations. However, our policies and procedures may not be sufficient, and our directors, officers, employees, representatives,
consultants, agents, and business partners could engage in improper conduct for which we may be held responsible.

 Non-compliance
with anti-corruption, anti-bribery, anti-money laundering or financial and economic sanctions laws could subject us to whistleblower
complaints, adverse media coverage, investigations, and severe administrative, civil and criminal sanctions, collateral consequences,
remedial measures and legal expenses, all of which could materially and adversely affect our business, results of operations, financial
condition and reputation. In addition, changes in economic sanctions laws in the future could adversely impact our business and investments
in our shares.

Risks

 Weakened
global economic conditions may harm our industry, business and results of operations.

 Our
overall performance depends in part on worldwide economic conditions. Global financial developments and downturns seemingly unrelated
to us or the cosmetic clinic industry may harm us. Japan, the United States and other key international economies have been affected
from time to time by falling demand for a variety of goods and services, restricted credit, poor liquidity, reduced corporate profitability,
volatility in credit, equity and foreign exchange markets, bankruptcies, and overall uncertainty with respect to the economy, including
with respect to tariff and trade issues. If economic conditions in Japan, the United States, Singapore, Vietnam, or any other future
key markets for our franchisee clinics remain uncertain or deteriorate further, it could adversely affect clinic customers' ability
or willingness to purchase cosmetic products or services and delay prospective customers' purchasing decisions, all of which could
harm our operating results. A decrease in the revenue of the MCs' franchisee clinics as a result of such worldwide economic conditions
would directly result in a reduction of the Company's revenue since we receive substantial revenue from the MCs as part of our
compensation for management services.

 We
are exposed to fluctuations in currency exchange rates.

 We
face exposure to movements in currency exchange rates, which may cause our revenue and operating results to differ materially from expectations.
As exchange rates vary, revenue, cost of revenue, operating expenses and other operating results, when re-measured, may differ materially
from expectations. In addition, our operating results are subject to fluctuation if our mix of U.S. and foreign currency denominated
transactions and expenses changes in the future. Furthermore, global political events and developments, fluctuating commodity prices
and trade tariff developments, have caused global economic uncertainty, which could amplify the volatility of currency fluctuations.
Such volatility, even when it increases our revenues or decreases our expenses, impacts our ability to predict our future results and
earnings accurately. Although we may apply certain strategies to mitigate foreign currency risk, these strategies might not eliminate
our exposure to foreign exchange rate fluctuations and would involve costs and risks of their own, such as ongoing management time and
expertise, external costs to implement the strategies and potential accounting implications. Additionally, as we anticipate growing our
business further outside of Japan, the effects of movements in currency exchange rates will increase as our transaction volume outside
of Japan increases.

 Our
actual operating results may differ significantly from our guidance and projections.

 From
time to time, we may provide forward-looking estimates regarding our future performance that represent management's estimates as
of a point in time. These forward-looking statements are based on projections prepared by our management. These projections are not and
were not prepared with a view toward compliance with published guidelines of the American Institute of Certified Public Accountants,
and neither our independent registered public accountants nor any other independent expert or outside party compiles or examines the
projections and, accordingly, no such person expresses any opinion or any other form of assurance on our projections.

 Projections
are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to significant
business, economic and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific
assumptions with respect to future business decisions and conditions, some of which will change. The principal reason that we provide
forward-looking information is to provide a basis for our management to discuss its business outlook with stakeholders. Forward-looking
statements are necessarily speculative in nature, and it can be expected that some or all of the assumptions of its forward-looking statements
will not materialize or will vary significantly from actual results. Accordingly, our forward-looking statements are only an estimate
of what management believes is realizable as of the date of release. Actual results will vary from our forward-looking statements and
the variations may be material. In light of the foregoing, investors are urged not to rely upon, or otherwise consider, our guidance
or projections in making investment decisions.

 Risk
Relating to Ownership of Our Securities

 An
active market for our securities may not develop, which would adversely affect the liquidity and price of our securities.

 Our
common stock began trading on the Nasdaq Global Market under the symbol "SBC" and our public warrants began trading on the
Nasdaq Capital Market under the symbol "SBCWW" on September 18, 2024. The price of our securities may vary significantly
due to factors specific to the Company as well as to general market or economic conditions. Furthermore, an active trading market for
our securities may never develop or, if developed, it may not be sustained. You may be unable to sell your securities unless a market
can be established and sustained.

 Nasdaq
may delist our securities from trading on its exchange, which could limit investors' ability to make transactions in our securities
and subject the Company to additional trading restrictions.

 Our
common stock began trading on the Nasdaq Global Market under the symbol "SBC" and our public warrants began trading on the
Nasdaq Capital Market under the symbol "SBCWW" on September 18, 2024. However, we cannot assure you that our securities will
continue to be listed on Nasdaq in the future. In order to continue listing its securities on Nasdaq, the Company must maintain certain
financial, distribution and stock price levels. Generally, the Company must maintain a minimum number of holders of its securities (generally
400 public holders).

 If
Nasdaq delists the Company's securities from trading on its exchange and the Company is not able to list its securities on another
national securities exchange, we expect our securities could be quoted on an over-the-counter market. If this were to occur, the Company
could face significant material adverse consequences, including:

 a
 limited availability of market quotations for its securities;

 reduced
 liquidity for its securities;

 a
 determination that our common stock is a "penny stock" which will require brokers trading in the common stock to adhere
 to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

 a
 limited amount of news and analyst coverage; and

 a
 decreased ability to issue additional securities or obtain additional financing in the future.

 The
market price of our common stock may decline.

 The
market price of our common stock and public warrants may decline as a result of the Business Combination for a number of reasons including
if:

 investors
 react negatively to the prospects of our business and the prospects of the Business Combination;

 the
 effect of the Business Combination on our business and prospects is not consistent with the expectations of financial or industry
 analysts; or

 We
 do not achieve the perceived benefits of the Business Combination as rapidly or to the extent anticipated by financial or industry
 analysts.

 The
market price of our common stock may be volatile, and you could lose all or part of your investment.

 The
trading price of our common stock is likely to be volatile. The stock market recently has experienced extreme volatility. This volatility
often has been unrelated or disproportionate to the operating performance of particular companies. You may not be able to resell your
shares of common stock and/or Private Placement Warrants at an attractive price due to a number of factors such as those listed in this
Risk Factors section and the following:

 results
 of operations that vary from the expectations of securities analysts and investors;

 results
 of operations that vary from those of the Company's competitors;

 in expectations as to the Company's future financial performance, including financial estimates and investment recommendations
 by securities analysts and investors;

 declines
 in the market prices of stocks generally;

 strategic
 actions by the Company or its competitors;

 announcements
 by the Company or its competitors of significant contracts, acquisitions, joint ventures, other strategic relationships or capital
 commitments;

 announcements
 of estimates by third parties of actual or anticipated changes in the size of the Company's customer base or the level of customer
 engagement;

 any
 significant change in the Company's management;

 in general economic or market conditions or trends in the Company's industry or markets;

 in business or regulatory conditions, including new laws or regulations or new interpretations of existing laws or regulations applicable
 to the Company's business;

 additional
 shares of the Company's securities being sold or issued into the market by the Company or any of the existing stockholders
 or the anticipation of such sales, including if the Company issues shares to satisfy restricted stock unit related tax obligations
 or if existing stockholders sell shares into the market when applicable "lock-up" periods end;

 investor
 perceptions of the investment opportunity associated with the Company's common stock relative to other investment alternatives;

 the
 public's response to press releases or other public announcements by the Company or third parties, including the Company's
 filings with the SEC;

 litigation
 involving the Company, the Company's industry, or both, or investigations by regulators into the Company's operations
 or those of the Company's competitors;

 guidance,
 if any, that the Company provides to the public, any changes in this guidance or the Company's failure to meet this guidance;

 the
 development and sustainability of an active trading market for the Company's common stock;

 actions
 by institutional or activist stockholders;

 developments
 in new legislation and pending lawsuits or regulatory actions, including interim or final rulings by judicial or regulatory bodies;

 in accounting standards, policies, guidelines, interpretations or principles; and

 other
 events or factors, including those resulting from pandemics, natural disasters, war, acts of terrorism or responses to these events.

 These
broad market and industry fluctuations may adversely affect the market price of the Company's common stock and Private Placement
Warrants, regardless of the Company's actual operating performance. In addition, price volatility may be greater if the public
float and trading volume of the Company's common stock and/or Private Placement Warrants is low.

 In
the past, following periods of market volatility, stockholders have instituted securities class action litigation. If the Company'
was involved in securities litigation, it could have a substantial cost and divert resources and the attention of executive management
from our business regardless of the outcome of such litigation.

 Because
there are no current plans to pay cash dividends on the Company's common stock for the foreseeable future, you may not receive
any return on investment unless you sell your shares of the Company's common stock at a price greater than what you paid for it.

 The
Company intends to retain future earnings, if any, for future operations, expansion and debt repayment, and there are no current plans
to pay any cash dividends for the foreseeable future. The declaration, amount and payment of any future dividends on shares of the Company's
common stock will be at the sole discretion of the Company's board of directors. The Company's board of directors may take
into account general and economic conditions, the Company's financial condition and results of operations, the Company's
available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax and regulatory restrictions, implications
of the payment of dividends by the Company to its stockholders or by its subsidiaries to it and such other factors as the Company's
board of directors may deem relevant. As a result, you may not receive any return on an investment in the Company's common stock
unless you sell your shares of the Company's common stock for a price greater than that which you paid for it.

 The
Company's stockholders may experience dilution in the future.

 The
percentage of shares of the Company's common stock owned by current stockholders may be diluted in the future because of equity
issuances for acquisitions, capital market transactions or otherwise, including, without limitation, equity awards that the Company may
grant to its directors, officers and employees, exercise of the Company's warrants. Such issuances may have a dilutive effect on
the Company's earnings per share, which could adversely affect the market price of the Company's common stock.

 If
securities or industry analysts do not publish research or reports about the Company's business, if they change their recommendations
regarding the Company's common stock or if the Company's operating results do not meet their expectations, the Company's
common stock price and trading volume could decline.

 The
trading market for the Company's common stock and public warrants will depend in part on the research and reports that securities
or industry analysts publish about the Company or its businesses. If no securities or industry analysts commence coverage of the Company,
the trading price for the Company's common stock and/or public warrants could be negatively impacted. In the event securities or
industry analysts initiate coverage, if one or more of the analysts who cover the Company downgrade its securities or publish unfavorable
research about its businesses, or if the Company's operating results do not meet analyst expectations, the trading price of the
Company's common stock and/or public warrants would likely decline. If one or more of these analysts cease coverage of the Company
or fail to publish reports on the Company regularly, demand for the Company's common stock and/or public warrants could decrease,
which might cause the Company's common stock and/or public warrants price and trading volume to decline.

 Future
sales, or the perception of future sales, by the Company or its stockholders in the public market following the Business Combination
could cause the market price for the Company's common stock to decline.

 The
sale of shares of the Company's common stock and/or public warrants in the public market, or the perception that such sales could
occur, could harm the prevailing market price of shares of the Company's common stock and/or public warrants. These sales, or the
possibility that these sales may occur, also might make it more difficult for the Company to sell equity securities in the future at
a time and at a price that it deems appropriate.

 As
an emerging growth company within the meaning of the Securities Act, the Company is permitted to rely on certain exemptions from disclosure
requirements available to emerging growth companies, this could make our securities less attractive to investors and may make it more
difficult to compare our performance with other public companies.

 We
qualify as an "emerging growth company" within the meaning of the Securities Act, as modified by the JOBS Act. We plan to
continue to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in periodic reports and proxy
statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved. As a result, the company's stockholders may not have access to certain
information they may deem important. We cannot predict whether investors will find securities issued by the Company less attractive because
the Company will rely on these exemptions. If some investors find those securities less attractive as a result of its reliance on these
exemptions, the trading prices of the Company's securities may be lower than they otherwise would be, there may be a less active
trading market for the Company's securities and the trading prices of the Company's securities may be more volatile.

 Further,
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do
not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such
extended transition period, which means that when a standard is issued or revised and it has different application dates for public or
private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt
the new or revised standard. This may make comparison of the Company's financial statements with another public company that is
neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult
or impossible because of the potential differences in accountant standards used.

 The
Company will remain an emerging growth company until the earliest of: (i) the last day of the fiscal year following the fifth anniversary
of the closing of the IPO, (ii) the last day of the fiscal year in which the Company has total annual gross revenue of at least $1.235
billion; (iii) the last day of the fiscal year in which the Company is deemed to be a "large accelerated filer" as defined
in Rule 12b-2 under the Exchange Act, which would occur if the market value of the Company's common stock held by non-affiliates
exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; or (iv) the date on which the Company
has issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

 The
Company may redeem unexpired public warrants prior to their exercise at a time that is disadvantageous for the Company's warrant
holders.

 The
Company will have the ability to redeem outstanding public warrants at any time after they become exercisable and prior to their expiration,
at a price of $0.01 per warrant, provided that the last reported sales price of the Company's common stock equals or exceeds $18.00
per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within
a 30 trading-day period ending on the third trading day prior to the date the Company sends the notice of redemption to the warrant holders.
If and when the public warrants become redeemable by the Company, the Company may exercise its redemption right if there is a current
registration statement in effect with respect to the shares of the Company's common stock underlying such warrants. Redemption
of the outstanding public warrants could force you to: (i) exercise your warrants and pay the related exercise price at a time when it
may be disadvantageous for you to do so; (ii) sell your warrants at the then-current market price when you might otherwise wish to hold
your warrants; or (iii) accept the nominal redemption price which, at the time the outstanding public warrants are called for redemption,
is likely to be substantially less than the market value of your warrants.

 Our
securities holders may face significant restrictions on the resale of our securities due to state "Blue Sky" laws.

 Each
state has its own securities laws, often called "blue sky" laws, which (i) limit sales of securities to a state's residents
unless the securities are registered in that state or qualify for an exemption from registration, and (ii) govern the reporting requirements
for broker-dealers doing business directly or indirectly in the state. Before a security is sold in a state, there must be a registration
in place to cover the transaction, or the transaction must be exempt from registration. The applicable broker must be registered in that
state. We do not know whether our common stock will be registered or exempt from registration under the laws of any state. There may
be significant state blue sky law restrictions on the ability of investors to sell, and on purchasers to buy, our common stock. You should
therefore consider the resale market for our common stock to be limited, as you may be unable to resell your common stock without the
significant expense of state registration or qualification.

 Substantial
future sales of shares of our common stock could cause the market price of our common stock to decline.

 The
market price of shares of our common stock could decline as a result of substantial sales of our common stock, particularly sales by
our directors, executive officers and significant stockholders, a large number of shares of our common stock becoming available for sale
or the perception in the market that holders of a large number of shares intend to sell their shares.

 If
we fail to maintain effective internal control over financial reporting, the price of our securities may be adversely affected.

 Our
internal control over financial reporting may have weaknesses and conditions that could require correction or remediation, the disclosure
of which may have an adverse impact on the price of our common stock. We are required to establish and maintain appropriate internal
control over financial reporting. Failure to establish those controls, or any failure of those controls once established, could adversely
affect our public disclosures regarding our business, prospects, financial condition or results of operations. In addition, management's
assessment of internal control over financial reporting may identify weaknesses and conditions that need to be addressed in our internal
control over financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions
that need to be addressed in our internal control over financial reporting or disclosure of management's assessment of our internal
control over financial reporting may have an adverse impact on the price of our common stock.

 As
an emerging growth company, our auditor is not required to attest to the effectiveness of our internal controls.

 Our
independent registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting
while we are an emerging growth company. This means that the effectiveness of our financial operations may differ from our peer companies
in that they may be required to obtain independent registered public accounting firm attestations as to the effectiveness of their internal
controls over financial reporting and we are not. While our management will be required to attest to internal control over financial
reporting and we will be required to detail changes to our internal controls on a quarterly basis, we cannot provide assurance that the
independent registered public accounting firm's audit process in assessing the effectiveness of our internal controls over financial
reporting, if obtained, would not find one or more material weaknesses or significant deficiencies. Further, once we cease to be an emerging
growth company and cease to be a smaller reporting company (as described below), we will be subject to independent registered public
accounting firm attestation regarding the effectiveness of our internal controls over financial reporting. Even if management finds such
controls to be effective, our independent registered public accounting firm may decline to attest to the effectiveness of such internal
controls and issue a qualified report.

 Our
common stock and warrants may be subject to the "penny stock" rules in the future. It may be more difficult to resell securities
classified as "penny stock."

 Our
common stock may be subject to "penny stock" rules (generally defined as non-exchange traded stock with a per-share price
below $5.00) in the future. While our common stock and warrants are not currently considered "penny stock" since it is listed
on Nasdaq, if we are unable to maintain that listing and our common stock and/or warrants are no longer listed on Nasdaq, unless we maintain
a per-share price above $5.00, our common stock and/or warrants will become "penny stock." These rules impose additional
sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other than those who qualify
as "established customers" or "accredited investors." For example, broker-dealers must determine the appropriateness
for non-qualifying persons of investments in penny stocks. Broker-dealers must also provide, prior to a transaction in a penny stock
not otherwise exempt from the rules, a standardized risk disclosure document that provides information about penny stocks and the risks
in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock,
disclose the compensation of the broker-dealer and its salesperson in the transaction, furnish monthly account statements showing the
market value of each penny stock held in the customer's account, provide a special written determination that the penny stock is
a suitable investment for the purchaser, and receive the purchaser's written agreement to the transaction.

 Legal
remedies available to an investor in "penny stocks" may include the following:

 If
 a "penny stock" is sold to the investor in violation of the requirements listed above, or other federal or states securities
 laws, the investor may be able to cancel the purchase and receive a refund of the investment.

 If
 a "penny stock" is sold to the investor in a fraudulent manner, the investor may be able to sue the persons and firms
 that committed the fraud for damages.

 These
requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that becomes
subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage broker-dealers
from effecting transactions in our securities, which could severely limit the market price and liquidity of our securities. These requirements
may restrict the ability of broker-dealers to sell our common stock or our Private Placement Warrants and may affect your ability to
resell our common stock and our Private Placement Warrants.

 Many
brokerage firms will discourage or refrain from recommending investments in penny stocks. Most institutional investors will not invest
in penny stocks. In addition, many individual investors will not invest in penny stocks due, among other reasons, to the increased financial
risk generally associated with these investments.

 For
these reasons, penny stocks may have a limited market and, consequently, limited liquidity. We can give no assurance at what time, if
ever, our common stock or our Private Placement Warrants will not be classified as a "penny stock" in the future.

 We
believe we will be considered a smaller reporting company and will be exempt from certain disclosure requirements, which could make our
common stock less attractive to potential investors.

 Rule
12b-2 of the Exchange Act defines a "smaller reporting company" as an issuer that is not an investment company, an asset-backed
issuer, or a majority-owned subsidiary of a parent that is not a smaller reporting company and that:

 had
 a public float of less than $250 million as of the last business day of its most recently completed second fiscal quarter, computed
 by multiplying the aggregate worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the
 price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market
 for the common equity; or

 in
 the case of an initial registration statement under the Securities Act or the Exchange Act for shares of its common equity, had a
 public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed
 by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of
 a Securities Act registration statement, the number of such shares included in the registration statement by the estimated public
 offering price of the shares; or

 in
 the case of an issuer whose public float as calculated under paragraph (1) or (2) of this definition was zero or whose public float
 was less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year for which
 audited financial statements are available.

 As
a smaller reporting company, we are not required to, and may not, include a Compensation Discussion and Analysis section in our proxy
statements; we will provide only two years of financial statements; and we need not provide the table of selected financial data. We
also will have other "scaled" disclosure requirements that are less comprehensive than issuers that are not smaller reporting
companies which could make our common stock less attractive to potential investors, which could make it more difficult for our stockholders
to sell their shares.

 We
incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new
compliance initiatives.

 As
a public company, we incur significant legal, accounting and other expenses that we did not previously incur as a private company. In
addition, the Sarbanes-Oxley Act has imposed various requirements on public companies, including requiring establishment and maintenance
of effective disclosure and financial controls. Our management and other personnel need to devote a substantial amount of time to these
compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance
costs and will make some activities more time-consuming and costly. We cannot predict or estimate the amount of additional costs we will
incur as a public company or the timing of such costs.

 The
Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure
controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial
reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section
404 of the Sarbanes-Oxley Act. In addition, will be required to have our independent registered public accounting firm attest to the
effectiveness of our internal control over financial reporting in the first annual
report on Form 10-K following the date on which we are no longer an emerging growth company or non-accelerated filer. Our compliance
with Section 404 of the Sarbanes-Oxley Act will require that we incur substantial expense and expend significant management efforts.
We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate
public company experience and technical accounting knowledge. If we are not able to comply with the requirements of Section 404 in a
timely manner, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial
reporting that are deemed to be material weaknesses, the value of our securities could decline and we could be subject to sanctions or
investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.

 Our
ability to successfully implement our business plan and comply with Section 404 requires us to be able to prepare timely and accurate
financial statements. We expect that we will need to continue to improve existing, and implement new operational and financial systems,
procedures and controls to manage our business effectively. Any delay in the implementation of, or disruption in the transition to, new
or enhanced systems, procedures or controls, may cause our operations to suffer and we may be unable to conclude that our internal control
over financial reporting is effective and to obtain an unqualified report on internal controls from our auditors as required under Section
404 of the Sarbanes-Oxley Act. This, in turn, could have an adverse impact on value of our securities, and could adversely affect our
ability to access the capital markets.

 Delaware
law and the Company certificate of incorporation and bylaws contains certain provisions, including anti-takeover provisions, that limit
the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable.

 The
Amended Charter and the Company's bylaws and the DGCL, contain provisions that could have the effect of rendering more difficult,
delaying, or preventing an acquisition deemed undesirable by the Company's board of directors and therefore depress the trading
price of the Company's common stock. These provisions could also make it difficult for stockholders to take certain actions, including
electing directors who are not nominated by the Company's board of directors or taking other corporate actions, including effecting
changes in the management of the Company. Among other things, the Amended Charter and the Company's bylaws include provisions regarding:

 the
 ability of the Company's board of directors to issue shares of preferred stock, including "blank check" preferred
 stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval,
 which could be used to significantly dilute the ownership of a hostile acquirer;

 a
 classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership
 of a majority of the Board;

 the
 limitation of the liability of, and the indemnification of, the Company's directors and officers;

 the
 exclusive right of the Company's board of directors to elect a director to fill a vacancy created by the expansion of the Company's
 board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies
 on the Company's board of directors;

 the
 requirement that directors may only be removed from the Company's board of directors for cause;

 a
 prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting
 of stockholders and could delay the ability of stockholders to force consideration of a stockholder proposal or to take action, including
 the removal of directors;

 the
 requirement that a special meeting of stockholders may be called only by the Company's board of directors, the chairperson
 of the Company's board of directors, the Company's chief executive officer or the Company's president (in the absence
 of a chief executive officer), which could delay the ability of stockholders to force consideration of a proposal or to take action,
 including the removal of directors;

 the
 procedures for the conduct and scheduling of board of directors and stockholder meetings;

 the
 requirement for the affirmative vote of holders of at least 2/3 of the voting power of all of the then outstanding shares of the
 voting stock, voting together as a single class, to amend, alter, change or repeal any provision of the Amended Charter or the Company's
 bylaws, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes
 in the Company's board of directors and also may inhibit the ability of an acquirer to effect such amendments to facilitate
 an unsolicited takeover attempt;

 the
 ability of the Company's board of directors to amend the bylaws, which may allow the Company's board of directors to
 take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the bylaws to facilitate
 an unsolicited takeover attempt; and

 advance
 notice procedures with which stockholders must comply to nominate candidates to the Company's board of directors or to propose
 matters to be acted upon at a stockholders' meeting, which could preclude stockholders from bringing matters before annual
 or special meetings of stockholders and delay changes in the Company's board of directors and also may discourage or deter
 a potential acquirer from conducting a solicitation of proxies to elect the acquirer's own slate of directors or otherwise
 attempting to obtain control of the Company.

 These
provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in the Company's board
of directors or management.

 Any
provision of the Amended Charter, the Company's bylaws or Delaware law that has the effect of delaying or preventing a change in
control could limit the opportunity for stockholders to receive a premium for their shares of the Company's capital stock and could
also affect the price that some investors are willing to pay for the Company's common stock.

 The
Amended Charter designates a state or federal court located within the State of Delaware as the exclusive forum for substantially all
disputes between the Company and its stockholders, and also provide that the federal district courts will be the exclusive forum for
resolving any complaint asserting a cause of action arising under the Securities Act, each of which could limit the ability of the Company's
stockholders to choose the judicial forum for disputes with the Company or its directors, officers, or employees.

 The
Amended Charter provides that, unless the Company consents in writing to the selection of an alternative forum, the sole and exclusive
forum for (i) any derivative action or proceeding brought on its behalf, (ii) any action asserting a claim of breach of a fiduciary duty
owed by any of its directors, officers, or other employees to the Company or its stockholders, (iii) any action arising pursuant to any
provision of the DGCL, or the certificate of incorporation or the bylaws or (iv) any other action asserting a claim that is governed
by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have
jurisdiction, the federal district court for the District of Delaware), in all cases subject to the court having jurisdiction over indispensable
parties named as defendants. The Amended Charter also provides that the federal district courts of the United States of America will
be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. The exclusive forum
provision will be applicable to the fullest extent permitted by applicable law, subject to certain exceptions. Section 27 of the Exchange
Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the
rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability
created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. We note, however, that there
is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities
laws and the rules and regulations thereunder. Section 22 of the Securities Act creates concurrent jurisdiction for state and federal
courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

 Any
person or entity purchasing or otherwise acquiring any interest in any of the Company's securities shall be deemed to have notice
of and consented to this provision. This exclusive-forum provision may limit a stockholder's ability to bring a claim in a judicial
forum of its choosing for disputes with the Company or its directors, officers, or other employees, which may discourage lawsuits against
the Company and its directors, officers, and other employees. If a court were to find the exclusive-forum provision to be inapplicable
or unenforceable in an action, the Company may incur additional costs associated with resolving the dispute in other jurisdictions, which
could harm its results of operations.

 Anti-takeover
effects of certain provisions of Delaware state law could hinder a potential takeover of the Company.

 The
Company is subject to statutory "anti-takeover" provisions under Delaware law; the provisions of Section 203 of the DGCL,
an anti-takeover law. In general, Section 203 of the DGCL which may prohibit certain business combinations with stockholders owning 15%
or more of the Company's outstanding voting stock. These anti-takeover provisions and other provisions in the Company's Amended
Charter and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of the
Company's board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or
impede a merger, tender offer or proxy contest involving the Company. These provisions could also discourage proxy contests and make
it more difficult for you and other stockholders to elect directors of your choosing or cause the Company to take other corporate actions
you desire. Any delay or prevention of a change of control transaction or changes in the Company's board of directors could cause
the market price of the Company's common stock to decline.

 Certain
provisions of the Company's amended and restated bylaws are intended to strengthen the position of the Company's board of
directors in the event of a hostile takeover attempt. These provisions have the effect of providing the Company's board of directors
with the sole power to fill vacancies on the Company's board of directors and providing that stockholders may only call a special
meeting by the request, in writing, of stockholders owning individually or together ten percent (10%) or more of the entire capital stock
of the corporation issued and outstanding and entitled to vote. The Company may include provisions in its certificate of incorporation
that may discourage a third party from making a proposal to acquire us, even if some of its stockholders might consider the proposal
to be in their best interests. For example, the Company may amend its certificate of incorporation to authorize its board of directors
to issue one (1) or more classes or series of preferred stock that could discourage or delay a tender offer or change in control. In
addition, the Company may enter into a stockholder rights plan, commonly known as a "poison pill," that may delay or prevent
a change of control.

 Provisions
in the Amended Charter and Delaware law may have the effect of discouraging lawsuits against the Company and its directors and officers.

 The
Amended Charter requires, unless the Company consents in writing to the selection of an alternative forum, that (i) any derivative action
or proceeding brought on the Company's behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director,
officer or other employee to the Company or the Company's stockholders, (iii) any action asserting a claim against the Company,
the Company's directors, officers or employees arising pursuant to any provision of the DGCL or the Amended Charter or the Company's
bylaws, or (iv) any action asserting a claim against the Company, the Company's directors, officers or employees governed by the
internal affairs doctrine may be brought only in the Court of Chancery in the State of Delaware, except any claim (A) as to which the
Court of Chancery of the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court
of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following
such determination), (B) which is vested in the exclusive jurisdiction of a Court or forum other than the Court of Chancery or (C) for
which the Court of Chancery does not have subject matter jurisdiction. If an action is brought outside of Delaware, the stockholder bringing
the suit will be deemed to have consented to service of process on such stockholder's counsel. Although the Pono believes this
provision benefits it by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies,
a Court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of
discouraging lawsuits against the Company's directors and officers, although the Company's stockholders will not be deemed
to have waived the Company's compliance with federal securities laws and the rules and regulations thereunder.

 The
Company's bylaws further provide that, unless the Company consents in writing to an alternative forum, the United States District
Court for the District of Delaware will be the exclusive forum for resolving any complaint asserting a cause of action arising under
the Securities Act. The Company's bylaws also provide that any person or entity purchasing or otherwise acquiring any interest
in shares of the Company's capital stock will be deemed to have notice of and to have consented to this choice of forum provision.
The Company recognizes that the forum selection clause in the Company's bylaws may impose additional litigation costs on stockholders
in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum
selection clause in the Company's bylaws may limit the Company's stockholders' ability to bring a claim in a forum
that they find favorable for disputes with us or the Company's directors, officers or employees, which may discourage such lawsuits
against us and the Company's directors, officers and employees even though an action, if successful, might benefit the Company's
stockholders. If a court were to find these exclusive-forum provisions in the Company's certificate of incorporation or bylaws
to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving the dispute in other
jurisdictions, which could seriously harm the Company's business. Nothing in the Company's certificate of incorporation or
bylaws will preclude stockholders that assert claims under the Securities Act or the Exchange Act from bringing such claims in state
or federal court, subject to applicable law.

 The
Company is a "controlled company" within the meaning of the applicable rules of Nasdaq and, as a result, we qualify for exemptions
from certain corporate governance requirements. If the Company relies on these exemptions, its stockholders will not have the same protections
afforded to stockholders of companies that are subject to such requirements.

 As
of December 31, 2024, Dr. Yoshiyuki Aikawa controls approximately 8 7.36 %
of the voting power of our outstanding common stock, and, therefore controls a majority of the voting power of the Company's
outstanding common stock, and the Company is a "controlled company" within the meaning of applicable rules of Nasdaq.
Under these rules, a company of which more than 50% of the voting power for the election of directors is held by an individual,
group or another company is a "controlled company" and may elect not to comply with certain corporate governance
requirements, including the requirements:

 that
 a majority of the board consists of independent directors;

 for
 an annual performance evaluation of the nominating and corporate governance and compensation committees;

 that
 the controlled company has a nominating and corporate governance committee that is composed entirely of independent directors with
 a written charter addressing the committee's purpose and responsibilities; and

 that
 the controlled company has a compensation committee that is composed entirely of independent directors with a written charter addressing
 the committee's purpose and responsibility.

 While
the Company does not intend to rely on these exemptions, the Company may use these exemptions now or in the future. As a result, the
Company's stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq
corporate governance requirements.

 If
the voting power of our capital stock continues to be highly concentrated, it may prevent you and other minority shareholders from influencing
significant corporate decisions and may result in conflicts of interest.

 As
of December 31, 2024, Dr. Aikawa controls approximately 8 7.36%
of the voting power of our outstanding shares of common stock. As a result, Dr. Aikawa has majority voting power over all matters
requiring shareholder votes, including: the election of directors; mergers, consolidations and acquisitions; the sale of all or
substantially all of our assets and other decisions affecting our capital structure; amendments to our certificate of incorporation
or our bylaws; and our winding up and dissolution.

 This
concentration of voting power may delay, deter or prevent acts that would be favored by our other stockholders. The interests of Dr.
Aikawa may not always coincide with our interests or the interests of our other stockholders. This concentration of voting power may
also have the effect of delaying, preventing or deterring a change in control of us. Also, Dr. Aikawa may seek to cause us to take courses
of action that, in his judgment, could enhance his investment in us, but which might involve risks to our other stockholders or adversely
affect us or our other stockholders. As a result, the market price of our shares of common stock could decline or stockholders might
not receive a premium over then-current market price of our shares of common stock upon a change in control. In addition, this concentration
of voting power may adversely affect the trading price of our shares of common.

 In
the event that our common stock price does not exceed the exercise price of the Private Placement Warrants during the period when the
Private Placement Warrants are exercisable, the Private Placement Warrants may not have any value.

 The
warrants will be immediately exercisable and expire on the fifth anniversary following the closing of the Business Combination. The Private
Placement Warrants will have an initial exercise price per share equal to $11.50. In the event that our common stock price does not exceed
the exercise price of the Private Placement Warrants during the period when the Private Placement Warrants are exercisable, the Private
Placement Warrants may not have any value.

 There
is no established trading market for the Private Placement Warrants to be sold in this offering, and the market for the Private Placement
Warrants may be highly volatile or may decline regardless of our operating performance. We do not intend to list the Private Placement
Warrants, nor do we expect the Private Placement Warrants to be quoted, on any securities exchange.

 There
must be a current registration statement in order for you to exercise the Private Placement Warrants.

 Holders
of Private Placement Warrants will be able to exercise the Private Placement Warrants only if a current registration statement relating
to the common stock underlying the Private Placement Warrants is then in effect. Although we will attempt to maintain the effectiveness
of a current registration statement covering the common stock underlying the Private Placement Warrants, there can be no assurance that
we will be able to do so. If the registration statement covering the shares issuable upon exercise of the Private Placement Warrants
is no longer effective, the Private Placement Warrants may only be exercised on a "cashless" basis and will be issued with
restrictive legends unless such shares are eligible for sale under Rule 144 of the Securities Act of 1933, as amended.

 Holders
of our Private Placement Warrants will have no rights as a common stockholder until they acquire our common stock.

 Until
you acquire shares of our common stock upon exercise of your Private Placement Warrants, you will have no rights with respect to our
common stock. Upon exercise of your Private Placement Warrants, you will be entitled to exercise the rights of a common stockholder only
as to matters for which the record date occurs after the exercise date.

 Item
1B. Unresolved Staff Comments.

 None.

 Item
1C. Cybersecurity.

 The
Company prioritizes the security of its information systems and data integrity. We have developed a cybersecurity strategy to manage
and mitigate potential cybersecurity risks. Our strategy is designed to safeguard our systems and data.

 Cybersecurity
Risk Management and Strategy

 The
Company's Information Systems Department is in charge of network construction and cybersecurity management. If a system failure,
serious accident, or sign of such an accident is detected, the Information Systems Department reports to the CEO and other executives,
who then consider countermeasures. The following are considered important cybersecurity issues, and countermeasures are being implemented.:

 Malware
 infection: There is a risk of losing sales due to information leaks or system downtime caused by unauthorized access due to malware
 infection. We are protecting against this by introducing email training and detection products.

 Vulnerability:
 There is a risk of loss of corporate trust and sales opportunities due to system downtime or information leaks caused by the exploitation
 of vulnerabilities in servers, etc. We are conducting vulnerability assessments for services that are open to the public, and will
 continue to expand the scope of these assessments in the future.

 Ransomware:
 If the system is infected with ransomware, there is a risk of data being encrypted, resulting in business stoppages and information
 leaks. We have prepared multiple backup mechanisms and recovery procedures in case of damage.

 leaks: If data is taken from databases or other sources due to unauthorized access or internal crime, the Company's credibility
 will be lost, resulting in a loss of profits or the occurrence of compensation for damages.

 Denial
 of Service (DOS) attacks: There is a risk that a DOS attack could bring down our website and make it impossible to make appointments
 at clinics, which would have a negative impact on sales. For this reason, we have introduced a WAF to prevent malicious access and
 DOS attacks.

 Applying
 patches and upgrading: There is a risk that not applying patches and upgrades could leave the system vulnerable to attacks, allowing
 unauthorized access. We are taking measures by regularly updating the operating system and applying patches.

 Governance
and Oversight

 There
is currently no director specializing in cybersecurity. Important cybersecurity matters are reported to the board of directors, and implementations
are carried out based on the Company's organizational chart, with the approval and oversight of the board of directors, CEO, and/or
other executive officers, as applicable.

 Employee
Training and Awareness

 Cybersecurity
threats are monitored and prevented by the head of the Information Systems Department, and the training plan is reported to the CEO and
other executives, who implement the following:

 We
 are planning to conduct annual training for the entire company on cybersecurity response.

 We
 are conducting recovery simulation training in the event of a system failure.

 We
 are conducting email training that simulates malicious attacks.

 Third-Party
Service Providers

 To
operate our business, we utilize certain third-party service providers to perform a variety of functions. We intend to use the same outsourcing
partners as much as possible for consistency. We are planning to establish selection and management policies in the future.

 Item
2. Properties.

 Our
headquarters is located at 200 Spectrum Center Dr., Suite 300, Irvine, CA 92618, where we lease and occupy our office space with an aggregate
floor area of approximately 215 square feet from an unrelated third party under an operating lease agreement.

 As
of the date of this Annual Report, we do not currently own any of our facilities. The following table shows the location of our primary
leased facilities, the name of the entity leasing the space, the annual rent, approximate square footage, primary use, and lease expiration
date.

 We
believe that our existing facilities are generally adequate to meet our current needs, but we expect to seek additional space as needed
to accommodate our future growth. There are no major facilities currently inactive. Annual rent below does not include consumption tax.

 Name of Lessee

 Location

 Primary Use

 Annual rent

(US dollars)

 Approximate

Size in

Square Feet

 Lease

Expiration

Date

 Note

(Related

Party)

 SBC Medical Group Holdings Incorporated

 California

 Headquarters

 8,520

 07/01/2025

 Tokyo

 553,808

 9,536

 10/31/2025

 Tokyo

 Meeting Room

 403,903

 7,543

 12/31/2025

 Tokyo

 Beauty salon

 128,280

 1,807

 1/31/2025

 Tokyo

 Lounge

 66,586

 1,048

 4/22/2025

 Tokyo

 Equipment warehouse

 67,044

 1,843

 2/9/2026

 Tokyo

 Main Office

 99,914

 1,935

 6/30/2030

 Tokyo

 237,139

 4,280

 8/31/2025

 Osaka

 53,849

 3,338

 7/31/2026

 Osaka

 Call center

 236,999

 6,121

 8/31/2026

 Tokyo

 56,828

 2,402

 2/28/2025

 Shobikai Co., Ltd.

 Kanagawa

 Main Office

 10,437

 1,882

 9/30/2027

 Y

 Shobikai Co., Ltd.

 Tokyo

 Call center

 114,479

 4,853

 1/31/2026

 Shobikai Co., Ltd.

 Sendai

 Call center

 87,233

 5,754

 10/31/2026

 SBC Sealane Co., Ltd.

 Tokyo

 Main Office

 38,268

 4,558

 4/30/2026

 Wen & Weng Medical Group PTE LTD

 165,710

 1,206

 2025/5/12

 Wen & Weng Medical Group PTE LTD

 137,542

 1,001

 2025/11/30

 Item
3. Legal Proceedings.

 From
time to time and in the course of business, we may become involved in various legal proceedings seeking monetary damages and other relief.
The amount of the ultimate liability, if any, from such claims cannot be determined. As of the date hereof, there are no legal claims
currently pending or, to our knowledge, threatened against us or any of our officers or directors in their capacity as such or against
any of our properties that, in the opinion of our management, would be likely to have a material adverse effect on our financial position,
results of operations or cash flows.

 Item
4. Mine Safety Disclosures.

 Not
applicable.

 PART
II

 Item
5.
 Market
 for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 Market

 Our
common stock began trading on the Nasdaq Global Market under the symbol "SBC" and our warrants began trading on the Nasdaq
Capital Market under the symbol "SBCWW" on September 18, 2024. On March 21, 2025, the closing price of our common stock was
$3.74 per share and the closing price of our warrants was $0.201.

 Holders
of Record

 As of February 28, 2025, we had approximately
34 holders of record of our common stock, with 103,881,251 shares issued (including 270,000 shares of treasury stock) and 103,611,251
shares outstanding. We also had two holders of record of our Public Warrants, consisting of 11,500,000 Public Warrants originally issued
in Legacy Pono's IPO and 634,375 Private Placement Warrants held by the Sponsor, with total of 12,134,375 warrants issued and outstanding.
The number of record holders does not include beneficial owners of common stock or warrants whose shares are held in the names of banks,
brokers, nominees, or other fiduciaries.

 Dividends

 We
have not paid any cash dividends on our common stock and do not currently anticipate paying cash dividends in the foreseeable future.
The agreements into which we may enter in the future, including indebtedness, may impose limitations on our ability to pay dividends
or make other distributions on our capital stock. Payment of future dividends on our common stock, if any, will be at the discretion
of our board of directors and will depend on, among other things, our results of operations, cash requirements and surplus, financial
condition, contractual restrictions and other factors that our board of directors may deem relevant. We intend to retain future earnings,
if any, for reinvestment in the development and expansion of our business.

 Transfer
Agent and Registrar

 The
Company's transfer agent and registrar for our Common Stock and Public Warrants is Continental Stock Transfer & Trust Company
located at 1 State Street, New York, NY 10004 and their telephone is (212) 509-4000.

 Unregistered
Stock Issuances

 Simultaneously
with the closing of the Company's Initial Public Offering on August 9, 2022, the Company consummated the sale of 634,375 units
(the "Placement Units") at a price of $10.00 per Placement Unit in a private placement to Mehana Capital LLC (the "Sponsor"),
including 63,000 Placement Units issued pursuant to the exercise of the underwriters' over-allotment option in full, generating
gross proceeds of $6,343,750.

 Stock
Performance Graph

 As
a "smaller reporting company" as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), the Company is not required to provide the information required under this Item.

 Item
6.
 [Reserved].

 Item
7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 The following discussion
and analysis summarize the significant factors affecting our operating results, financial condition, liquidity, and cash flows for the
periods presented below. The following discussion and analysis should be read in conjunction with the consolidated financial statements
and related notes included elsewhere in this Annual Report. The forward-looking statements contained herein are based on management's
judgment, assumptions made by management and information currently available to it. Actual results could differ materially from those
discussed or implied in the forward-looking statements as a result of various factors, including those described below and elsewhere in
this Annual Report, particularly in "Part I, Item 1A. Risk Factors" and the section entitled "Cautionary Note Regarding
Forward-Looking Statements."

 Unless the
context otherwise requires, any reference in this section of this Annual Report to the "Company," "SBC,"
"we," "us" or "our" refers to Legacy SBC and its consolidated subsidiaries and variable interest
entity ("VIE"), prior to the consummation of the Business Combination and to SBC Medical Group Holdings Incorporated, the Combined Entity and its consolidated subsidiaries and VIE following
the Business Combination.

 SBC
Medical Group, Inc. (formerly known as SBC Medical Group Holdings Incorporated), a Delaware corporation and subsidiary of the Company
("Legacy SBC") is a management company headquartered in Irvine, California and Tokyo, Japan, that provides management services
to cosmetic treatment centers mainly in Japan. The Company and its subsidiaries are primarily focused on providing comprehensive management
services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social
media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance
with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical
consumables procurement ( resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure
of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not
limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point
program), and payment tools for the franchisee clinics.

 Our
wholly owned subsidiaries, SBC Medical Group Co., Ltd., a Japan corporation ("SBC Medical Sub"), L'Ange Cosmetique
Co., Ltd., a Japan corporation ("Lange Sub"), and Shobikai Co., Ltd., a Japan corporation ("Shobikai Sub"), are
each designated as a "medical service corporation" in Japan. In Japan, a medical service corporation is a legal entity that
provides management service to "medical corporations". The management services are conducted through franchisor-franchisee
contracts and/or service contracts between certain subsidiaries of the Company (SBC Medical Sub, Lange Sub, and Shobikai Sub) and the
medical corporations that own all 241 of the treatment centers in Japan. These clinics provide include but are not limited to breast
augmentation, liposuction, rejuvenation treatments (including treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration,
and signs of aging), laser skin toning and spot removal, eyes double fold surgery, rhinoplasty, treatment of osmidrosis and hyperhidrosis,
hair transplants, gynecological formation treatments, laser hair removal, face line surgeries, cosmetical dental procedures, tattoo removal,
lasik eye surgery, lateral canthoplasty, brow lift procedures, androgenetic alopecia treatment, and cheek sagging prevention methods.

 There
are currently six medical corporations that the Company's subsidiaries have entered into franchisor-franchisee contracts and service
contracts, consisting of Medical Corporation Shobikai, Medical Corporation Kowakai, Medical Corporation Nasukai, Medical Corporation
Aikeikai, Medical Corporation Jukeikai and Medical Corporation Ritz Cosmetic Surgery. In addition, the Company has entered into service
contracts since September 2023 with two additional medical corporations, Medical Corporation Association Furinkai and Medical Corporation
Association Junikai (collectively with the six franchisee medical corporations, the "Medical Corporations" or "MCs").
All of the Medical Corporations are deemed to be related parties of the Company since relatives of the CEO of the Company are the members
(or shain) of general meetings of members of the Medical Corporations. The CEO of the Company was previously a member of the six
franchisee Medical Corporations until he ceased being a member in July 2023. The Company, through SBC Medical Sub, owns equity "deposit"
interests (or mochibun) of the Medical Corporations (except Medical Corporation Association Furinkai and Medical Corporation Association
Junikai). Although the Company, through SBC Medical Sub, has an equity "deposit" interest to the rights to receive a distribution
of residual assets in proportion to the amount of contribution in certain circumstances as provided in the articles of incorporation
of each of the Medical Corporations (except Medical Corporation Association Furinkai and Medical Corporation Association Junikai), the
Company or SBC Medical Sub does not have voting control over the corporate actions at general meetings of members (or shain) of
the Medical Corporations per the requirements of the Japanese Medical Care Act.

 For
the years ended December 31, 2024 and 2023, we generated revenues of $205,415,542 and $193,542,423, respectively, we reported net income
attributable to SBC Medical Group Holdings Incorporated of $46,614,275 and $39,370,036, respectively, and cash flow provided by operating
activities of $20,582,933 and $50,670,322, respectively. As of December 31, 2024, we had retained earnings of $ 189,463,007.

 Our
primary mission is to provide quality comprehensive management services to the Medical Corporations and expand our "Shonan Beauty
Clinic" brand. We plan to achieve the mission by maintaining and strengthening our market position and brand in the cosmetic medical
treatment management market in Japan, Vietnam, and the United States, and by growing our presence globally.

 Further
information regarding our business is provided in "Part 1, Item 1. Business" of this Annual Report.

 Results
of Operations

 Comparison
of Results of Operations for the Years Ended December 31, 2024 and 2023

 The
following table summarizes our operating income as reflected in our audited consolidated statements of operations and comprehensive income
for the years ended December 31, 2024 and 2023, and presents information regarding amounts and percentage changes during those periods.

 For
 the Years Ended December 31,

 2024

 2023

 %
 of revenue

 %
 of revenue

 %

 Revenues, net (including net revenues
 provided to related parties)

 $

 %

 $

 %

 $
 11,873,119

 6.13
 %

 Cost of revenues

 49,365,035

 24.03
 %

 56,238,385

 29.06
 %

 (6,873,350
)

 (12.22
)%

 Gross profit

 156,050,507

 75.97
 %

 137,304,038

 70.94
 %

 18,746,469

 13.65
 %

 Operating expenses

 85,746,797

 41.74
 %

 66,643,972

 34.43
 %

 19,102,825

 28.66
 %

 Income from operations

 70,303,710

 34.23
 %

 70,660,066

 36.51
 %

 (356,356
)

 (0.50
)%

 Other income

 3,152,107

 1.53
 %

 2,919,269

 1.51
 %

 232,838

 7.98
 %

 Income before income
 taxes

 73,455,817

 35.76
 %

 73,579,335

 38.02
 %

 (123,518
)

 (0.17
)%

 Income tax expense

 26,765,925

 13.03
 %

 35,018,729

 18.09
 %

 (8,252,804
)

 (23.57
)%

 46,689,892

 22.73
 %

 38,560,606

 19.93
 %

 8,129,286

 21.08
 %

 Less: net income (loss)
 attributable to non-controlling interests

 75,617

 0.04
 %

 (809,430
)

 (0.41
)%

 885,047

 (109.34
)%

 Net
 income attributable to SBC Medical Group Holdings Incorporated

 $
 46,614,275

 22.69
 %

 $
 39,370,036

 20.34
 %

 $
 7,244,239

 18.40
 %

 Revenues,
Net

 Revenues,
net generated from different revenue streams consist of the following:

 For
 31,

 2024

 2023

 %

 Franchising revenue

 $
 61,033,032

 $
 42,103,380

 $
 18,929,652

 44.96
 %

 Procurement revenue

 54,814,399

 53,186,662

 1,627,737

 3.06
 %

 Management services revenue

 53,113,155

 72,282,549

 (19,169,394
)

 (26.52
)%

 Rental services revenue

 16,141,714

 7,336,768

 8,804,946

 120.01
 %

 20,313,242

 18,633,064

 1,680,178

 9.02
 %

 Total

 $

 $

 $
 11,873,119

 6.13
 %

 Revenues,
net, increased by 6.13% from $193,542,423 for the year ended December 31, 2023 to $205,415,542 for the year ended December 31, 2024.

 Japanese
Yen ("JPY") against the U.S. dollar depreciated during the year ended December 31, 2024, compared to the year ended December
31, 2023. The spot rate against the dollar was 156.7890 yen on December 31, 2024 compared to 141.0350 yen on December 31, 2023 and the
average rate against the dollar was 151.4405 yen for the year ended December 31, 2024 compared to 140.5261 yen for the same period in
2023. For the years ended December 31, 2024 and 2023, we generated net revenues of $205,415,542 (JPY31,108 million) and $193,542,423
(JPY 27,198 million), respectively. For the years ended December 31, 2024 and 2023, we reported net income of $46,689,892 (JPY7,059 million)
and $38,560,606 (JPY 5,419 million), respectively. Overall, the unfavorable impacts of the year-to-year foreign exchange rate changes
on net revenues and net income were $15,954,241 and $3,545,053, respectively, for the year ended December 31, 2024.

 The
main reasons for the variance of $11,873,119 in revenues, net per revenue stream are as follows:

revenue for the year ended December 31, 2024 increased to $61,033,032 by $18,929,652 or 44.96% from $42,103,380 for the same period in
2023. This increase was mainly due to (i) a change in the billing base of royalty fees from a percentage of sales of MCs to a fixed amount
for each clinic of MCs since April 2023 combined with an increase in the number of clinics operated by MCs, (ii) authorizing the six
MCs, which are our main recurring customers, to use our patents and trademarks starting from September 2023, and (iii) the business expansion
of the MCs, partially offset by the depreciation of JPY.

 The
procurement revenue for the year ended December 31, 2024 increased to $54,814,399 by $1,627,737 or 3.06% from $53,186,662 for the same
period in 2023. This increase was mainly due to the increase in the demand on medical materials due to the business expansion of MCs,
partially offset by the depreciation of JPY.

 The
management services revenue for the year ended December 31, 2024 decreased to $53,113,155 by $19,169,394 or 26.52% from $72,282,549 for
the same period in 2023. This decrease was mainly due to (i) the discontinuation of clinic operation staff supporting services provided
by Shobikai Sub to MCs since the third quarter of 2024, because the Company plans to merge Shobikai Sub with and into Lange Sub and the
related business license, held by Shobikai Sub, will be invalid upon the merger, (ii) a significant decline in loyalty program management
services revenue compared with 2023, primarily because the charge rate of handling fee decreased from 5% to 4%, and there were more free
point redemptions, and (iii) the depreciation of JPY, partially offset by (i) the increase in revenue generated from management consulting
services and loyalty program management services provided to two MCs that the Company started to conduct business since September 2023
(Medical Corporation Association Furinkai and Medical Corporation Association Junikai), (ii) the business expansion of MCs and (iii)
the increase in the number of the clinics of MCs.

 The
rental services revenue for the year ended December 31, 2024 increased to $16,141,714 by $8,804,946 or 120.01% from $7,336,768 for the
same period in 2023. This increase was mainly due to the increased demand for medical equipment from MCs due to the business expansion
of MCs, partially offset by the depreciation of JPY.

 The
other revenues for the year ended December 31, 2024 increased to $20,313,242 by $1,680,178 or 9.02% from $18,633,064 for the same period
in 2023. This increase was mainly due to the business expansion of the subsidiary acquired in April 2023, partially offset by the depreciation
of JPY.

 Cost
of Revenues

 Cost
of revenues, for the year ended December 31, 2024, was $49,365,035 compared to $56,238,385 for the same period in 2023. The decrease
by $6,873,350 or 12.22% was mainly due to the Company's effort of the cost reduction for the year ended December 31, 2024, as well
as the discontinuation of clinic operation supporting services provided by Shobikai Sub to MCs since the third quarter of 2024, and the
Company then terminated the employment of the related staff. As a result, labor cost significantly decreased.

 Gross
Profit

 Gross
profit, for the year ended December 31, 2024, was $156,050,507 compared to $137,304,038 for the same period in 2023. The increase in
gross profit by $18,746,469 or 13.65% was mainly due to the increase in franchising revenue with a relatively high gross margin as a
result of the factors described above, offset by the decrease in management services revenue as a result of the factors described above.

Expenses

expenses for the years ended December 31, 2024 and 2023 were as follows:

 For
 31,

 2024

 2023

 %

 Salaries and welfare

 $
 26,843,524

 $
 26,847,863

 $
 (4,339
)

 (0.02
)%

 Depreciation and amortization expense

 2,258,364

 10,924,452

 (8,666,088
)

 (79.33
)%

 Impairment loss on intangible asset

 15,058,965

 —

 15,058,965

 %

 Consulting and professional service fees

 14,555,087

 9,481,719

 5,073,368

 53.51
 %

 Advertising expense

 2,782,944

 3,367,608

 (584,664
)

 (17.36
)%

 Taxes and dues

 596,122

 1,904,967

 (1,308,845
)

 (68.71
)%

 Recruiting expense

 1,570,299

 2,038,591

 (468,292
)

 (22.97
)%

 Lease expense

 2,369,666

 2,897,683

 (528,017
)

 (18.22
)%

 Office, utility and other expenses

 6,689,134

 8,772,059

 (2,082,925
)

 (23.74
)%

 Misappropriation loss

 —

 409,030

 (409,030
)

 (100.00
)%

 Stock-based compensation

 —

 %

 Total

 $
 85,746,797

 $
 66,643,972

 $
 19,102,825

 28.66
 %

 The
operating expenses increased to $85,746,797 for the year ended December 31, 2024 by $19,102,825 or 28.66% from $66,643,972 for the same
period in 2023.The increase in operating expenses was mainly attributed to the increase in impairment loss on intangible asset, the
increase in stock-based compensation, and the increase in consulting and professional service fees, partially offset by the decrease
in depreciation and amortization expenses.

 Depreciation
and amortization expense decreased to $2,258,364 by $8,666,088 or 79.33% for the year ended December 31, 2024 from $10,924,452 for the
same period in 2023, mainly because the decrease in amortization expense incurred from the intangible assets owned by Cell Pro Japan
Co., Ltd. ("Cellpro"), a former subsidiary of the Company, due to the disposal of Cellpro on January 1, 2024.

and professional service fees increased to $14,555,087 by $5,073,368 or 53.51% for the year ended December 31, 2024 from $9,481,719 for
the same period in 2023, mainly due to the increase of the professional service fees incurred related to the business combination transaction.

 Stock-based
compensation relates to the warrants issued to the service provider that supported SBC's listing process. These warrants were issued
in November 2022 and became exercisable upon the consummation of business combination with Pono Two Capital, Inc., and the fair value
was recognized as an expense.

 For
the year ended December 31, 2024, the Company fully impaired an intangible asset, patent use right, because the estimated cash flows
from the use and its eventual disposal of this intangible asset were determined to be negligible. This conclusion was reached through a careful decision-making process and was approved by the Company's board
of directors.

 Other
Income (Expenses)

 Other
income (expenses) for the years ended December 31, 2024 and 2023, were as follows:

 For
 the Years ended
 31,

 2024

 2023

 %

 Interest income

 $
 19,943

 $
 86,748

 $
 (66,805
)

 (77.01
)%

 Interest expense

 (28,300
)

 (45,292
)

 16,992

 (37.52
)%

 Other income

 4,810,008

 3,623,332

 1,186,676

 32.75
 %

 Other expenses

 (5,463,153
)

 (745,519
)

 (4,717,634
)

 632.80
 %

 Gain on disposal of subsidiary

 3,813,609

 —

 3,813,609

 %

 Total

 $
 3,152,107

 $
 2,919,269

 $
 232,838

 7.98
 %

an unrealized loss was recognized from the Company's investment in a public entity with readily determinable fair value under other expenses, a gain on disposal of subsidiary was recorded due to the disposal of Cellpro on January 1, 2024. The total other
income (expenses) for the year ended December 31, 2024 was $3,152,107, compared to $2,919,269 for the same period in 2023, reflecting
only a minor overall fluctuation.

Tax Expense

tax expense, for the year ended December 31, 2024, was $26,765,925 compared to $35,018,729 for the same period in 2023. The decrease
in income tax expense by $8,252,804 or 23.57% was mainly due to the increase in the deferred tax benefit as no valuation allowance on
deferred tax assets of Lange Sub was reserved during the year ended December 31, 2024. It was mainly due to the merger among SBC Medical
Sub, Lange Sub and Shobikai Sub, with Lange Sub as the surviving entity after the merger, that expected to be effective in January 2025,
resulting in the potential ability of Lange Sub to generate income and utilize the carried forward net operating loss.

 The
effective tax rate for the fiscal year ended December 31, 2024 was 36.44%, a decrease of 11.16% compared to the 47.59% rate for the fiscal
year ended December 31, 2023. This decrease was mainly due to a reduction in valuation allowance on deferred tax assets as described
in the income tax expense comparison above.

 Net

 As
a result of the foregoing, we reported a net income of $46,689,892 for the year ended December 31, 2024, representing an increase of
$8,129,286 from $38,560,606 for the year ended December 31, 2023.

 Net
Income (Loss) Attributable to Non-controlling Interests

 Net
Income attributable to non-controlling interests was $75,617 for the year ended December 31, 2024, as compared to the net loss attributable
to non-controlling interests of $809,430 for the year ended December 31, 2023, which was mainly due to the disposal of Cellpro on January
1, 2024.

 Liquidity
and Capital Resources

 As
of December 31, 2024, the Company had $125,044,092 in cash and cash equivalents compared to $103,022,932 as of December 31, 2023. In
addition, the Company had $30,260,113 in accounts receivable as of December 31, 2024 compared to $35,113,749 as of December 31, 2023.
The Company's accounts receivable includes balances due from customers for the services and goods provided by the Company and accepted
by customers.

 As
of December 31, 2024, the Company's working capital balance was $123,259,130. In assessing liquidity, management monitors and analyzes
the Company's cash and cash equivalents, ability to generate sufficient future earnings, and operating and capital investment commitments.
The Company believes that its current cash and cash equivalents from operations and borrowings from banks will be sufficient to meet
its working capital needs for the next 12 months from the date of issuance of the audited financial statements included in this Annual
Report.

 To
the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate
that they will be obtained through the incurrence of indebtedness, equity financings or a combination of these potential sources of funds.
While we face uncertainties regarding the size and timing of our fundraising, which will be affected by general economic, financial,
and other factors that may be beyond our control, we believe that we will be able to continue to meet our current business needs through
the use of cash flows generated from operations and stockholder working capital, as needed.

 The
Company evaluates its capital allocation practices with the objective of enhancing shareholder value, while considering performance,
the business environment, macroeconomic conditions and other relevant factors. The Company expects to deploy capital for investment opportunities
that align with its growth strategy, selectively pursuing prospects in the expanding global medical aesthetics market.

 Cash
Flows for the Years Ended December 31, 2024 and 2023

 The
following table provides a summary of our cash flows for the years indicated.

 For
 the Years ended

 2024

 2023

 %

 Net cash provided by operating
 activities

 $
 20,582,933

 $
 50,670,322

 $
 (30,087,389
)

 (59.38
)%

 Net cash provided by (used in) investing activities

 (10,102,410
)

 1,793,631

 (11,896,041
)

 (663.24
)%

 Net cash provided by financing activities

 22,965,400

 6,135,368

 16,830,032

 274.31
 %

 Effect of changes in foreign
 currency exchange rate

 (11,424,763
)

 (7,314,383
)

 (4,110,380
)

 56.20
 %

 Net change in cash and cash equivalents

 22,021,160

 51,284,938

 (29,263,778
)

 (57.06
)%

 Cash and cash equivalents
 as of the beginning of the period

 51,737,994

 51,284,938

 99.12
 %

 Cash and cash equivalents
 as of the end of the period

 $
 125,044,092

 $

 $
 22,021,160

 21.38
 %

Activities

 Net
cash provided by operating activities for the year ended December 31, 2024 was $20,582,933, compared to net cash provided in operating
activities of $50,670,322 for the year ended December 31, 2023, reflecting a decrease of $30,087,389. The decrease was mainly due to
a decrease in changes in notes payable - related parties of $34.7 million, finance lease receivables – related parties of $22.6
million and accounts payable of $21.8 million, partially offset by an increase in changes in accounts receivable - related parties of
$23.8 million and accrued retirement compensation expense – related party of $22.1 million.

 Investing
Activities

the year ended December 31, 2024, net cash used in investing activities of $10,102,410 was mainly the result of payments made on behalf
of a related party of $5.6 million, cash paid for acquisition of a subsidiary, net of cash received of $4.2 million, purchase of property
and equipment of $2.6 million and purchase of convertible note of $1.7 million, partially offset by repayments from related parties of
$6.6 million. During the year ended December 31, 2023, net cash provided by investing activities of $1,793,631 was mainly the result
of proceeds from disposal of property and equipment of $8.0 million, sales of short-term investments of $4.1 million, and proceeds from
surrender of life insurance policies of 4.0 million, and offset by payments made for the purchase of property and equipment of $8.5 million,
purchase of short-term investments of $2.1 million and advances to related parties of $2.3 million.

 Financing
Activities

the year ended December 31, 2024, net cash provided by financing activities of $22,965,400 was the result of proceeds from reverse recapitalization,
net of transaction costs of $11.7 million, borrowings from a long-term loan of $6.6 million and borrowings from related parties of $5.5
million. During the year ended December 31, 2023, net cash provided by financing activities of $6,135,368 was the result of borrowings
from related parties of $12.3 million and deemed contribution in connection with disposal of property and equipment of $9.6 million and
offset by repayments of long-term loans of $8.7 million and repayments to related parties of $7.7 million.

 Recent
Developments

 Upcoming
Changes to Service Fee Structure

 The Company has decided to
revise the fee structure to pursue a long-term growth strategy aimed at expanding and stabilizing the business foundation by creating
an environment that can better facilitate the establishment of new clinics by MCs.

 If
the revised fee structure had been applied starting in April 2024, it is estimated that total revenues for fiscal year 2024 would have
decreased by approximately 10%. However, the Company expects the impact on total revenues and income from operations for fiscal year
2025 to be offset by the absence of one-time losses that were recorded in fiscal year 2024, which were impairment loss on intangible
asset and stock-based compensation. Nevertheless, the ultimate financial impact remains uncertain and will depend on a number of factors,
many of which are beyond the Company's control.

 Upcoming
Insurance Policy Maturing

 Certain
corporate-owned life insurance policies that the Company purchased to insure its CEO and a key officer will mature on March 29, 2025,
according to the contract term.

 The
policies of these life insurances were structured so that the surrender value was equivalent to 50% of the initial premium before
the maturity of the contract and the initial premium was paid out in a lump sum at the inception of the contract. The surrender
value as of the contract mature date agreed to be the initial premium or accumulated initial premium amount considering interest, which is larger. As
of December 31, 2024, the insurance policies were recorded at their cash surrender values, included in other assets in the
consolidated balance sheets with changes in cash surrender value during the period recorded in selling, general and administrative
expenses.

 The
Company expected the maturity of these policies would result in a gain on surrender of life insurance policies of approximately $9.3
million in the first quarter of fiscal year 2025.

 Misappropriations
of Funds

 In
January 2024, before the issuance of the Company's consolidated financial statements as of December 31, 2023 and for the year
then ended, in connection with a routine tax examination of the Company's income tax returns, the Japanese tax authority
discovered misappropriations of Company funds by a former director of general affairs and legal department of L'Ange
Cosmetique Co., Ltd., which is a subsidiary of the Company (the "former director"), not a relative of the CEO of the
Company or any identified related party, who received kickbacks from multiple vendors of SBC Japan (collectively with the former
director, the "participants") possibly beginning as early as 2012 until the misappropriations were discovered. The
former director was suspended immediately upon the discovery and was terminated effective February 23, 2024. The Company has
commenced a criminal complaint in Tokyo against the participants, which was accepted by the police on February 25, 2025.

 Shortly
after this discovery, the Company engaged independent legal counsel and forensic consultants to investigate the misappropriations. The
investigation, which was completed in March 2024, revealed that the participants had misappropriated approximately JPY632 million ($5.6
million), including consumption tax, from the Company of which the former director received approximately JPY335 million ($3.0 million),
between April 2016 and the discovery of the misappropriations in January 2024. The amount misappropriated prior to April 2016 could not
be accurately determined because certain data for the period prior to April 2016 was unavailable, the Company does not expect such amount
to be material based on current estimates.

 The
Company found no evidence that any other employee of the Company was aware of, or colluded in, the misappropriations of Company
funds or that there was any unlawful activity apart from that associated with the participants' misappropriations of Company
funds. The misappropriated amounts, excluding the consumption tax, representing advertising services purchased on behalf of a
related-party MC, were originally included in the revenues reported on a net basis. After discovery of the misappropriations, the
amounts were reported as a misappropriation loss. For the year ended December 31, 2023, the Company recorded
a misappropriation loss of $409,030.

 Contractual
Obligations

 Lease
Agreements

 The
Company has 95 leases classified as operating leases for offices and sublease purposes.

 As
of December 31, 2024, the future maturity of lease liabilities is as follows:

 Years ending

 Lease

 Payment

 2025

 $
 4,361,879

 2026

 712,869

 2027

 263,412

 2028

 109,906

 2029

 109,906

 Thereafter

 54,950

 Total undiscounted lease
 payments

 5,612,922

 Less: imputed interest

 (29,874
)

 Total
 operating lease liabilities

 $
 5,583,048

 Bank
and Other Borrowings

 The
Company borrowed loans from various banks and a financial institution for working capital purpose.

 As
of December 31, 2024, future minimum borrowing payments are as follows:

 Years ending

 Principal

 Repayment

 2025

 $
 96,824

 2026

 66,580

 2027

 6,436,102

 2028

 —

 2029 and thereafter

 —

 Total

 $
 6,599,506

 Off-Balance
Sheet Arrangements (Off-Balance Sheet Transactions)

 There
are no off-balance sheet arrangements as of December 31, 2024 and 2023.

 Foreign
Exchange Rate Risk

 We
are exposed to foreign currency exchange rate fluctuations because our business is primarily conducted in Japan and most of our revenues
and costs are denominated in Japanese yen, whereas our reporting currency is U.S. dollar. The weakening of the Japanese yen against the
U.S. dollar would have a negative impact on our financial results and vice versa.

 Critical
Accounting Policies and Estimates

 We
prepare our consolidated financial statements in conformity with U.S. GAAP, which requires us to make judgments, estimates and assumptions.
We continually evaluate these estimates and assumptions based on the most recently available information, our own historical experiences
and various other assumptions that we believe to be reasonable under the circumstances. Since the use of estimates is an integral component
of the financial reporting process, actual results could differ from our expectations as a result of changes in our estimates. Some of
our accounting policies require a higher degree of judgment than others in their application and require us to make significant accounting
estimates. We believe that critical accounting policies as disclosed in this Annual Report reflect the more significant judgements and
estimates used in preparation of our consolidated financial statements.

 The
following descriptions of critical accounting policies and estimates should be read in conjunction with our consolidated financial statements
and other disclosures included in this Annual Report. When reviewing our consolidated financial statements, you should consider our selection
of critical accounting policies, the judgments and other uncertainties affecting the application of such policies and the sensitivity
of reported results to changes in conditions and assumptions.

Recognition

 The
Company recognizes revenue from franchising services, procurement services, management services and other services under ASC Topic 606,
"Revenue from Contracts with Customers".

 To
determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price
to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation. Revenue amount represents the invoiced value, net of consumption tax and applicable local government levies, if any. The
consumption tax on sales is calculated at 10% of gross sales. The Company does not have significant remaining unfulfilled performance
obligations or contract balances.

 The
Company reports revenue on a gross or net basis based on management's assessment of whether the Company acts as a principal or
agent in the transaction. The determination of whether the Company acts as a principal or an agent in a transaction is based on the evaluation
of whether (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company
has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer
and (iii) the Company has discretion in establishing the price for the specified good or service. If the terms of a transaction do not
indicate the Company is acting as a principal in the transaction, then the Company is acting as an agent in the transaction and the associated
revenues are recognized on a net basis.

 The
Company recognizes revenue from rental services under ASC Topic 842, "Leases".

 The
Company currently generates its revenue from the following main sources:

 The
Company generates franchising revenue (royalty income) by licensing its intellectual properties, including but not limited to the Company's
brand name ("Shonan Beauty Clinic"), trade name, patents, and trademarks, as a franchisor pursuant to franchise agreements
with certain MCs (the "MCs") in Japan. Prior to April 2023, Franchising Revenue is based on a percentage of sales and recognized
at the time when the related sales occurred; since April 2023, it is based on a fixed amount to each clinic of the MCs; since September
2023, it is based on a fixed amount to each MC and a fixed amount to each clinic of the MCs and recognized over time as services are
rendered.

 The
Company generates procurement revenue by purchasing primarily advertising services and medical materials from qualified vendors on behalf
of MCs to maintain brand quality consistency. Procurement revenue is recognized at the point in time upon the delivery of products or
over time as services are performed. Occasionally, the Company receives vendor discounts on certain large purchases. It recognizes revenue
based on actual payments and will return the over-collection resulting from such discounts to MCs.

 The
Company provides loyalty program management services, labor supporting services, function supporting services and management consulting
services to MCs.

 Loyalty
 program management services

 The
Company awards loyalty points on behalf of MCs to MCs' customers, who earn loyalty points from each qualified purchase made at
the loyalty program participating clinics of MCs, in exchange for a handling fee. The revenue is based on a percentage of the related
payment amount made by MCs' customers and is recognized when the loyalty points are awarded.

 At
the time loyalty points are awarded, a MC pays the Company cash in an amount equivalent to the awarded loyalty points, which is recorded
as advances from customers. When a MC's customers redeem the loyalty points, the Company returns the cash back to the MC in an
amount equivalent to the redeemed loyalty points. The awarded loyalty points expire if a MC's customer does not make any additional
qualified purchase at a participating clinic within a year. The Company accumulates and tracks the points on behalf of MCs until the
loyalty points expire, at which time the Company recognizes an amount equivalent to the expired loyalty points as revenue, which is normally
not significant.

 The
Company also awards certain points to MCs' customers on behalf of MCs for free in order to increase the volume of MC's sales,
from which the Company earns other types of revenues, such as franchising revenue. When a MC's customers redeem such points, the
Company reimburses MC in an amount equivalent to the used free points and records it as a reduction of the revenue recognized.

 The
Company is an agent in the management of loyalty programs, and as a result, revenues are recognized net of the cost of redemptions.

 Labor

 The
Company generates revenue by dispatching staff to MCs to provide a range of services, primarily including clinic operation, IT, and administrative
services, among which, clinic operation service has been fully terminated since October 2024. The Company recognizes the revenue over
the time when services are rendered.

 Function

 The
revenue is derived from providing functional supporting services to MCs, such as accounting and human resources services. The Company

 consulting services

 The
Company generates revenue by providing consulting services to MCs in relation to business operations of cosmetic dermatology. The Company

 The
Company generates rental income from operating leases and sales-type leases, which is accounted for under ASC Topic 842. Operating lease
revenue is generally recognized on straight-line basis over the terms of the lease agreements and sales-type leases revenue is generally
recognized on the lease commitment date.

 Other

 The
Company generates other miscellaneous revenues such as accommodation services income, medicine dispensed sales revenue, brokerage services
revenue, construction services revenue, pilot training services revenue, interest income, etc. These revenues are recognized when the
Company satisfies performance obligations.

Investments in MCs — Related Parties

investments in MCs — related parties represent the payments to obtain equity interests of the MCs in Japan, made by the Company
through SBC Japan, a company designated as a MSC in Japan. In accordance with the Japanese Medical Care Act and articles of incorporation
of the MCs, which are non-profit organizations, the equity interest holders of MCs are prohibited from receiving any profit distribution
from MCs but have the right to receive distribution of the residual assets of the MCs in proportion to the amount of their contribution.
As of the balance sheet dates, the investments represent probable future benefit to be realized at the time of dissolution of MCs or
the equity interests being sold. The payments made for such investments are classified as investing activities in the consolidated statements
of cash flows. The MCs are considered related parties as the relatives of the Chief Executive Officer ("CEO") of the Company
being the Members of the MCs.

 The
investments in MCs — related parties are accounted for using a measurement alternative, under which the investments are measured
at cost, less impairment, and adjusted for observable price changes. The Company reviews the investments in MCs for impairment whenever
events or changes in circumstances indicate that the carrying amount may not be recoverable, especially the investments in Medical Corporation
Jukeikai ("MC Jukeikai") and Medical Corporation Ritz Cosmetic Surgery ("MC Ritz"), which represent the vast
majority of the Company's investments in MCs balance.

 Impairment
Consideration of Investments in MC Jukeikai and MC Ritz

these two MCs are non-profit entities, their principal operations are providing health care services and they derive primary source of
their revenue from the sale of goods and services, rather than the fund contributions.

 No
indicator of impairment was noticed based on the Company's qualitative assessment of impairment. As the Company provides comprehensive
management services to these two MCs, including accounting and bookkeeping services, the Company has access to MCs' unaudited financial
information. In addition to the external market conditions and trends within the MCs' industry, the Company considered the MCs'
operating performance, such as sales, increase in sales, and net income (loss) when performing its qualitative assessment. As of December
31, 2024, the carrying value of the investments in the two MCs was higher than their net assets, respectively, because the Company acquired
the equity interests with the considerations paid higher than the net asset values at the respective purchase dates due to the expected
growth and expansion of the MCs.

 For
management's additional internal analysis purposes, the Company estimates the residual values of the two MCs at dissolution when
needed, using the income approach with the discounted cash flow method, which estimates the fair values of the MCs by the present worth
of the net economic benefit to be received by MCs. Management applies significant judgment and assumptions related to estimation, including
but not limited to the forecasted revenues, the selection of an expected EBITDA margin assumption for the forecast period, forecasted
future cash flows, and the discounted rate. The Company currently expects the residual values at the dissolution of the MCs will not
be less than the carrying values of the investments in MCs. The management is not aware of any legal or regulatory limitations on the
Company's ability to realize the full amount of proceeds generated from a liquidation of the MCs.

 Stock
Based Compensation

 The
Company accounts for stock-based compensation awards in accordance with ASC Topic 718, "Compensation — Stock Compensation",
under which the Company determines whether stock-based compensation awards should be classified and accounted for as an equity award.
There were no liability awards granted during any of the periods stated herein. For all grants of stock-based compensation classified
as equity awards, the cost of services received from employees and non-employees in exchange for awards is recognized in the consolidated
statements of operations and comprehensive income based on the estimated fair value of those awards on the grant date and amortized on
a straight-line basis over the requisite service period or vesting period. The Company records forfeitures and cancellations as they
occur.

 The
Company, with the assistance of an independent valuation specialist, determined the fair value of the warrants recognized in the consolidated
financial statements using the binomial option pricing model, and the equity value as of the grant date was estimated using 1) income
approach with the discounted cash flow valuation method, which requires management to make significant estimates and assumptions related
to forecasted revenues and cash flows and the discount rates, and 2) market approach with metrics of publicly traded companies or historically
completed transactions of comparable businesses. The Company applied a weighting to the income approach and market approach to determine
the fair value. We believe the accounting estimate for valuation of stock-based compensation is a critical accounting estimate because
our estimates of fair value of stock-based compensation are based upon assumptions believed to be reasonable, but which are inherently
uncertain and, as a result, actual results may differ from estimates.

 Emerging
Growth Company

 We
are an "emerging growth company," as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and we will
take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404
of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any
golden parachute payments not previously approved.

 Further,
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do
not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended
transition period, which means that when a standard is issued or revised and it has different application dates for public or private
companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised
standard.

 Smaller
Reporting Company

 Additionally,
we are a "smaller reporting company," as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held
by non-affiliates exceeds $250 million as of the last business day of our second fiscal quarter, or (ii) our annual revenue exceeded
$100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as
of the last business day of our second fiscal quarter. If we continue to be a smaller reporting company at the time we cease to be an
emerging growth company, we may continue to rely on exemptions from these certain reduced disclosure requirements that are available
to smaller reporting companies.

 Item
7A. Quantitative and Qualitative Disclosures About Market Risk.

 We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise
required under this item.

 Item
8.
 Statements and Supplementary Data.

 SBC

TO FINANCIAL STATEMENTS

 Page

 Report
 of Independent Registered Public Accounting Firm (PCAOB ID: 206)

 Consolidated
 Balance Sheets as of December 31, 2024 and 2023

 Consolidated
 Statements of Operations and Comprehensive Income for the year s ended December 31, 2024 and 2023

 Consolidated
 Statements of Changes in Stockholders' Equity for the year s ended December 31, 2024 and 2023

 Consolidated
 Statements of Cash Flows for the year s ended December 31, 2024 and 2023

 Notes
 to Consolidated Financial Statements

 F- 1

 REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 To
the Shareholders and Board of Directors of

 SBC
Medical Group Holdings Incorporated

 Opinion
on the Financial Statements

 We
have audited the accompanying consolidated balance sheets of SBC Medical Group Holdings Incorporated and its subsidiaries (the "Company")
as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive income, changes in stockholders'
equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements").
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles
generally accepted in the United States of America.

 Basis
for Opinion

 These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.

 /s/
 MaloneBailey, LLP

 www.malonebailey.com

 We
have served as the Company's auditor since 2023.

 Tokyo,
Japan

 March

 F- 2

 SBC

BALANCE SHEETS

 2024

 2023

 As
 of December 31,

 2024

 2023

 ASSETS

 Current assets:

 Cash and cash
 equivalents

 $
 125,044,092

 $

 Accounts receivable

 1,413,433

 1,437,077

 Accounts receivable –
 related parties

 28,846,680

 33,676,672

 receivable

 28,846,680

 33,676,672

 1,494,891

 3,090,923

 Finance lease receivables,
 current – related parties

 5,992,585

 6,143,564

 Customer loans receivable,
 current

 10,382,537

 8,484,753

 Prepaid
 expenses and other current assets

 11,276,802

 10,050,005

 Total current assets

 184,451,020

 165,905,926

 Non-current assets:

 Property and equipment,
 net

 8,771,902

 13,582,017

 Intangible assets, net

 1,590,052

 19,739,276

 Long-term investments,
 net

 3,049,972

 849,434

 Goodwill, net

 4,613,784

 3,590,791

 Finance lease receivables,
 non-current – related parties

 8,397,582

 3,420,489

 Operating lease right-of-use

 5,267,056

 5,919,937

 Deferred tax assets

 9,798,071

 —

 Customer loans receivable,
 non-current

 5,023,551

 6,444,025

 Long-term prepayments

 1,745,801

 4,099,763

 Long-term investments in
 MCs – related parties

 17,820,910

 19,811,555

 Other

 15,553,453

 15,442,058

 Total
 non-current assets

 81,632,134

 92,899,345

 Total

 $
 266,083,154

 $
 258,805,271

 LIABILITIES AND STOCKHOLDERS'
 EQUITY

 Current liabilities:

 Accounts payable

 $
 13,875,179

 $
 26,531,944

 Accounts payable –
 related party

 —

 payable

 —

 Current portion of long-term
 loans

 96,824

 156,217

 Notes payable, current

 26,255

 3,369,203

 820,898

 2,074,457

 11,739,533

 23,058,175

 Advances
 from customers

 11,739,533

 23,058,175

 Income tax payable

 18,705,851

 8,782,930

 Operating lease liabilities,
 current

 4,341,522

 3,885,812

 Accrued liabilities and
 other current liabilities

 8,103,194

 21,009,009

 Due
 to related party

 2,823,590

 3,583,523

 Total current liabilities

 61,191,890

 92,451,270

 F- 3

 SBC

BALANCE SHEETS — (Continued)

 As
 of December 31,

 2024

 2023

 Non-current liabilities:

 Long-term loans

 6,502,682

 1,062,722

 Notes payable, non-current

 5,334

 11,948,219

 Deferred tax liabilities

 926,023

 6,013,565

 Operating lease liabilities,
 non-current

 1,241,526

 2,444,316

 Other

 1,193,541

 1,074,930

 Total
 non-current liabilities

 9,869,106

 22,543,752

 Total

 71,060,996

 114,995,022

 Stockholders' equity:

 Preferred stock ($ 0.0001
 par value, 20,000,000
 shares authorized; no
 shares issued and outstanding as of December 31, 2024 and
 2023) **

 —

 —

 Common stock ($ 0.0001
 par value, 400,000,000
 shares authorized, 103,020,816
 and 94,192,433
 shares issued, 102,750,816
 and 94,192,433
 shares outstanding as of December 31, 2024 and 2023, respectively) **

 10,302

 9,419

 Additional paid-in capital **

 62,513,923

 36,879,281

 Treasury stock (at cost, 270,000 and nil shares as of December 31, 2024 and 2023, respectively)

 ( 2,700,000
)

 —

 Retained earnings

 189,463,007

 142,848,732

 Accumulated
 other comprehensive loss

 ( 54,178,075
)

 ( 37,578,255
)

 Total SBC Medical Group
 Holdings Incorporated stockholders' equity

 195,109,157

 142,159,177

 Non-controlling
 interests

 ( 86,999
)

 1,651,072

 Total
 stockholders' equity

 195,022,158

 143,810,249

 Total
 liabilities and stockholders' equity

 $
 266,083,154

 $
 258,805,271

 **
 Retrospectively
 restated for effect of reverse recapitalization on September 17, 2024.

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 4

 SBC

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

 2024

 2023

 For
 31,

 2024

 2023

 Revenues, net

 $
 195,173,889

 $
 182,738,049

 Revenues,
 net

 10,241,653

 10,804,374

 Total revenues, net

 Cost of revenues (including cost of revenues from a related party of $ 8,472,202 and $ 2,842,588 for the years ended December 31, 2024
and 2023, respectively)

 49,365,035

 56,238,385

 Gross profit

 156,050,507

 137,304,038

 Operating expenses:

 Selling, general and administrative
 expenses

 57,665,140

 66,234,942

 Stock-based compensation

 —

 Impairment
 loss on intangible asset

 15,058,965

 —

 Misappropriation
 loss

 —

 409,030

 Total
 operating expenses

 85,746,797

 66,643,972

 from operations

 70,303,710

 70,660,066

 Other income (expenses):

 Interest income

 19,943

 86,748

 Interest expense

 ( 28,300
)

 ( 45,292
)

 Other income (including other income from related parties of $ 2,673,077 and nil for the years ended December 31, 2024 and 2023,
respectively)

 4,810,008

 3,623,332

 Other expenses

 ( 5,463,153
)

 ( 745,519
)

 Gain
 on disposal of subsidiary

 3,813,609

 —

 Total
 other income

 3,152,107

 2,919,269

 Income before income taxes

 73,455,817

 73,579,335

 tax expense

 26,765,925

 35,018,729

 46,689,892

 38,560,606

 Less:
 net income (loss) attributable to non-controlling interests

 75,617

 ( 809,430
)

 Net
 income attributable to SBC Medical Group Holdings Incorporated

 $
 46,614,275

 $
 39,370,036

 Other comprehensive loss:

 Foreign currency translation
 adjustment

 $
 ( 16,557,607
)

 $
 ( 12,855,686
)

 Reclassification
 of unrealized gain on available-for-sale debt security to net income when realized, net of tax effect of nil
 and $ 3,869
 for the years ended December 31, 2024 and 2023, respectively

 —

 ( 8,760
)

 Total comprehensive income

 30,132,285

 25,696,160

 Less:
 comprehensive income (loss) attributable to non-controlling interests

 117,830

 ( 948,896
)

 Comprehensive
 income attributable to SBC Medical Group Holdings Incorporated

 $
 30,014,455

 $
 26,645,056

 Net income per share attributable
 to SBC Medical Group Holdings Incorporated**

 Basic
 and diluted

 $
 0.48

 $
 0.42

 Weighted average shares outstanding**

 Basic
 and diluted

 96,561,041

 94,192,433

 **

 Retrospectively
 restated for effect of reverse recapitalization on September 17, 2024.

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 5

 SBC

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

 FOR
THE YEARS ENDED DECEMBER 31, 2024 AND 2023

 Capital*

 Earnings

 Loss

 Interests

 Common
 Stock *

 Additional

 Paid-in

 Treasury

Stock

 Retained

 Accumulated

 Other

 Comprehensive

 Total
 SBC

 Group

 Holdings

 Incorporated

 Stockholders'

 Non-

 controlling

 Total

 Stockholders'

 Capital *

 Earnings

 Loss

 Interests

 Balance as of December 31,
 2022, previously reported

 $
 —

 $
 26,624,694

 —

 $
 —

 $
 103,478,696

 $
 ( 24,853,275
)

 $
 105,250,115

 $
 2,599,968

 $
 107,850,083

 Effect of reverse recapitalization

 —

 —

 —

 —

 —

 —

 —

 —

 —

 Balance as of December 31, 2022, restated

 —

 26,624,694

 —

 —

 103,478,696

 ( 24,853,275
)

 105,250,115

 2,599,968

 107,850,083

 Issuance of common stock *

 94,192,421

 9,419

 ( 8,614
)

 —

 —

 —

 —

 —

 —

 —

 —

 —

 —

 39,370,036

 —

 39,370,036

 ( 809,430
)

 38,560,606

 Reclassification of unrealized gain on available-for-sale
 debt security to net income when realized, net of tax effect of $ 3,869

 —

 —

 —

 —

 —

 —

 ( 8,760
)

 ( 8,760
)

 —

 ( 8,760
)

 Deemed contribution in connection with disposal
 of property and equipment

 —

 —

 9,620,453

 —

 —

 —

 —

 9,620,453

 —

 9,620,453

 Deemed contribution in connection with disposal
 of reorganization

 —

 —

 642,748

 —

 —

 —

 —

 642,748

 —

 642,748

 Foreign currency translation
 adjustment

 —

 —

 —

 —

 —

 —

 ( 12,716,220
)

 ( 12,716,220
)

 ( 139,466
)

 ( 12,855,686
)

 Balance as of December 31, 2023

 94,192,433

 9,419

 36,879,281

 —

 —

 142,848,732

 ( 37,578,255
)

 142,159,177

 1,651,072

 143,810,249

 Balance

 94,192,433

 9,419

 36,879,281

 —

 —

 142,848,732

 ( 37,578,255
)

 142,159,177

 1,651,072

 143,810,249

 Disposal of subsidiary

 —

 —

 —

 —

 —

 —

 —

 —

 ( 1,221,795
)

 ( 1,221,795
)

 Reverse recapitalization, net of transaction
 costs

 5,080,820

 8,407,380

 —

 —

 —

 —

 8,407,888

 —

 8,407,888

 Issuance of common stock to settle convertible
 note

 270,000

 2,699,973

 ( 270,000
)

 ( 2,700,000
)

 —

 —

 —

 —

 —

 Issuance of common stock as incentive shares

 339,565

 ( 34
)

 —

 —

 —

 —

 —

 —

 —

 Stock-based compensation

 —

 —

 —

 —

 —

 —

 —

 Issuance of common stock from exercise of stock
 warrants

 3,137,998

 31,060

 —

 —

 —

 —

 31,374

 —

 31,374

 Deemed contribution in connection with disposal
 of subsidiaries

 —

 —

 1,473,571

 —

 —

 —

 —

 1,473,571

 ( 634,106
)

 839,465

 —

 —

 —

 —

 —

 46,614,275

 —

 46,614,275

 75,617

 46,689,892

 Foreign currency translation
 adjustment

 —

 —

 —

 —

 —

 —

 ( 16,599,820
)

 ( 16,599,820
)

 42,213

 ( 16,557,607
)

 Balance as of December
 31, 2024

 103,020,816

 $
 10,302

 $
 62,513,923

 ( 270,000
)

 $
 ( 2,700,000
)

 $
 189,463,007

 $
 ( 54,178,075
)

 $
 195,109,157

 $
 ( 86,999
)

 $
 195,022,158

 Balance

 103,020,816

 $
 10,302

 $
 62,513,923

 ( 270,000
)

 $
 ( 2,700,000
)

 $
 189,463,007

 $
 ( 54,178,075
)

 $
 195,109,157

 $
 ( 86,999
)

 $
 195,022,158

 *

 Retrospectively
 restated for effect of share issuances on September 8, 2023.

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 6

 SBC

STATEMENTS OF CASH FLOWS

 2024

 2023

 For
 31,

 2024

 2023

 CASH FLOWS FROM OPERATING

 $
 46,689,892

 $
 38,560,606

 Adjustments to reconcile
 net income to net cash provided by operating activities:

 Depreciation and amortization
 expense

 3,799,377

 12,246,942

 Non-cash lease expense

 3,870,198

 3,297,824

 Provision for (reversal
 of) credit losses

 ( 402,196
)

 370,754

 Stock-based compensation

 —

 Impairment loss on property
 and equipment

 —

 204,026

 Impairment loss on intangible
 asset

 15,058,965

 —

 Impairment loss on long-term
 investment

 529,596

 —

 Realized gain on short-term
 investments

 —

 ( 223,164
)

 Fair value change of long-term
 investments

 2,617,435

 —

 Gain on disposal of subsidiary

 ( 3,813,609
)

 —

 Loss (gain) on disposal
 of property and equipment and intangible assets

 511,947

 ( 249,532
)

 Deferred income taxes

 ( 14,417,087
)

 4,113,395

 Changes in operating assets
 and liabilities:

 Accounts receivable

 ( 733,219
)

 ( 596,069
)

 Accounts receivable –
 related parties

 1,350,413

 ( 22,402,301
)

 1,124,805

 ( 1,825,942
)

 Finance lease receivables

 ( 5,991,486
)

 16,575,319

 Customer loans receivable

 18,477,327

 413,867

 Prepaid expenses and other
 current assets

 ( 2,268,209
)

 4,102,808

 Long-term prepayments

 1,910,274

 ( 3,539,280
)

 Other assets

 ( 1,692,642
)

 ( 1,328,682
)

 Accounts payable

 ( 9,588,067
)

 12,201,755

 Accounts payable –
 related party

 682,320

 —

 Notes payable – related
 parties

 ( 34,756,754
)

 ( 23,816
)

 ( 1,476,240
)

 461,043

 ( 9,144,031
)

 ( 4,264,184
)

 Advances
 from customers

 ( 9,144,031
)

 ( 4,264,184
)

 Income tax payable

 11,228,429

 13,359,434

 Operating lease liabilities

 ( 3,950,587
)

 ( 3,158,619
)

 Accrued liabilities and
 other current liabilities

 ( 12,096,825
)

 4,452,022

 Accrued retirement compensation
 expense – related party

 —

 ( 22,082,643
)

 Other

 40,215

 4,759

 NET CASH PROVIDED BY OPERATING

 20,582,933

 50,670,322

 CASH FLOWS FROM INVESTING

 Purchase of property and
 equipment

 ( 2,564,643
)

 ( 8,543,351
)

 Purchase of intangible

 —

 ( 1,683,030
)

 Purchase of convertible
 note

 ( 1,700,000
)

 ( 1,000,000
)

 Prepayments for property
 and equipment

 ( 843,740
)

 ( 981,567
)

 Advances to related parties

 ( 622,804
)

 ( 2,283,020
)

 Payments made on behalf
 of a related party

 ( 5,572,564
)

 —

 Purchase of short-term
 investments

 —

 ( 2,106,720
)

 Purchase of long-term investments

 ( 331,496
)

 —

 Long-term investments in
 MCs – related parties

 —

 ( 26,780
)

 Cash received (paid) for
 acquisition of subsidiaries, net of cash acquired

 ( 4,236,009
)

 722,551

 Long-term loans to others

 ( 172,411
)

 ( 926,020
)

 Repayments from related
 parties

 6,597,564

 1,912,266

 Repayments from others

 176,109

 581,274

 Proceeds from sales of
 short-term investments

 —

 4,127,261

 Proceeds from surrender
 of life insurance policies

 —

 3,954,760

 Disposal of subsidiaries,
 net of cash disposed of

 ( 832,416
)

 —

 Proceeds
 from disposal of property and equipment

 —

 8,046,007

 NET CASH PROVIDED BY (USED
 IN) INVESTING ACTIVITIES

 ( 10,102,410
)

 1,793,631

 F- 7

 SBC

STATEMENTS OF CASH FLOWS — (Continued)

 As
 of December 31,

 2024

 2023

 CASH FLOWS FROM FINANCING

 Borrowings
 from a long-term loan

 6,603,253

 —

 Borrowings from related
 parties

 5,481,787

 12,310,106

 Proceeds from reverse recapitalization,
 net of transaction costs

 11,707,417

 —

 Proceeds from issuance
 of common stock

 —

 Proceeds from exercise
 of stock warrants

 31,374

 —

 Repayments of long-term
 loans

 ( 119,017
)

 ( 8,730,942
)

 Repayments to related parties

 ( 739,414
)

 ( 7,707,007
)

 Deemed contribution in
 connection with disposal of property and equipment

 —

 9,620,453

 Deemed
 contribution in connection with reorganization

 —

 642,748

 NET CASH PROVIDED BY FINANCING

 22,965,400

 6,135,368

 Effect of changes in foreign
 currency exchange rate

 ( 11,424,763
)

 ( 7,314,383
)

 NET INCREASE IN CASH AND
 CASH EQUIVALENTS

 22,021,160

 51,284,938

 CASH
 AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE YEAR

 51,737,994

 CASH
 AND CASH EQUIVALENTS AS OF THE END OF THE YEAR

 $
 125,044,092

 $

 SUPPLEMENTAL DISCLOSURE
 OF CASH FLOW INFORMATION

 Cash
 paid for interest expense

 $
 28,300

 $
 45,292

 Net
 cash paid for income taxes

 $
 30,239,002

 $
 17,842,407

 NON-CASH INVESTING AND FINANCING

 Property
 and equipment transferred from long-term prepayments

 $
 597,602

 $
 7,681,830

 An
 intangible asset transferred from long-term prepayments

 $
 —

 $
 17,666,115

 Deemed
 contribution in connection with disposal of subsidiaries

 $
 1,473,571

 $
 —

 Settlement
 of loan payable to a related party in connection with disposal of property and equipment

 $
 —

 $
 4,163,604

 lease right-of-use assets obtained in exchange for operating lease liabilities

 $
 —

 $
 2,305,199

 Remeasurement
 of operating lease liabilities and right-of-use assets due to lease modifications

 $
 2,908,554

 $
 2,110,079

 Issuance
 of common stock from conversion of convertible note

 $
 2,700,000

 $
 —

 Settlement
 of loan payable to a related party in connection with issuance of common stock

 $
 —

 $

 Non-cash
 purchase consideration for an asset acquisition

 $
 —

 $
 705,528

 Issuance
 of promissory notes to related parties in connection with loan services provided

 $
 20,524,499

 $
 15,396,709

 The
accompanying notes are an integral part of these consolidated financial statements.

 F- 8

 SBC

 NOTES

 NOTE
1 — ORGANIZATION AND DESCRIPTION OF BUSINESS

 SBC
Medical Group Holdings Incorporated ("SBC Holding") was originally incorporated under the laws of the state of Delaware on
March 11, 2022 as a special purpose acquisition corporation under the name Pono Two Capital, Inc. ("Pono") for the purpose
of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination
with one or more businesses.

 SBC
Medical Group, Inc. (formerly known as SBC Medical Group Holdings Incorporated, "SBC USA", "Legacy SBC"), through
its consolidated subsidiaries and variable interest entity ("VIE"), is principally engaged in medical industry to provide
comprehensive management services to the medical corporations and their clinics, including but not limited to licensure of the use of
the trademark and brand name of "Shonan Beauty Clinic", sales of medical equipment, medical consumables procurement services,
and management of customer's loyalty program, etc.

 Reverse
Recapitalization

 On
September 17, 2024, Pono consummated the merger transaction pursuant to the agreement by and among Pono, Pono Two Merger Sub, Inc., a
Delaware corporation ("Merger Sub") and a wholly-owned subsidiary of Pono, and SBC USA (the "Merger Agreement"),
whereby Merger Sub merged with and into SBC USA, the separate corporation existence of Merger Sub ceased and SBC USA survived the merger
as a wholly owned subsidiary of Pono ("Pono Merger"). In connection with the consummation of Pono Merger, Pono changed its
name to "SBC Medical Group Holdings Incorporated" and SBC USA changed its name to "SBC Medical Group, Inc." and,
among other transactions contemplated by the Merger Agreement, the existing equity holders of SBC USA exchanged their equity interests
of SBC USA for equity interests of Pono.

 On
September 17, 2024, the Company received net cash of $ 11,707,417
 from Pono Merger. The Company also assumed $ 416,799
 in prepaid expenses and other current assets,
$ 1,108
 in accounts payable, $ 14,431
 in income tax payable, $ 2,700,000
 in convertible note payable, which was subsequently
converted to 270,000
 shares upon the consummation of Pono Merger,
$ 1,000,789
 in accrued liabilities and other current liabilities,
common stock of $ 508
 and additional paid-in capital of $ 8,407,380.

 The
total funds from Pono Merger of $ 11,707,417
 were available to repay certain indebtedness,
transaction costs and for general corporate purposes, which primarily consisted of investment banking, legal, accounting, and other professional
fees as follows:

OF PROCEEDS FROM MERGER

 Cash—Pono working capital
 cash

 $
 766,735

 Cash—Pono trust

 16,731,409

 Less: transaction costs
 and advisory fees

 5,790,727

 Net proceeds from Pono
 Merger

 $
 11,707,417

 Pono
Merger was accounted for as a reverse recapitalization under the accounting principles generally accepted in the United States of America
("U.S. GAAP"). SBC USA was determined to be the accounting acquirer and Pono was treated as the acquired company for financial
reporting purposes. Accordingly, the financial statements of the combined company represent a continuation of the financial statements
of SBC USA.

 Unless
the context indicates otherwise, any references herein to the "Company", "we", "us" and "our"
refer to 1) SBC USA and its consolidated subsidiaries and VIE prior to the consummation of Pono Merger and to 2) SBC Holding and its
consolidated subsidiaries and VIE following Pono Merger; and reference herein to "Pono" refers to SBC Holding prior to the
consummation of Pono Merger.

 Reorganization

 In
June 2020 and April 2022, SBC Inc., a company incorporated in Japan in June 2007, and Advice Innovation Co., Ltd., a company incorporated
in Japan in December 2018, were merged with and into SBC Medical Group Co., Ltd. ("SBC Japan"), respectively, with SBC Japan
being the surviving entity in such mergers. SBC Japan is a company incorporated in Japan in September 2017 and previously known as Aikawa
Medical Management Co., Ltd.

 In
April 2023, SBC Japan acquired 100 %
equity interest of L'Ange Cosmetique Co., Ltd. ("L'Ange Sub"), a company incorporated in Japan in June 2003,
and Shobikai Co., Ltd. ("Shobikai Sub"), a company incorporated in Japan in June 2014, through share exchange. As a result,
L'Ange Sub and Shobikai Sub become wholly owned subsidiaries of SBC Japan.

 In
August 2023, SBC Japan and L'Ange Sub disposed of their entire equity interest in Ai Inc. and Lange Inc., respectively, both incorporated
in the Federated States of Micronesia in January 2022, for cash. As a result, Ai Inc. and Lange Inc. cease to be subsidiaries of the
Company, with the related investment in capital being treated as a deemed distribution and the disposal proceeds treated as a deemed
contribution.

 In
September 2023, SBC USA acquired 100 %
equity interest of SBC Japan through share exchange with one share of its common stock. As a result, SBC Japan becomes a wholly owned
subsidiary of SBC USA.

 The
above reorganization has been accounted for as a recapitalization among entities under common control since the same controlling shareholder
controlled these entities before and after the reorganization. The consolidation of the Company has been accounted for at historical
cost and prepared on the basis as if the transactions had become effective as of the beginning of the earliest period presented in the
accompanying consolidated financial statements.

 F- 9

 SBC

 NOTES

 NOTE
1 — ORGANIZATION AND DESCRIPTION OF BUSINESS (cont.)

 Corporate
Structure

 As
of December 31, 2024, the Company's major subsidiaries and VIE are as follows:

OF MAJOR SUBSIDIARIES

 Name

 Place
 of

 Incorporation

 Date
 of

 Incorporation or

 Acquisition

 Percentage

 of
 Ownership

 Principal
 Activities

 SBC Medical Group, Inc.

 January
 20, 2023

 %

 Investment
 holding

 Japan

 29, 2017

 %

 Franchising,
 procurement and management services for the medical corporations

 Japan

 June
 18, 2003

 %

 and rental services for the medical corporations

 Shobikai Co., Ltd.

 Japan

 June
 4, 2014

 %

 Procurement,
 management and rental services for the medical corporations

 Liesta Co., Ltd.

 Japan

 15, 2020

 %

 Real
 estate brokerage services

 SBC Sealane Co., Ltd.

 Japan

 June
 7, 2022

 %

 Construction
 services

 SBC Marketing Co., Ltd.

 Japan

 June
 30, 2022

 %

 Marketing services

 Medical Payment Co., Ltd.

 Japan

 June
 30, 2022

 %

 Loan
 services

 SBC Medical Consulting Co., Ltd.

 Japan

 August
 2, 2022

 %

 Human
 resource services

 Shoubikai Medical Vietnam Co., Ltd.

 Vietnam

 August
 29, 2013

 %

 Cosmetic
 clinic

 SBC Healthcare Inc.

 16, 2019

 %

 services for cosmetic clinic in the United States

 SBC Irvine, LLC *

 27, 2018

 %

 services for cosmetic clinic in the United States

 Aesthetic Healthcare Holdings Pte. Ltd.

 %

 Investment
 holding

 Wen & Weng Family Clinic Pte. Ltd.**

 %

 outpatient medical services

 Wen & Weng Medical Group Pte. Ltd.**

 %

 Healthcare-related
 businesses

 Rochor Clinic Pte. Ltd.**

 %

 outpatient medical services

 Dermasolutions Pte. Ltd.**

 %

 Cosmetic
 and dermatological treatments and products

 Dermasolutions Services Pte. Ltd.**

 %

 Cosmetic
 services and products

 Aikawa Medical Management, Inc.

 May
 10, 2017

 VIE

 services for cosmetic clinic in the United States

 *

 A
 subsidiary of SBC Healthcare Inc.

 **

 Subsidiaries
 of Aesthetic Healthcare Holdings Pte. Ltd. ("AHH")

 NOTE
2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 (a)
 Basis of Presentation and Principles of Consolidation

 The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations
of the Securities and Exchange Commission ("SEC").

 The
consolidated financial statements include the financial statements of the Company, its subsidiaries, and consolidated VIE for which the
Company is the primary beneficiary. The results of the subsidiaries are consolidated from the date on which the Company obtained control
and continues to be consolidated until the date that such control ceases. All significant transactions and balances among the Company's
subsidiaries, including the VIE, have been eliminated upon consolidation.

 The
Company reports AHH and its subsidiaries on a three-month calendar lag allowing for the timely preparation of financial statements. This
three-month reporting lag is with the exception of significant transactions or events that occur during the intervening period,
if any.

 Variable
Interest Entities

 In
accordance with ASC Topic 810, "Consolidation", the Company identifies its variable interests and analyzes to determine if
the entity in which the Company has a variable interest is a VIE. Determination if a variable interest is a VIE includes both quantitative
and qualitative consideration. For those entities determined to be VIEs within the scope of the VIE model, a further quantitative and
qualitative analysis is performed to determine if the Company is deemed the primary beneficiary. The primary beneficiary is the party
who has the power to direct the activities of a VIE that most significantly impact the entity's economic performance and who has
an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant.

 The
Company would consolidate those entities in which it is determined to be the primary beneficiary. The Company based its qualitative analysis
on its review of the design of the entity, its organizational structure including decision-making ability and the relevant development,
operating management and financial agreements.

 F- 10

 SBC

 NOTES

 NOTE

 The
Company evaluates its relationship with its VIE on an ongoing basis to determine whether it continues to be the primary beneficiary of
its consolidated VIE, or whether it has become the primary beneficiary of the VIE it does not consolidate.

 Voting
Model

 If
a legal entity fails to meet any of the three characteristics of a VIE, we then evaluate such entity under the voting model. Under the
voting model, we consolidate the entity if we determine that we, directly or indirectly, have greater than 50% of the voting rights and
that other equity holders do not have substantive participating rights.

 Assessment
of Medical Corporations in Japan

 SBC
Japan, L'Ange Sub and Shobikai Sub are each designated as a medical service corporation (the "MSC") to provide services
to the Medical Corporations (the "MCs") in Japan. To maintain and strengthen the business relationship and to secure the
source of revenues from the MCs, the Company acquired equity interests in the following MCs throughout the years.

OF ACQUIRED EQUITY INTERESTS

 Name of the
 MC

 Percentage
 of
 Interest
 Acquired

 Percentage
 of
 Voting
 Interest
 Held

 Medical Corporation Shobikai

 %

 %

 Medical Corporation Kowakai

 %

 %

 Medical Corporation Nasukai

 %

 %

 Medical Corporation Aikeikai

 %

 %

 Medical Corporation Jukeikai

 %

 %

 Medical Corporation Ritz Cosmetic Surgery

 %

 %

 As
non-profit organizations, MCs are required to comply with the medical-related laws and regulations of the Japanese Medical Care Act (the
"Act", "Medical Care Act"). In accordance with the Act, the highest authority of MCs is its general meeting of
members (the "Members"), with each Member having one voting right. The Company, through the MSCs, has no right to elect the
Members, no decision-making ability and no right to dividend or any profit distribution, but has the right to receive distribution of
the residual assets of the MCs.

 Since
the not-for-profit entities scope exception to the variable interest model is applicable to the MCs, the Company evaluates its business
relationship, franchisor-franchisee agreements and/or services agreements with the MCs in Japan under the voting model. The Company has
concluded that consolidation of the MCs is not appropriate for the periods presented as it does not have a majority voting interest in
the Members of the MCs nor does it have a controlling financial interest in the MCs. The equity interests in the MCs held by the Company
are recorded as long-term investments in MCs — related parties on the consolidated balance sheets. The transactions between the
Company and the MCs are disclosed in Note 18 Related Party Transactions.

 (b)
 Foreign Currency

 The
Company maintains its books and record in its local currency, Japanese YEN ("JPY" or " "), which is a functional
currency as being the primary currency of the economic environment in which its operation is conducted. Transactions denominated in currencies
other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction.
Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency
using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statements of
operations.

 The
reporting currency of the Company is the United States Dollars ("US$" or "$"), and the accompanying financial
statements have been expressed in US$. In accordance with ASC Topic 830-30, "Translations of Financial Statements", assets
and liabilities of the Company whose functional currency is not US$ are translated into US$, using the exchange rate on the balance sheet
date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from the translation
of financial statements are recorded as a separate component of accumulated other comprehensive loss within the statements of changes
in stockholders' equity.

 Translation
of amounts from local currency of the Company into US$1 has been made at the following exchange rates:

OF LOCAL CURRENCY EXCHANGE RATES

 31,
 2024

 31,
 2023

 Current JPY: US$1 exchange rate

 156.7890

 141.0350

 Average JPY: US$1 exchange rate

 151.4405

 140.5261

 Exchange rate

 151.4405

 140.5261

 F- 11

 SBC

 NOTES

 NOTE

 (c)
 Non-controlling Interests

 Non-controlling
interests in the consolidated balance sheets represent the portion of the equity in the subsidiaries not attributable, directly or indirectly,
to the Company. The portion of the income or loss applicable to the non-controlling interests in subsidiaries is also separately reflected
in the statements of operations.

 (d)
 Use of Estimates

 In
preparing the consolidated financial statements in conformity with U.S. GAAP, management is required to make certain estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are
based on information available as of the date of the consolidated financial statements. Significant estimates required to be made by
management include, but are not limited to, useful lives and impairment of long-lived assets, impairment of goodwill, impairment of
long-term investments in MCs — related parties, valuation of stock-based compensation, valuation allowance of deferred tax
assets, uncertain income tax positions, the recognition and measurement of impairment of investments in securities, allowance for
credit losses, implicit interest rate of operating leases, valuation of intangible assets acquired in a business combination.
Management bases its estimates on historical experience and other assumptions it believes to be reasonable under the circumstances
and evaluates these estimates on an on-going basis. Actual results could differ from those estimates.

 (e)
 Business Combinations and Asset Acquisitions

combinations are recorded using the acquisition method of accounting. The purchase price of the acquisition is allocated to the tangible
assets, liabilities, identifiable intangible assets acquired and non-controlling interest, if any, based on their estimated fair values
as of the acquisition date. The excess of the purchase price over those fair values is recorded as goodwill. Acquisition-related expenses
are expensed as incurred. Consideration transferred in a business acquisition is measured at the fair value as of the date of acquisition.
Transaction costs directly attributable to the acquisition are expensed as incurred.

 If
investment involves the acquisition of an asset or group of assets that does not meet the definition of a business, the transaction is
accounted for as an asset acquisition. An asset acquisition is recorded at cost, which includes capitalized transaction costs, and does
not result in the recognition of goodwill. The cost of the acquisition is allocated to the assets acquired on the basis of relative fair
values.

 Fair
value is determined based upon the guidance of ASC Topic 820, Fair Value Measurements and Disclosures, and generally are determined using
Level 2 inputs and Level 3 inputs. The determination of fair value involves the use of significant judgment and estimates. The Company
utilizes the assistance of a third-party appraiser to determine the fair value as of the date of an acquisition.

 In
a business combination or asset acquisition, the Company may recognize identifiable intangibles that meet either or both the contractual
legal criterion or the separability criterion.

 (f)
 Cash and Cash Equivalents

 Cash
and cash equivalents include cash on hand and deposits in banks and other financial institutions that are unrestricted as to withdrawal
or use, and which have original maturities of three months or less. The Company maintains bank accounts in the United States, Japan,
Singapore and Vietnam.

 (g)
 Accounts Receivable

receivable represent the Company's right to an amount of consideration that is unconditional (only the passage of time is required
before payment of the consideration is due). The Company's accounts receivable balances are unsecured, bear no interest and are
due upon normally within a year from the date of the sale.

 F- 12

 SBC

 NOTES

 NOTE

 The
Company adopted Accounting Standards Updates ("ASU") No. 2016-13, Financial Instruments — Credit Losses: Measurement
of Credit Losses on Financial Instruments on January 1, 2021.

 The
allowance for credit losses reflects the Company's current estimate of credit losses expected to be incurred over the life of the
receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including
the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company
also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect
a customer's ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable balances are written
off after all collection efforts have ceased.

 (h)

 Inventories,
mainly consist of medical supplies, beauty and skincare products and PC equipment, are stated at the lower of cost or estimated net realizable
value, with cost computed on the first-in, first-out ("FIFO") basis. The Company records inventory reserves for obsolete
and slow-moving inventory and for estimated shrinkage between physical inventory counts. Inventory reserves are recorded based on inventory
obsolescence trends, historical experience and application of the specific identification method, if any.

 (i)
 Finance Lease Receivables

lease receivables, which result from sales-type leases, are measured at the discounted present value of (i) future minimum lease payments,
(ii) any residual value not subject to a bargain purchase option, as finance lease receivables on its consolidated balance sheets, and
(iii) accrued interest on the balance of the finance lease receivables based on the interest rate inherent in the applicable lease over
the term of the leases.

periodically evaluates individual customer's financial condition, credit history and the current economic conditions to make adjustments
in the allowance when necessary. Finance lease receivables are charged off against the allowance after all means of collection have been
exhausted and the potential for recovery is considered remote. As of December 31, 2024 and 2023, the Company determined no allowance
for doubtful accounts was necessary for finance lease receivables.

 (j)
 Customer Loans Receivable and Note Payables — Related Parties

 In
February 2023, the Company started to provide loan services to certain customers of the related-party MCs ("End Customers").
When a loan is granted to finance an End Customer's purchase, the Company issues a promissory note to the MC to pay off the purchase
transaction on behalf of the End Customer, and the End Customer is required to repay the Company in monthly installments. The loans provided
to the End Customers are unsecured, interest-bearing, and due in three months to five years, depending on the End Customers' choice
of the loan service term.

 The
Company records the customer loans receivables at gross loan receivables less unamortized costs of issuance fees or discounts, which
are amortized over the life of the loan to interest income. During the years ended December 31, 2024 and 2023, the Company generated
interest income of $ 1,075,094 and
$ 112,619,
respectively, from the loan services, which were included in revenues.

 F- 13

 SBC

 NOTES

 NOTE

periodically evaluates individual End Customer's financial condition, credit history and the current economic conditions to make
adjustments in the allowance when necessary. Customer loans receivable is charged off against the allowance after all means of collection
have been exhausted and the potential for recovery is considered remote. During the years ended December 31, 2024 and 2023, the Company
recorded $ 169,968 and
 nil allowance
for doubtful accounts, respectively, for customer loans receivable.

 The
Company repays each promissory note issued to the MCs when the End Customer fully repays the corresponding loan receivable or at an earlier
date agreed by the parties. The promissory notes are unsecured, bear no interest, and are due in three months to five years, depending
on the term of the loans provided to the corresponding End Customers.

 (k)
 Property and Equipment, Net

 Property
and equipment are measured using the cost model and are stated at cost less accumulated depreciation. Acquisition cost includes mainly
the costs directly attributable to the acquisition. Depreciation is calculated using the straight-line and declining methods over the
following estimated useful lives:

OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES

 Depreciation

 Useful
 Life

 Land

 Not depreciated

 —

 Buildings and facilities attached to buildings

 Straight-line method

 – 47
 years

 Machinery, equipment and automobiles

 Declining balance method

 – 15
 years

 Aircraft

 Declining balance method

 – 8
 years

 Software*

 Straight-line method

 years

 *

 Represents
 software that is non-detachable to the hardware.

 The
costs incurred for assets that were still under construction as of the year-end were reported as construction in progress. No provision
for depreciation is made on the assets under construction until such time as the relevant assets are completed and ready for their intended
use.

 Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. When items are retired or otherwise
disposed of, income is charged or credited for the difference between net book value of the item disposed and proceeds realized thereon.

 (l)
 Intangible Assets, Net

assets with an indefinite life are not amortized and are tested for impairment annually or more frequently if events or changes in circumstances
indicate that they might be impaired.

assets with finite lives are initially recorded at cost and amortized on a straight-line basis over the estimated economic useful lives
of the respective assets. Acquired intangible assets from business combination are recognized and measured at fair value at the time
of acquisition. Those assets represent assets with finite lives are further amortized on a straight-line basis over the estimated economic
useful lives of the respective assets.

 The
estimated useful lives of intangible assets are as follows:

OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS

 Useful
 Life

 Patent use right

 years

 Trademarks

 years

 Customer Relationships

 – 4
 years

 years

 F- 14

 SBC

 NOTES

 NOTE

 (m)
 Goodwill, Net

 Goodwill
represents the excess of the purchase price over the fair value of the identifiable assets and liabilities acquired in the business combination.
In accordance with FASB ASC Topic 350, "Intangibles-Goodwill and Others", goodwill is subject to at least an annual assessment
for impairment or more frequently if events or changes in circumstances indicate that an impairment may exist, applying a fair-value
based test.

 The
Company would recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds its fair value up
to the amount of goodwill allocated to that reporting unit.

 When
performing the annual impairment test, the Company has the option of performing a qualitative or quantitative assessment to determine
if an impairment has occurred. If a qualitative assessment indicates that it is more likely than not that the fair value of a reporting
unit is less than its carrying amount, the Company would be required to perform a quantitative impairment analysis for goodwill. The
quantitative analysis requires a comparison of the fair value of the reporting unit to its carrying value, including goodwill. If the
carrying value of the reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited
to the total amount of goodwill allocated to that reporting unit. The fair value is generally determined using the income approach with
the discounted cash flow valuation method, which requires management to make significant estimates and assumptions related to forecasted
revenues and cash flows and the discount rates.

 (n)
 Impairment of Long-lived Assets Other Than Goodwill

 Long-lived
assets with finite lives, primarily property and equipment, intangible assets, and operating lease right-of-use assets are reviewed for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated
cash flows from the use of the asset and its eventual disposition are below the asset's carrying value, then the asset is deemed
to be impaired and written down to its fair value.

 (o)
 Long-term Investments, Net

 Investments
in equity securities with readily determinable fair values

 The
Company holds investments in equity securities of publicly listed companies, for which the Company does not have significant influence.
Investments in equity securities with readily determinable fair values are measured at fair value and any changes in fair value are recognized
in other income (expenses).

 Investments
in privately held companies and organizations that do not report Net Asset Value (the "NAV") per share

 The
Company's long-term investments in privately held entities that do not report NAV per share are accounted for using a measurement
alternative, under which these investments are measured at cost, adjusted for observable price changes and impairments, with changes
recognized in other income (expenses).

 The
Company recognizes both realized and unrealized gain and losses in its consolidated statements of operations and comprehensive income,
classified with other income (expenses). Unrealized gains and losses represent observable price changes for investments in privately
held entities that do not report NAV per share. Realized gains and losses represent the difference between proceeds received upon disposition
of investments and their historical or adjusted cost. Impairments are realized losses, which result in an adjusted cost, and represent
charges to reduce the carrying values of investments in privately held entities that do not report NAV per share, if impairments are
deemed other than temporary, to their estimated fair values.

 (p)
 Long-term Prepayments

prepayments consist primarily of prepayments made for purchasing property and equipment, cloud-based services, and deferred consumption
tax.

 (q)
 Long-term Investments in MCs — Related Parties

investments in MCs — related parties represent the payments to obtain equity interests of the MCs in Japan, made by the Company
through SBC Japan, a company designated as a MSC in Japan. In accordance with the Act and articles of incorporation of the MCs, which
are non-profit organizations, the equity interest holders of MCs are prohibited from receiving any profit distribution from MCs but have
the right to receive distribution of the residual assets of the MCs in proportion to the amount of their contribution. As of the balance
sheet dates, the investments represent probable future economic benefit to be realized at the time of dissolution of MCs or the equity
interests being sold.

 F- 15

 SBC

 NOTES

 NOTE

 The
investments in MCs — related parties are accounted for using a measurement alternative, under which these investments are measured
at cost, less impairment, and adjusted for observable price changes. The Company reviews the investments in MCs for impairment whenever
events or changes in circumstances indicate that the carrying amount may not be recoverable. The payments made for such investments are
classified as investing activities in the consolidated statements of cash flows. The MCs are considered related parties as the relatives
of the Chief Executive Officer ("CEO") of the Company being the Members of the MCs. Also see Note 2(a) for further details.

 (r)
 Corporate-owned Life Insurance Policies

 The
Company has purchased corporate-owned life insurance policies to insure its CEO and a key officer of the Company. Management considers
these policies to be operating assets. These insurance policies are recorded at their cash surrender values, included in other assets
in the consolidated balance sheets with change in cash surrender value during the period recorded in selling, general and administrative
expenses.

 (s)
 Lease

 The
Company determines if an arrangement is or contains a lease at inception or modification of the arrangement. An arrangement is or contains
a lease if there are identified assets and the right to control the use of an identified asset is conveyed for a period in exchange for
consideration. Control over the use of the identified assets means the lessee has both the right to obtain substantially all of the economic
benefits from the use of the asset and the right to direct the use of the asset.

 The
Company classifies its leases as either finance leases or operating leases if it is the lessee, or sale-type, direct financing, or operating
leases if it is the lessor. The following criteria is used to determine if a lease is a finance lease (as a lessee) or sales-type or
direct financing lease (as a lessor):

 (i)
ownership is transferred from lessor to lessee by the end of the lease term;

 (ii)
an option to purchase is reasonably certain to be exercised;

 (iii)
the lease term is for the major part of the underlying asset's remaining economic life;

 (iv)
the present value of lease payments equals or exceeds substantially all of the fair value of the underlying assets; or

 (v)
the underlying asset is specialized and is expected to have no alternative use at the end of the lease term.

 If
any of the above criteria is met, the Company accounts for the lease as a finance, a sales-type, or a direct financing lease. If none
of the criteria is met, the Company accounts for the lease as an operating lease.

 Lessee
accounting

 The
Company recognizes right-of-use assets and lease liabilities for all leases other than those with a term of twelve months or less as
the Company has elected to apply the short-term lease recognition exemption. Right-of-use assets represent the Company's right
to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments arising
from the lease. Right-of-use assets and lease liabilities are classified and recognized at the commencement date of a lease. Lease liabilities
are measured based on the present value of fixed lease payments over the lease term. Right-of-use assets consist of (i) initial measurement
of the lease liability; (ii) lease payments made to the lessor at or before the commencement date less any lease incentives received;
and (iii) initial direct costs incurred by the Company.

 As
the rates implicit on the Company's leases for which it is the lessee are not readily determinable, the Company uses its incremental
borrowing rate based on information available at the commencement date in determining the present value of lease payments. When determining
the incremental borrowing rate, the Company assesses multiple variables such as lease term, collateral, economic conditions, and its
creditworthiness.

 F- 16

 SBC

 NOTES

 NOTE

 From
time to time, we may enter into sublease agreements with third parties. Our subleases generally do not relieve us of our primary obligations
under the corresponding head lease. As a result, we account for the head lease based on the original assessment at lease inception. We
determine if the sublease arrangement is either a sales-type, direct financing, or operating lease at inception of the sublease. If the
total remaining lease cost on the head lease for the term of the sublease is greater than the anticipated sublease income, the right-of-use
asset is assessed for impairment. Our subleases are generally operating leases and we recognize sublease income on a straight-line basis
over the sublease term.

 Lessor
accounting — operating leases

 The
Company accounts for the revenue from its lease contracts by utilizing the single component accounting policy. This policy requires the
Company to account for, by class of underlying asset, the lease component and nonlease component(s) associated with each lease as a single
component if two criteria are met.

 (i)
the timing and pattern of transfer of the lease component and the nonlease component(s) are the same; and

 (ii)
the lease component would be classified as an operating lease if it were accounted for separately.

 Lease
components consist primarily of fixed rental payments, which represent scheduled rental amounts due under our leases. Nonlease components
consist primarily of tenant recoveries representing reimbursements of rental operating expenses, including recoveries for utilities,
repairs and maintenance and common area expenses.

 If
the lease component is the predominant component, we account for all revenues under such lease as a single component in accordance with
the lease accounting standard. Conversely, if the nonlease component is the predominant component, all revenues under such lease are
accounted for in accordance with the revenue recognition accounting standard. Our operating leases qualify for the single component accounting,
and the lease component in each of our leases is predominant. Therefore, we account for all revenues from our operating leases under
the lease accounting standard and classify these revenues as rental income.

 The
Company commences recognition of rental income related to the operating leases at the date the property is ready for its intended use
by the tenant and the tenant takes possession or controls the physical use of the leased asset. Income from rentals related to fixed
rental payments under operating leases is recognized on a straight-line basis over the respective operating lease terms. Amounts received
currently but recognized as revenue in future periods are classified in other liabilities in the Company's consolidated balance
sheets.

 Lessor
accounting — sales-type leases

 The
Company purchases medical equipment from vendors and leases them to its customers, who are required to pay installments throughout the
term of the leases. The lease agreements include lease payments that are fixed, do not contain residual value guarantees or variable
lease payments. The lease terms are based on the non-cancellable term of the lease and the buyer may have options to terminate the lease
in advance when meets certain conditions. The customers obtain control of the medical equipment when they physically possess the equipment.

 The
Company recognizes sales from sales-type leases equal to the present value of the minimum lease payments discounted using the implicit
interest rate in the lease and cost of sales equal to carrying amount of the asset being leased and any initial direct costs incurred,
less the present value of the unguaranteed residual. Interest income from the leases is recognized over the lease terms and included
in revenues, net.

 The
Company excludes from the measurement of its lease revenues any tax assessed by a governmental authority that is both imposed on and
concurrent with a specific revenue-producing transaction and collected from a customer.

 (t)
 Revenue Recognition

 The
Company recognizes revenue from franchising services, procurement services, management services and other services or product sales under
ASC Topic 606, "Revenue from Contracts with Customers".

 F- 17

 SBC

 NOTES

 NOTE

 To
determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price
to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation. Revenue amount represents the invoiced value, net of consumption tax and applicable local government levies, if any. The
consumption tax on sales is calculated at 10% of gross sales. The Company does not have significant remaining unfulfilled performance
obligations or contract balances.

 The
Company reports revenue on a gross or net basis based on management's assessment of whether the Company acts as a principal or
agent in the transaction. The determination of whether the Company acts as a principal or an agent in a transaction is based on the evaluation
of whether (i) the Company is primarily responsible for fulfilling the promise to provide the specified goods or service, (ii) the Company
has inventory risk before the specified good or service has been transferred to a customer or after transfer of control to the customer
and (iii) the Company has discretion in establishing the price for the specified good or service. If the terms of a transaction do not
indicate the Company is acting as a principal in the transaction, then the Company is acting as an agent in the transaction and the associated
revenues are recognized on a net basis.

 The
Company recognizes revenue from rental services under ASC Topic 842, "Leases".

 The
Company currently generates its revenue from the following main sources:

 The
Company generates franchising revenue (royalty income) by licensing its intellectual properties, including but not limited to the Company's
brand name ("Shonan Beauty Clinic"), trade name, patents, and trademarks, as a franchisor pursuant to franchise agreements
with the medical corporations (the "MCs") in Japan. Prior to April 2023, royalty income was based on a percentage of sales
and recognized at the time when the related sales occurred; since April 2023, it is based on a fixed amount to each clinic of the MCs;
since September 2023, it is based on a fixed amount to each MC and a fixed amount to each clinic of the MCs and recognized over time
as services are rendered.

 The
Company generates procurement services revenue by purchasing primarily advertising services and medical materials from qualified vendors
on behalf of MCs to maintain brand quality consistency. Procurement services revenue is recognized at the point in time upon the delivery
of products or over time as services are performed. Occasionally, the Company receives vendor discounts on certain large purchases. It
recognizes revenue based on actual payments and will return the over-collection resulting from such discounts to MCs.

 The
Company provides loyalty program management services, labor supporting services, function supporting services, and management consulting
services to MCs.

 Loyalty
program management services

 The
Company awards loyalty points on behalf of MCs to MCs' customers, who earn loyalty points from each qualified purchase made at
the loyalty program participating clinics of MCs, in exchange for a handling fee. The revenue is based on a percentage of the related
payment amount made by MCs' customers and is recognized when the loyalty points are awarded.

 At
the time loyalty points are awarded, a MC pays the Company cash in an amount equivalent to the awarded loyalty points, which is recorded
as advances from customers. When a MC's customers redeem the loyalty points, the Company returns the cash back to the MC in an
amount equivalent to the redeemed loyalty points. The awarded loyalty points expire if a MC's customer does not make any additional
qualified purchase at a participating clinic within a year. The Company accumulates and tracks the points on behalf of MCs until the
loyalty points expire, at which time the Company recognizes an amount equivalent to the expired loyalty points as revenue, which is normally
not significant.

 F- 18

 SBC

 NOTES

 NOTE

 The
Company also awards certain points to MCs' customers on behalf of MCs for free in order to increase the volume of MC's sales,
from which the Company earns other types of revenues, such as royalty income. When a MC's customers redeem such points, the Company
reimburses MC in an amount equivalent to the used free points and records it as a reduction of the revenue recognized.

 The
Company is an agent in the management of loyalty programs, and as a result, revenues are recognized net of the cost of redemptions.

 Labor

 The
Company generates revenue by dispatching staff to MCs to provide a range of services, primarily including clinic operation, IT, and administrative
services, among which, clinic operation service has been fully terminated since October 2024. The Company recognizes the revenue over
the time when services are rendered.

 Function

 The
revenue is derived from providing functional supporting services to MCs, such as accounting and human resources services. The Company

consulting services

 The
Company generates revenue by providing consulting services to MCs in relation to business operations of cosmetic dermatology. The Company

 The
Company generates rental income from operating leases and sales-type leases, which is accounted for under ASC Topic 842. Operating lease
revenue is generally recognized on straight-line basis over the terms of the lease agreements and sales-type leases revenue is generally
recognized on the lease commitment date. Also see Note 2(s).

 Other

 The
Company generates other miscellaneous revenues such as accommodation services income, medicine dispensed sales revenue, brokerage services
revenue, construction services revenue, pilot training services revenue, interest income, etc. These revenues are recognized when the
Company satisfies performance obligations.

 (u)
 Cost of Revenues

 Cost
of revenues primarily consists of costs of goods sold associated with sales-type leases, rent expenses associated with operating subleases,
salaries and related expenses for personnel directly involved in delivery of services to customers, and allocation of indirect costs
such as corporate overhead.

 (v)
 Advertising Expenses

 Advertising
expenses consist primarily of costs of promotion and marketing for the Company's image and services and are included in selling,
general and administrative expenses. The Company expenses advertising costs as incurred or the first time the advertising takes place,
whichever is earlier, in accordance with the ASC 720-35, "Advertising Costs". The advertising expenses were $ 2,782,944
 and $ 3,367,608
 for the years ended December 31, 2024 and 2023,
respectively.

 F- 19

 SBC

 NOTES

 NOTE

 (w)
 Concentration of Credit Risk

instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents, accounts receivable and
customer loans receivable. The Company places its cash and cash equivalents with financial institutions. The Company does not require
collateral or other security to support financial instruments subject to credit risk. The Company conducts periodic reviews of the financial
condition and payment practices of its customers to minimize collection risk on accounts receivable.

 For
the year ended December 31, 2024, customer A, B and C represent 26 %,
 23 %
and 23 %
of the Company's total revenues, respectively. For the year ended December 31, 2023, customer A, B, C and D represent 29 %,
 24 %,
 23 %
and 11 %
of the Company's total revenues, respectively.

 As
of December 31, 2024, customer A, B, C and D represent 17 %,
 28 %,
 26 %
and 10 %
of the Company's total outstanding accounts receivable, respectively. As of December 31, 2023, customer A, B, C and D represent
 26 %,
 24 %,
 22 %
and 13 %
of the Company's total outstanding accounts receivable, respectively.

 For
the year ended December 31, 2024, no vendor accounts for more than 10 %
of the Company's total purchase. For the year ended December 31, 2023, vendor A and B represent 14 %
and 12 %
of the Company's total purchase, respectively.

 As
of December 31, 2024, vendor A and B represent 12 %
and 15 %
of the Company's total outstanding accounts payable, respectively. As of December 31, 2023, vendor A, B and C represent 19 %,
 14 %
and 14 %
of the Company's total outstanding accounts payable, respectively.

 (x)
 Segment Reporting

 ASC
Topic 280, "Segment Reporting," requires use of the "management approach" model for segment reporting. The management
approach model is based on the way a company's chief operating decision maker organizes segments within the company for making
operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography,
legal structure, management structure, or any other manner in which management disaggregates a company.

determined the Company's operations constitute a single reporting segment.

 (y)
 Comprehensive Income or Loss

 ASC
Topic 220, "Comprehensive Income," establishes standards for reporting and display of comprehensive income or loss, its components
and accumulated balances. Comprehensive income or loss as defined includes all changes in stockholders' equity during a period
from non-owner sources.

 (z)
 Net Income Per Share

 Basic
net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the reporting
period. Diluted net income per share reflects the potential dilution that could occur if stock options and other commitments to issue
common shares were exercised or equity awards vest resulting in the issuance of common shares that could share in the net income of the
Company.

 (aa)
 Stock Based Compensation

 The
Company accounts for stock-based compensation awards in accordance with ASC Topic 718, "Compensation — Stock Compensation",
under which the Company determines whether stock-based compensation awards should be classified and accounted for as an equity award.
There were no liability awards granted during any of the periods stated herein. For all grants of stock-based compensation classified
as equity awards, the cost of services received from employees and non-employees in exchange for awards is recognized in the consolidated
statements of operations and comprehensive income based on the estimated fair value of those awards on the grant date and amortized on
a straight-line basis over the requisite service period or vesting period. The Company records forfeitures and cancellations as they
occur.

 F- 20

 SBC

 NOTES

 NOTE

 (bb)
 Related Parties and Transactions

 The
Company identifies related parties, and accounts for, discloses related party transactions in accordance with ASC Topic 850, "Related
Party Disclosures," and other relevant ASC standards.

 Parties,
which can be an entity or individual, are considered to be related if they have the ability, directly or indirectly, to control the Company
or exercise significant influence over the Company in making financial and operational decisions. Entities are also considered to be
related if they are subject to common control or common significant influence.

 Transactions
involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive,
free market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related
party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations
can be substantiated.

 (cc)
 Income Taxes

taxes are accounted for using an asset and liability method in accordance with ASC Topic 740, "Income Taxes." Under this
method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current period and (ii) deferred
tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements
or tax returns. Deferred tax assets also include the prior years' net operating losses carried forward. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences
are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in
the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax
assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all
of the deferred tax assets will not be realized.

 The
Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement
of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets
and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated
with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 Under
the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination
by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position
that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which,
based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination,
including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more
than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax
positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the
accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general
and administrative expenses in the consolidated statements of operations and comprehensive income.

 F- 21

 SBC

 NOTES

 NOTE

 (dd)
 Fair Value Measurements

 The
Company performs fair value measurements in accordance with ASC Topic 820. Fair value is defined as the price that would be received
to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic
820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. An asset's or a liability's categorization within the fair value hierarchy is based upon
the lowest level of input that is significant to the fair value measurement. ASC Topic 820 establishes three levels of inputs that may
be used to measure fair value:

 Level 1: quoted prices in
 active markets for identical assets or liabilities;

 Level 2: inputs other than
 Level 1 that are observable, either directly or indirectly; or

 Level 3: unobservable inputs
 that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.

 As
of December 31, 2024 and 2023, the carrying values of current assets and current liabilities approximated their fair values reported
in the consolidated balance sheets due to the short-term maturities of these instruments. Debt that bears variable interest rates index
to prime also approximates fair value as it reprices when market interest rates change.

measured at fair value on a recurring basis as of December 31, 2024 and 2023 are summarized below.

OF FAIR VALUE ON A RECURRING BASIS

 Quoted
 Prices
 in
 Active
 Markets
 for
 Identical
 1)

 Significant
 Other
 Observable
 2)

 Unobservable
 3)

 Fair
 Value
 at
 31,
 2024

 Fair
 Value Measurements as of December 31, 2024

 Quoted
 Prices
 in
 Active
 Markets
 for
 Identical
 1)

 Significant
 Other
 Observable
 2)

 Unobservable
 3)

 Fair
 Value
 at
 31,
 2024

 Long-term investments:

 Equity investments at fair value
 with readily determinable fair value

 $
 2,478,531

 —

 —

 $
 2,478,531

 Quoted
 Prices
 in
 Active
 Markets
 for
 Identical
 1)

 Significant
 Other
 Observable
 2)

 Unobservable
 3)

 Fair
 Value
 at
 31,
 2023

 Fair
 Value Measurements as of December 31, 2023

 Quoted
 Prices
 in
 Active
 Markets
 for
 Identical
 1)

 Significant
 Other
 Observable
 2)

 Unobservable
 3)

 Fair
 Value
 at
 31,
 2023

 Long-term investments:

 Equity investments at fair value with readily
 determinable fair value

 —

 —

 —

 —

 (ee)
 Commitments and Contingences

 Liabilities
for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable
that a liability has been incurred and the amount of the assessment can be reasonably estimated.

 (ff)
 Recent Accounting Pronouncements

 In
November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements
to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through
enhanced disclosures about significant segment expenses. ASU No. 2023-09 is effective for public entities for annual reporting periods
beginning after December 15, 2023, on a retrospective basis. Early adoption is permitted. The Company adopted this standard on December 31, 2024. See Note 20 for relevant segment disclosures.

 F- 22

 SBC

 NOTES

 NOTE

 In
December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvement to Income Tax Disclosures" to enhance
the transparency and decision usefulness of income tax disclosures, primarily related to the rate reconciliation and income taxes paid
information. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024, on a prospective
basis. Early adoption is permitted. In addition, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2023-09. The Company
is currently evaluating the impact of this accounting standard update on its consolidated financial statements and related disclosures.

 In
November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses" to improve disclosures about the nature of expenses
in commonly presented financial statement captions. ASU 2024-03 is effective for all public business entities for annual reporting periods
beginning after December 15, 2026, on either a prospective or retrospective basis. Early adoption permitted. The Company is currently
evaluating the impact of this accounting standard update on its consolidated financial statements and related disclosures.

 NOTE
3 — VARIABLE INTEREST ENTITY

 A
VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity
investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right
to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has
both the power to direct the activities of the VIE that most significantly affect the entity's economic performance and the obligation
to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.

 The
Company followed ASC Topic 810, "Consolidation", utilizing a qualitative approach, and determined that it is the primary
beneficiary of its VIE, Aikawa Medical Management, Inc. ("AMM") and consolidated the result of operations, financial conditions,
and cash flows of AMM in the consolidated financial statements.

 The
following amounts and balances of AMM were included in the Company's consolidated financial statements of December 31, 2024 and
2023 and for the years then ended:

OF CONSOLIDATED FINANCIAL STATEMENTS OF VARIABLE INTEREST ENTITY

 2024

 2023

 As
 of December 31,

 2024

 2023

 ASSETS

 Current assets

 Cash and cash equivalents

 $
 41,247

 $
 28,934

 Accounts receivable

 20,076

 26,916

 Prepaid expenses and other
 current assets

 32,493

 11,074

 Total Current Assets

 93,816

 66,924

 Property and equipment, net

 1,799,372

 1,799,372

 Loans receivable from subsidiaries of the Company

 3,122,157

 3,060,581

 Other assets

 2,275

 2,275

 Total
 Non-Current Assets

 4,923,804

 4,862,228

 Total

 $
 5,017,620

 $
 4,929,152

 LIABILITIES

 Current Liabilities

 Accounts payable

 $
 18,904

 $
 17,942

 Accrued liabilities and other current liabilities

 17,824

 17,824

 Due to related party

 2,797,018

 2,875,408

 Total Current Liabilities

 2,833,746

 2,911,174

 Loan payable to a subsidiary
 of the Company

 8,245,328

 9,157,660

 Total
 Non-current Liabilities

 8,245,328

 9,157,660

 Total
 Liabilities

 $
 11,079,074

 $
 12,068,834

 F- 23

 SBC

 NOTES

 NOTE
3 — VARIABLE INTEREST ENTITY (cont.)

 2024

 2023

 For
 31,

 2024

 2023

 $
 269,800

 $
 163,146

 Cost of revenues

 $
 56,510

 $
 61,647

 Total operating expenses

 $
 402,397

 $
 128,549

 Net loss

 $
 ( 47,782
)

 $
 ( 27,050
)

 Net cash provided by (used in) operating activities

 $
 ( 182,991
)

 $
 202,624

 Net cash provided by (used in) investing activities

 $
 195,000

 $
 ( 90,000
)

 Net cash used in financing activities

 $
 ( 78,390
)

 $
 ( 158,714
)

 NOTE
4 — BUSINESS COMBINATION AND ASSET ACQUISITION

Combination and Goodwill

 The
Company accounted for business combination using the acquisition method of accounting under ASC Topic 805. The total purchase price
was allocated to the tangible and identifiable intangible assets acquired, liabilities assumed and non-controlling interest based on
their estimated fair values as of the acquisition date. The excess of the purchase price over those fair values is recorded as goodwill.

 The
determination of fair values involves the use of significant judgments and estimates. The judgments used to determine the estimated fair
value assigned to assets acquired and liabilities assumed, and the intangible asset useful lives, as well as the expected future revenue
from the identifiable intangible assets and related discount rates, can materially impact the Company's consolidated financial
statements. Significant inputs and assumptions used for the model included the amount and timing of expected future revenues and discount
rates.

Healthcare Holdings Pte. Ltd.

 On
November 20, 2024, the Company acquired 100 %
equity interest in Aesthetic Healthcare Holdings Pte. Ltd. ("AHH") and its subsidiaries, which operate medical aesthetics
clinics in Singapore, with a cash consideration of 7.80
 million Singapore Dollars ($ 5,725,590).
The Company aimed to enter the medical aesthetics industry in the Singaporean market through this acquisition.

 The purchase price allocation was determined by the Company with assistance
of a third-party valuation. The
purchase price was allocated on the acquisition date as follows:

OF PURCHASE PRICE CONSIDERATION

 Cash
 and cash equivalents

 $
 1,489,581

 259,086

 Prepaid
 expense and other current assets

 114,379

 Property
 and equipment, net

 650,119

 assets, net

 1,534,349

 lease right-of-use assets

 1,187,640

 prepayments

 398,834

 Other

 352,802

 payable

 ( 399,037
)

 Accrued
 liabilities and other current liabilities

 ( 354,557
)

 Advance
 from customers

 ( 726,857
)

 lease liabilities, current

 ( 832,314
)

 Current
 portion of long-term loans

 ( 35,742
)

 tax payable

 ( 47,229
)

 tax liabilities

 ( 345,269
)

 lease liabilities, non-current

 ( 405,107
)

 Other

 ( 269,155
)

 Total identifiable net assets

 2,571,523

 Goodwill

 3,154,067

 Total
 purchase consideration

 $
 5,725,590

 The
intangible assets identified in conjunction with the acquisition of AHH primarily consist of trademarks, which will be amortized over a useful life of twenty years on a straight-line basis.

 F- 24

 Pro
forma results of operations for the business combination have not been presented because they are not material to the consolidated
statements of operations and comprehensive income for the years ended December 31, 2024 and 2023.

 The Company consolidates AHH
and its subsidiaries' financial information on a three-month reporting lag. Accordingly, given the acquisition closing date of November
20, 2024, the operating results of AHH for the period subsequent to the acquisition date will be recorded in the Company's consolidated
financial statements beginning 2025.

 The
Company's policy is to perform its annual impairment testing on goodwill for its reporting unit at the end of each fiscal year
or more frequently if events or changes in circumstances indicate that an impairment may exist. The Company did not recognize any impairment
loss on goodwill during the years ended December 31, 2024 and 2023.

 Asset
Acquisition

 The
following acquisition did not meet the definition of a business combination under ASC Topic 805, so the Company accounted for the
transaction as asset acquisition. In an asset acquisition, goodwill is not recognized, but rather any excess consideration transferred
over the fair value of the net assets acquired is allocated on a relative fair value basis to the identifiable net assets. In addition,
related transaction expenses are capitalized and allocated to the net assets acquired on a relative fair value basis.

 Kijimadairakanko
Inc.

 On
April 3, 2023, the Company acquired 100 %
equity interest of Kijimadairakanko Inc. ("Kijima"), a company operating ski resorts and tourism-related business, with a
cash consideration of JPY 1,026,152
 ($ 7,029).
Meanwhile, the Company's preexisting loans of JPY 103,000,000
 ($ 705,528)
to Kijima were considered effectively settled upon the acquisition. The settlement amount was included in the total purchase consideration
summarized as follows:

OF TOTAL PURCHASE CONSIDERATION

 Cash consideration

 $
 7,029

 Effective settlement of
 preexisting loans

 705,528

 Total
 consideration

 $
 712,557

 The
following table summarizes the amounts for the Kijima acquisition which were allocated to the fair value of aggregated net assets acquired:

OF FAIR VALUE OF AGGREGATED NET ASSETS ACQUIRED

 Cash and cash equivalents

 $
 729,580

 Accounts receivable

 36,389

 17,636

 Prepaid expenses and other current assets

 5,717

 Property and equipment, net

 889,397

 Other assets

 30,983

 Accounts payable

 ( 143,340
)

 ( 647,061
)

 Income tax payable

 ( 1,250
)

 Long-term loans

 ( 205,494
)

 Net
 assets acquired

 $
 712,557

 The
assets in the purchase price allocation are stated at fair value based on estimates of fair value using available information and making
assumptions management believes are reasonable.

 The
results of operations, financial position and cash flows of Kijima have been included in the Company's consolidated financial statements
since the date of acquisition.

 F- 25

 SBC

 NOTES

 NOTE
5 — DISPOSAL OF SUBSIDIARIES

 Cellpro
Japan Co., Ltd.

 On
January 1, 2024, the Company disposed of its subsidiary, Cellpro Japan Co., Ltd. ("Cellpro"), to Waqoo Inc. ("Waqoo"),
a Japanese company listed on the Tokyo Stock Exchange, of which the CEO of the Company is a non-controlling shareholder with more
than 10 %
ownership interest, in exchange for 353,600 shares
of Waqoo's common stock through a share exchange agreement. The disposal of Cellpro did not constitute a strategic shift that would
have a major effect on the Company's operations and financial results. As a result, the results of operations for Cellpro were not reported as discontinued operations. During the year
ended December 31, 2024, the Company recognized a gain of $ 3,813,609 on the disposal of Cellpro.

 After
the stock exchange, SBC Japan became a shareholder with less than 10 %
ownership interest of Waqoo. The common stock of Waqoo was recorded as an investment in a public entity with readily determinable fair
value, which was included in long-term investments. Also see Note 10 for further details.

 Kijimadairakanko
 Inc. and Skynet Academy Co., Ltd.

 On
December 23, 2024, the Company disposed of its subsidiary, Kijimadairakanko Inc. ("Kijima") to SBC Inc., formerly known
as SBC China Inc., a company controlled by the CEO of the Company, who is also the controlling shareholder of the Company, for a
cash consideration of JPY 1. In connection with this transaction, Kijima's existing loans of JPY 826,000,000 ($ 5,268,227)
from SBC Inc. were deemed effectively settled as a result of the disposal. The settlement amount was included in the total disposal
consideration summarized as follows:

OF TOTAL SALES CONSIDERATION

 Cash consideration

 $

 settlement of existing loans

 5,268,227

 Total
 consideration

 $
 5,268,227

 On
December 23, 2024, the Company disposed of its subsidiary, Skynet Academy Co., Ltd. ("Skynet"), to Hariver Inc., a company
controlled by the CEO of the Company, who is also the controlling shareholder of the Company, for a cash consideration of JPY 70,000,000
 ($ 446,460).

 The
consideration received in excess of the net book value of net assets disposed, totaling $ 1,473,571
for Kijima and Skynet, was included as a deemed contribution in
connection with disposal of subsidiaries in the Company's consolidated statements of changes in stockholders' equity,
including the derecognition of goodwill of $ 1,724,040. The disposal of Kijima and Skynet did not constitute a strategic shift that would have a major effect on the
Company's operations and financial results. As a result, the results of operations for Kijima and Skynet were not reported as
discontinued operations.

 NOTE
6 — PREPAID EXPENSES AND OTHER CURRENT ASSETS

 As
of December 31, 2024 and 2023, prepaid expenses and other current assets consist of the following:

OF PREPAID EXPENSES AND OTHER CURRENT ASSETS

 31,
 2024

 31,
 2023

 Advances
 to suppliers

 $
 9,693,043

 $
 6,497,608

 Convertible
 note receivable *

 —

 1,000,000

 Other
 receivables **

 1,558,223

 2,390,276

 25,536

 162,121

 Total

 $
 11,276,802

 $
 10,050,005

 *

 In
 May 2023, the Company purchased from Pono, a special purpose acquisition company, a convertible promissory note ("Pono Promissory
 Note") in aggregate principal amount of $ 1,000,000, which will automatically convert into shares of Class A common stock of Pono
 at a conversion price of $ 10.00 per unit immediately prior to the expected Pono Merger. In February 2024, the Company and Pono entered
 into an Amendment to the Note Purchase Agreement, which increased the principal amount of the convertible promissory note from $ 1,000,000
 to $ 2,700,000. On September 17, 2024, upon the consummation of Pono Merger, the promissory note was converted into 270,000 common shares.
 See Note 16 for further details.

 **

 Represent
 a refundable deposit to be returned by a supplier, reimbursement receivables from a business partner, and other miscellaneous receivables.

 F- 26

 SBC

 NOTES

 NOTE
7 — FINANCE LEASE RECEIVABLES

 As
of December 31, 2024 and 2023, finance lease receivables consist of the following:

OF FINANCE LEASE RECEIVABLES

 31,
 2024

 31,
 2023

 Future
 minimum lease payments receivable

 $
 14,427,511

 $
 9,586,741

 Estimated
 residual value

 —

 —

 Gross
 finance lease receivables

 14,427,511

 9,586,741

 Less:
 unearned interest income

 ( 37,344
)

 ( 22,688
)

 lease receivables

 $
 14,390,167

 $
 9,564,053

 lease receivables, current

 $
 5,992,585

 $
 6,143,564

 lease receivables, non-current

 $
 8,397,582

 $
 3,420,489

 As
of December 31, 2024, maturities of the Company's gross finance lease receivables are as follow:

OF MATURITIES OF THE FINANCE LEASE RECEIVABLES

 Years
 ending December 31,

 2025

 $
 6,000,609

 2026

 5,505,139

 2027

 2,921,763

 Thereafter

 —

 Total

 $
 14,427,511

 NOTE
8 — PROPERTY AND EQUIPMENT, NET

 As
of December 31, 2024 and 2023, property and equipment, net consist of the following:

OF PROPERTY AND EQUIPMENT

 31,
 2024

 31,
 2023

 Land

 $
 2,008,132

 $
 1,799,443

 Buildings
 and facilities attached to buildings

 5,373,424

 8,412,348

 Machinery,
 equipment and automobiles

 4,312,270

 5,539,542

 Aircraft

 3,510,376

 4,091,772

 Software

 4,811,260

 3,778,911

 Construction
 in progress

 —

 591,306

 Subtotal

 20,015,462

 24,213,322

 Less:
 accumulated depreciation

 ( 8,749,391
)

 ( 8,231,990
)

 Less:
 accumulated impairment

 ( 2,494,169
)

 ( 2,399,315
)

 Property
 and equipment, net

 $
 8,771,902

 $
 13,582,017

 In
August 2023, the Company disposed of certain properties to General Incorporated Association SBC, an entity controlled by the CEO of the
Company, who is the sole stockholder of the Company. The payment in excess of the net book value received from General Incorporated Association
SBC of $ 9,620,453
 was included as a deemed contribution in connection
with disposal of property and equipment in the Company's consolidated statements of changes in stockholders' equity.

 Depreciation
expense was $ 2,726,348 and
$ 6,586,036 for
the years ended December 31, 2024 and 2023, respectively.

 The
Company recognized an impairment loss of nil
 and $ 204,026,
and a gain on disposal of property and equipment of $ 325,761
 and $ 249,532
 for the years ended December 31, 2024 and
2023, respectively.

 F- 27

 SBC

 NOTES

 NOTE
9 — INTANGIBLE ASSETS, NET

 INTANGIBLE
ASSETS, NET

 As
of December 31, 2024 and 2023, intangible assets, net consist of the following:

OF INTANGIBLE ASSETS

 31,
 2024

 31,
 2023

 Assembled
 workforce

 $
 —

 $
 8,976,567

 use right

 16,582,795

 18,435,140

 Trademarks

 1,237,820

 —

 Customer
 Relationships

 192,911

 —

 159,321

 212,190

 Subtotal

 18,172,847

 27,623,897

 Less:
 accumulated amortization

 ( 2,072,849
)

 ( 7,884,621
)

 Less:
 accumulated impairment

 ( 14,509,946
)

 —

 assets, net

 $
 1,590,052

 $
 19,739,276

 Amortization
expense was $ 1,073,029 and
$ 5,660,906 for
the years ended December 31, 2024 and 2023, respectively.

 The
Company recognized an impairment loss of $ 15,058,965
 on patent use right for the year ended December 31, 2024.

 Estimated
future amortization expense related to intangible assets as of December 31, 2024 is as follows:

OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS

 For
 the Years Ended December 31,

 Amortization
 Expenses

 2025

 $
 133,945

 2026

 160,734

 2027

 160,734

 2028

 78,365

 2029

 61,891

 Thereafter

 994,383

 Total

 $
 1,590,052

 NOTE
10 — LONG-TERM INVESTMENTS, NET

 As
of December 31, 2024 and 2023, long-term investments, net consist of the following:

OF LONG-TERM INVESTMENTS

 31,
 2024

 31,
 2023

 Investments
 in private entities or organizations that do not report NAV per share:

 Entities
 or organizations without observable price changes

 $
 1,719,770

 $
 1,557,366

 Investment
 in a public entity with readily determinable fair value – related party

 2,478,531

 —

 Less:
 accumulated impairment

 ( 1,148,329
)

 ( 707,932
)

 investments, net

 $
 3,049,972

 $
 849,434

 The
Company recognized a realized gain on available-for-sale debt securities of nil
 and $ 223,164
 for the years ended December 31, 2024 and 2023, respectively.

 In
January 2024, in connection with the disposal of Cellpro, the Company acquired 353,600
 shares of common stock of Waqoo, representing
less than a 10 %
ownership interest, a related-party company listed on the Tokyo Stock Exchange. During the year ended December 31, 2024, the Company
recognized an unrealized loss of $ 2,617,435
 on the investment in Waqoo.

 The
Company recognized an impairment loss of $ 529,596 and nil on
long-term investments in privately held entities that do not repot NAV per share for the years ended December 31, 2024 and 2023,
respectively.

 F- 28

 SBC

 NOTES

 NOTE
11 — OTHER ASSETS

 As
of December 31, 2024 and 2023, other assets consist of the following:

OF OTHER ASSETS

 31,
 2024

 31,
 2023

 Security
 deposits

 $
 2,921,855

 $
 3,049,112

 Corporate-owned
 life insurance policies

 11,563,720

 11,529,700

 loans receivable, primarily student loans

 578,995

 647,641

 488,883

 215,605

 Total

 $
 15,553,453

 $
 15,442,058

 NOTE
12 — ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES

 As
of December 31, 2024 and 2023, accrued liabilities and other current liabilities consist of the following:

OF ACCRUED AND OTHER CURRENT LIABILITIES

 31,
 2024

 31,
 2023

 Individual
 income tax withheld on behalf of employees

 $
 859,446

 $
 943,195

 Wages
 and bonus payables

 3,173,679

 6,264,711

 Consumption
 tax payable

 3,827,080

 12,968,580

 Liabilities
 assumed in connection with purchase of property and equipment

 25,312

 656,508

 Excise
 and franchise tax payable

 15,095

 —

 202,582

 176,015

 Total

 $
 8,103,194

 $
 21,009,009

 NOTE
13 — LONG-TERM LOANS

 As
of December 31, 2024 and 2023, the Company's long-term loans from banks and other financial institution consist of following:

 OF LONG TERM LOANS

 Indebtedness

 Average
 Interest
 Rate*

 Average
 Years
 to
 Maturity*

 31,
 2024

 31,
 2023

 Guaranteed
 loans

 Fixed
 rate loans

 0.04
 %

 0.08

 $
 185,766

 $
 575,191

 Variable
 rate loans

 1.15
 %

 2.83

 6,377,998

 289,226

 Subtotal

 1.19
 %

 2.91

 6,563,764

 864,417

 Unsecured
 loans

 Fixed
 rate loans

 0.01
 %

 0.00

 35,742

 354,522

 Subtotal

 0.01
 %

 0.00

 35,742

 354,522

 Total
 long-term loans

 1.20
 %

 2.91

 6,599,506

 1,218,939

 Less:
 current portion

 ( 96,824
)

 ( 156,217
)

 Non-current
 portion

 $
 6,502,682

 $
 1,062,722

 *
 Pertained
 to information for loans outstanding as of December 31, 2024.

 F- 29

 SBC

 NOTES

 NOTE
13 — LONG-TERM LOANS (cont.)

 The
Company borrowed loans from various banks and a financial institution for working capital purposes.

 Interest
expense was $ 28,300 and
$ 45,292 for
the years ended December 31, 2024 and 2023, respectively.

 The
guaranteed information of the Company's outstanding loans as of December 31, 2024 and 2023 consists of the following:

OF OUTSTANDING LOANS

 31,
 2024

 31,
 2023

 Co-guaranteed
 by CEO of subsidiaries within the Company's organizational structure and Tokyo Credit Guarantee Association

 $
 185,766

 $
 747,474

 Co-guaranteed
 by CEO of a subsidiary within the Company's organizational structure and Kanagawa Credit Guarantee Association

 $
 —

 $
 116,943

 Guaranteed
 by a subsidiary within the Company's organizational structure

 $
 6,377,998

 $
 —

 As
of December 31, 2024, future minimum payments for long-term loans are as follows:

OF MATURITIES OF LONG TERM DEBT

 Years
 ending December 31,

 Principal
 Repayment

 2025

 $
 96,824

 2026

 66,580

 2027

 6,436,102

 2028

 —

 2029
 and thereafter

 —

 Total

 $
 6,599,506

 NOTE
14 — OPERATING LEASES — AS A LESSEE

 The
Company has entered into operating leases for offices and sublease purposes, with terms ranging from two to seven years. The estimated
effect of lease renewal and termination options, as applicable, that are reasonably certain to be exercised in the determination of the
lease term and initial measurement of right-of-use assets and lease liabilities was included in the consolidated financials.

the years ended December 31, 2024 and 2023, certain operating leases were guaranteed by related parties of the Company.

lease expenses for lease payments are recognized on a straight-line basis over the lease term. Leases with an initial term of twelve months
or less are not recorded on the consolidated balance sheets.

 The
components of lease costs are as follows:

OF LEASE COSTS

 2024

 2023

 For

 2024

 2023

 lease costs

 $
 3,877,048

 $
 4,056,387

 Short-term
 lease costs

 286,009

 757,457

 Total
 lease costs

 $
 4,163,057

 $
 4,813,844

 F- 30

 SBC

 NOTES

 NOTE
14 — OPERATING LEASES — AS A LESSEE (cont.)

 The
following table presents supplemental information related to the Company's operating leases:

OF SUPPLEMENTAL INFORMATION OPERATING LEASES

 2024

 2023

 For
 31,

 2024

 2023

 cash flows from operating leases

 $
 4,105,434

 $
 4,005,952

 lease right-of-use assets obtained in exchange for operating lease liabilities

 $
 —

 $
 2,305,199

 Remeasurement
 of operating lease liabilities and right-of use assets due to lease modifications

 $
 2,908,554

 $
 2,110,079

 average remaining lease term (years)

 1.66

 2.30

 Weighted average discount
 rate (per annum)

 0.65
 %

 0.19
 %

 As
of December 31, 2024, the future maturity of lease liabilities is as follows:

OF MATURITY OF LEASE LIABILITIES

 Years
 ending December 31,

 Lease
 Payment

 2025

 $
 4,361,879

 2026

 712,869

 2027

 263,412

 2028

 109,906

 2029

 109,906

 Thereafter

 54,950

 Total
 undiscounted lease payments

 5,612,922

 Less:
 imputed interest

 ( 29,874
)

 Total
 operating lease liabilities

 $
 5,583,048

 NOTE
15 — INCOME TAXES

 United States

 SBC
Holding, SBC USA, SBC Healthcare Inc., SBC Irvine, LLC, and Aikawa Medical Management, Inc. are incorporated in the
United States and subject to federal income tax rate at 21 %
and California state income tax rate at 6.98 %.

 Japan

 The
Company conducts its major businesses in Japan and is subject to tax in this jurisdiction. During the years ended December 31, 2024
and 2023, substantially all the taxable income of the Company is generated in Japan. As a result of its business activities, the Company
files tax returns that are subject to examination by the local tax authority. Income taxes in Japan applicable to the Company are imposed
by the national, prefectural, and municipal governments, and in the aggregate resulted in an effective statutory rate of approximately
 34.69 %
and 34.69 %
for the years ended December 31, 2024 and 2023, respectively.

 Vietnam

 Shoubikai
Medical Vietnam Co., Ltd. is incorporated in Vietnam and subject to income tax rate at 20 %
statutory tax rate with respect to the assessable profits generated from Vietnam.

Healthcare Holdings Pte. Ltd. and its subsidiaries are incorporated in Singapore and subject to income tax rate at 17 %
statutory tax rate with respect to the assessable profits generated from Singapore.

 F- 31

 SBC

 NOTES

 NOTE
15 — INCOME TAXES (cont.)

 For
the years ended December 31, 2024 and 2023, the Company's income tax expenses are as follows:

OF INCOME TAX EXPENSES

 2024

 2023

 For

 31,

 2024

 2023

 Current

 $
 41,183,012

 $
 30,905,334

 ( 14,417,087
)

 4,113,395

 Total

 $
 26,765,925

 $
 35,018,729

 From
October 2023, the Company underwent a tax examination conducted by the Japanese tax authority for the income tax returns filed by
SBC Japan for the years ended March 31, 2016 through March 31, 2023, the income tax returns filed by L'Ange Sub for the years
ended February 28, 2021 through February 28, 2023, and the income tax returns filed by Shobikai Sub for the years ended March 31,
2021 through March 31, 2023. The tax examination was completed, and the subsidiaries of the Company filed the amended tax returns or
received the correction notices from the Japanese tax authority in May 2024. There was no material difference between the final
result and the income tax liabilities recorded by the Company for the year ended December 31, 2023.

 A
reconciliation of the effective income tax rates reflected in the accompanying consolidated statements of operations and comprehensive
income to the statutory federal tax rates for the years ended December 31, 2024 and 2023 are as follows:

OF FEDERAL INCOME TAX RATE

 2024

 2023

 For
 31,

 2024

 2023

 Statutory
 federal rate

 21.00
 %

 34.69
 %

 State
 income tax expense, net of federal income tax effect

 6.98
 %

 —

 Effect
 of income tax rate difference under different tax jurisdictions

 8.79
 %

 0.59
 %

 Expenses
 not deductible for tax purpose

 0.46
 %

 ( 1.88
)%

 Effect of change in valuation allowance

 2.10
 %

 12.04
 %

 Effect
 of tax payments and dues

 ( 3.27
)%

 ( 1.38
)%

 Other
 adjustments

 0.38
 %

 3.53
 %

 tax rate

 36.44
 %

 47.59
 %

 The
tax effects of temporary differences that give rise to the deferred income tax assets and liabilities on December 31, 2024 and 2023 are
presented below:

OF NET DEFERRED TAX ASSETS AND LIABILITIES

 31,
 2024

 31,
 2023

 income tax assets

 and expense adjustments

 $
 2,317,931

 $
 4,142,338

 Change
 in cash surrender value of life insurance policies

 370,625

 ( 1,168,097
)

 Lease

 1,507,518

 2,195,824

 Net
 operating losses carried forward

 13,543,915

 7,397,655

 Impairment
 on intangible asset

 5,498,205

 —

 Fair
 value change of long-term investments

 877,026

 —

 178,597

 220,885

 Total
 deferred income tax assets

 24,293,817

 12,788,605

 Less:
 valuation allowance

 ( 8,640,332
)

 ( 7,397,655
)

 Total
 deferred income tax assets, net

 $
 15,653,485

 $
 5,390,950

 F- 32

 SBC

 NOTES

 NOTE
15 — INCOME TAXES (cont.)

 31,
 2024

 31,
 2023

 income tax liabilities

 and expense adjustments

 $
 ( 2,602,712
)

 $
 ( 9,131,874
)

 Change
 in cash surrender value of life insurance policies

 ( 1,720,120
)

 —

 Right-of-use

 ( 1,415,168
)

 ( 2,053,535
)

 assets acquired through business acquisition

 ( 354,739
)

 —

 ( 688,698
)

 ( 219,106
)

 Total
 deferred income tax liabilities

 $
 ( 6,781,437
)

 $
 ( 11,404,515
)

 income tax assets, net

 $
 9,798,071

 $
 —

 income tax liabilities, net

 $
 ( 926,023
)

 $
 ( 6,013,565
)

 The
realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future
periods. The Company regularly assesses the ability to realize its deferred tax assets and establishes a valuation allowance if it is
more-likely-than-not that some portion of the deferred tax assets will not be realized. The Company weighs all available positive and
negative evidence, including its earnings history and results of recent operations, projected future taxable income, and tax planning
strategies.

 The
amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward
period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional
weight may be given to subjective evidence such as the Company's projections for growth. The adjustments of a valuation allowance
against deferred tax assets may cause greater volatility in the effective tax rate in the periods in which the valuation allowance is
adjusted. Based upon the level of historical taxable profit and projections for future taxable profit over the periods for which the
deferred tax assets are deductible, management believes it is probable that the Company will utilize the benefits of these deferred tax
assets as of December 31, 2024 and 2023. Uncertainty of estimates of future taxable profit could increase due to changes in the economic
environment surrounding the Company, effects by market conditions, effects of currency fluctuations or other factors.

 Uncertain
tax positions

 The
Company evaluates each uncertain tax position (including the applicability of interest and penalties) based on technical merits, and
measures the unrecognized benefits associated with the tax positions. As of December 31, 2024 and 2023, the management considered the
Company did not have any significant unrecognized uncertain tax positions. The Company does not participate in any significant increases
or decreases in unrecognized tax benefits in the next twelve months from December 31, 2024. Open tax years in Japan are five years. The
Company's income tax returns filed in Japan for the tax years prior March 31, 2023 were examined by the relevant tax authorities.

 F- 33

 SBC

 NOTES

 NOTE
16 — SHAREHOLDERS' EQUITY

 The
Company is authorized to issue 400,000,000 shares of common stock, par value of $ 0.0001
 per share ("Common Stock"), and 20,000,000
 shares of undesignated preferred stock, par value
of $ 0.0001 per
share.

 Shares
issued under Pono Merger

 On
September 17, 2024, upon the consummation of Pono Merger, the Company issued 94,192,433
 shares of common stock to the former shareholder
of SBC USA as merger consideration, and the Company gave effect to the issuance of 5,080,820
 shares of common stock for the Class A common
stock that were previously issued by Pono and outstanding at the closing date of Pono Merger. In addition, Pono Promissory Note of $ 2,700,000
 was automatically converted to 270,000
 shares of common stock, held by SBC USA, which
were recorded as treasury stock on the consolidated balance sheets.

 On
September 18, 2024, the Company issued 339,565
 shares of common stock for no proceeds as follows:
(i) 83,250
 shares to Wolverine Flagship Fund Trading Limited,
(ii) 96,030
 shares to Amethyst Arbitrage International Master
Fund, (iii) 100,000
 shares to Radcliffe SPAC Master Fund, L.P. and
(iv) 60,285
 shares to Verition Multi-Strategy Master Fund
Ltd. as incentive shares pursuant to the Non-Redemption Agreements, entered into in May 2023, by and among Pono, Mehana Capital LLC and
certain unaffiliated stockholders, including Wolverine Flagship Fund Trading Limited, Amethyst Arbitrage International Master Fund, Radcliffe
SPAC Master Fund, L.P. and Verition Multi-Strategy Master Fund Ltd ("Non-Redemption Agreements").

 As
of December 31, 2024 and December 31, 2023, there were 103,020,816
 and 94,192,433
 shares issued, 102,750,816
 and 94,192,433
 shares outstanding, respectively, and no
 preferred stock issued and outstanding, after
giving retrospective effects of reverse recapitalization on September 17, 2024.

 Stock-based
compensation

 On
November 18, 2022 ("Effective Date"), the Company entered into a Common Stock Purchase Warrant Agreement (the "Warrant
Agreement") with HeartCore Enterprise, Inc. ("HeartCore") pursuant to which it agreed to compensate HeartCore with
common stock purchase warrants (the "Warrants") in exchange for professional services to be provided by HeartCore in connection
with its merger or other transaction with a special purpose acquisition company ("SPAC") wherein the Company becomes a subsidiary
of the SPAC (the "Merger"). The Warrants were fully vested as of the Effective Date, however, HeartCore can exercise the
Warrants in 10 years
only upon the Company's consummation of the Merger or the occurrence of other fundamental events defined in the Warrant Agreement
to purchase 2.7 %
of the fully diluted shares of the Company's common stock as of the date of the Merger, for an exercise price per share of $ 0.01.
As the performance condition of exercisability was satisfied upon the consummation of Pono Merger, the Company recognized stock-based
compensation of $ 13,022,692
 during the year ended December 31, 2024. On September
27, 2024, the Warrants were fully exercised, and 3,137,998
 shares of common stock were issued.

 In
January 2024, the Company terminated 449,190
 common stock options granted to doctors of related-party
MCs (the "Holders") in September 2023. In connection with the termination, the Company entered into a common stock purchase
warrant agreement (the "Warrant Agreement III") pursuant to which the Company issued to the Holders warrants to acquire an
equal number of shares of common stock as previously subject to the options issued to each of the Holders in September 2023. The warrants
may be exercised on the three-month, fifteen-month, and twenty-seven-month anniversary of the date of the Company completes its merger
or other transaction with a special purpose acquisition company ("SPAC") wherein the Company becomes a subsidiary of the
SPAC (the "Merger") or the occurrence of other fundamental events defined in the Warrant Agreement III (the "Trigger
Date"), to acquire an amount equal to one-third of the applicable shares of common stock, respectively, with an exercise price
per share of $ 0.0001.
The warrants were fully vested on the grant date and will expire on the tenth anniversary of the Trigger Date.

 In
June and July 2024, the Company terminated all common stock options and warrants ever granted, except for Warrants granted to HeartCore
in November 2022.

 As
of December 31, 2024 and 2023, there were nil
and 1,131,810
 common stock options and warrants granted to
related parties of the Company, respectively.

 F- 34

 SBC

 NOTES

 NOTE
16 — SHAREHOLDERS' EQUITY (cont.)

 The
following table summarizes the stock option/warrant activities and related information for the years ended December 31, 2024 and 2023:

OF STOCK OPTION/WARRANTS ACTIVITIES

 of
 Warrants*

 Average
 Exercise
 Price

 Average
 Remaining
 Term
 (Years)

 Intrinsic
 Value

 As of January
 1, 2023

 3,137,998

 $
 0.01

 10.00

 $
 —

 Granted

 1,781,000

 0.0001

 10.00

 —

 Exercised

 —

 —

 —

 —

 Forfeited

 —

 —

 —

 —

 As
 of December 31, 2023

 4,918,998

 $
 0.0064

 10.00

 $
 —

 Granted

 449,190

 0.0001

 10.00

 —

 Additions
 pursuant to Pono Merger **

 12,134,375

 11.50

 5.00

 —

 Exercised

 ( 3,137,998
)

 0.01

 —

 —

 Forfeited/Cancelled

 ( 2,230,190
)

 0.0001

 —

 —

 As
 of December 31, 2024 **

 12,134,375

 $
 11.50

 4.80

 $
 —

 Vested
 and exercisable as of December 31, 2024

 12,134,375

 $
 11.50

 4.80

 $
 —

 *

 The
 number of Warrants granted to HeartCore was updated to reflect the adjustment upon the consummation of Pono Merger.

 **

 As
 of December 31, 2024, there were 12,134,375 warrants issued by Pono, prior to Pono Merger, among which 11,500,000 warrants were issued
 through its initial public offering ("IPO") ("Public Warrants") and 634,375 were issued through a private
 placement ("Placement Warrants"). Each warrant entitles the registered holder to purchase one share of common stock at
 a price of $ 11.50 per share at any time commencing on October 17, 2024 until October 17, 2029, or earlier upon redemption or liquidation.

 The
fair value of the stock-based compensation recognized in the consolidated financial statements was estimated using the binomial option
pricing model, and based on the equity value estimated using 1) income approach with the discounted cash flow valuation method, which
requires management to make significant estimates and assumptions related to forecasted revenues and cash flows and the discount rates,
and 2) market approach with metrics of publicly traded companies or historically completed transactions of comparable businesses, with
the assistance of an independent valuation specialist. The Company applied a weighting to the income approach and market approach to
determine the fair value.

 NOTE
17 — DISAGGREGATION OF REVENUES

generated from different revenue streams consist of the following:

OF DISAGGREGATION OF REVENUE

 2024

 2023

 For
 31,

 2024

 2023

 revenue

 $
 61,033,032

 $
 42,103,380

 revenue

 54,814,399

 53,186,662

 services revenue

 53,113,155

 72,282,549

 services revenue

 16,141,714

 7,336,768

 20,313,242

 18,633,064

 Total

 $

 $

 F- 35

 SBC

 NOTES

 NOTE
17 — DISAGGREGATION OF REVENUES (cont.)

the years ended December 31, 2024 and 2023, the Company recognized revenue of $ 1,970,889
 and $ 973,866
 from the opening balance of advances from customers,
respectively; and revenue of nil
 and $ 1,382,803
 from the opening balance of advances from customers
— related parties, respectively.

 As
of December 31, 2024 and 2023, and for the years then ended, substantially all of our long-lived assets and revenues generated were
attributed to the Company's operation in Japan.

 NOTE
18 — RELATED PARTY TRANSACTIONS

 The
related parties that had material transactions for the years ended December 31, 2024 and 2023 consist of the following:

 Name
 of Related Parties

 Nature
 of Relationship as of December 31, 2024

 Controlling
 shareholder, director and CEO of the Company

 Yoshiko

 Representative
 director of subsidiaries of the Company

 Mizuho
 Yamashita

 of a subsidiary of the Company

 The

 The

 The

 The

 The

 The

 The

 The

 Japan

 SBC
 Inc., previously known as SBC China Inc.

 Hariver
 Inc.

 Incorporated Association SBC

 The
 CEO of the Company being the Member of General Incorporated Association SBC

 Public
 Interest Foundation SBC Medical Promotion Foundation

 The
 relative of CEO of the Company being a Member of Public Interest Foundation SBC Medical Promotion Foundation

 AI
 Med Inc.

 The CEO of the Company is a principal shareholder of AI Med Inc.

 Amulet
 Inc.

 by Mizuho Yamashita, a director of a subsidiary of the Company

 SBC

 Significantly
 influenced by the Company

 SBC
 Tokyo Medical University, previously known as Ryotokuji University

 The
 CEO of the Company is the chairman of SBC Tokyo Medical University

 SBC
 Shonan Osteopathic Clinic Inc.

 The
 CEO of the Company is a principal shareholder of SBC Shonan Osteopathic Clinic Inc.

 Waqoo
 Inc.

 The
 CEO of the Company is a principal shareholder of Waqoo Inc.

 Incorporated Association Taiseikai

 The
 relatives of CEO of the Company being the Members of General Incorporated Association Taiseikai

 Skynet
 Academy Co., Ltd.*

 Kijimadairakanko
 Inc.*

 *

 Former
 subsidiaries of the Company that were disposed of to companies controlled by the CEO of the Company on December 23, 2024.

 F- 36

 SBC

 NOTES

 NOTE
18 — RELATED PARTY TRANSACTIONS (cont.)

the years ended December 31, 2024 and 2023, the transactions with related parties are as follows:

OF RELATED PARTY TRANSACTIONS

 from related parties

 2024

 2023

 For

 from related parties

 2024

 2023

 $
 53,862,520

 $
 56,554,316

 46,756,189

 45,115,149

 46,355,437

 45,893,461

 17,997,072

 21,521,302

 5,666,907

 4,518,846

 7,435,446

 2,603,405

 Japan

 39,620

 488,023

 Hariver
 Inc.

 19,810

 21,740

 SBC
 Inc., previously known as SBC China Inc.

 2,512

 Public
 Interest Foundation SBC Medical Promotion Foundation

 Incorporated Association SBC

 SBC
 Tokyo Medical University, previously known as Ryotokuji University

 45,286

 231,191

 98,445

 67,516

 Mizuho
 Yamashita

 —

 19,214

 Amulet
 Inc.

 —

 3,587

 AI
 Med Inc.

 556,397

 SBC

 1,204,107

 1,298,539

 11,708,183

 2,923,608

 3,923,228

 851,105

 Incorporated Association Taiseikai

 —

 SBC
 Shonan Osteopathic Clinic Co., Ltd.

 56,740

 69,227

 Total

 $
 195,173,889

 $
 182,738,049

 transactions with related parties

 $
 195,173,889

 $
 182,738,049

 F- 37

 SBC

 NOTES

 NOTE
18 — RELATED PARTY TRANSACTIONS (cont.)

 As
of December 31, 2024 and 2023, the balances with related parties are as follows:

 receivable

 31,
 2024

 31,
 2023

 $
 5,091,430

 $
 9,251,427

 8,552,722

 8,447,448

 7,742,251

 7,841,059

 3,071,378

 4,661,649

 993,944

 1,358,213

 1,263,602

 1,039,074

 817,283

 520,891

 283,298

 348,187

 Japan

 —

 139,767

 SBC
 Tokyo Medical University, previously known as Ryotokuji University

 66,546

 AI
 Med Inc.

 2,329

 SBC
 Inc., previously known as SBC China Inc.

 Public
 Interest Foundation SBC Medical Promotion Foundation

 SBC
 Shonan Osteopathic Clinic Co., Ltd.

 —

 SBC

 693,850

 —

 Kijimadairakanko
 Inc.

 336,176

 —

 Total

 $
 28,846,680

 $
 33,676,672

 receivable with related parties

 $
 28,846,680

 $
 33,676,672

 lease receivables

 31,

 2024

 31,

 2023

 $
 1,877,291

 $
 2,568,709

 2,490,705

 2,779,347

 3,872,683

 2,019,117

 1,047,821

 1,782,124

 2,479,771

 79,439

 500,244

 335,317

 1,891,412

 —

 197,452

 —

 SBC
 Shonan Osteopathic Clinic Co., Ltd.

 32,788

 —

 Total

 $
 14,390,167

 $
 9,564,053

 lease receivables

 $
 14,390,167

 $
 9,564,053

 Less:
 current portion

 ( 5,992,585
)

 ( 6,143,564
)

 lease receivables Less: current portion

 ( 5,992,585
)

 ( 6,143,564
)

 Non-current
 portion

 $
 8,397,582

 $
 3,420,489

 lease receivables Non-current portion

 $
 8,397,582

 $
 3,420,489

 Due
 from related party, net

 31,

 2024

 31,

 2023

 SBC

 $
 2,836,013

 $
 3,238,209

 Less:
 allowance for credit loss

 ( 2,836,013
)

 ( 3,238,209
)

 Total

 $
 —

 $
 —

 Due from related
 party, net

 $
 —

 $
 —

 investments in MCs - related parties

 31,

 2024

 31,

 2023

 $
 6,378

 $
 7,090

 6,378

 7,090

 6,378

 7,090

 6,378

 7,090

 6,859,913

 7,626,184

 10,935,485

 12,157,011

 Total

 $
 17,820,910

 $
 19,811,555

 Long-term investments
 in MCs – related parties

 $
 17,820,910

 $
 19,811,555

 F- 38

 SBC

 NOTES

 NOTE
18 — RELATED PARTY TRANSACTIONS (cont.)

 payable

 31,

 2024

 31,

 2023

 Japan

 $

 $
 —

 Total

 $

 $
 —

 payable

 $

 $
 —

 Advances
 from customers

 31,

 2024

 31,

 2023

 $
 5,076,300

 $
 13,438,645

 1,801,034

 4,237,765

 1,745,069

 4,117,597

 379,931

 1,168,947

 140,170

 85,044

 45,701

 10,177

 SBC
 Shonan Osteopathic Clinic Co., Ltd.

 16,395

 —

 940,007

 —

 1,594,926

 —

 Total

 $
 11,739,533

 $
 23,058,175

 Advances from
 customers

 $
 11,739,533

 $
 23,058,175

 Notes
 payable – related parties

 31,

 2024

 31,

 2023

 $
 4,653

 $
 5,264,101

 14,672

 3,855,650

 8,827

 4,099,032

 2,236

 1,561,642

 —

 268,552

 1,201

 268,445

 Total

 $
 31,589

 $
 15,317,422

 Notes
 payable – related parties

 $
 31,589

 $
 15,317,422

 Less:
 current portion

 ( 26,255
)

 ( 3,369,203
)

 Notes
 payable – related parties Less: current portion

 ( 26,255
)

 ( 3,369,203
)

 Non-current
 portion

 $
 5,334

 $
 11,948,219

 Notes
 payable – related parties Non-current portion

 $
 5,334

 $
 11,948,219

 Due
 to related party

 31,

 2024

 31,

 2023

 $
 2,823,590

 $
 3,583,523

 Total

 $
 2,823,590

 $
 3,583,523

 Due to related
 party

 $
 2,823,590

 $
 3,583,523

 Allowance
 for credit loss movement

 31,

 2024

 31,

 2023

 Beginning
 balance

 $
 3,238,209

 $
 2,867,455

 Provision
 for credit loss

 622,804

 370,754

 Reversal
 of credit loss

 ( 1,025,000
)

 —

 Ending
 balance

 $
 2,836,013

 $
 3,238,209

 Other income

 31,

 2024

 31,

 2023

 Medical Corporation Shobikai

 $

 999,350

 $

 —

 Medical Corporation Kowakai

 568,092

 —

 Medical Corporation Nasukai

 764,809

 —

 Medical Corporation Aikeikai

 316,352

 —

 Medical Corporation Jukeikai

 24,474

 —

 Total

 $

 2,673,077

 $

 —

 Other income

 $

 2,673,077

 $

 —

 The
balances of due to and due from related parties represent the outstanding loans to and from related parties, respectively, as of December
31, 2024 and 2023. These loans are non-secured, interest-free and due on demand.

 In
February 2023, the Company paid off the retirement compensation expense accrued to Yoshiko Aikawa.

the years ended December 31, 2024 and 2023, the Company purchased medical equipment and cosmetics of $ 8,472,202
 and $ 2,842,588,
respectively, from Japan Medical & Beauty Inc., which was recognized and included in the cost of revenues.

 Also
see Note 2(a), 5, 8, 10, 13, 14, 16, 17 and 21 for more transactions with related parties.

 F- 39

 SBC

 NOTES

 NOTE 19 — MISAPPROPRIATION
LOSS

 In January 2024,
before the issuance of the Company's consolidated financial statements as of December 31, 2023 and for the year then ended, in connection
with a routine tax examination of the Company's income tax returns, the Japanese tax authority discovered misappropriations of Company
funds by a former director of general affairs and legal department of L'Ange Cosmetique Co., Ltd., which is a subsidiary of the
Company (the "former director"), who received kickbacks from multiple vendors of SBC Japan (collectively with the former director,
the "participants") possibly beginning as early as 2012 until the misappropriations were discovered. The former director was
suspended immediately upon the discovery and was terminated effective February 23, 2024. The Company has commenced a criminal complaint
in Tokyo against the participants.

 Shortly after this
discovery, the Company engaged independent legal counsel and forensic consultants to investigate the misappropriations. The
investigation, which was completed in March 2024, revealed that the participants had misappropriated approximately
JPY 632 million ($ 5.6 million), including consumption tax, from the Company of which the former director received
approximately JPY 335 million ($ 3.0 million), between April 2016 and the discovery of the misappropriations in
January 2024. The amount misappropriated prior to April 2016 could not be accurately determined because certain data for the
period prior to April 2016 was unavailable, the Company does not expect such amount to be material based on current estimates.

 The Company found no
evidence that any other employee of the Company was aware of, or colluded in, the misappropriations of Company funds or that there was
any unlawful activity apart from that associated with the participants' misappropriations of Company funds. The misappropriated
amounts, excluding the consumption tax, representing advertising service s
purchased on behalf of a related-party MC, were originally included in the revenues reported on a net basis. After discovery of the misappropriations,
the amounts were reported as a misappropriation loss. For the year ended December 31, 2023, the Company recorded a misappropriation loss
of $ 409,030.

 NOTE
20 — SEGMENT REPORTING

 The
Company's chief operating decision maker ("CODM"), Chief Executive Officer, reviews consolidated results of operations
to make decisions, therefore the Company views its operations and manages its business as a single operating segment. The Company's
revenues for its single operating segment are derived from providing comprehensive management services to MCs and their clinics.

 The
accounting policies for the single operating segment are the same as those described in Note 2. The CODM evaluates performance for
the Company's single operating segment and decides how to allocate resources based on the Company's consolidated net
income that is reported in the consolidated statements of operations and comprehensive income as net income. The measure of segment
assets is reported on the consolidated balance sheets as total assets. The CODM allocates resources across the Company based on
consolidated net income derived during the annual budgeting process and throughout the year in monitoring actual results compared to
budget and updated forecasts. These results are used to assess segment performance.

 The
operating segment financial information regularly reviewed by the CODM, inclusive assets, revenues, expenses, profit or loss, and noncash
items are presented on a consolidated basis in the same amount and using the same captions as those included in the consolidated statements
of operations and comprehensive income, consolidated balance sheets, and consolidated statements of cash flows. There are no additional
segment expense categories regularly provided to the CODM. Therefore, there are also no amounts classified as other segment items requiring
disclosure.

 NOTE
21 — COMMITMENT

 As
of December 31, 2024 and 2023, a subsidiary of the Company provided a guarantee on the debt of its CEO in the amounts of $ 262,095 and
$ 329,155,
respectively. As of December 31, 2024 and 2023, the Company did not record a liability in the consolidated balance sheets for the
guarantee because it was not probable that the Company would be required to make payments under the guarantee.

 NOTE
22 — SUBSEQUENT EVENTS

 In
January 2025, the Company effected a merger in which SBC Japan and Shobikai Sub merged with and into L'Ange Sub. As a result,
the separate corporate existence of SBC Japan and Shobikai Sub ceased, with L'Ange Sub continuing as the surviving company. Following the merger, L'Ange Sub changed its name to SBC Medical Group Co., Ltd.

 In
February 2025, the Company issued 860,435 shares of common stock, with no proceeds, to Mehana Capital LLC as incentive shares pursuant
to the Non-Redemption Agreements.

 F- 40

 Item
9.
 Changes
 in and Disagreements With Accountants on Accounting and Financial Disclosure.

 None.

 Item
9A.
 Controls
 and Procedures.

of Disclosure Controls and Procedures

 Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Annual
Report. Based on this evaluation, management concluded that our disclosure controls and procedures were not effective as of December
31, 2024 to provide reasonable assurance that information required to be disclosed in periodic SEC filings is recorded, processed, summarized
and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated
to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding
required disclosure. Specifically, as previously disclosed, as of the fiscal year ended December 31, 2023, and as described below, we
identified material weaknesses in our internal control over financial reporting.

 Despite
the identified material weaknesses, we believe that our consolidated financial statements and other information contained in this Annual
Report fairly present, in all material respects, our financial condition, and results of operations for the periods presented.

 We
remain committed to ongoing improvements in our disclosure controls and internal control over financial reporting, as outlined in the
remediation plan below.

 Material
Weaknesses

 A
material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that
there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely
basis.

 In
connection with the discovery of the misappropriations of funds as described in more details under "Part II, Item 7. Management's
Discussion and Analysis of Financial Condition and Results of Operations—Misappropriations of Funds", we
have identified material weaknesses as of December 31, 2023, which remain un-remediated as of December 31, 2024, in our internal control
over financial reporting resulting from our failure to maintain an effective control environment, risk assessment processes and monitoring
activities.

 Our
system of internal control failed to detect the misappropriations of funds due to the following material weaknesses of the Company:

 1.
 Control Environment. We did not maintain an effective control environment that fully emphasized the establishment of adherence
to effective internal control over financial reporting throughout our management. We did
not give sufficient consideration to the risk of senior management override of internal control. We
had not ensured that certain personnel were adequately trained to properly execute critical internal control.

 2.
 Control Activities. We did not effectively implement or maintain control activities, such as ensuring a sufficient functioning
of the mechanism of reconciliation of invoices to contracts and multi-level approvals of contracts, invoices and payments. We did not maintain sufficient segregation of duties with respect to certain activities and did not maintain adequate
monitoring and oversight for those activities.

 3.
 Risk Assessment. We did not have an effective risk assessment process and the related documentation.

 4.
 Information and Communication. We did not adequately communicate to all employees of the organization information regarding
the importance of internal control over financial reporting and employees' duties and responsibilities, including segregation of
duties.

 5.
 Monitoring Activities. We did not maintain effective monitoring controls related to the evaluation and testing of our internal
control over financial reporting.

 In
addition, the Company completed its business combination in September 2024. Prior to the business combination, the Company operated as
a private corporation with limited accounting personnel and supervisory resources necessary to support its accounting processes and address
its internal control over financial reporting requirements. As a result, the existing internal control are no longer sufficient to meet
the post-business combination financial reporting demands, and the Company is actively updating these controls. The design and implementation
of internal control over financial reporting in a post-business combination environment has required, and will continue to require, significant
time and resources from management and other personnel.

the process of assessing the Company's internal controls, management has summarized the material
weaknesses in our internal control over financial reporting as follows:

 Lack
 of sufficient controls implemented to ensure all the related party transactions are identified, approved and reported in compliance with the established related party
 policy.

 Lack
 of sufficient financial reporting and accounting personnel to formalize, design, implement and operate key controls over financial
 reporting process in order to report financial information in accordance with U.S. GAAP and SEC reporting requirements.

 Lack
 of well-established procedures to ensure all the services provided by subcontractors or vendors are reviewed and verified before
 the approval of payments.

 Lack
 of well-established procedures to prevent and detect fraudulent transactions or override of control activities, specifically failure
 to maintain sufficient segregation of duties with respect to certain activities of its former manager of general affairs and legal
 department of one of its subsidiaries and failure to maintain adequate monitoring and oversight of the work performed by this former
 manager.

 Remediation
Plan

 With
respect to the material weaknesses identified in connection with the misappropriations of funds, management has implemented, or is in
the process of implementing, the following changes to our internal control systems and procedures:

 We
 established a related party policy in September 2024 to identify, approve, and report related party transactions; and implemented
 the corresponding procedures since November 2024.

 We
 will clarify the organization structure and employee positions promoting (i) segregation of duties, (ii) monitoring and oversight,
 (iii) reconciliation of invoices to contracts and (iv) multi-level approvals of contracts, invoices and payments.

 We
 will communicate to all employees of the organization information regarding the importance of internal control and employees'
 duties and responsibilities, including segregation of duties.

 We
 have updated our delegation of authority over banking activities and are establishing a new treasury function. This improvement enhances
 the segregation of duties related to the general manager role, thereby strengthening the safeguarding of cash.

 We
 are progressing with a project, led by our Head of Internal Control and Internal Audit Office, to design, implement, and
 document internal controls to address risks related to financial reporting. This year, our activities are focused on "laying
 the foundation to complete our response to key financial reporting risks by the end of 2025," and we are making progress as
 planned.

 Furthermore,
management is fully committed to addressing the control deficiencies that contributed to the material weaknesses in a post-business combination
environment. The steps we have already taken in 2024, and those we plan to take in 2025, are as follows:

 We
 added accounting and finance personnel to strengthen our team. This has allowed us to enhance segregation of duties in the preparation
 and review of financial reporting, while improving oversight, structure, and reporting lines.

 We
 have improved the financial reporting process of our group, including consolidated subsidiaries. As a result, the monitoring
 function over the application of U.S. GAAP, including financial statement disclosures, has been enhanced, allowing for more accurate
 and timely reporting than before.

 To
 support the execution of the aforementioned project for designing, implementing, and documenting internal controls, we have engaged
 external consultants with expertise in SOX (The Sarbanes-Oxley Act of 2002 compliance. As a result, we expect to complete
 our response to key financial reporting risks by the end of 2025.

 We
plan to confirm at the end of the fiscal year (end of 2025) that internal controls are operating effectively as a result of the implementation
of the above remediation plans. In particular, we plan to focus on verifying the remediation status of the identified material weaknesses.

 Thereafter,
under the direction of our Audit Committee, management will continue to strengthen corporate governance and aim to establish a system
in which internal controls operate effectively throughout the year. During this process, we may adjust our remediation plans or take
additional measures to address control deficiencies as necessary. We believe that these continuous efforts will remediate the deficiencies
in internal controls, including the identified material weaknesses, and significantly improve our internal control over financial reporting.

 Management's
Report on Internal Control over Financial Reporting

 As
discussed elsewhere in this Annual Report, we completed the Business Combination on September 17, 2024. Prior to the Business Combination,
Pono was a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition,
stock purchase, reorganization or similar business combination with one or more businesses. As a result, previously existing internal
controls are no longer applicable or comprehensive enough as of the assessment date as the operations prior to the Business Combination
were insignificant compared to those post-Business Combination. The design of internal controls over financial reporting for the Company
post-Business Combination has required and will continue to require significant time and resources from management and other personnel.
As a result, management was unable, without incurring unreasonable effort or expense to conduct an assessment
of our internal control over financial reporting as of December 31, 2024. Accordingly, we are excluding management's report on internal
control over financial reporting pursuant to Section 215.02 of the SEC Division of Corporation Finance's Regulation S-K Compliance &
Disclosure Interpretations.

 Inherent
Limitation on the Effectiveness of Internal Control

 The
effectiveness of any system of internal control over financial reporting is subject to inherent limitations. These include the exercise
of judgment in designing, implementing, and operating controls, as well as the inherent inability to completely eliminate the risk of
misconduct or error. Accordingly, while we aim to establish robust controls, any system, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired control objectives.

 Additionally,
the design of our disclosure controls and procedures is impacted by resource constraints and the necessity for management to balance
the benefits of potential controls against their associated costs. Moreover, projections of effectiveness into future periods are subject
to risks that controls may become inadequate over time due to evolving conditions or diminished compliance. We will continue to monitor
and enhance our internal control as necessary or appropriate, but we cannot provide assurance that these improvements will fully eliminate
all risks of material misstatement.

 Changes
in Internal Control over Financial Reporting

 Other
than the remediation efforts described above, there have been no material changes in our internal control over financial reporting during
the three months ended December 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.

 Item
9B. Other Information.

 None

 On March 27, 2025, the Company's Board of Directors
approved certain executive officer updates, including the replacement of Ryoji Murata, the Company's current Chief Financial Officer
(principal financial officer), effective April 1, 2025. Yuya Yoshida, 46, the Company's current Chief Operating Officer will
continue in that role and also serve as Chief Financial Officer (principal financial officer), effective April 1, 2025. Mr. Murata
will continue to serve as the Company's principal accounting officer.

 Mr. Yoshida has served as our Chief Operating Officer
and member of our Board of Directors since September 17, 2024, and in the same positions, since September 29, 2023, with SBC Medical Group, Inc. (the legacy business that because the Company's business). Mr. Yoshida has also served as the Executive Vice President and the Chief Financial Officer of SBC Medical Group Co., Ltd. (Japan)
since July 1, 2023. From January 2016 to June 2023, Mr. Yoshida worked in Corporate Development (Global Head and Director of Corporate
Development in 2018) at Rakuten Group Co., Ltd. From 2003 to 2016, Mr. Yoshida worked in securities, principal M&A, and investment
banking at Mitsubishi UFJ Financial Group. Mr. Yoshida has extensive knowledge in E-Commerce, logistics, settlement, finance, mergers
and acquisitions and divestiture transactions. Mr. Yoshida graduated with a Master of Law degree from Keio University in 2003. Mr. Yoshida
also graduated with a Master of Business Administration degree from UCLA Anderson Business School in 2014.

 Mr. Yoshida was not
appointed pursuant to any arrangement or understanding with any other person, has no family relationships with any director or
executive officer of the Company, and other than his previously reported employment arrangement with the Company, and other than his
previously reported employment arrangement with the Company, and there are no transactions involving Mr. Yoshida that would be
required to be reported under Item 404(a) of Regulation S-K.

 Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

 Not
applicable.

 PART
III

 Item
10. Directors, Executive Officers and Corporate Governance.

 The
information required by this Item will be set forth in our definitive proxy statement for our 2025 Annual Meeting of Stockholders (the
"Proxy Statement") and is incorporated herein by reference.

 Item
11. Executive Compensation.

 The
information required by this Item will be set forth in the Proxy Statement and is incorporated herein by reference.

 Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 The
information required by this Item will be set forth in the Proxy Statement and is incorporated herein by reference.

 Item
13. Certain Relationships and Related Transactions, and Director Independence.

 The
information required by this Item will be set forth in the Proxy Statement and is incorporated herein by reference.

 Item
14. Principal Accountant Fees and Services.

 The
information required by this Item will be set forth in the Proxy Statement and is incorporated herein by reference.

 PART
IV

 Item
15.
 Exhibits
 and Financial Statement Schedules

 a)
 Statements and Schedules: The required information is set forth in "Part II, Item 8
 - Financial Statements and Supplementary Data" in this Annual Report.

 b)
 Exhibits:
 The following exhibits are filed or furnished as an exhibit to this Annual Report on Form
 10-K.

 Exhibit
 No.

 Description

 2.1

 Agreement
 and Plan of Merger, dated January 31, 2023, by and among Pono Capital Two, Inc., Pono Two Merger Sub, Inc., SBC Medical Group Holdings
 Incorporated, Mehana Capital LLC in its capacity as the representative of the stockholders of Pono Capital Two, Inc., and Yoshiyuki
 Aikawa in his personal capacity and his capacity as the representative of the stockholders of SBC Medical Group Holdings Incorporated
 (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Pono Capital Two, Inc. with the SEC on February
 2, 2023).

 2.2

 First
 Amendment to the Agreement and Plan of Merger, dated April 26, 2023, by and among Pono Capital Two, Inc., Pono Two Merger Sub, Inc.,
 SBC Medical Group Holdings Incorporated, Mehana Capital LLC in its capacity as the representative of the stockholders of Pono Capital
 Two, Inc., and Yoshiyuki Aikawa in his personal capacity and his capacity as the representative of the stockholders of SBC Medical
 Group Holdings Incorporated (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Pono Capital Two,
 Inc. with the SEC on May 1, 2023).

 2.3

 Second
 Amendment to the Agreement and Plan of Merger, dated May 30, 2023, by and among Pono Capital Two, Inc., Pono Two Merger Sub, Inc.,
 SBC Medical Group Holdings Incorporated, Mehana Capital LLC in its capacity as the representative of the stockholders of Pono Capital,
 Two Inc., and Yoshiyuki Aikawa in his personal capacity and his capacity as the representative of the stockholders of SBC Medical
 Group Holdings Incorporated (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Pono Capital Two,
 Inc. with the SEC on June 2, 2023).

 2.4

 Third
 Amendment to the Agreement and Plan of Merger, dated June 15, 2023, by and among Pono Capital Two, Inc., Pono Two Merger Sub, Inc.,
 SBC Medical Group Holdings Incorporated, Mehana Capital LLC in its capacity as the representative of the stockholders of Pono Capital
 Two Inc., and Yoshiyuki Aikawa in his personal capacity and his capacity as the representative of the stockholders of SBC Medical
 Group Holdings Incorporated (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Pono Capital Two,
 Inc. with the SEC on June 16, 2023).

 2.5

 Amended
 and Restated Agreement and Plan of Merger, dated June 21, 2023, by and among Pono Capital Two, Inc., Pono Two Merger Sub, Inc., SBC
 Medical Group Holdings Incorporated, Mehana Capital LLC in its capacity as the representative of the stockholders of Pono Capital
 Two, Inc., and Yoshiyuki Aikawa in his personal capacity and his capacity as the representative of the stockholders of SBC Medical
 Group Holdings Incorporated (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Pono Capital Two,
 Inc. with the SEC on June 22, 2023).

 2.6

 First
 Amendment to the Amended and Restated Agreement and Plan of Merger, dated September 8, 2023, by and among Pono Capital Two, Inc.,
 Pono Two Merger Sub, Inc., SBC Medical Group Medical Holdings Incorporated, Mehana Capital LLC in its capacity as the representative
 of the stockholders of Pono Capital Two, Inc., and Yoshiyuki Aikawa in his personal capacity and his capacity as the representative
 of the stockholders of SBC (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Pono Capital Two,
 Inc. with the SEC on September 11, 2023).

 2.7

 Second
 Amendment to the Amended and Restated Agreement and Plan of Merger, dated October 26, 2023, by and among Pono Capital Two Inc., Pono
 Two Merger Sub, Inc., SBC Medical Group Holdings Incorporated, Mehana Capital LLC in its capacity as the representative of the stockholders
 of Pono Capital Two Inc., and Yoshiyuki Aikawa in his personal capacity and his capacity as the representative of the stockholders
 of SBC Medical Group Holdings Incorporated (incorporated by reference to Exhibit 2.2 to Form 8-K filed by Pono Capital Corp. with
 the SEC on October 26, 2023).

 2.8

 Third
 Amendment to the Amended and Restated Agreement and Plan of Merger, dated December 28, 2023, by and among Pono Capital Two, Inc.,
 Pono Two Merger Sub, Inc., SBC Medical Group Holdings Incorporated, Mehana Capital LLC in its capacity as the representative of the
 stockholders of Pono Capital Two, Inc., and Yoshiyuki Aikawa in his personal capacity and his capacity as the representative of the
 stockholders of SBC Medical Group Holdings Incorporated (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K
 filed by Pono Capital Two, Inc. with the SEC on December 29, 2023).

 2.9

 Fourth
 Amendment to the Amended and Restated Agreement and Plan of Merger, dated April 22, 2024, by and among Pono Capital, Two Inc., Pono
 Two Merger Sub, Inc., SBC Medical Group Holdings Incorporated Mehana Capital LLC in its capacity as the representative of the stockholders
 of Pono Capital, Two Inc., and Yoshiyuki Aikawa in his personal capacity and his capacity as the representative of the stockholders
 of SBC Medical Group Holdings Incorporated (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Pono
 Capital Two, Inc. with the SEC on April 23, 2024).

 3.1

 Fourth
 Amended and Restated Certificate of Incorporation of SBC Medical Group Holdings Incorporated (incorporated by reference to Exhibit
 3.1 to the Current Report on Form 8-K filed by SBC Medical Group Holdings Incorporated on September 20, 2024).

 3.2

 Amended
 and Restated Bylaws of SBC Medical Group Holdings Incorporated (incorporated by reference to Exhibit 3.2 to the Current Report on
 Form 8-K filed by SBC Medical Group Holdings Incorporated on September 20, 2024).

 4.1

 Warrant
 Agreement, dated August 4, 2022, by and between Pono Capital Two, Inc. and Continental Stock Transfer & Trust Company, as warrant
 agent (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by Pono Capital Two, Inc. with the SEC on
 August 9, 2022).

 4.2

 Specimen
 Warrant Certificate (incorporated by reference to Exhibit 4.4 to the Amendment No. 1 to the Registration Statement on Form S-1, filed
 by Pono Capital Two, Inc. on July 22, 2022).

 4.3*

 Description of Securities

 10.1+*

 Form of SBC Medical Group Holdings Incorporated Equity Incentive Plan.

 10.2

 Form
 of Indemnification Agreement (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by SBC Medical Group
 Holdings Incorporated on September 20, 2024).

 10.3*

 Form of Registration Rights Agreement by certain SBC Medical Group Holdings Incorporated equity holders.

 10.4*

 Form of Lock-Up Agreement by certain SBC Medical Group Holdings Incorporated equity holders.

 10.5

 Letter
 Agreement, dated August 4, 2022, by and among Pono Capital Two Inc., its officers, directors, and Mehana Capital LLC (incorporated
 by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Pono Capital Two, Inc. with the SEC on August 9, 2022).

 10.6

 Purchaser
 Support Agreement, dated January 31, 2023 (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by Pono
 Capital Two, Inc. with the SEC on February 2, 2023).

 10.7

 Voting
 Agreement, dated January 31, 2023 (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed by Pono Capital
 Two, Inc. with the SEC on February 2, 2023).

 10.8+

 Employment Agreement between SBC Medical Group Holdings and Yoshiyuki Aikawa, dated September 17, 2024 (incorporated by reference
 to Exhibit 10.8 to the Current Report on Form 8-K filed by SBC Medical Group Holdings Incorporated on September 20, 2024).

 10.9+

 Employment Agreement between SBC Medical Group Holdings and Yuya Yoshida, dated September 17, 2024 (incorporated by reference to Exhibit
 10.9 to the Current Report on Form 8-K filed by SBC Medical Group Holdings Incorporated on September 20, 2024).

 10.10+

 Employment Agreement between SBC Medical Group Holdings and Ryoji Murata, dated September 17, 2024 (incorporated by reference to Exhibit
 10.10 to the Current Report on Form 8-K filed by SBC Medical Group Holdings Incorporated on September 20, 2024).

 10.11+

 Employment Agreement between SBC Medical Group Holdings and Akira Komatsu, dated September 17, 2024 (incorporated by reference to
 Exhibit 10.11 to the Current Report on Form 8-K filed by SBC Medical Group Holdings Incorporated on September 20, 2024).

 10.12*

 Form of Non-Competition and Non-Solicitation Agreement.

 19.1*

Policy on Insider Trading

 21.1*

 List
of Subsidiaries of the Registrant

 31.1*

 Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.

 31.2*

 Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.

 32.1**

 Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.

 32.2**

 Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.

 97.1*

 Clawback
Policy

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 Cover

 *

 Filed
 herewith

 **

 Furnished
 herewith

 +

 Indicates
 a management or compensatory plan

 Schedules
 to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish a copy of
 any omitted schedules to the SEC upon request.

 Item
16.
 Form
 10-K Summary

 None.

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

 SBC
 Medical Group Holdings Incorporated

 Dated:
 March 28, 2025

 /s/ Yoshiyuki Aikawa

 Name:

 Title:

 Director,
 Chairman and Chief Executive Officer

 Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

 Name

 Position

 Date

 /s/ Yoshiyuki Aikawa

 Director,
 Chairman and Chief Executive Officer

 March

 (Principal
 Executive Officer)

 /s/ Ryoji Murata

 Chief
 Financial Officer

 March

 Ryoji
 Murata

 (Principal
 Financial and Accounting Officer)

 /s/ Yuya Yoshida

 and Chief Operating Officer

 March

 Yuya
 Yoshida

 /s/
 Ken Edahiro

 Independent

 March

 Ken
 Edahiro

 /s/ Mike Sayama

 Independent

 March

 Mike
 Sayama

 /s/
Fumitoshi Fujiwara

 Independent

 March

 Fumitoshi
 Fujiwara